Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

US PATENT APPLICATIONS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED 2001 TO 2005



Application No.: US20010000185A1  Published: 05/Apr/2001

Title: Extracorporeal blood processing methods and apparatus

Applicant/Assignee: GAMERO INC

Application No.: 09/729578   Filing Date: 04/Dec/2000

Abstract:Improved extracorporeal blood processing methods and apparatus are disclosed. In one aspect of the invention, an extracorporeal method for the collection of platelets and red blood cells, and if desired plasma, is provided, wherein the collection of platelets and red blood cells may occur in differing time periods utilizing the same blood processing vessel. The flow of blood to the blood processing vessel and return of uncollected blood components may be provided via a single needle, wherein blood is removed and returned to a donor/patient during alternating blood removal and blood return submodes. Prior to red blood cell collection, a set-up phase may be carried out during which a predetermined hematocrit and AC ratio is established.

Priority: US1997-924519 Applic. Date: 1997-09-05

Inventor: KELLER MURIEL [US]; BAINBRIDGE MARLENE [US]


Application No.: US20010000802A1  Published: 03/May/2001

Title: Implantable system with drug-eluting cells for on-demand local drug delivery

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/745144   Filing Date: 20/Dec/2000

Abstract:An implantable system that includes a carrier and eukaryotic cells, which produce and release a therapeutic agent, and a stimulating element for stimulating the release of the therapeutic agent. The system can also include a sensing element for monitoring a physiological condition and triggering the stimulating element to stimulate the delivery device to release the therapeutic agent. Alternatively, the patient in which the system is implanted can activate the stimulating element to release the therapeutic agent.

Priority: US1998-144420 Applic. Date: 1998-08-31; US1998-070480 Applic. Date: 1998-04-30

Inventor: SOYKAN ORHAN [US]; DONOVAN MAURA G [US]


Application No.: US20010001316A1  Published: 17/May/2001

Title: Clotting cascade initiating apparatus and methods of use and methods of closing wounds

Applicant/Assignee: CLOSYS CORPORATION

Application No.: 09/732423   Filing Date: 07/Dec/2000

Abstract:Wound closure methods and apparatus are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparatus for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

Priority: US1998-212080 Applic. Date: 1998-12-15; US19970069894P Applic. Date: 1997-12-17

Inventor: NOWAKOWSKI KAROL L [US]


Application No.: US20010005791A1  Published: 28/Jun/2001

Title: Method and apparatus for regional and whole body temperature modification

Applicant/Assignee: RADIANT MEDICAL, INC

Application No.: 09/739134   Filing Date: 15/Dec/2000

Abstract:Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region.

Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority: US1998-138830 Applic. Date: 1998-08-24; US1996-584013 Applic. Date: 1996-01-08; US1994-324853 Applic. Date: 1994-10-18; US1993-015774 Applic. Date: 1993-02-10; US1996-769931 Applic. Date: 1996-12-19

Inventor: GINSBURG ROBERT [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]


Application No.: US20010006791A1  Published: 05/Jul/2001

Title: CONTAINERS AND KITS FOR THE DETERMINATION OF CELL FUNCTIONS, AND METHOD FOR THE DETERMINATION THEREOF

Applicant/Assignee: SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA

Application No.: 09/068027   Filing Date: 01/Apr/1998

Abstract:An object is to obtain a container for measurement of cell functions which is simplified in operation, less risky and capable of measuring the cell functions very accurately. A container for measurement of cell functions, for use in the determination of a physiologically active substance produced by blood cells, is constituted such that an amount of material capable of inducing production of the physiologically active substance, when extracted by collecting water of a volume equal to a liquid volume to be subjected to measurement, is controlled at a level insufficient to induce production of the physiologically active substance from the blood cells.

A container for measurement of cell functions in which a material capable of inducing production of a physiologically active substance in blood when contacted with the blood is accommodated in such a condition as being contactable with blood, and in which an amount of the material capable of inducing production of the physiologically active substance in the container before use is limited to a level insufficient to influence a measured value of the physiologically active substance.

Priority: JP19960212488 Applic. Date: 1996-08-12; JP19960264832 Applic. Date: 1996-10-04; JP19970040814 Applic. Date: 1997-02-25; JP19970050403 Applic. Date: 1997-03-05; JP19970132445 Applic. Date: 1997-05-22; WO1997JP02776 Applic. Date: 1997-08-08

Inventor: KOBAYASHI KOJI [JP]; SETOGUCHI YUJI [JP]; KURIYAMA KIYOSHI [JP]


Application No.: US20010007956A1  Published: 12/Jul/2001

Title: Valve prosthesis for implantation in body channels

Applicant/Assignee:

Application No.: 09/795802   Filing Date: 28/Feb/2001

Abstract:The present invention is aimed to provide a valve prothesis (IV) especially used in case of aortic stenosis, which structure is capable of resisting the powerful recoil force and to stand the forceful balloon inflation performed to deploy the valve and to embed it in the aortic annulus. A valve prothesis for implantation in a body channel according to the invention comprises a collapsible valvular structure and an expandable frame on which said valvular structure is mounted. The valvular structure is composed of a valvular tissue compatible with the human body and blood, the valvular tissue being sufficiently supple and resistant to allow said valvular structure to be deformed from a closed state to an opened state. Said valvular tissue forms a continuous surface and is provided with guiding means formed or incorporated within, said guiding means creating stiffened zones which induce said valvular structure to follow a patterned movement in its expansion to its opened state and in its turning back to its closed state. The valvular structure can be extended to an internal cover which is fastened to the lower end of the valvular structure to prevent from regurgitation.

Priority: EP19960402929 Applic. Date: 1996-12-31; US1999-345824 Applic. Date: 1999-06-30

Inventor: LETAC BRICE [FR]; CRIBIER ALAIN [FR]


Application No.: US20010010017A1  Published: 26/Jul/2001

Title: Alve prosthesis for implantation in body channels

Applicant/Assignee:

Application No.: 09/795803   Filing Date: 28/Feb/2001

Abstract:The present invention is aimed to provide a valve prothesis (IV) especially used in case of aortic stenosis, which structure is capable of resisting the powerful recoil force and to stand the forceful balloon inflation performed to deploy the valve and to embed it in the aortic annulus. A valve prothesis for implantation in a body channel according to the invention comprises a collapsible valvular structure and an expandable frame on which said valvular structure is mounted. The valvular structure is composed of a valvular tissue compatible with the human body and blood, the valvular tissue being sufficiently supple and resistant to allow said valvular structure to be deformed from a closed state to an opened state. Said valvular tissue forms a continuous surface and is provided with guiding means formed or incorporated within, said guiding means creating stiffened zones which induce said valvular structure to follow a patterned movement in its expansion to its opened state and in its turning back to its closed state. The valvular structure can be extended to an internal cover which is fastened to the lower end of the valvular structure to prevent from regurgitation.

Priority: WO1997EP07337 Applic. Date: 1997-12-31; US1999-345924 Applic. Date: 1999-07-01; EP19960402929 Applic. Date: 1996-12-31

Inventor: LETAC BRICE [FR]; CRIBIER ALAIN [FR]


Application No.: US20010011180A1  Published: 02/Aug/2001

Title: Reinforced monorail balloon catheter

Applicant/Assignee: AVE CONNAUGHT MEDTRONIC AVE, INC

Application No.: 09/788896   Filing Date: 19/Feb/2001

Abstract:The invention is a dilation catheter which comprises an elongated catheter shaft, a guide wire tube, and an angioplasty balloon. The distal end of the balloon is attached to the distal portion of the guide wire tube, and the proximal portion of the balloon is attached to the distal portion of the catheter shaft. A stiffening wire is attached to the inner wall of the catheter shaft at a plurality of points along its length. The distal extremity of the guide wire tube is decreased in size relative to the proximal portion of the guide wire tube. A fluid is contained within the guide wire lumen.

Priority: US1997-859654 Applic. Date: 1997-05-20; US1996-737055 Applic. Date: 1996-10-24

Inventor: FITZMAURICE THOMAS K [IE]; GILSON PAUL [IE]; DUANE PATRICK J E [IE]


Application No.: US20010012634A1  Published: 09/Aug/2001

Title: Method for determining platelet inhibitor response

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/810747   Filing Date: 16/Mar/2001

Abstract:An apparatus for performing a platelet inhibition test on a sample of blood is provided, comprising a plurality of test cells, the cells being adapted for receiving an aliquot portion of the sample, wherein each of the cells comprises an anticoagulant and a clotting activator, and wherein at least one of the cells further comprises a platelet inactivating agent, wherein a clotting time is determined for each of the aliquot portions, and wherein a relative clotting time for each of the aliquot portions comprising the platelet inhibitor is determined as compared to a reference clotting time for a cell containing no platelet inhibitor, wherein the relative clotting times for the cells are determinative of the platelet inhibition of the sample.

Priority: US1999-225051 Applic. Date: 1999-01-04; US1996-640277 Applic. Date: 1996-04-30

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Application No.: US20010014443A1  Published: 16/Aug/2001

Title: Container for measurement of cell functions, kit for measurement of cell functions and method for measuring cell functions

Applicant/Assignee: SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA

Application No.: 09/753518   Filing Date: 04/Jan/2001

Abstract:An object is to obtain a container for measurement of cell functions which is simplified in operation, less risky and capable of measuring the cell functions very accurately. A container for measurement of cell functions, for use in the determination of a physiologically active substance produced by blood cells, is constituted such that an amount of material capable of inducing production of the physiologically active substance, when extracted by collecting water of a volume equal to a liquid volume to be subjected to measurement, is controlled at a level insufficient to induce production of the physiologically active substance from the blood cells.

A container for measurement of cell functions in which a material capable of inducing production of a physiologically active substance in blood when contacted with the blood is accommodated in such a condition as being contactable with blood, and in which an amount of the material capable of inducing production of the physiologically active substance in the container before use is limited to a level insufficient to influence a measured value of the physiologically active substance.

Priority: JP19960212488 Applic. Date: 1996-08-12; JP19960264832 Applic. Date: 1996-10-04; JP19970040814 Applic. Date: 1997-02-25; JP19970050403 Applic. Date: 1997-03-05; JP19970132445 Applic. Date: 1997-05-22; US1998-068027 Applic. Date: 1998-04-01

Inventor: KOBAYASHI KOJI [JP]; SETOGUCHI YUJI [JP]; KURIYAMA KIYOSHI [JP]


Application No.: US20010018215A1  Published: 30/Aug/2001

Title: Method for determining platelet inhibitor response

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/810740   Filing Date: 16/Mar/2001

Abstract:A method of determining a contact activator for platelet activation and/or clotting activation is provided, comprising placing a predetermined amount of an anticoagulant in each cell of a multicell test cartridge, placing a predetermined amount of a platelet inactivating agent in each cell, and placing a measured amount of contact activator in each cell, the amount of contact activator in each cell differing from the amount in each other cell. An aliquot of a blood sample is added to each cell, and the blood sample aliquot, clotting reagent and platelet inactivating agent are mixed. Each cell sample is allowed to clot, and the clotting time for each cell is measured. The relative clotting times are used to determine the platelet activation and/or clotting activation effect of the clotting activator.

Priority: US1999-225051 Applic. Date: 1999-01-04; US1996-640277 Applic. Date: 1996-04-30

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Application No.: US20010021355A1  Published: 13/Sep/2001

Title: Method for determining platelet inhibitor response

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/811216   Filing Date: 16/Mar/2001

Abstract:An apparatus is provided for performing an activated clotting time test on a sample of blood containing platelets using a plunger sensor technique, the apparatus comprising a test cell, and wherein the test cell comprises an anticoagulant, a contact activator, and a predetermined amount of a platelet inactivating agent.

Priority: US1999-225051 Applic. Date: 1999-01-04; US1996-640277 Applic. Date: 1996-04-30

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Application No.: US20010021866A1  Published: 13/Sep/2001

Title: Method of making selective organ cooling catheter

Applicant/Assignee: INNERCOOL THERAPIES INC INNERCOOL THERAPIES, INC

Application No.: 09/836585   Filing Date: 16/Apr/2001

Abstract:A heat transfer device has first and second elongated, articulated segments, each having a turbulence-inducing exterior surface. A flexible joint connects the first and second elongated, articulated segments. An inner coaxial lumen is disposed within the first and second elongated, articulated segments. The inner coaxial lumen is capable of transporting a pressurized working fluid to a distal end of the first elongated, articulated segment

Priority: US2000-566531 Applic. Date: 2000-05-08; US1998-103342 Applic. Date: 1998-06-23; US1998-047012 Applic. Date: 1998-03-24; US1998-012287 Applic. Date: 1998-01-23

Inventor: DOBAK JOHN D [US]; LASHERAS JUAN C [US]


Application No.: US20010023308A1  Published: 20/Sep/2001

Title: Intravascular radiation delivery system

Applicant/Assignee: SCIMED LIFE SYSTEMS, INC

Application No.: 09/808315   Filing Date: 14/Mar/2001

Abstract:An intravascular radiation delivery system including a catheter, a radiation source disposed in an open-ended lumen in the catheter and a closed-ended sheath surrounding the radiation source so as to prevent blood and other fluids from coming into contact with the radiation source. Preferably, the open-ended lumen is centered in the balloon for uniform radiation delivery. The catheter may include a blood perfusion lumen under the balloon or around the balloon. The open-ended lumen in the catheter may have a reduced diameter adjacent the distal end of the catheter to prevent the radiation source from exiting the lumen. Methods of using the radiation delivery system are also disclosed. An alternative method of delivering radiation to a treatment site inside the vasculature of a patient using a gas-filled balloon catheter and a radiation source disposed in the balloon catheter.

The treatment site is exposed to radiation, preferably beta radiation, through the gas-filled balloon.

Priority: US1997-782471 Applic. Date: 1997-01-10; US1996-608655 Applic. Date: 1996-02-29

Inventor: HASTINGS ROGER N [US]; HEKTNER THOMAS R [US]; KUME STEWART M [US]


Application No.: US20010024781A1  Published: 27/Sep/2001

Title: Isoalloxazine derivatives to neutralize biological contaminants

Applicant/Assignee: GAMBRO, INC

Application No.: 09/777727   Filing Date: 05/Feb/2001

Abstract:Methods are provided for neutralization of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an activation-effective amount of a microorganism neutralizer with an isoalloxazine backbone to a fluid and exposing the fluid to a triggering event. Preferred triggering events include light of a suitable wavelength and intensity to activate the microorganism neutralizer or a pH sufficient to activate the microorganism neutralizer. Other fluids, including juices, water and the like, may also be decontaminated by these methods as may surfaces of foods, animal carcasses, wounds, food preparation surfaces and bathing and washing vessel surfaces. Compounds with an isoalloxazine backbone are also provided.

Priority: US1999-420652 Applic. Date: 1999-10-19

Inventor: PLATZ MATTHEW STEWART [US]; GOODRICH RAYMOND PAUL [US]


Application No.: US20010027300A1  Published: 04/Oct/2001

Title: Device for treatment of venous congestion

Applicant/Assignee:

Application No.: 09/745298   Filing Date: 20/Dec/2000

Abstract:A device for treatment of venous congestion provides for subcutaneous introduction of anticoagulant through an incision positioned within a collection shell for withdrawal of a effused material. A wash of saline and anticoagulant agitated by an air-input stream and periodic rotation of the subcutaneous device may be used to reduce clotting.

Priority: US19990171351P Applic. Date: 1999-12-22

Inventor: HARTIG GREGORY K [US]; CONNOR NADINE P [US]; CONFORTI MICHAEL L [US]


Application No.: US20010031445A1  Published: 18/Oct/2001

Title: Dental implant and operative method of implantation

Applicant/Assignee: ARTAL CARLOS ARRUGA

Application No.: 09/823090   Filing Date: 30/Mar/2001

Abstract:Dental implant and operative method of implantation, being of the type of implant comprising a body that is threaded into the jawbone via which the appropriate securing and fastening bodies for the dental prosthesis are located, the implant body (1) displaying an axial cavity (2) along its entire length, and whose internal base for implantation displays certain drilled holes and/or angular cuts (3) in its lateral surface that define end tabs, the implants being presented individually in their respective sterilized receptacles (5), being joined to the cap body (6) of the receptacle (5) via an intermediate body (7), the cap body (6) defining a cavity (11) with respect to its external base, in which is housed a body (12) made of rubber or similar material.

Priority: ES20000000984 Applic. Date: 2000-04-14

Inventor: ARRUGA ARTAL ALBERTO [ES]


Application No.: US20010031870A1  Published: 18/Oct/2001

Title: Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS INC

Application No.: 09/796319   Filing Date: 28/Feb/2001

Abstract:The present invention is directed to aminoguanidine and alkoxyguanidine compounds, including compounds of Formula I: wherein X is O or NH, L is -O- or -SO2-, and R1-R4, R9-R19, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing the compounds of Formula I. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal.

Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage.

Priority: US1999-283241 Applic. Date: 1999-04-01; US19980080568P Applic. Date: 1998-04-03

Inventor: SOLL RICHARD M [US]; LU TIANBAO [US]; TOMCZUK BRUCE E [US]; MARKOTAN THOMAS P [US]; SIEDEM COLLEEN [US]


Application No.: US20010034037A1  Published: 25/Oct/2001

Title: Pyrogenicity test for use with automated immunoassay systems

Applicant/Assignee: BAXTER INTERNATIONAL INC NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL

Application No.: 09/727561   Filing Date: 01/Dec/2000

Abstract:The invention concerns an improved pyrogenicity test for use in automated immunoassay systems, in which a sample is incubated with a monocyte-containing reagent in a pyrogen-free assay system preferably comprising a surface coated with pyrogen-free anti-cytokine antibodies. The invention also concerns pyrogen-free assay systems coated with pyrogen-free antibodies for use in these tests. The invention also relates to a test to measure the basal production of endogenous mediators of the inflammatory response by leukocytes and a method of measuring the capacity of a leukocyte to respond to a stimuli.

Priority: US19990168972P Applic. Date: 1999-12-03

Inventor: PATEL MEHUL [US]; POOLE STEPHEN [GB]


Application No.: US20010037039A1  Published: 01/Nov/2001

Title: Aminoguanidines and alkoxyguanidines as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 09/809293   Filing Date: 16/Mar/2001

Abstract:Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula . The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Priority: US1997-979234 Applic. Date: 1997-11-26; US19960031822P Applic. Date: 1996-11-26

Inventor: TOMCZUK BRUCE E [US]; SOLL RICHARD M [US]; LU TIANBAO [US]; FEDDE CYNTHIA L [US]; ILLIG CARL R [US]; MARKOTAN THOMAS P [US]; STAGNARO THOMAS P [US]


Application No.: US20010044123A1  Published: 22/Nov/2001

Title: Assays for diagnosis of thrombophilic disease

Applicant/Assignee: MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK

Application No.: 09/796023   Filing Date: 28/Feb/2001

Abstract:The present invention provides methods for diagnosing and/or monitoring thrombophilic disease in a patient that can result from the antiphospholipid antibody syndrome (aPL syndrome). The methods of the invention are premised on the inhibition of binding of an anticoagulant protein, annexin, preferably annexin-V, to phospholipids by antiphospholipid (aPL) antibodies in a patient blood sample.

Priority: US1998-113715 Applic. Date: 1998-07-10; US19970052313P Applic. Date: 1997-07-11

Inventor: RAND JACOB H [US]


Application No.: US20010044454A1  Published: 22/Nov/2001

Title: Thrombin receptor antagonists

Applicant/Assignee: MERCK & CO., INC

Application No.: 09/772352   Filing Date: 30/Jan/2001

Abstract:A thrombin receptor antagonist having the formula or a pharmaceutically acceptable salt thereof, useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.

Priority: US20000179342P Applic. Date: 2000-01-31

Inventor: NANTERMET PHILIPPE G [US]; BARROW JAMES C [US]; SELNICK HAROLD G [US]


Application No.: US20010044584A1  Published: 22/Nov/2001

Title: In vivo delivery methods and compositions

Applicant/Assignee:

Application No.: 09/819924   Filing Date: 28/Mar/2001

Abstract:Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

Priority: US2000-727950 Applic. Date: 2000-12-01; US2000-628401 Applic. Date: 2000-08-01; US2000-501856 Applic. Date: 2000-02-10; US1999-439795 Applic. Date: 1999-11-12; US1997-919906 Applic. Date: 1997-08-28

Inventor: KENSEY KENNETH R [US]


Application No.: US20010046981A1  Published: 29/Nov/2001

Title: COMPOUNDS

Applicant/Assignee: ASTRAZENECA AB

Application No.: 09/214143   Filing Date: 29/Dec/1998

Abstract:There is provided compounds of formula I, wherein R1, R2, R3, Rx, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE19970004543 Applic. Date: 1997-12-05; WO1998SE02187 Applic. Date: 1998-12-01

Inventor: KARLSSON OLLE [SE]; LINSCHOTEN MARCEL [SE]; NYSTROM JAN-ERIK [SE]


Application No.: US20010047196A1  Published: 29/Nov/2001

Title: Method and apparatus for regional and whole body temperature modification

Applicant/Assignee: RADIANT MEDICAL, INC

Application No.: 09/739427   Filing Date: 15/Dec/2000

Abstract:Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region.

Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority: US1998-138830 Applic. Date: 1998-08-24; US1996-584013 Applic. Date: 1996-01-08; US1994-324853 Applic. Date: 1994-10-18; US1993-015774 Applic. Date: 1993-02-10; US1996-769931 Applic. Date: 1996-12-19

Inventor: GINSBURG ROBERT [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]


Application No.: US20010056123A1  Published: 27/Dec/2001

Title: Benzamidine derivatives

Applicant/Assignee: AJINOMOTO CO., INC

Application No.: 09/731729   Filing Date: 08/Dec/2000

Abstract:Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.

Priority: JP19980159627 Applic. Date: 1998-06-08; JP19980159628 Applic. Date: 1998-06-08; WO1999JP03055 Applic. Date: 1999-06-08

Inventor: NAKAGAWA TADAKIYO [JP]; SAGI KAZUYUKI [JP]; YOSHIDA KAORU [JP]; FUKUDA YUMIKO [JP]; SHOJI MASATAKA [JP]; TAKEHANA SHUNJI [JP]; KAYAHARA TAKASHI [JP]; TAKAHARA AKIRA [JP]


Application No.: US20020001834A1  Published: 03/Jan/2002

Title: METHOD FOR ATTACHMENT OF BIOMOLECULES TO MEDICAL DEVICE SURFACES

Applicant/Assignee: MEDTRONIC, INC

Application No.: 09/257543   Filing Date: 24/Feb/1999

Abstract:A method for making a medical device having at least one biomolecule immobilized on a substrate surface is provided. One method of the present invention includes immobilizing a biomolecule comprising an unsubstituted amide moiety on a biomaterial surface. Another method of the present invention includes immobilizing a biomolecule on a biomaterial surface comprising an unsubstituted amide moiety. Still another method of the present invention may be employed to crosslink biomolecules comprising unsubstituted amide moieties immobilized on medical device surfaces. Additionally, one method of the present invention may be employed to crosslink biomolecules comprising unsubstituted amide moieties in solution, thereby forming a crosslinked biomaterial or a crosslinked medical device coating.

Priority: US1998-067188 Applic. Date: 1998-04-27; US1997-001994 Applic. Date: 1997-12-31; US1996-635187 Applic. Date: 1996-04-25; US1997-984922 Applic. Date: 1997-12-04; US1996-694535 Applic. Date: 1996-08-09; US1998-012056 Applic. Date: 1998-01-22; US1998-010906 Applic. Date: 1998-01-22

Inventor: KEOGH JAMES R [US]; TRESCONY PAUL V [US]


Application No.: US20020002349A1  Published: 03/Jan/2002

Title: Systems and methods for delivering drugs to selected locations within the body

Applicant/Assignee: TRANSVASCULAR, INC

Application No.: 09/826049   Filing Date: 03/Apr/2001

Abstract:A transvascular system (10) for delivering a drug to a tissue region from a blood vessel, such as a coronary vein, includes a catheter (12) having a distal portion (26) with puncturing (14), orientation (16), drug delivery (62), and imaging elements (18). The puncturing element (14) is deployable for penetrating the vessel wall to access the tissue region. The orientation element (16), e.g. a "cage" including a plurality of struts (38) (40) and/or a radiopaque marker, has a predetermined relationship with the puncturing element (14), the imaging element (18) detecting the location of the orientation element (16) with respect to the tissue region to orient the puncturing element.

The catheter (12) is percutaneously introducing into the vessel, the puncturing element (14) is oriented towards the tissue region, the puncturing element (14) is deployed to access the tissue region, and the drug is delivered to the tissue region. An ablation device (230) may also be deployed to create a cavity in the tissue region for receiving the drug therein, or an indwelling catheter (214) may be advanced into and left in the tissue region. An implantable reservoir device (400) is also disclosed, including an enclosed membrane (408) on an expandable frame (402) that defines a reservoir (410) and includes a porous region (418). The reservoir device (400) may be deployed and expanded within a blood vessel, and may be filled in situ or prefilled with a drug that passes through the porous region (418).

Alternatively, a pair of expandable endovascular blockers (500) may be used to isolate a section of a blood vessel which may be filled with a drug that may be absorbed by the surrounding tissue.

Priority: US1998-048147 Applic. Date: 1998-03-25; US1996-730327 Applic. Date: 1996-10-11; US1996-730496 Applic. Date: 1996-10-11

Inventor: FLAHERTY J CHRISTOPHER [US]; MAKOWER JOSHUA [US]; EVARD PHILIP C [US]; MACAULAY PATRICK E [US]; WHITT JASON B [US]; COLLOTON ROBERT C [US]; MACFARLANE K ANGELA [US]


Application No.: US20020002355A1  Published: 03/Jan/2002

Title: Apparatus and method for collecting blood from an umbilical cord

Applicant/Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER OF NORTHERN CALIFORNIA

Application No.: 09/740616   Filing Date: 18/Dec/2000

Abstract:An apparatus and method for collecting a large volume of blood from an umbilical cord in a sterile environment are shown and described. A housing having an inner region adapted to retain an umbilical cord in a desired location is provided, the housing having an opening through which the cord extends from the inner region of the housing to a region external to the housing. The cord is cut by a blade coupled to the housing, either by the motion of the blade from a first position to a second position, or by the movement of two portions of the housing from a first extended position to a second collapsed position. The newly cut end of the umbilical cord falls and hangs freely in the inner region of the housing, blood flowing from the placenta and umbilical cord via gravity into a blood collection region of the housing.

The blood collection region may be flexible, and may be coupled to a conventional blood collection bag.

Priority: US1999-310895 Applic. Date: 1999-05-12; US1997-856252 Applic. Date: 1997-05-14; US1996-742438 Applic. Date: 1996-10-30; US19960017402P Applic. Date: 1996-05-14

Inventor: KUYPERS FRANCISCUS A [US]; COLE ROBERT B [US]; MEYST RICHARD P [US]; GORTON LANNY A [US]; WRIGHT JAMES I [US]


Application No.: US20020006443A1  Published: 17/Jan/2002

Title: Pharmaceutical compositions providing enhanced drug concentrations

Applicant/Assignee:

Application No.: 09/742785   Filing Date: 20/Dec/2000

Abstract:A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.

Priority: US19990171841P Applic. Date: 1999-12-23

Inventor: CURATOLO WILLIAM J [US]; SHANKER RAVI M [US]; BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; NIGHTINGALE JAMES A S [US]; LORENZ DOUGLAS A [US]


Application No.: US20020007045A1  Published: 17/Jan/2002

Title: Thrombin receptor antagonists

Applicant/Assignee: MERCK & CO., INC

Application No.: 09/772353   Filing Date: 30/Jan/2001

Abstract:A thrombin receptor antagonist having the formula useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic amount of such compound to a mammal, preferably a human.

Priority: US20000179184P Applic. Date: 2000-01-31

Inventor: BARROW JAMES C [US]; NANTERMET PHILIPPE G [US]; SELNICK HAROLD G [US]; HUTCHINSON JOHN H [US]; BRESLIN MICHAEL J [US]; GLASS KRISTEN L [US]; CONNOLLY THOMAS M [US]; STERN ANDREW [US]


Application No.: US20020007070A1  Published: 17/Jan/2002

Title: Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 09/827292   Filing Date: 06/Apr/2001

Abstract:Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR9 and Het, R1, R7, R8, R 12-R15, Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US2000-482540 Applic. Date: 2000-01-14; US1998-199167 Applic. Date: 1998-11-25; US19980079107P Applic. Date: 1998-03-23; US19970067324P Applic. Date: 1997-12-05; US19970066475P Applic. Date: 1997-11-26

Inventor: LU TIANBAO [US]; TOMCZUK BRUCE E [US]; MARKOTAN THOMAS P [US]; SIEDEM COLLEEN [US]


Application No.: US20020007181A1  Published: 17/Jan/2002

Title: Expandable vein ligator catheter having multiple electrode leads, and method

Applicant/Assignee: VNUS MEDICAL TECHNOLOGIES, INC

Application No.: 09/866517   Filing Date: 25/May/2001

Abstract:A catheter includes a plurality of primary leads to deliver energy for ligating a hollow anatomical structure. Each of the primary leads includes an electrode located at the working end of the catheter. Separation is maintained between the primary leads such that each primary lead can individually receive power of selected polarity. The primary leads are constructed to expand outwardly to place the electrodes into apposition with an anatomical structure. High frequency energy can be applied from the leads to create a heating effect in the surrounding tissue of the anatomical structure. The diameter of the hollow anatomical structure is reduced by the heating effect, and the electrodes of the primary leads are moved closer to one another.

Where the hollow anatomical structure is a vein, energy is applied until the diameter of the vein is reduced to the point where the vein is occluded. In one embodiment, a secondary lead is surrounded by the primary leads, and extends beyond the primary leads. The secondary lead includes an electrode at the working end of the catheter. The secondary lead can have a polarity opposite to the polarity of the primary leads in a bipolar configuration. The polarity of the leads can be switched and the catheter can be moved during treatment to ligate an extended length of the vein. The catheter can include a lumen to accommodate a guide wire or to allow fluid delivery.

Priority: US1999-267756 Applic. Date: 1999-03-10; US1997-927251 Applic. Date: 1997-09-11

Inventor: ZIKORUS ARTHUR W [US]; PARKER MARK P [US]; JONES CHRISTOPHER S [US]; PETTY DOUGLAS M [US]; FARLEY BRIAN E [US]; TARTAGLIA JOSEPH M [US]


Application No.: US20020016562A1  Published: 07/Feb/2002

Title: DEVICE AND METHOD FOR ENHANCING TRANSDERMAL FLUX OF AGENTS BEING DELIVERED OR SAMPLED

Applicant/Assignee: ALZA CORPORATION

Application No.: 08/877155   Filing Date: 17/Jun/1997

Abstract:A percutaneous agent delivery or sampling device comprising a sheet having a plurality of microblades for piercing and anchoring to the skin for increasing transdermal flux of an agent and for improving the attachment of the device to the skin.

Priority: US19960019990P Applic. Date: 1996-06-18

Inventor: CORMIER MICHEL J N [US]; NEUKERMANS ARMAND P [US]; BLOCK BARRY [US]; THEEUWES FELIX T [US]; AMKRAUT ALFRED A [US]


Application No.: US20020019371A1  Published: 14/Feb/2002

Title: New amino acid derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 09/844427   Filing Date: 30/Apr/2001

Abstract:There is provided compounds of formula I, wherein R1, R2, R3, Rx, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE19960002263 Applic. Date: 1996-06-07; WO1997SE00989 Applic. Date: 1997-06-05; US1997-860871 Applic. Date: 1997-07-14

Inventor: GUSTAFSSON DAVID [SE]; NYSTROM JAN-ERIK [SE]


Application No.: US20020022054A1  Published: 21/Feb/2002

Title: Drug delivery system for averting pharmacokinetic drug interaction and method thereof

Applicant/Assignee: YAMANOUCHI PHARMACEUTICAL CO., LTD

Application No.: 09/834414   Filing Date: 12/Apr/2001

Abstract:The present invention is a system for averting undesirable pharmacokinetic drug interaction between a drug and concomitant drug(s), which consists of controlling the in vivo release time and/or release site of the drug and/or the concomitant drug.

Priority: US20000197574P Applic. Date: 2000-04-17

Inventor: SAWADA TOYOHIRO [JP]; SAKO KAZUHIRO [JP]; YOSHIOKA TATSUNOBU [JP]; WATANABLE SHUNSUKE [JP]


Application No.: US20020022612A1  Published: 21/Feb/2002

Title: New amidino derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 09/844428   Filing Date: 30/Apr/2001

Abstract:There is provided compounds of formula I, wherein R1, Rx, Y, Ry, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE19970002378 Applic. Date: 1997-06-19; SE19980001099 Applic. Date: 1998-03-30; WO1998SE01103 Applic. Date: 1998-06-09; US1998-091994 Applic. Date: 1998-06-26

Inventor: KARLSSON OLLE [SE]; LINSCHOTEN MARCEL [SE]; NYSTROM JAN-ERIK [SE]


Application No.: US20020022615A1  Published: 21/Feb/2002

Title: Cyclic oxyguanidine protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 09/919815   Filing Date: 02/Aug/2001

Abstract:Cyclic oxyguanidine compounds, including compounds of Formulae I and II: wherein R1, R3-R6, R21-R26, L, Y, Z, and A are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formulae I and II. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Priority: US20000223223P Applic. Date: 2000-08-04

Inventor: WANG AIHUA [US]; LU TIANBAO [US]; TOMCZUK BRUCE EDWARD [US]; SOLL RICHARD M [US]; SPURLINO JOHN CURTIS [US]; BONE ROGER FRANCIS [US]


Application No.: US20020022772A1  Published: 21/Feb/2002

Title: Animal health diagnosis

Applicant/Assignee:

Application No.: 09/908407   Filing Date: 22/Aug/2001

Abstract:Laboratory test data are analyzed in relation to the health assessment data of an animal together with the genetic data related to that same animal. These data are relevant to the likely morbidity, likely longevity, and/or the potential risk for disease or disorder for the animal, including temperament, immune stimulation and cellular inflammatory response mediators, markers for neoplastic or paraneoplastic change, inherited organ dysfunction or dysplasia, autoimmune thyroiditis, mammary cancer, immune surveillance markers, and inherited bleeding tendency. A panel of tests relates to at least one of endocrine function, immunologic function, gastrointestinal function and nutritional analysis, inborn errors of metabolism, paternity, DNA fingerprinting, hemostasis and coagulation function, vaccinal antibody status, adverse and potential adverse vaccine reaction, infectious diseases, pathology, blood typing and bone marrow analysis, cell cytotoxicity, cytokine and allergy testing, and markers of neoplastic and paraneoplastic change.

Priority: US1999-432851 Applic. Date: 1999-11-02

Inventor: DODDS W JEAN [US]


Application No.: US20020028201A1  Published: 07/Mar/2002

Title: INTERACTIVE SYSTEM FOR PRESENTING AND ELIMINATING SUBSTANCES

Applicant/Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V., BERLIN

Application No.: 09/417534   Filing Date: 14/Oct/1999

Abstract:The present invention relates to an interactive system comprising at least one active surface of plastic from monomers containing at least one structural element derived from a carbon dioxide (A), and at least one substance associated to a linker with at least one structural element (B) capable of establishing a hydrogen bond, and involving an interaction between the structural elements (A) and (B). That interactive system is suitable for presenting and eliminating substances in liquids.

Priority: DE19971015504 Applic. Date: 1997-04-14; WO1998EP02183 Applic. Date: 1998-04-14

Inventor: BUCHA ELKE [DE]; NOWAK GOTZ [DE]


Application No.: US20020032149A1  Published: 14/Mar/2002

Title: In vivo delivery methods and compositions

Applicant/Assignee:

Application No.: 09/841389   Filing Date: 24/Apr/2001

Abstract:Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

Priority: US2001-819924 Applic. Date: 2001-03-28; US2000-727950 Applic. Date: 2000-12-01; US2000-628401 Applic. Date: 2000-08-01; US2000-501856 Applic. Date: 2000-02-10; US1999-439795 Applic. Date: 1999-11-12; US1997-919906 Applic. Date: 1997-08-28

Inventor: KENSEY KENNETH [US]


Application No.: US20020032171A1  Published: 14/Mar/2002

Title: Clear oil-containing pharmaceutical compositions containing a therapeutic agent

Applicant/Assignee: LIPOCINE, INC

Application No.: 09/877541   Filing Date: 08/Jun/2001

Abstract:The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier, where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.

Priority: US1999-345615 Applic. Date: 1999-06-30; US2000-751968 Applic. Date: 2000-12-29; US1999-375636 Applic. Date: 1999-08-17

Inventor: CHEN FENG-JING [US]; PATEL MAHESH V [US]; FIKSTAD DAVID T [US]


Application No.: US20020033370A1  Published: 21/Mar/2002

Title: Extracorporeal blood processing methods and apparatus

Applicant/Assignee: GAMBRO INC

Application No.: 09/803304   Filing Date: 09/Mar/2001

Abstract:Methods and apparatus particularly involving the separation of blood into blood components and the collection of such components are disclosed. In one aspect, an extracorporeal method for the collection of plasma and red blood cells is provided, wherein the collection of plasma and red blood cells may occur simultaneously or subsequently utilizing the same dual stage blood processing vessel. The flow of blood to the blood processing vessel and return of uncollected blood components may be provided via a single needle, wherein blood is removed from and returned to a donor/patient during alternating blood removal and blood return submodes. Platelet separation and collection options are also described. In either case, prior to red blood cell collection, a set-up phase may be carried out to set a predetermined hematocrit and AC ratio.

Replacement fluid delivery may optionally also be provided either substantially continuously during any collection phase(s) and/or in a bolus mode.

Priority: US20000188133P Applic. Date: 2000-03-09

Inventor: BAINBRIDGE MARLENE [US]; KELLER MURIEL [US]; GORDON TIMOTHY M [US]; MCATEER MICHAEL J [US]; BUTZKE SCOTT D [US]


Application No.: US20020037358A1  Published: 28/Mar/2002

Title: Loading and release of water-insoluble drugs

Applicant/Assignee:

Application No.: 09/978763   Filing Date: 18/Oct/2001

Abstract:A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coating is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.

Priority: US1998-172026 Applic. Date: 1998-10-14; US1998-133603 Applic. Date: 1998-08-13; US1997-910136 Applic. Date: 1997-08-13

Inventor: BARRY JAMES J [US]; PALASIS MARIA [US]


Application No.: US20020037528A1  Published: 28/Mar/2002

Title: Method for detecting procoagulant genetic and metabolic conditions associated with, and potentially predispositional for, activation of the coagulation response

Applicant/Assignee:

Application No.: 09/966311   Filing Date: 28/Sep/2001

Abstract:Methods for diagnosing and identifying genetic and metabolic factors associated with a physiologic procoagulant predisposition for and concurrent activation of the coagulation response in patients suffering from conditions such as chronic fatigue syndrome, fibromyalgia, Gulf War illness and cardiovascular disease are disclosed. Diagnostic assays utilized in the methods include measurement of blood levels of Protein C, Protein S, antithrombin, activated protein C resistance, prothrombin plasminogen activator inhibitor-1, lipoprotein (a) and homocysteine. Treatment regimens include anticoagulant therapies comprising administering warfarin or heparin as needed.

Priority: US19990148799P Applic. Date: 1999-08-13

Inventor: BERG DAVID E [US]; BERG LOIS HILL [US]; HARRISON HAROLD H [US]


Application No.: US20020039994A1  Published: 04/Apr/2002

Title: Use of anticoagulant agents in the extracorporeal treatment of blood

Applicant/Assignee:

Application No.: 09/811410   Filing Date: 20/Mar/2001

Abstract:The present invention relates to the use of anticoagulant agents, and in particular of PEG-hirudin, for treating individuals with extracorporeal circulation for prophylaxis of vascular complications after the extracorporeal circulation. It is thus possible in particular to treat individuals with chronic renal insufficiency requiring regular hemodialysis and moreover prevent vascular complications which conventionally result in a high morbidity and mortality rate for dialysis patients treated longer-term.

Priority: EP20000105867 Applic. Date: 2000-03-20; US20000190103P Applic. Date: 2000-03-20

Inventor: SCHERHAG RUDI [DE]; BACHER PETER [DE]; PAROW CHRISTOPHER [DE]; ESSLINGER HANS-ULRICH [DE]; ABEL FLORIAN [DE]


Application No.: US20020040012A1  Published: 04/Apr/2002

Title: Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits

Applicant/Assignee:

Application No.: 10/005793   Filing Date: 02/Nov/2001

Abstract:A method for preventing clotting in an extracorporeal blood circuit by administering a synthetic oligosaccharide that is a selective inhibitor of factor Xa, acting via antithrombin III.

Priority: EP19970201586 Applic. Date: 1997-05-27; US1999-424626 Applic. Date: 1999-11-24

Inventor: JOHANNES STIEKEMA JACOBUS CHRI [NL]; HERBERT JEAN MARC [FR]


Application No.: US20020040043A1  Published: 04/Apr/2002

Title: Amidino derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 09/839609   Filing Date: 23/Apr/2001

Abstract:There is provided compounds of formula I, wherein R1, R2, R3, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE19960002646 Applic. Date: 1996-07-04; US1997-894833 Applic. Date: 1997-08-29; WO1997SE01150 Applic. Date: 1997-06-26

Inventor: ANTONSSON THOMAS [SE]


Application No.: US20020042396A1  Published: 11/Apr/2002

Title: Amino acid derivatives

Applicant/Assignee: ASTRA AB ASTRAZENECA AB

Application No.: 09/995564   Filing Date: 29/Nov/2001

Abstract:There is provided amino acid derivatives of formula I, wherein p, q, R1, R2, R3, R4, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as hirombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: GB19950026411 Applic. Date: 1995-12-22; SE19950002487 Applic. Date: 1995-07-06; SE19950002504 Applic. Date: 1995-07-07; SE19950002505 Applic. Date: 1995-07-07; SE19950003923 Applic. Date: 1995-11-07; SE19950004349 Applic. Date: 1995-12-05; WO1996SE00878 Applic. Date: 1996-07-02; US2000-537344 Applic. Date: 2000-03-29

Inventor: GUSTAFSSON DAVID [SE]; NYSTROM JAN-ERIK [SE]


Application No.: US20020046975A1  Published: 25/Apr/2002

Title: Method and apparatus for producing blood component products

Applicant/Assignee: GAMBRO, INC

Application No.: 09/981932   Filing Date: 17/Oct/2001

Abstract:A method and apparatus for producing blood component products. In one embodiment, a plurality of a predetermined type of blood component is harvested from a source of whole blood. At least two on-line yield determination techniques are utilized to determine the yield for the harvested blood components. One is a predetermined yield prediction technique and the second is a predetermined yield monitoring technique, each of which are individually calibrated in relation to a predetermined off-line yield determination technique. The predetermined yield prediction and monitoring techniques each provide the yield for the harvested blood components and each is then utilized to provide a determined yield. Consequently, when the harvested blood components are packaged the determined yield my be associated therewith, thereby providing a blood component product.

Priority: US1992-912973 Applic. Date: 1992-07-10

Inventor: LANGLEY ROBERT WARNER [US]; DUMONT LARRY JOE [US]


Application No.: US20020049155A1  Published: 25/Apr/2002

Title: Cobalamin compounds useful as cardiovascular agents and as imaging agents

Applicant/Assignee:

Application No.: 09/873142   Filing Date: 31/May/2001

Abstract:The invention provides cobalamin derivatives linked to a cardiovascular agent, as well as pharmaceutical compositions comprising the compounds and methods for using the compounds in treatment or diagnosis of a cardiovascular disease.

Priority: US20000208140P Applic. Date: 2000-05-31; US20010267782P Applic. Date: 2001-02-09

Inventor: HOGENKAMP HENRICUS P C [US]


Application No.: US20020054852A1  Published: 09/May/2002

Title: System and method for the local delivery of drugs

Applicant/Assignee:

Application No.: 10/022021   Filing Date: 13/Dec/2001

Abstract:A method of treating a specific site in a mammal with a drug comprises (a) providing a carrier material which reflects or absorbs or emits electromagnetic or mechanical vibrations enabling the monitoring of the carrier material, (b) providing a drug associated with the carrier material, (c) providing a targeting agent associated with the carrier material, the targeting agent being capable of binding to the specific site in the mammal, (d) delivering the carrier material and the drug to the specific site in the mammal, and (e) monitoring the mammal to detect arrival of the carrier material at the specific site. A local and site-specific drug delivery system for delivering a drug to a specific site within an individual comprises a carrier material which reflects or absorbs or emits electromagnetic or mechanical vibrations enabling the monitoring of the carrier material, a drug associated with the carrier material, and a targeting agent associated with the carrier material that delivers the carrier material and the drug to a specific site within the individual, the targeting agent being capable of binding to the specific site within the individual.

Priority: WO1995NL00028 Applic. Date: 1995-01-19; US1997-893206 Applic. Date: 1997-07-15

Inventor: CATE FOLKERT JAN TEN [NL]


Application No.: US20020061835A1  Published: 23/May/2002

Title: In vivo delivery methods and compositions

Applicant/Assignee:

Application No.: 09/828761   Filing Date: 09/Apr/2001

Abstract:Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

Priority: US2000-727950 Applic. Date: 2000-12-01; US2000-628401 Applic. Date: 2000-08-01; US2000-501856 Applic. Date: 2000-02-10; US1999-439795 Applic. Date: 1999-11-12; US1997-919906 Applic. Date: 1997-08-28

Inventor: KENSEY KENNETH R [US]


Application No.: US20020061872A1  Published: 23/May/2002

Title: Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 09/971000   Filing Date: 05/Oct/2001

Abstract:Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof

wherein R3-R6, R11, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US20000238132P Applic. Date: 2000-10-06

Inventor: PAN WENXI [US]; LU TIANBAO [US]; MARKOTAN THOMAS P [US]; TOMCZUK BRUCE E [US]


Application No.: US20020062100A1  Published: 23/May/2002

Title: Blood collection systems and methods that derive estimated effects upon the donor's blood volume and hematocrit

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 09/789183   Filing Date: 20/Feb/2001

Abstract:Blood processing systems and methods convey blood drawn from a donor through a blood processing circuit to separate the blood into at least one targeted blood component for collection. The systems and methods derive an estimated effect of the procedure upon the donor. The estimated effect can be expressed in terms of a net blood fluid volume loss, or as a hematocrit of the donor after completion of the desired blood collection procedure. The systems and methods present the estimated effect to an operator for viewing, reading, or offloading.

Priority: US1999-419742 Applic. Date: 1999-10-16

Inventor: PIERCE JENNIFER A [US]; PATNO TIMOTHY J [US]; CAIRONE ROBERT [US]; FOLEY JOHN T [US]


Application No.: US20020062119A1  Published: 23/May/2002

Title: Methods and apparatuses for drug delivery to an intravascular occlusion

Applicant/Assignee: MEDTRONIC AVE, INC

Application No.: 10/035389   Filing Date: 28/Dec/2001

Abstract:A method for delivering a drug to the site of an intravascular occlusion. A guidewire having a balloon at one end is advanced across the occlusion using a guide catheter, and the balloon is inflated distal to the occlusion to occlude the blood vessel. An aspiration catheter is then inserted into the vessel with its tip less than about 5 mm from the surface of the balloon, and a drug is delivered which flows distal to proximal to treat the occlusion.

Priority: US2000-537471 Applic. Date: 2000-03-24; US1998-049857 Applic. Date: 1998-03-27; US1999-314054 Applic. Date: 1999-05-18; US1997-813807 Applic. Date: 1997-03-06; US1998-049712 Applic. Date: 1998-03-27; US1997-975723 Applic. Date: 1997-11-20; US1997-812139 Applic. Date: 1997-03-06; US1996-650464 Applic. Date: 1996-05-20; US1999-438030 Applic. Date: 1999-11-10; US1999-270150 Applic. Date: 1999-03-16; US1997-933816 Applic. Date: 1997-09-19; US1997-813810 Applic. Date: 1997-03-06; US2001-837872 Applic. Date: 2001-04-17; US1999-415607 Applic. Date: 1999-10-08; US1997-812876 Applic. Date: 1997-03-06; US1997-812570 Applic. Date: 1997-03-06

Inventor: ZADNO-AZIZI GHOLAM-REZA [US]


Application No.: US20020064480A1  Published: 30/May/2002

Title: Fluidic device for medical diagnostics

Applicant/Assignee:

Application No.: 10/052447   Filing Date: 17/Jan/2002

Abstract:A fluidic medical diagnostic device permits measurement of analyte concentration or a property of a biological fluid, particularly the coagulation time of blood. The device has at one end a sample port for introducing a sample and at the other end a bladder for drawing the sample to a measurement area. A channel carries the sample from the sample port to the measurement area, and a stop junction, between the measurement area and bladder, halts the sample flow. The desired measurement can be made by placing the device into a meter which measures a physical property of the sample-typically, optical transmittance-after it has interacted with a reagent in the measurement area.

Priority: US1999-333765 Applic. Date: 1999-06-15; US19980093421P Applic. Date: 1998-07-20

Inventor: SHARTLE ROBERT JUSTICE [US]


Application No.: US20020065493A1  Published: 30/May/2002

Title: Apparatus for the controllable modification of compound concentration in a tube

Applicant/Assignee: BIOSYNERGETICS, INC

Application No.: 10/039797   Filing Date: 26/Oct/2001

Abstract:Apparatus and methods for delivery of a drug or compound into a fluid flowing within a tube or catheter. In one embodiment a catheter includes an inner surface coated with a polymer matrix such as a hydrogel. The hydrogel includes captured within it a therapeutic agent. The method of capture may be by various means, including photolabile bonds between the therapeutic agent and the hydrogel. The therapeutic agent is released from the hydrogel by the application of energy to the hydrogel, such as by a laser emitting a wavelength which resonates and breaks the photolabile bond. The released therapeutic agent diffuses out of the hydrogel into the liquid flowing within a lumen of the catheter.

Priority: US2000-692857 Applic. Date: 2000-10-20; US19990161130P Applic. Date: 1999-10-22; US19990170051P Applic. Date: 1999-12-10

Inventor: NYHART ELDON H [US]


Application No.: US20020068092A1  Published: 06/Jun/2002

Title: BIOADHESIVE NANOPARTICULATE COMPOSITIONS HAVING CATIONIC SURFACE STABILIZERS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 09/414159   Filing Date: 08/Oct/1999

Abstract:Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surface stabilizers prevent aggregation of the nanoparticles and increase bioadhesion of the nanoparticles to biological substrates, such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, plant tissue, etc. The particles may consist of pharmacologically active compounds (e.g., drug compounds for human or veterinary use), agricultural chemicals (pesticides, herbicides, fertilizers, and the like), cosmetic agents, consumer products (coloring agents, flavors, or fragrances), or other materials which function by interacting with biological substrates. In addition, the invention relates to methods of preparing and using such bioadhesive nanoparticulate compositions.

Priority:

Inventor: BOSCH H WILLIAM [US]; COOPER EUGENE R [US]; MCGURK SIMON L [US]


Application No.: US20020068713A1  Published: 06/Jun/2002

Title: Genetic engineering of vascular grafts to resist disease

Applicant/Assignee: THE JOHNS HOPKINS UNIVERISTY

Application No.: 09/863803   Filing Date: 22/May/2001

Abstract:Disclosed are methods for treating a vascular graft that include introducing an effective amount of at least one nucleic acid encoding at least one agent that increases activated protein C (APC), expressing the agent in the cells

and increasing the APC sufficient to treat the blood vessel. Also provided are vascular grafts engineered to resist early and/or late graft failure.

Priority: US20000206162P Applic. Date: 2000-05-22

Inventor: RADE JEFFREY J [US]; KIM ANTONY Y [US]; SOHN RICHARD H [US]


Application No.: US20020068730A1  Published: 06/Jun/2002

Title: New amidino derivatives and their use as thormbin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 09/900903   Filing Date: 10/Jul/2001

Abstract:There is provided compounds of formula I, wherein Y and R1 have meanings given in the description, and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE20000002921 Applic. Date: 2000-08-16; SE20000002922 Applic. Date: 2000-08-16

Inventor: INGHARDT TORD [SE]; SVENSSON ARNE N [SE]


Application No.: US20020076354A1  Published: 20/Jun/2002

Title: Apparatus and methods for separating components of particulate suspension

Applicant/Assignee:

Application No.: 09/997895   Filing Date: 30/Nov/2001

Abstract:An optical bio-disc used in separating components of particulate suspension has separation, fluid metering, and fluid assay chambers. The separation chamber contains a particulate suspension having a fluid component and a particulate matter component. The fluid metering chamber communicates with the separation chamber by a first conduit that has an entry point at the separation chamber. The entry point is accessible to the fluid component when the bio-disc is rotated causing separation of the fluid component and the particulate matter component in the separation chamber. The fluid assay chamber communicates with the fluid metering chamber by a second conduit.

Priority: US20000250588P Applic. Date: 2000-12-01

Inventor: COHEN DAVID SAMUEL [US]


Application No.: US20020082220A1  Published: 27/Jun/2002

Title: Composition and method for the repair and regeneration of cartilage and other tissues

Applicant/Assignee:

Application No.: 09/896912   Filing Date: 29/Jun/2001

Abstract:The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.

Priority: US20000214717P Applic. Date: 2000-06-29

Inventor: HOEMANN CAROLINE D [CA]; BUSCHMANN MICHAEL D [CA]; MCKEE MARC D [CA]


Application No.: US20020084221A1  Published: 04/Jul/2002

Title: Method for precipitating red blood cells

Applicant/Assignee:

Application No.: 10/001966   Filing Date: 05/Dec/2001

Abstract:A method for washing collected blood uses an inert anticoagulant during collection of the blood. The inert anticoagulant does not interfere with agglomeration of the red blood cells so that gravity sedimentation separation is facilitated. The preferred inert anticoagulant is CPD.

Priority: US20000251047P Applic. Date: 2000-12-05

Inventor: VERKAART WESLEY H [US]; ELLSWORTH JAMES R [US]


Application No.: US20020086872A1  Published: 04/Jul/2002

Title: Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 10/012445   Filing Date: 12/Dec/2001

Abstract:Aminoguanidine and alkoxyguanidine compounds are described, including componds of the Formula VII: wherein X is O or NR9 and Het, R1, R7, R8, R12-R15 Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US2001-827292 Applic. Date: 2001-04-06; US2000-482540 Applic. Date: 2000-01-14; US1998-199167 Applic. Date: 1998-11-25; US19980079107P Applic. Date: 1998-03-23; US19970067324P Applic. Date: 1997-12-05; US19970066475P Applic. Date: 1997-11-26

Inventor: LU TIANBAO [US]; TOMCZUK BRUCE E [US]; MARKOTAN THOMAS P [US]; SIEDEM COLLEEN [US]


Application No.: US20020094346A1  Published: 18/Jul/2002

Title: METHOD AND COMPOSITIONS FOR IMPROVING DIGESTION AND ABSORPTION IN THE SMALL INTESTINE

Applicant/Assignee:

Application No.: 09/420046   Filing Date: 18/Oct/1999

Abstract:The present invention provides methods and compositions for slowing gastrointestinal transit and prolonging residence time to optimize presentation and absorption of ingested nutrients and/or pharmacologically active agents in the small intestine to prevent and/or reduce ineffectiveness thereof due to malabsorption. The present invention further provides methods and compositions for enhancing the bioavailability and therapeutic effectiveness of pharmacologically active agents.

Priority: US1999-359583 Applic. Date: 1999-07-22; US1997-832307 Applic. Date: 1997-04-03; US1995-442843 Applic. Date: 1995-05-17

Inventor: LIN M D HENRY C [US]


Application No.: US20020095218A1  Published: 18/Jul/2002

Title: Tissue repair fabric

Applicant/Assignee:

Application No.: 09/843172   Filing Date: 26/Apr/2001

Abstract:This invention is directed to prosthesis, which, when implanted into a mammalian patient, serves as a functioning replacement for a body part, or tissue structure, and will undergo controlled biodegradation occurring concomitantly with bioremodeling by the patient's living cells. The prosthesis is treated so that it is rendered non-antigenic so as not to elicit a significant humoral immune response. The prosthesis of this invention, in its various embodiments, thus has dual properties. First, it functions as a substitute body part, and second, it functions as bioremodeling template for the ingrowth of host cells.

Priority: WO1996US03336 Applic. Date: 1996-03-12; US1997-930756 Applic. Date: 1997-10-07

Inventor: CARR ROBERT M [US]; CONDON KIMBERLIE D [US]; TERMIN PAUL L [US]; YOUNG JANET HARDIN [US]


Application No.: US20020098176A1  Published: 25/Jul/2002

Title: Inhibition of tumor growth by a nematode anticoagulant protein

Applicant/Assignee:

Application No.: 09/905033   Filing Date: 12/Jul/2001

Abstract:The present invention relates to compositions and uses of nematode anticoagulant proteins (NAPs). More specifically, the invention relates to the use of rNAPc2 and rNAP5 for the inhibition of endothelial cell proliferation and the inhibition of angiogenesis. The invention also relates to methods for the treatment of angiogenesis-mediated diseases, such as cancer.

Priority: US20000217795P Applic. Date: 2000-07-12

Inventor: HEMBROUGH TODD A [US]; GREEN SHAWN J [US]


Application No.: US20020099000A1  Published: 25/Jul/2002

Title: COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF UNCONTROLLED FORMATION OF INTRAVASCULAR FIBRIN CLOTS

Applicant/Assignee: TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Application No.: 09/454666   Filing Date: 03/Dec/1999

Abstract:Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.

Priority: WO1999US10547 Applic. Date: 1999-05-12; US19980086262P Applic. Date: 1998-05-21

Inventor: MUZYKANTOV VLADIMIR R [US]; HIGAZI ABD AL-ROOF [US]; MURCIANO JUAN CARLOS [US]; CINES DOUGLAS [US]


Application No.: US20020099005A1  Published: 25/Jul/2002

Title: Mucin comprising vehicle for the transport of biologically-active agents

Applicant/Assignee:

Application No.: 09/767462   Filing Date: 23/Jan/2001

Abstract:In the present invention we describe a vehicle for the transport of biologically active or therapeutic agents into organisms, such as human beings. The vehicle described in the present invention comprises mucin, wherein said mucin is present in a natural or modified form. The mucin component of the vehicle, as described in the present invention, serves to enhance the transport of biologically active agents, such as therapeutic agents into living organisms

to control and/or improve the delivery of biologically active agents to cells, tissues, organs or organelles

to increase the level of specificity in targeting particular cells or cells types

and/or, to enhance the activity of such therapeutic agents once they enter an organism. The vehicle described in the present invention is used to carry and deliver biologically active agents and can be used for biochemical, biomedical, therapeutic, clinical, or other applications in organisms and cells including, but not limited to, delivery of DNA, RNA, PNA, polynucleotides and proteins into cells, tissues or organisms

gene delivery applications

in vivo gene therapy, ex vivo gene therapy or in vitro gene therapy

customized therapeutics

vaccination of organisms

genetic vaccination of organisms

and, delivery of pharmaceutical products or biologically active chemical, biochemical or biological agents into cells and organisms.

Priority:

Inventor: SHUKLA ASHOK KUMAR [US]; SHUKLA MUKTA [US]; SHUKLA AMITA [US]


Application No.: US20020099299A1  Published: 25/Jul/2002

Title: Cuff for blood pressure monitor

Applicant/Assignee: OMRON CORPORATION

Application No.: 10/047994   Filing Date: 17/Jan/2002

Abstract:To provide a cuff for a blood pressure monitor having a curled elastic member which is easily attached to an arm, does not make the subject feel pain when attached, and exhibits a characteristic of excellent fitting. A curled elastic member 1A has one end portion 12 extending outward so as to enwind the other end portion 11 inward. Specifically, from the other end portion 11 to a position where the other end portion 11 is mutually opposite, the radius of curvature gently increases. From the mutually opposite portion to the one end portion 12, the radius of curvature largely increases.

Priority: JP20010013921 Applic. Date: 2001-01-23

Inventor: INAGAKI TAKASHI [JP]


Application No.: US20020103526A1  Published: 01/Aug/2002

Title: Protective coating for stent

Applicant/Assignee:

Application No.: 10/017341   Filing Date: 13/Dec/2001

Abstract:The following invention discloses a coating for a stent which protects the stent during handling and insertion of the stent into a body lumen, prevents movement of the stent on the catheter delivery system during insertion, and dissolves or degrades to allow stent deployment.

Priority: US20000255995P Applic. Date: 2000-12-15

Inventor: STEINKE TOM [US]


Application No.: US20020104808A1  Published: 08/Aug/2002

Title: Method and apparatus for producing platelet rich plasma and/or platelet concentrate

Applicant/Assignee:

Application No.: 10/106248   Filing Date: 27/Mar/2002

Abstract:Platelet rich plasma and/or platelet concentrate is prepared by placing whole blood in a first chamber of a sterile processing disposable having two chambers. The processing disposable is subjected to a first centrifugation to separate red blood cells, and the resulting platelet rich plasma supernatant is decanted to the second chamber. The processing disposable is subjected to a second centrifugation to concentrate platelets. A volume of the platelet poor plasma supernatant in the second chamber is removed, and the platelets are re-suspended in the remaining plasma. The second chamber may contain anticoagulant to preclude aggregation of the platelets.

Priority: US2000-582730 Applic. Date: 2000-06-30

Inventor: BLASETTI LOU [US]; KEVY SHERWIN V [US]


Application No.: US20020106805A1  Published: 08/Aug/2002

Title: Measurement of accelerated whole blood clotting time

Applicant/Assignee: PROPHYLAXIS LIMITED

Application No.: 09/907280   Filing Date: 17/Jul/2001

Abstract:Disclosed is The method of in vitro testing of the state of the blood coagulation system. The Accelerated Whole Blood Clotting Time (A. W. B. C. T.) reflects the degree of over or under activity of the coagulation system of the blood.

Priority: GB19990001504 Applic. Date: 1999-01-22; WO2000GB00170 Applic. Date: 2000-01-24

Inventor: GRAY CHARLES RICHARDSON WHITE [GB]


Application No.: US20020107290A1  Published: 08/Aug/2002

Title: Benzamidine derivative

Applicant/Assignee: AJINOMOTO CO., INC

Application No.: 10/073985   Filing Date: 14/Feb/2002

Abstract:Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.

Priority: JP19980159627 Applic. Date: 1998-06-08; JP19980159628 Applic. Date: 1998-06-08; WO1999JP03055 Applic. Date: 1999-06-08; US2000-731729 Applic. Date: 2000-12-08

Inventor: NAKAGAWA TADAKIYO [JP]; SAGI KAZUYUKI [JP]; YOSHIDA KAORU [JP]; FUKUDA YUMIKO [JP]; SHOJI MASATAKA [JP]; TAKEHANA SHUNJI [JP]; KAYAHARA TAKASHI [JP]; TAKAHARA AKIRA [JP]


Application No.: US20020107469A1  Published: 08/Aug/2002

Title: Apheresis methods and devices

Applicant/Assignee:

Application No.: 10/008857   Filing Date: 02/Nov/2001

Abstract:An apheresis method that includes drawing blood from a mammal, adding an amount of an agent effective in preventing coagulation, wherein the agent is an anticoagulant, extracting one or more constituent components from the blood, wherein an extracted blood and constituent component result therefrom, and diminishing the activity of said anticoagulant by introducing an antidote, wherein the amount of antidote introduced is coupled with the amount of anticoagulant added. The antidote is provided either to the processed blood prior to reintroduction to the donor or directly to the donor. The invention also includes an apheresis machine that includes an antidote delivery conduit, wherein the antidote delivery conduit delivers an amount of antidote that is coupled with an amount of anticoagulant delivered.

Priority: US20000245901P Applic. Date: 2000-11-03

Inventor: BOLAN CHARLES [US]; LEITMAN SUSAN F [US]; CULLIS HERB [US]


Application No.: US20020107473A1  Published: 08/Aug/2002

Title: APPARATUS FOR EMERGENCY TREATMENT OF PATIENTS EXPERIENCING A THROMBOTIC VASCULAR OCCLUSION

Applicant/Assignee: TRANSON, LLC

Application No.: 10/016773   Filing Date: 02/Nov/2001

Abstract:Acute care method and apparatus for treating a patient experiencing thrombotic vascular occlusion includes introducing a selected dose of an active agent proximate a vascular occlusion in the patient in order to lyse the vascular occlusion and radiating the vascular occlusion and active agent.

Priority: US1999-277359 Applic. Date: 1999-03-26

Inventor: BOND GEOFFREY [US]; PETERSON THOMAS M [US]


Application No.: US20020110486A1  Published: 15/Aug/2002

Title: Analyte test strip with two controls

Applicant/Assignee:

Application No.: 10/121636   Filing Date: 11/Apr/2002

Abstract:A fluidic medical diagnostic device permits measurement of analyte concentration or a property of a biological fluid, particularly the coagulation time of blood. The device has at one-end a sample port for introducing a sample and at the other end a bladder for drawing the sample to a measurement area. A channel carries the sample from the sample port to the measurement area, and a stop junction, between the measurement area and bladder, halts the sample flow. The desired measurement can be made by placing the device into a meter which measures a physical property of the sample-typically, optical transmittance-after it has interacted with a reagent in the measurement area.

Priority: US1999-333765 Applic. Date: 1999-06-15; US19980093421P Applic. Date: 1998-07-20

Inventor: SHARTLE ROBERT JUSTICE [US]; CHOW HERBERT [US]; HARTMANN CHRISTA [US]


Application No.: US20020110597A1  Published: 15/Aug/2002

Title: Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/075443   Filing Date: 15/Feb/2002

Abstract:Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.

Priority: US2000-666539 Applic. Date: 2000-09-21

Inventor: RYDE NIELS P [US]; RUDDY STEPHEN B [US]


Application No.: US20020110922A1  Published: 15/Aug/2002

Title: Vacuum loaded test strip and method of use

Applicant/Assignee:

Application No.: 10/121425   Filing Date: 11/Apr/2002

Abstract:A fluidic medical diagnostic device permits measurement of analyte concentration or a property of a biological fluid, particularly the coagulation time of blood. The device has at one end a sample port for introducing a sample and at the other end a bladder for drawing the sample to a measurement area. A channel carries the sample from the sample port to the measurement area, and a stop junction, between the measurement area and bladder, halts the sample flow. The desired measurement can be made by placing the device into a meter which measures a physical property of the sample-typically, optical transmittance-after it has interacted with a reagent in the measurement area.

Priority: US1999-333765 Applic. Date: 1999-06-15; US19980093421P Applic. Date: 1998-07-20

Inventor: SHARTLE ROBERT JUSTICE [US]; CHOW HERBERT [US]; HARTMANN CHRISTA [US]


Application No.: US20020111331A1  Published: 15/Aug/2002

Title: FGF-affinity chromatography

Applicant/Assignee: THE TEXAS A&M UNIVERSITY SYSTEM

Application No.: 09/990578   Filing Date: 21/Nov/2001

Abstract:The present invention relates to a method and apparatus for isolating anticoagulant heparin or heparan sulfate by binding the anticoagulant heparin or anticoagulant heparan sulfate onto an affinity matrix and separating the non-bound material from the bound material. The affinity matrix is made of a fibroblast growth factor immobilized on a support. The invention also relates to a method and composition for neutralizing anticoagulation catalyzed by heparin, a heparin mimic, or a heparin derivative, by contacting heparin, a heparin mimic, or a heparin derivative with a fibroblast growth factor.

Priority: US20000252225P Applic. Date: 2000-11-21; US20010277735P Applic. Date: 2001-03-21; US20010325613P Applic. Date: 2001-09-28; US20010325502P Applic. Date: 2001-09-28

Inventor: MCKEEHAN WALLACE L [US]; LUO YONGDE [US]


Application No.: US20020115118A1  Published: 22/Aug/2002

Title: Multi-functional reagent for erythrocytes

Applicant/Assignee: IMMUNOTECH IMMUNOTECH, S.A

Application No.: 09/951903   Filing Date: 14/Sep/2001

Abstract:A multifunctional reagent for erythrocytes containing an amount sufficient to produce the lysis of erythrocytes or the sphering of erythrocytes in such a way that they can be detected by a cytometer or an automatic counting device, of a carbamate or of an agent inducing the formation by the erythrocytes, from carbonate and from a nitrogenated heterocycle or ammonium ions, of a carbamate combined with the absorption of CO2 by said erythrocytes, process for lysing or sphering erythrocytes and preparation process for leucocytes.

Priority: FR20000011746 Applic. Date: 2000-09-14

Inventor: AGTHOVEN ANDRE VAN [FR]; DAZIANO JEAN-PIERRE [FR]; MAPLES JOHN ALLEN [US]


Application No.: US20020115127A1  Published: 22/Aug/2002

Title: In vitro methods for screening for blood coagulation disorders using metal ions

Applicant/Assignee: INSTRUMENTATION LABORATORY, S.P.A

Application No.: 10/050441   Filing Date: 16/Jan/2002

Abstract:In vitro methods for qualitative screening and/or quantitative determination of the functional activity of components of the Protein C anticoagulant pathway of blood coagulation are described. The methods entail measuring the conversion rate of a substrate by an enzyme, the activity of which is related to the Protein C anticoagulant activity, in a blood sample of a human comprising coagulation factors and said substrate, after at least partial activation of coagulation through the intrinsic, extrinsic or common pathway and triggering coagulation by adding calcium ions

and comparing said conversion rate with the conversion rate of a normal human blood sample determined in the same way. The methods include the addition of additional metal ions to the sample to enhance activity, sensitivity and resolution. Kits and reagents for use in the methods are also provided.

Priority: EP19980105043 Applic. Date: 1998-03-19; US1999-273413 Applic. Date: 1999-03-19

Inventor: ROSEN BERT STEFFEN [SE]; HALL CHRISTINA MARIA YVONNE [SE]


Application No.: US20020115222A1  Published: 22/Aug/2002

Title: Modified erythrocyte sedimentation rate

Applicant/Assignee:

Application No.: 09/915198   Filing Date: 25/Jul/2001

Abstract:Methods for enhancing the value of the traditional erythrocyte sedimentation rate (ESR) test are provided by including an ESR-modifying agent, such as a metal ion, in the sample. Results of the resulting modified ESR are correlated with the health status of the animal.

Priority: US20000221464P Applic. Date: 2000-07-26

Inventor: SPILLERT CHARLES R [US]; KHALIL MARCELLE [US]


Application No.: US20020115958A1  Published: 22/Aug/2002

Title: Manufacturing methods for an apparatus for the controllable modification of compound concentration in a tube

Applicant/Assignee: BIOSYNERGETICS, INC

Application No.: 10/045550   Filing Date: 26/Oct/2001

Abstract:Apparatus and methods for delivery of a drug or compound into a fluid flowing within a tube or catheter. In one embodiment a catheter includes an inner surface coated with a polymer matrix such as a hydrogel. The hydrogel includes captured within it a therapeutic agent. The method of capture may be by various means, including photolabile bonds between the therapeutic agent and the hydrogel. The therapeutic agent is released from the hydrogel by the application of energy to the hydrogel, such as by a laser emitting a wavelength which resonates and breaks the photolabile bond. The released therapeutic agent diffuses out of the hydrogel into the liquid flowing within a lumen of the catheter.

Priority: US2000-692857 Applic. Date: 2000-10-20; US19990161130P Applic. Date: 1999-10-22; US19990170051P Applic. Date: 1999-12-10

Inventor: NYHART ELDON H [US]


Application No.: US20020120333A1  Published: 29/Aug/2002

Title: Method for coating medical device surfaces

Applicant/Assignee:

Application No.: 10/054447   Filing Date: 22/Jan/2002

Abstract:A method for coating a medical device with a hydrophilic polymer is provided. One method of the present invention includes chemically binding under appropriate reaction conditions a hydrophilic polymer to a biomaterial surface. Another method of the present invention includes chemically binding under appropriate reaction conditions a hydrophilic polymer to a primer located on a biomaterial surface. Another method of the present invention includes chemically binding under appropriate reaction conditions a biomolecule to a hydrophilic polymer located on a biomaterial surface.

Priority: US20010265370P Applic. Date: 2001-01-31

Inventor: KEOGH JAMES R [US]; TRESCONY PAUL V [US]; VERHOEVEN MICHEL [NL]; KOULLICK EDOUARD [NL]


Application No.: US20020123141A1  Published: 05/Sep/2002

Title: Method of collecting placental stem cells

Applicant/Assignee: ANTHROGENESIS CORPORATION

Application No.: 10/004942   Filing Date: 05/Dec/2001

Abstract:A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.

Priority: US20000251900P Applic. Date: 2000-12-06

Inventor: HARIRI ROBERT J [US]


Application No.: US20020128585A1  Published: 12/Sep/2002

Title: Medical system, method and apparatus employing mems

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 10/031112   Filing Date: 14/Jan/2002

Abstract:A biological suspension processing system is disclosed that may include a suspension treatment device for treating one or more components of a biological suspension, a first fluid flow path for introducing a suspension into the treatment device and a second fluid flow path for withdrawing a constituent of the suspension from the device. At least on microelectromechanical (MEM) sensor communicates with one of the fluid flow paths for sensing a selected characteristic of the fluid therewith. The MEM sensor may be located elsewhere, such as on a container or bag and communicate with the interior for sensing a characteristic of the fluid contained therein. A wide variety of characteristics may be sensed, such as flow rate, pH, cell type, cell antigenicity, DNA, viral or bacterial presence, cholesterol, hematocrit, cell concentration, cell count, partial pressure, pathogen presence, or viscosity.

Priority: US20000216640P Applic. Date: 2000-07-07; WO2001US21188 Applic. Date: 2001-07-03

Inventor: CORK WILLIAM H [US]; ULMES JAMES J [US]; WEST RICHARD L [US]; LO YING-CHENG [US]; WEBER MARK C [US]; MIN KYUNGYOON [US]


Application No.: US20020128683A1  Published: 12/Sep/2002

Title: Method and apparatus for preparing fibrinogen adhesive from whole blood

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 10/072509   Filing Date: 05/Feb/2002

Abstract:A process and apparatus for one-step preparation of fibrinogen adhesive by polyethylene glycol-mediated precipitation from plasma are disclosed. The methods and apparatus of the invention permit preparation of autologous fibrinogen adhesive composition from the patient during surgery, and can be applied generally to provide such compositions. Also disclosed are an apparatus and method for application of sealant comprising this fibrinogen adhesive composition.

Priority: US1997-863883 Applic. Date: 1997-05-28; US1996-703148 Applic. Date: 1996-08-29; US1996-645464 Applic. Date: 1996-05-13; US1995-370793 Applic. Date: 1995-01-10; US1993-090587 Applic. Date: 1993-07-12; US1989-372443 Applic. Date: 1989-06-23

Inventor: EPSTEIN GORDON H [US]


Application No.: US20020132776A1  Published: 19/Sep/2002

Title: Inhibitors of transglutaminase

Applicant/Assignee: N-ZYME BIOTECH GMBH

Application No.: 10/004110   Filing Date: 02/Nov/2001

Abstract:The present invention relates to a chemical compound of the formula (I): in which R1 is: R2 is H, alkyl, which may optionally be substituted by halogen or N2, or NH2

m and o are 0 to 3 and n is 0 or 1

ap, bq and cr are amino acid chains and p, q and r denote the number of amino acids, where a and/or b and/or c may likewise comprise at least one side chain represented by (CH2)mYn(CH2)oC(Z)R2 where Y, Z, R2, m, n, and o have the same meanings as in formula (I), and p, q and r may be identical or different and are an integer from 0 to 1000

R3 and R4 are, independently of one another, H, alkyl, aryl, a heterocycle, an amino protective group or a carboxyl protective group

R5 and R6 are, independently of one another, alkyl which may comprise at least one heteroatom selected from N, O and S, aryl or a heterocycle

X is a methine group, a nitrogen or phosphorus atom

Y is an oxygen atom, sulfur atom or an NH group

and Z is an oxygen atom, sulfur atom or an NR7 group, where R7 is H, alkyl, aryl, a heterocycle, O-alkyl, O-aryl, O-heterocycle, NR2 or NHCONR2, where R is H, alkyl, aryl or a heterocycle, and to the use thereof as inhibitor of transglutaminases.

Priority: DE20001054687 Applic. Date: 2000-11-03

Inventor: FUCHSBAUER HANS-LOTHAR [DE]; PASTERNACK RALF [DE]; ZOTZEL JENS [DE]


Application No.: US20020137673A1  Published: 26/Sep/2002

Title: Factor VII glycoforms

Applicant/Assignee: NOVO NORDISK HEALTH CARE A/S

Application No.: 09/969357   Filing Date: 02/Oct/2001

Abstract:The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.

Priority: DK20000001456 Applic. Date: 2000-10-02; DK20010000262 Applic. Date: 2001-02-16; DK20010000430 Applic. Date: 2001-03-14; DK20010000751 Applic. Date: 2001-05-14; US20000238944P Applic. Date: 2000-10-10; US20010271581P Applic. Date: 2001-02-26; US20010276322P Applic. Date: 2001-03-16

Inventor: PINGEL HANS KURT [DK]; KLAUSEN NIELS KRISTIAN [DK]


Application No.: US20020138066A1  Published: 26/Sep/2002

Title: Multiple compartment bag with openable closure assembly

Applicant/Assignee: GAMBRO, INC

Application No.: 10/104766   Filing Date: 21/Mar/2002

Abstract:A container for pathogen inactivating and storing blood or blood components, which includes multiple sub-compartments fluidly interconnected by an openable closure assembly. Each sub-compartment may contain a component necessary for pathogen inactivation or blood storage. Upon opening the openable closure assembly, the sub-compartments become one compartment and the components contained within each sub-compartment may be mixed together to form a combined solution for pathogen inactivation and/or storage of blood or blood components.

Priority: US20010278318P Applic. Date: 2001-03-23

Inventor: MANICA KEITH [US]; HLAVINKA DENNIS J [US]; WOODS JEANNIE M [US]


Application No.: US20020142291A1  Published: 03/Oct/2002

Title: Positive detection lateral-flow apparatus and method for small and large analytes

Applicant/Assignee: A-FEM MEDICAL CORPORATION

Application No.: 09/835304   Filing Date: 13/Apr/2001

Abstract:Methods and devices for the detection and/or quantification of an analyte in a sample are provided. These are positive detection methods and devices, in that the more analyte is present in the sample, the stronger the signal that is provided. Devices of the invention include a mobilization zone including a mobile or mobilizable detectable analyte analog, a sample application area, primary and secondary capture areas each including an immobilized binding partner having a binding affinity for the analyte being tested for a detectable analyte analog. The mobilization zone, sample application area, primary and secondary capture area are in fluid continuous contact with each other. In these devices, the first immobilized binding partner has an equal or lower apparent affinity for the analyte than it has for the detectable analyte analog.

Methods of this invention involve introducing a sample (which is suspected of containing the analyte to be tested for) to a device such as those described herein, and permitting the sample to migrate from the application area to and through the first and secondary binding zones. A detectable tracer conjugate is also permitted to migrate through the device, usually slightly behind the sample so that any analyte in the sample contacts the first binding partner before the conjugate. Results of such methods are read based on the presence and/or intensity of the detectable signal given by conjugate that binds in the second capture area.

Priority: US20000197365P Applic. Date: 2000-04-14; US20000203696P Applic. Date: 2000-05-11

Inventor: BAUER JEFFREY S [US]; HYATT TIMOTHY P [US]; WANG HUIYING [US]


Application No.: US20020142968A1  Published: 03/Oct/2002

Title: Prodrugs of thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 10/074008   Filing Date: 14/Feb/2002

Abstract:There is provided compounds of formula I, R1O(O)C-CH2-(R)Cgl-Aze-Pab-R2 I wherein R1 and R2 have meanings given in the description, which are usefull as prodrugs of inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (eg thrombosis) or as anticoagulants.

Priority: GB19950026273 Applic. Date: 1995-12-21; SE19960000556 Applic. Date: 1996-02-15; US2000-708449 Applic. Date: 2000-11-09; US1999-353644 Applic. Date: 1999-07-15; US1997-776231 Applic. Date: 1997-01-31

Inventor: ANTONSSON THOMAS [SE]; GUSTAFSSON DAVID [SE]; HOFFMANN KURT-JURGEN [SE]; NYSTROM JAN-ERIK [SE]; SORENSEN HENRIK [SE]; SELLEN MIKAEL [SE]


Application No.: US20020143298A1  Published: 03/Oct/2002

Title: Blunt cannula and filter assembly and method of use with point-of-care testing cartridge

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 10/109300   Filing Date: 27/Mar/2002

Abstract:A kit includes a point-of-care testing cartridge and a blunt cannula assembly. The blunt cannula assembly includes a blunt cannula that has a filter therein for filtering cellular components from whole blood and enabling plasma to be delivered by the blunt cannula to the testing cartridge.

Priority: US20010280436P Applic. Date: 2001-03-30; US20010280401P Applic. Date: 2001-03-30

Inventor: MARSDEN STEWART [US]


Application No.: US20020147184A1  Published: 10/Oct/2002

Title: Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions

Applicant/Assignee: SCHERING CORPORATION

Application No.: 10/056680   Filing Date: 25/Jan/2002

Abstract:The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor

and (b) at least one blood modifier, which can be useful for treating vascular conditions and lowering plasma levels of sterols.

Priority: US20010324123P Applic. Date: 2001-09-21; US20010264396P Applic. Date: 2001-01-26; US20010264600P Applic. Date: 2001-01-26; US20010264275P Applic. Date: 2001-01-26

Inventor: KOSOGLOU TEDDY [US]; RESS RUDYARD J [US]; STRONY JOHN T [US]; VELTRI ENRICO P [US]


Application No.: US20020151471A1  Published: 17/Oct/2002

Title: Factor VII glycoforms

Applicant/Assignee:

Application No.: 09/969358   Filing Date: 02/Oct/2001

Abstract:The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.

Priority: DK20000001456 Applic. Date: 2000-10-02; DK20010000262 Applic. Date: 2001-02-16; DK20010000430 Applic. Date: 2001-03-14; DK20010000751 Applic. Date: 2001-05-14; US20000238944P Applic. Date: 2000-10-10; US20010271581P Applic. Date: 2001-02-26; US20010276322P Applic. Date: 2001-03-16

Inventor: PINGEL HANS KURT [DK]; KLAUSEN NIELS KRISTIAN [DK]


Application No.: US20020151866A1  Published: 17/Oct/2002

Title: Method and apparatus for intracellular delivery of an agent

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 09/833149   Filing Date: 11/Apr/2001

Abstract:A method and an apparatus for electropermeabilization-mediated intracellular delivery of an agent are provided.

Priority:

Inventor: LUNDKVIST ANDRE-JEAN S [US]; ALDRIDGE ELISA J [US]; BHAT VINAYAK D [US]; SLATER RENEE C [US]


Application No.: US20020151945A1  Published: 17/Oct/2002

Title: Indwelling heat exchange catheter and method of using same

Applicant/Assignee:

Application No.: 10/127209   Filing Date: 22/Apr/2002

Abstract:A catheter is adapt to exchange heat with a body fluid, such as blood, flowing in a body conduit, such as a blood vessel. The catheter includes a shaft with a heat exchange region disposed at its distal end. This region may include at least one balloon which is adapted to receive a remotely cooled heat exchange fluid preferably flowing in a direction counter to that of the body fluid. Embodiments including multiple balloons enhance the surface area of contact, and the mixing of both the heat exchange and the body fluid. The catheter car be positioned to produce hypothermia in a selective area of the body without cooling the entire body system. It is of particular advantage in brain surgeries where stroke, trauma or cryogenic tumors can best be addressed under hypothermic conditions.

Priority: US2000-546814 Applic. Date: 2000-04-11; US1998-063984 Applic. Date: 1998-04-21

Inventor: GOBIN YVES PIERRE [US]; EVANS SCOTT M [US]; JONES MIKE [US]; NODA WAYNE A [US]


Application No.: US20020160428A1  Published: 31/Oct/2002

Title: Quantitative non-instrumental immunoassay and device using coloured particles

Applicant/Assignee:

Application No.: 10/132989   Filing Date: 26/Apr/2002

Abstract:The present invention provides a reproducible method of analysis for determining the concentration of one or several analytes in a sample, a device for performing the method, use of the method to perform specific analysis and a kit for performing the method.

Priority: NO20010002150 Applic. Date: 2001-04-30

Inventor: SUNDREHAGEN ERLING [NO]


Application No.: US20020160495A1  Published: 31/Oct/2002

Title: Soluble ischemia activated protein

Applicant/Assignee: UNIVERSITY OF MEDICINE AND DENTISTRY

Application No.: 09/960631   Filing Date: 20/Sep/2001

Abstract:The present invention provides a novel gene, IAP, which encodes a soluble protein that is involved in the initiation of an inflammatory cytokine response and which may interact with the anti-inflammatory IL-13. The protein of the present invention may be involved as a central mediator in ischemia, reperfusion, asthma and other inflammation-induced pathological conditions. The invention relates to methods for using isolated polypeptides and polynucleotides, for detecting the early onset of chronic asthma, psoriasis, stroke, ischemia, reperfusion, leishmaniasis, helminthiasis, hypoxia, or other causes of renal, liver or heart failure in a mammal, where increased cytokine activity is known to play a role. The invention, further, relates to methods and compositions for detecting ischemia, specifically silent ischemia, by obtaining a test sample from a mammal, measuring the level of IAP mRNA or protein in the test sample, and determining if the level of IAP mRNA or protein measured in the test sample correlates with elevated levels indicative of an ischemia associated disease.

Priority: US20000233819P Applic. Date: 2000-09-20

Inventor: MIROCHNITCHENKO OLEG [US]; WEI JIANG [US]; INOUYE MASAYORI [US]


Application No.: US20020160510A1  Published: 31/Oct/2002

Title: Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells

Applicant/Assignee: ANTHROGENESIS CORPORATION

Application No.: 10/074976   Filing Date: 13/Feb/2002

Abstract:A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

Priority: US20010268560P Applic. Date: 2001-02-14

Inventor: HARIRI ROBERT J [US]


Application No.: US20020160523A1  Published: 31/Oct/2002

Title: Method for monitoring resting and activated platelets in unfixed blood samples

Applicant/Assignee: SURROMED, INC

Application No.: 09/957624   Filing Date: 20/Sep/2001

Abstract:The amount of platelet surface proteins in a sample may be measured by collecting a sample containing platelets into a collection tube containing a platelet stabilizing composition, labeling the platelet surface protein and detecting by cytometry.

Priority: US20000234065P Applic. Date: 2000-09-20

Inventor: WYANT TIMOTHY L [US]; RAJU PAUL A [US]; KANTOR AARON B [US]


Application No.: US20020161197A1  Published: 31/Oct/2002

Title: Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier

Applicant/Assignee: BIOPURE CORPORATION

Application No.: 09/795821   Filing Date: 28/Feb/2001

Abstract:Red blood cells are purified by defibrinating whole blood and then filtering the defibrinated whole blood, whereby at least a portion of a plasma component is separated from the red blood cells to form a suspension of red blood cells, thereby purifying the red blood cells. Whole blood is defibrinated by, for example, using a chemical coagulating agent or mechanical agitation. Separation of the plasma component from red blood cells can be completed by, for example, diafiltration. The suspension of red blood cells can then be employed to produce a hemoglobin-based oxygen carrier.

Priority:

Inventor: GAWRYL MARIA S [US]; HOUTCHENS ROBERT A [US]; LIGHT WILLIAM R [US]


Application No.: US20020169129A1  Published: 14/Nov/2002

Title: Method for improving the quality of life of patients by administration of erythropoietin (RhuEPO)

Applicant/Assignee:

Application No.: 10/133545   Filing Date: 26/Apr/2002

Abstract:A method for providing various benefits with the administration of different quantities of Erythropoietin. The method provides for enhancing the of quality of life by administration of Erythropoietin before a substantial increases in hemoglobin occurs. The improvement in quality of life is independent of the hemopoietic effect. In larger quantities the administration of RhuEPO leads to repair of vascular damage and leads to the redistribution of the iron trapped in storage organs, from where it cannot be used for red blood cell production, into the hemopoietic system leading to enhanced red blood cell production.

Priority: US2001-872630 Applic. Date: 2001-06-01; US1999-335076 Applic. Date: 1999-06-17; US1998-018815 Applic. Date: 1998-02-04; US19980091598P Applic. Date: 1998-07-02; US19990125253P Applic. Date: 1999-03-19; US20010287206P Applic. Date: 2001-04-28

Inventor: ZAHARIA VERONICA C [US]


Application No.: US20020169408A1  Published: 14/Nov/2002

Title: Systems and methods for preparing autologous fibrin glue

Applicant/Assignee: CASCADE MEDICAL ENTERPRISES LLC

Application No.: 10/053247   Filing Date: 15/Jan/2002

Abstract:The invention provides a system for preparing an autologous solid-fibrin web suitable for regenerating tissue in a living organism. The system includes a sealed primary container containing a separation medium and a low-density high-viscosity liquid. The separation medium is capable of separating red blood cells from plasma when the container contains blood and is centrifuged, and the primary container has a first pressure. The system further includes a sealed secondary container containing a calcium-coagulation activator. The secondary container has a second pressure that is less than the first pressure. The system also comprises a transfer device including a cannula having a first end and a second end. The first and second ends are capable of puncturing the sealed primary and secondary containers in order to provide fluid communication between the first and second containers.

The low-density high-viscosity liquid of the primary container is capable of blocking flow through the cannula upon entering therein.

Priority: IT1997MI01490 Applic. Date: 1997-06-24; US2000-446729 Applic. Date: 2000-03-03; WO1998IT00173 Applic. Date: 1998-06-24

Inventor: BERETTA ROBERTO [IT]; GRIPPI NICHOLAS A [US]


Application No.: US20020172958A1  Published: 21/Nov/2002

Title: Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries

Applicant/Assignee: AGY THERAPEUTICS, INC

Application No.: 10/001051   Filing Date: 31/Oct/2001

Abstract:The present invention identifies a gene whose gene product provides a protective effect against neurological disorders or neuronal injuries. Further, the invention provides methods for diagnosing or assessing an individual's susceptibility to a neuronal injury such as stroke. Also provided are therapeutic methods for treating patients, and methods for prophylactically treating individuals susceptible to various neurological disorders or neuronal injuries. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have suffered or are at risk to suffer such disorders or injuries.

Priority: US20000244946P Applic. Date: 2000-11-01

Inventor: GONZALEZ-ZULUETA MIRELLA [US]; SHAMLOO MEHRDAD [US]; MCFARLAND K C [US]; CHIN DANIEL [US]; WIELOCH TADEUSZ [SE]; MELCHER THORSTEN [US]


Application No.: US20020177563A1  Published: 28/Nov/2002

Title: Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C

Applicant/Assignee:

Application No.: 10/086943   Filing Date: 28/Feb/2002

Abstract:The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in the presence but not absence of APC:protein S, indicating GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer, globotriaosylceramide, lactosylceramide, and galactosylceramide in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. Thus, the present invention provides neutral glycolipids such as GlcCer and Gb3Cer, as anticoagulant cofactors that contribute to the antithrombotic activity of the protein C pathway.

The present invention has also determined that a deficiency of plasma GlcCer is a risk factor for thrombosis. Methods are provided to determine individuals at risk for thrombosis, methods of treatment as well as methods of screening for antithrombotic factors from neutral glycolipids.

Priority: US20010272103P Applic. Date: 2001-02-28; US20010278045P Applic. Date: 2001-03-22

Inventor: GRIFFIN JOHN H [US]; DEGUCHI HIROSHI [US]; FERNANDEZ JOSE [US]


Application No.: US20020182195A1  Published: 05/Dec/2002

Title: Universally applicable blood plasma

Applicant/Assignee: OCTAPHARMA AG

Application No.: 10/117327   Filing Date: 08/Apr/2002

Abstract:A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.

Priority: EP19970113466 Applic. Date: 1997-08-05

Inventor: MARGUERRE WOLFGANG [SE]; SVE TOR-EINAR [NO]


Application No.: US20020182725A1  Published: 05/Dec/2002

Title: NEW ANTIGEN PRESENTING CELLS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS CELLULAR VACCINES

Applicant/Assignee:

Application No.: 09/194053   Filing Date: 23/Nov/1998

Abstract:The invention relates to monocytes derived antigen presenting cells (MDAPCs) characterized in that they have the following properties: they present on their surface: antigen CD14 and CD64 with a mean intensity of about 5 to about 200

antigen (CD80 and CD86 with a mean intensity of about 20 to about 200

antigen CI)40 and mannose receptor with a mean intensity of 50 to 500

they are substantiallv devoid of the surface antigens CD1a and CD1c

they present a phagocytosis property

they have the property of stimulating the proliferation of allogenic lymphocytes.

Priority: EP19960401099 Applic. Date: 1996-05-21

Inventor: CHOKRI MOHAMED [FR]; BARTHOLEYNS JACQUES [FR]; ROMET-LEMONNE JEAN-LOUP [FR]


Application No.: US20020182744A1  Published: 05/Dec/2002

Title: Whole blood collection device

Applicant/Assignee: BIOSAFE MEDICAL TECHNOLOGIES, INC

Application No.: 10/131768   Filing Date: 24/Apr/2002

Abstract:A system for collecting a whole blood sample includes a fill port (32), a metering chamber (72), a gasket or seal (16) and a reservoir (74). The gasket or seal (16) is positioned to a fill position, and a sample of whole blood is received in the metering chamber (72) until the metering chamber (72) is full. Then the seal (16) is moved to a closed position, thereby moving blood from the metering chamber (72) to the reservoir (74) and also sealing the reservoir (74). The seal (16), metering chamber (72) and fill port (32) together define a passageway at least a portion of which is coated with an anticoagulant. A diluting liquid contained in the reservoir (74) is mixed with the whole blood to dilute and stabilize the whole blood in the reservoir (74) for later analysis of one or more selected blood components.

Priority: US1999-464757 Applic. Date: 1999-12-16

Inventor: TYRRELL STEVEN P [US]; GRZEDA BARBARA R [US]


Application No.: US20020183679A1  Published: 05/Dec/2002

Title: Placental blood collection line including a rinsing bag

Applicant/Assignee: MACO PHARMA MACOPHARMA

Application No.: 10/160756   Filing Date: 31/May/2002

Abstract:The invention relates to a placental blood collection line including a collection bag (1) in fluid communication with at least one collection needle (4, 5) via a first tube (2) associated with an inlet orifice (3) of the bag (1), said line further including a bag (6) containing a rinsing solution and which is connected to or is organized to be connected to said first tube (2) via a second tube (7). The invention also relates to a method of collecting placental 10 blood by using such a line.

Priority: FR20010007262 Applic. Date: 2001-06-01

Inventor: DEVERRE FREDERIC [FR]


Application No.: US20020188325A1  Published: 12/Dec/2002

Title: Method and system for nerve stimulation prior to and during a medical procedure

Applicant/Assignee: MEDTRONIC, INC

Application No.: 10/207725   Filing Date: 29/Jul/2002

Abstract:A method of performing a medical procedure, such as surgery, is provided. A nerve is stimulated in order to adjust the beating of the heart to a first condition, such as a stopped or slowed condition. The medical procedure is performed on the heart or another organ. The stimulation of the nerve is stopped in order to adjust the beating of the heart to a second condition, such as a beating condition. The heart itself may also be stimulated to a beating condition, such as by pacing. The stimulation of the nerve may be continued in order to allow the medical procedure to be continued. Systems and devices for performing the medical procedure are also provided.

Priority: US2000-670441 Applic. Date: 2000-09-26; US1999-433323 Applic. Date: 1999-11-03; US1998-070506 Applic. Date: 1998-04-30; US1996-640013 Applic. Date: 1996-04-30

Inventor: HILL MICHAEL R S [US]; JAHNS SCOTT E [US]; KEOGH JAMES R [US]


Application No.: US20020192192A1  Published: 19/Dec/2002

Title: Antigen presenting cells, a process for preparing the same and their use as cellular vaccines

Applicant/Assignee: I.D.M. IMMUNO-DESIGNED

Application No.: 10/195065   Filing Date: 15/Jul/2002

Abstract:The invention relates to monocytes derived antigen presenting cells (MD-APCs) characterized in that they have the following properties: they present on their surface: antigen CD14 and CD64 with a mean intensity of about 5 to about 200

antigen CD80 and CD86 with a mean intensity of about 20 to about 200

antigen CD40 and mannose receptor with a mean intensity of 50 to 500

they are substantially devoid of the surface antigens CD1a and CD1c

they present a phagocytosis property

and they have the property of stimulating the proliferation of allogenic lymphocytes.

Priority: EP19960401099 Applic. Date: 1996-05-21; US1998-194053 Applic. Date: 1998-11-23

Inventor: CHOKRI MOHAMED [FR]; BARTHOLEYNS JACQUES [FR]; ROMET-LEMONNE JEAN-LOUP [FR]


Application No.: US20030007893A1  Published: 09/Jan/2003

Title: Volume meter testing device

Applicant/Assignee: BAYER HEALTHCARE LLC

Application No.: 10/174833   Filing Date: 20/Jun/2002

Abstract:A test device adapted to test a concentration of an analyte in a fluid has a pickup area having a first volume for receiving the fluid. In fluid communication with the pickup area is a read area having a second volume, which is less than the first volume. Since the second volume is less than the first volume, fluid from the pickup area will flow into the read area only after the pickup area is full. The read area also contains a reagent that is adapted to indicate the concentration of the analyte in the fluid.

Priority: US20010303550P Applic. Date: 2001-07-09

Inventor: PURCELL D GLENN [US]


Application No.: US20030008819A1  Published: 09/Jan/2003

Title: Targeting endothelium for tissue-specific delivery of agents

Applicant/Assignee:

Application No.: 10/056230   Filing Date: 24/Jan/2002

Abstract:Mechanisms and routes by which molecules can be delivered into cells, particularly endothelial cells, through the action of caveolae, G domains and other plasma membrane domains and components, are described, as are delivery systems comprising antibodies to caveolar proteins or receptors and also agents conjugated to the antibody or ligand, which can be used to deliver agents to, into, and/or across the endothelium.

Priority: US2000-734490 Applic. Date: 2000-12-11; US1998-029459 Applic. Date: 1998-06-25; US19960018791P Applic. Date: 1996-05-31; US19960018301P Applic. Date: 1996-05-24; US19950003453P Applic. Date: 1995-09-08

Inventor: SCHNITZER JAN E [US]


Application No.: US20030018357A1  Published: 23/Jan/2003

Title: Wound closure system and methods

Applicant/Assignee: BIOINTERACTIONS, LTD

Application No.: 10/143495   Filing Date: 09/May/2002

Abstract:A wound closure system and methods utilizes a patient's own blood. The system preferably includes a chamber with a needle and a plunger for transferring and storing blood prior to surgery and the use of reversible anticoagulants. The chamber is pre-loaded with a reversible anticoagulant to prevent the blood from clotting during storage. When the surgery is complete, a counteracting agent is mixed with the withdrawn blood to counteract the reversible anticoagulant and allow the blood to clot. The clottable blood is then reintroduced into the patient to close a wound.

Priority: US20010289754P Applic. Date: 2001-05-09

Inventor: LUTHRA AJAY K [GB]; SANDHU SHIVPAL S [GB]; ONIS SIMON JON [GB]


Application No.: US20030021826A1  Published: 30/Jan/2003

Title: Non-thrombogenic semipermeable membrane and method for making same

Applicant/Assignee: HOSPAL INDUSTRIE

Application No.: 09/937558   Filing Date: 03/Jan/2002

Abstract:The invention concerns a non-thrombogenic semipermeable membrane comprising a support semipermeable membrane and an anticoagulant suitable for treating blood and plasma by extracorpreal circulation. The invention is characterized in that: the support membrane is made essentially of a polyacrylinitrile, bearing anionic groups or groups capable of being anionic, the surface of the support semipermeable membrane designed to be in contact with blood or plasma is coated successively with a cationic polymer and an anticoagulant. The invention also concern an exchanger for treating blood or plasma by extracorporeal circulation comprising two sections separated by a non-thrombogenic semipermeable, membrane and a method for making the exchanger.

Priority: FR20000001065 Applic. Date: 2000-01-27; WO2001FR00248 Applic. Date: 2001-01-26

Inventor: CROST THIERRY [FR]; RENAUX JEAN-LOUIS [FR]; THOMAS MICHEL [FR]


Application No.: US20030021842A1  Published: 30/Jan/2003

Title: Means for creating a mass having structural integrity

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 10/245639   Filing Date: 18/Sep/2002

Abstract:The present invention relates to a means for creating a mass having structural integrity, including a rapidly disintegratable tablet for administration with or without the use of water. The present invention has a wide variety of different uses and applications. One embodiment is a tablet intended for oral administration. The tablet comprises at least one active ingredient and a mixture of excipients. The excipients provide desired characteristics and physical properties and when the tablet is sintered or heated, excellent tablet binding characteristics are obtained. The tablet is intended primarily for oral administration and dissolves in the presence of water. Also disclosed is a process for the preparation of a rapidly disintegratable tablet for administration with or without the use of water. The process comprising dissolving at least one bulking agent and at least one structural agent in a suitable solvent, wherein the solvent provides high porosity upon drying

spray-drying or dispersing said dissolved mixture to obtain a bead or granulated product

dry blending at least one binding agent, and at least one active ingredient with the bead or granulated product to obtain a preformulation product or adding at least one active ingredient to the preformulation product dissolved or dispersed components before spray-drying or dispersing

compressing the preformulation product

and sintering or heating the preformulation product for a sufficient time and temperature to allow the binding agent to change status or melt and allow the binding agent to resolidify as the temperature is reduced to ambient temperature.

Priority: US2001-902751 Applic. Date: 2001-07-12; US1999-366686 Applic. Date: 1999-08-04

Inventor: LAGOVIYER YURY [US]; LEVINSON R SAUL [US]; STOTLER DENIS [US]; RILEY THOMAS C [US]


Application No.: US20030031594A1  Published: 13/Feb/2003

Title: Vacuum loaded test strip with stop junction and bypass channel

Applicant/Assignee:

Application No.: 10/264662   Filing Date: 03/Oct/2002

Abstract:A fluidic medical diagnostic device permits measurement of analyte concentration or a property of a biological fluid, particularly the coagulation time of blood. The device has at one end a sample port for introducing a sample and at the other end a bladder for drawing the sample to a measurement area. A channel carries the sample from the sample port to the measurement area, and a stop junction, between the measurement area and bladder, halts the sample flow. The desired measurement can be made by placing the device into a meter which measures a physical property of the sample-typically, optical transmittance-after it has interacted with a reagent in the measurement area.

Priority: US1999-333765 Applic. Date: 1999-06-15; US19980093421P Applic. Date: 1998-07-20

Inventor: SHARTLE ROBERT JUSTICE [US]; CHOW HERBERT [US]; HARTMANN CHRISTA [US]


Application No.: US20030031721A1  Published: 13/Feb/2003

Title: Micro- and nano-particulate drugs and methods of making thereof

Applicant/Assignee:

Application No.: 10/022799   Filing Date: 20/Dec/2001

Abstract:A micro and nano-particulate drug comprising a drug substance and a surfactant in which the drug and surfactant form a eutectic mixture. The matrix formed between the drug substance and the surfactant has a melting point less than the decomposition temperature of the drug substance and thus provides the advantages of reduced irritation due to the melting process without the prior art problem of decomposition of the drug substance. In one embodiment, crystals are formed while the mixture is cooled at room temperature under high shear conditions. In a second embodiment, a flowable material may be formed which also contains the drug and that may be incorporated into a pharmaceutical delivery system is also disclosed. Methods of preparing the micro and nano-particulate drug crystals and non-crystalline substance are also contemplated in the inventive subject matter.

Priority: US20010308567P Applic. Date: 2001-07-31

Inventor: BOGUE BEUFORD ARLIE [US]


Application No.: US20030032179A1  Published: 13/Feb/2003

Title: Post-partum mammalian placenta, its use and placental stem cells therefrom

Applicant/Assignee:

Application No.: 10/076180   Filing Date: 13/Feb/2002

Abstract:The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.

Priority: US2001-004942 Applic. Date: 2001-12-05; US20000251900P Applic. Date: 2000-12-06; US20010268560P Applic. Date: 2001-02-14

Inventor: HARIRI ROBERT J [US]


Application No.: US20030032919A1  Published: 13/Feb/2003

Title: Device for treatment of venous congestion

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: 10/273215   Filing Date: 16/Oct/2002

Abstract:A device for treatment of venous congestion provides for subcutaneous introduction of anticoagulant through an incision positioned within a collection shell for withdrawal of an effused material. A widened delivery tip provides dispersal of the anticoagulant and may be agitated to disrupt clot formation.

Priority: US2000-745298 Applic. Date: 2000-12-20; US19990171351P Applic. Date: 1999-12-22

Inventor: HARTIG GREGORY K [US]; CONNOR NADINE P [US]; CONFORTI MICHAEL L [US]


Application No.: US20030045586A1  Published: 06/Mar/2003

Title: Use of amines

Applicant/Assignee: AMERSHAM HEALTH AS

Application No.: 10/242082   Filing Date: 12/Sep/2002

Abstract:This application relates to the use of certain amines of formula (I) for combatting and preventing systemic and local complement activation, and in particular to the use of meglumine and derivatives and optionally salts thereof in combatting and preventing said activation. The amines are also of use in combatting activation of the kinin/kallikrein system or blood coagulation system.

This application relates to the use of certain amines of formula (I) for combatting and preventing systemic and local complement activation, and in particular to the use of meglumine and derivatives and optionally salts thereof in combatting and preventing said activation. The amines are also of use in combatting activation of the kinin/kallikrein system or blood coagulation system

Priority: GB20000007239 Applic. Date: 2000-03-24; WO2001NO00123 Applic. Date: 2001-03-22

Inventor: JUELSRUD ANNE [NO]; BJERKE GUNN RAGNHILD HOIGAARD [NO]


Application No.: US20030054037A1  Published: 20/Mar/2003

Title: Pharmaceutical compositions of adsorbates of amorphous drug

Applicant/Assignee:

Application No.: 10/173987   Filing Date: 17/Jun/2002

Abstract:Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer.

Priority: US20010300260P Applic. Date: 2001-06-22

Inventor: BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; SHANKER RAVI M [US]; SMITHEY DANIEL T [US]; TADDAY RALPH [US]


Application No.: US20030055396A1  Published: 20/Mar/2003

Title: Extraction device with tubes having different cross-sections

Applicant/Assignee: MACOPHARMA

Application No.: 10/291977   Filing Date: 12/Nov/2002

Abstract:An extraction device for a biological fluid with an additive solution in which it is desirable for the additive solution to be present in a particular volume proportion to the biological fluid. The volume proportion of the additive solution is determined by the ratio of cross sections of two tubes, one which supplies the biological fluid to a collecting bag and a second which supplies the additive solution to a collecting bag. The tubes are periodically constricted in constriction areas by a pump. The tubes are configured so that the additive solution and the biological fluid only mix downstream of the constriction areas, thereby reducing the risk of supplying the additive solution to the source of the biological fluid. In an exemplary embodiment the biological fluid is blood collected from a patient or donor and the additive solution is an anticoagulant and/or preservation solution.

Priority: FR20000006081 Applic. Date: 2000-05-12; WO2001FR01329 Applic. Date: 2001-04-27

Inventor: GOUDALIEZ FRANCIS [FR]; VERPOORT THIERRY [FR]


Application No.: US20030055479A1  Published: 20/Mar/2003

Title: Encapsulated stent preform

Applicant/Assignee: IOWA-INDIA INVESTMENTS COMPANY, LIMITED VASCULAR CONCEPTS HOLDINGS LIMITED

Application No.: 10/286805   Filing Date: 04/Nov/2002

Abstract:The invention relates to a stent preform for implantation in a body lumen. The stent preform includes an elongated metal core having first and second core ends, a contact surface, and a solid cross-section, and a hollow outer sheath made of a biocompatible polymer and having first and second sheath ends, caps disposed on the sheath ends, and an interior surface. The outer sheath surrounds and contacts the contact surface of the core to prevent the core from directly contacting the body lumen. In another embodiment, the biocompatible polymer of the outer sheath is formed of a heat-shrinkable polymer material, and the elongated core is formed of a shape-memory alloy. In another embodiment, the outer sheath is formed from a polymer tape.

Priority: US1999-440926 Applic. Date: 1999-11-16

Inventor: JAYARAMAN SWAMINATHAN [US]


Application No.: US20030064414A1  Published: 03/Apr/2003

Title: Rapid assessment of coagulation activity in whole blood

Applicant/Assignee:

Application No.: 10/107409   Filing Date: 28/Mar/2002

Abstract:The present invention is directed to methods to rapidly assess the overall coagulant properties of a patient's blood sample by inhibiting the activation of the intrinsic contact activation pathway of coagulation and activating the extrinsic pathway of coagulation. When the sample is whole blood, the resulting clotting time represents the overall coagulant activity of the plasma and cellular components of the blood, which is indicative of existing or impending pathology arising from abnormal coagulability. The invention also provides a method for measuring the risk of a patient for a thrombotic event and for monitoring the effectiveness of procoagulant/anticoagulant therapy. A blood collection apparatus suitable for use in for performing the methods of the invention is also provided.

Priority: US20010279737P Applic. Date: 2001-03-30

Inventor: BENECKY MICHAEL J [US]; MOSKOWITZ KEITH A [US]; POST DIANE R [US]


Application No.: US20030064503A1  Published: 03/Apr/2003

Title: Device

Applicant/Assignee:

Application No.: 09/853188   Filing Date: 09/May/2001

Abstract:A device for preparing an undifferentiated cell, the device comprises means for contacting a more committed cell with an agent that causes the more committed cell to retrodifferentiate into an undifferentiated cell.

Priority: GB20010001315 Applic. Date: 2001-01-18; GB20010007093 Applic. Date: 2001-03-21; US2000-568254 Applic. Date: 2000-05-10; US20010271497P Applic. Date: 2001-02-26

Inventor: ABULJADAYEL ILHAM MOHAMED SALE [GB]


Application No.: US20030069635A1  Published: 10/Apr/2003

Title: Prosthetic heart valve

Applicant/Assignee:

Application No.: 10/157732   Filing Date: 28/May/2002

Abstract:A novel durable prosthetic heart valve compatible with implantation in a human natural heart valve annulus. The prosthetic heart valve comprises a tubular heart valve which in function resembles a human heart valve, but which is formed of either synthetic or biologic material. The present valve is capable of structurally complying with annular deformation during each heartbeat. Valve embodiments comprise aortic, mitral, tricuspid, and pulmonic implantable valves. Valves can be selectively impregnated with a group of biologically active substances consisting of antibiotics, bactericidal agents, anticoagulant medications, endothelial cells, genetic material, growth factors or other hormonal or biologically active substances. Use of non-thrombogenic biocompatible materials in the valve which mimics operation of a natural heart valve essentially eliminates the need for long term administration of anticoagulants. The current configuration of the valve allows for either percutaneous placement or placement through open techniques.

Priority: US20010294042P Applic. Date: 2001-05-29

Inventor: CARTLEDGE RICHARD G [US]; LEE LEONARD [US]


Application No.: US20030072783A1  Published: 17/Apr/2003

Title: Localized use of nitric oxide-adducts to prevent internal tissue damage

Applicant/Assignee:

Application No.: 10/253977   Filing Date: 25/Sep/2002

Abstract:A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device

can be coated per se on a surface of the medical device

can be directly or indirectly bound to reactive sites on a surface of the medical device

or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.

Priority: US2000-621610 Applic. Date: 2000-07-21; US1999-433550 Applic. Date: 1999-11-04; US1995-460465 Applic. Date: 1995-06-02; US1993-123331 Applic. Date: 1993-09-17

Inventor: STAMLER JONATHAN [US]; LOSCALZO JOSEPH [US]; FOLTS JOHN D [US]


Application No.: US20030073069A1  Published: 17/Apr/2003

Title: Drug rescue by redesign of ADMET/PK properties

Applicant/Assignee:

Application No.: 09/978671   Filing Date: 15/Oct/2001

Abstract:Otherwise efficacious drugs having an ADMET/PK (absorption, distribution, metabolism, elimination, toxicity, i.e., pharmacokinetic) problem are redesigned or "rescued" by applying computational techniques that identify related chemical structures that preserve the initial drug's effectiveness but improve its ADMET/PK properties. The otherwise efficacious drug may be subjected to a suite of computational tools that identify sites responsible for problematic ADMET/PK properties and/or identify related compounds that have improved ADMET/PK properties.

Priority:

Inventor: SELICK HAROLD E [US]; KORZEKWA KENNETH R [US]; MACKAREHTSCHIAN KATRIN [US]


Application No.: US20030073609A1  Published: 17/Apr/2003

Title: Enhanced pharmacokinetic profile of intradermally delivered substances

Applicant/Assignee:

Application No.: 09/897801   Filing Date: 29/Jun/2001

Abstract:A method for administration of a substance into the dermis of a mammal is disclosed. The method involves administration into the dermis by injection which results in improved systemic absorption relative to that obtained upon subcutaneous administration of the substance. The substance administered may be a growth hormone, a low molecular weight heparin or a dopamine receptor agonist.

Priority:

Inventor: PINKERTON THOMAS C [US]


Application No.: US20030073833A1  Published: 17/Apr/2003

Title: Aminopyridyl-substituted phenyl acetamides as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 10/262871   Filing Date: 03/Oct/2002

Abstract:Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof

wherein R3-R6, R11, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US2001-971000 Applic. Date: 2001-10-05; US20000238132P Applic. Date: 2000-10-06

Inventor: PAN WENXI [US]; LU TIANBAO [US]; MARKOTAN THOMAS P [US]; TOMCZUK BRUCE E [US]


Application No.: US20030077264A1  Published: 24/Apr/2003

Title: Antimicrobial blood treatment using allicin and related compounds

Applicant/Assignee:

Application No.: 10/247262   Filing Date: 18/Sep/2002

Abstract:Methods and compositions prolonging the storage life and/or increasing the safety of a blood product, such as whole blood, red blood cells, white blood cells, platelets, serum and aqueous additive solutions for storage of such blood products are provided. Storage solutions of this invention comprise a composition selected from the group consisting of garlic extract, allicin, other microorganism-growth-inhibiting compounds derived from garlic, and analogs and derivatives of allicin and said other compounds, in an amount effective to inhibit growth of at least one selected microorganism which is a bacterium, virus, fungus or parasite. The storage additive solutions of this invention can increase platelet storage life by at least about 20%, preferably at least about 40%.

Priority: US20010323669P Applic. Date: 2001-09-20

Inventor: GOODRICH LAURA L [US]


Application No.: US20030078517A1  Published: 24/Apr/2003

Title: In vivo delivery methods and compositions

Applicant/Assignee:

Application No.: 09/839785   Filing Date: 20/Apr/2001

Abstract:Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

Priority: US2001-819924 Applic. Date: 2001-03-28; US2000-727950 Applic. Date: 2000-12-01; US2000-628401 Applic. Date: 2000-08-01; US2000-501856 Applic. Date: 2000-02-10; US1999-439795 Applic. Date: 1999-11-12; US1997-919906 Applic. Date: 1997-08-28

Inventor: KENSEY KENNETH [US]


Application No.: US20030078559A1  Published: 24/Apr/2003

Title: Collection bag with insert

Applicant/Assignee:

Application No.: 10/239624   Filing Date: 23/Sep/2002

Abstract:The invention concerns a collection bag (1) for a fluid, in particular whole blood, comprising an outer envelope (2) formed with two sheets of flexible plastic material (3, 4) assembled on their periphery so as to define an inner volume, said outer envelope (2) being provided with at least an orifice designed to enable the fluid to be supplied and dispensed, wherein at least one insert (15) is fixed in the internal volume of the bag (1) to define at least two sub-volumes (16, 17) in the internal volume, said insert (15) being arranged to form a partial obstruction to the flow of the fluid inside said internal volume leaving at least a passage for the fluid (19, 20, 22, 24) between said two sub-volumes (16, 17).

Priority: FR20000003802 Applic. Date: 2000-03-24

Inventor: GOUDALIEZ FRANCIS [FR]; VERPOORT THIERRY [FR]


Application No.: US20030082238A1  Published: 01/May/2003

Title: Matrices for drug delivery and methods for making and using the same

Applicant/Assignee:

Application No.: 10/077475   Filing Date: 15/Feb/2002

Abstract:In one aspect, biocompatible matrices such as sol-gels encapsulating a reaction center may be administered to a subject for conversion of prodrugs into biologically active agents. In certain embodiments, the biocompatible matrices of the present invention are sol-gels. In one embodiment, the enzyme L-amino acid decarboxylase is encapsulated and implanted in the brain to convert L-dopa to dopamine for treatment of Parkinson's disease.

Priority: US19990119828P Applic. Date: 1999-02-12; US2000-503438 Applic. Date: 2000-02-14

Inventor: BABICH JOHN W [US]; ZUBIETA JON [US]; BONAVIA GRANT [US]


Application No.: US20030083698A1  Published: 01/May/2003

Title: Thrombolysis and chronic anticoagulation therapy

Applicant/Assignee: ADVANCED BIONICS CORPORATION

Application No.: 10/285803   Filing Date: 01/Nov/2002

Abstract:Thrombolytic and/or anticoagulation therapy of the present invention includes implantation of the discharge portion(s) of a catheter and, optionally, one or more electrodes on a lead, adjacent tissue(s) to be stimulated. Stimulation pulses, i.e., drug infusion pulses and optional electrical pulses, are supplied by a stimulator implanted remotely, and through the catheter or lead, which is tunneled subcutaneously between the stimulator and stimulation site. Stimulation sites include the coronary arteries, coronary veins, cerebral arteries, other blood vessels, chambers of the heart, mesenteric vessels, deep vessels of the leg, and other locations. Disclosed treatments include drugs used for chronic treatment and/or prevention of thromboembolic disease, for acute treatment of thromboembolic disease, for acute treatment of thrombosis, and combinations of these.

The invention reduces or eliminates the incidence of thromboembolic disease and related morbidities, improve symptoms resulting from thromboembolic disease, and improve patient quality of life.

Priority: US20010340076P Applic. Date: 2001-11-01

Inventor: WHITEHURST TODD K [US]; MCCLURE KELLY H [US]; THACKER JAMES R [US]


Application No.: US20030087878A1  Published: 08/May/2003

Title: Methods and formulations for minimizing spasticity in blood vessel grafts

Applicant/Assignee: EMORY UNIVERSITY

Application No.: 10/285219   Filing Date: 31/Oct/2002

Abstract:The present invention relates to me methods for minimizing spasticity in blood vessels during transplantation and more particularly for minimizing spasticity in arterial transplants, for both ex-vivo and in-vivo procedures. The invention also relates to formulations, which can be used in these methods.

Priority: US20010335642P Applic. Date: 2001-10-31; US20010336090P Applic. Date: 2001-10-31

Inventor: VINTEN-JOHANSEN JAKOB [US]; VELEZ DANIEL A [US]


Application No.: US20030087921A1  Published: 08/May/2003

Title: Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 10/241513   Filing Date: 12/Sep/2002

Abstract:Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR9 and Het, R1, R7, R8, R12-R15 Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US2001-012445 Applic. Date: 2001-12-12; US2001-827292 Applic. Date: 2001-04-06; US2000-482540 Applic. Date: 2000-01-14; US1998-199167 Applic. Date: 1998-11-25; US19980079107P Applic. Date: 1998-03-23; US19970067324P Applic. Date: 1997-12-05; US19970066475P Applic. Date: 1997-11-26

Inventor: LU TIANBAO [US]; TOMCZUK BRUCE E [US]; MARKOTAN THOMAS P [US]; SIEDEM COLLEEN [US]


Application No.: US20030093058A1  Published: 15/May/2003

Title: Cannula assembly

Applicant/Assignee:

Application No.: 10/258826   Filing Date: 25/Oct/2002

Abstract:A double cannula assembly for medical or veterinary use includes a first cannula (10) for insertion into a blood vessel in a conventional manner. This first cannula is an outer cannula and a second or inner cannula (12) is subsequently inserted through said first cannula to extend beyond the distal tip of the outer cannula. The inner cannula and outer cannulae are formed to prevent blood entering between the engaging surfaces.

Priority: SG20000002344 Applic. Date: 2000-04-28; WO2001SG00068 Applic. Date: 2001-04-19

Inventor: SIANG TEO RICHARD KENG [SG]


Application No.: US20030093116A1  Published: 15/May/2003

Title: Clotting cascade initiating apparatus and methods of use and methods of closing wounds

Applicant/Assignee: CLOSYS CORPORATION

Application No.: 10/291278   Filing Date: 08/Nov/2002

Abstract:Wound closure methods and apparatus are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparatus for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

Priority: US2000-732423 Applic. Date: 2000-12-07; US1998-212080 Applic. Date: 1998-12-15; US19970069834P Applic. Date: 1997-12-16

Inventor: NOWAKOWSKI KAROL L [US]


Application No.: US20030097086A1  Published: 22/May/2003

Title: Wearable continuous renal replacement therapy device

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 10/085349   Filing Date: 16/Nov/2001

Abstract:A continuous renal replacement therapy device adapted to be worn on a portion of the body of a patient, including: a plurality of contoured dialyzers, which are connected in series and utilize dialysate to remove impurities from the blood of the patient

and a plurality of contoured sorbent device, which are connected in series and are for regenerating the spent dialysate.

Priority:

Inventor: GURA VICTOR [US]


Application No.: US20030097087A1  Published: 22/May/2003

Title: Wearable ultrafiltration device

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 10/251937   Filing Date: 19/Sep/2002

Abstract:An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Priority: US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]


Application No.: US20030099469A1  Published: 29/May/2003

Title: Convection blood warming system with disposable flattened tube envelope incorporating paperboard needle for inserting envelope between heating plates and employing active and passive insulation of outlet flow path to provide normothermic fluid at zero to 600 milliliters per minute

Applicant/Assignee:

Application No.: 10/292749   Filing Date: 12/Nov/2002

Abstract:A thin, flat paperboard inserter or "needle" which is longer than the blood warmer heating plates is attached to the edge of the flattened tube envelope to enter the very narrow gap between the heating plates. The inserter is fed between the heating plates and advanced to emerge from the other end of the blood warmer where it is grasped and used to pull the envelope into operational position. A high air flow hydrophobic vent with check valve to prevent reverse flow is incorporated into the drip chamber to allow automatic priming and venting of air bubbles. A conductively heated and externally insulated drip chamber holder and a patient intravenous line that is passively insulated by a small annular air space extruded as part of the tube preserve heat in the warmed fluid, improving low flow rate performance.

A reusable external heater may optionally be applied to the distal portion of the patient line to provide normothermic fluid to the patient down to essentially zero flow rate.

Priority: US20010335862P Applic. Date: 2001-11-23

Inventor: BAKKE ALLAN P [US]


Application No.: US20030100885A1  Published: 29/May/2003

Title: Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption

Applicant/Assignee:

Application No.: 10/028988   Filing Date: 28/Dec/2001

Abstract:Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption.

Priority: US2001-893746 Applic. Date: 2001-06-29; US2001-835243 Applic. Date: 2001-04-13; US1999-417671 Applic. Date: 1999-10-14; US20010301531P Applic. Date: 2001-06-29

Inventor: PETTIS RONALD J [US]; HARVEY NOEL G [US]; ALCHAS PAUL G [US]; DOWN JAMES A [US]


Application No.: US20030100886A1  Published: 29/May/2003

Title: Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 09/997855   Filing Date: 29/Nov/2001

Abstract:A mechanical dilatation and medicament delivery device for enlarging a flow passage of a vessel by dilating and delivering a therapeutic agent or medicament to an obstruction in the vessel. The present invention comprises a substantially cylindrically shaped expansion member and includes a means engaged to the expansion member for altering the distance between the proximal end and the distal end of the expansion member thereby transforming the expansion member between a diametrically contracted configuration to diametrically expanded configuration. A therapeutic agent or medicament is coated on either the expansion member, or incorporated into a substrate coated on the expansion member.

The present method comprises the steps of advancing the coated expansion member to the obstruction in a vessel and applying opposed forces on said expansion member in an axial direction to move the expansion member to an expanded configuration wherein the expansion member dilates the obstruction and the expansion member either passively or actively delivers a therapeutic agent or medicament to the obstruction.

Priority:

Inventor: SEGAL JEROME [US]; SCOTT NEAL [US]


Application No.: US20030100887A1  Published: 29/May/2003

Title: Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 10/135709   Filing Date: 30/Apr/2002

Abstract:A mechanical dilatation and medicament delivery device for enlarging a flow passage of a vessel by dilating and delivering a liposome or micelle-encapsulated therapeutic agent or medicament to an obstruction in the vessel. The present invention comprises a substantially cylindrically shaped expansion member and includes a means engaged to the expansion member for altering the distance between the proximal end and the distal end of the expansion member thereby transforming the expansion member between a diametrically contracted configuration to diametrically expanded configuration. A liposome or micelle-encapsulated therapeutic agent or medicament is coated on either the expansion member, or incorporated into a substrate coated on the expansion member.

The present method comprises the steps of advancing the coated expansion member to the obstruction in a vessel and applying opposed forces on said expansion member in an axial direction to move the expansion member to an expanded configuration wherein the expansion member dilates the obstruction and the expansion member either passively or actively delivers a liposome or micelle-encapsulated therapeutic agent or medicament to the obstruction.

Priority: US2001-997855 Applic. Date: 2001-11-29

Inventor: SCOTT NEAL [US]; SEGAL JEROME [US]


Application No.: US20030104063A1  Published: 05/Jun/2003

Title: Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers

Applicant/Assignee:

Application No.: 10/175640   Filing Date: 19/Jun/2002

Abstract:A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.

Priority: US20010300261P Applic. Date: 2001-06-22

Inventor: BABCOCK WALTER C [US]; CURATOLO WILLIAM J [US]; FRIESEN DWAYNE T [US]; KETNER RODNEY J [US]; LO JULIAN B [US]; NIGHTINGALE JAMES A S [US]; SHANKER RAVI M [US]; WEST JAMES B [US]


Application No.: US20030104493A1  Published: 05/Jun/2003

Title: Method for predicting an increased likelihood of antiphospholipid syndrome in a patient

Applicant/Assignee:

Application No.: 10/185186   Filing Date: 28/Jun/2002

Abstract:A method for predicting that an individual has antiphospholipid syndrome or an increased likelihood of having antiphospholipid syndrome, includes: a) providing a test sample from an individual

b) combining the test sample with phospholipids

c) directing a light beam at the test sample and monitoring light scattering or transmittance over time so as to provide a time-dependent measurement profile

d) determining if a value or a slope at or over a particular time in the time-dependent measurement profile is beyond a corresponding predetermined value or slope threshold

and if the value or slope in the time-dependent measurement profile is beyond the predetermined threshold, then determining that the individual has antiphospholipid syndrome or an increased risk of antiphospholipid syndrome. The phospholipids can be provided as part of a coagulation reagent, or as part of a reagent where coagulation is not activated. Confirmatory assays for particular antibodies to phospholipid binding proteins can be performed.

Priority: US20010302261P Applic. Date: 2001-06-29; US20010318755P Applic. Date: 2001-09-11

Inventor: ORTEL THOMAS L [US]; SU ZUOWEI [US]; BRAUN PAUL J [US]; TEJIDOR LILIANA [US]


Application No.: US20030104508A1  Published: 05/Jun/2003

Title: Hematological assay and reagent

Applicant/Assignee: PENTAPHARM AG

Application No.: 10/168473   Filing Date: 29/Aug/2002

Abstract:A hematological assay is described in which the blood coagulation potential of a body fluid is assessed by reacting a sample of the body fluid with an amount of an activator reagent comprising: (a) a predetermined amount of factor Xa or a hematologically equivalent mutant thereof, and (b) a predetermined amount of factor Va, a hematologically equivalent mutant thereof or an enzyme activating endogenous factor V, (c) (optionally) phospholipids. The reagent may be dry (e.g. lyophilised) or in an aqueous solution preferably buffered to a pH from 6 to 10 (preferably 7 to 8), if desired incubating, if necessary inducing coagulation by the addition of one or more coagulation accelerants such as calcium chloride, and establishing a value indicative of the coagulation potential, e.g. by measuring the time to clotting on an optical coagulometer or through use of a chromogenic substrate.

It is preferred to use at (b) factor V activator from purified Russell's Viper venom (RVV-V). An activator reagent is also described containing the components mentioned above preferably in one or more buffer solutions or in dried, e.g. lyophilised form.

Priority: WO1999EP09952 Applic. Date: 1999-12-15; WO2000EP12753 Applic. Date: 2000-12-14

Inventor: GEMPELER PATRIZIA MARIA [CH]; CALATZIS ANDREAS [DE]


Application No.: US20030105069A1  Published: 05/Jun/2003

Title: Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy

Applicant/Assignee: MIRAVANT PHARMACEUTICALS, INC

Application No.: 10/159005   Filing Date: 31/May/2002

Abstract:Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease.

Priority: US20010295345P Applic. Date: 2001-05-31

Inventor: ROBINSON BYRON C [US]; LEITCH IAN M [US]; GREENE STEPHANIE [US]; RYCHNOVSKY STEVE [US]


Application No.: US20030108588A1  Published: 12/Jun/2003

Title: Stent coated with a sustained-release drug delivery and method for use thereof

Applicant/Assignee: PSIVIDA INC

Application No.: 10/245840   Filing Date: 17/Sep/2002

Abstract:An intraluminal medical device comprises a stent having a coating applied to at least part of an interior surface, an exterior surface, or both. The coating comprises a sustained release formulation of a combination of pharmaceutical compounds dispersed within a biologically tolerated polymer composition. The choice of the combination of pharmaceutical compounds are intended to reduce neointimal hyperplasia restenosis.

Priority: US20010322428P Applic. Date: 2001-09-17; US20020372761P Applic. Date: 2002-04-15

Inventor: CHEN JIANBING [US]; ASHTON PAUL [US]


Application No.: US20030108611A1  Published: 12/Jun/2003

Title: Bioadhesive nanoparticulate compositions having cationic surface stabilizers

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/004808   Filing Date: 07/Dec/2001

Abstract:Bioadhesive nanoparticulate compositions, comprising active agent particles and one or more cationic surface stabilizers, are described. The cationic surface stabilizers prevent aggregation of the nanoparticles and increase bioadhesion of the nanoparticles to biological substrates, such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, plant tissue, etc. The particles may consist of pharmacologically active compounds (e.g., drug compounds for human or veterinary use), agricultural chemicals (pesticides, herbicides, fertilizers, and the like), cosmetic agents, consumer products (coloring agents, flavors, or fragrances), or other materials which function by interacting with biological substrates. In addition, the invention relates to methods of preparing and using such bioadhesive nanoparticulate compositions.

Priority: US1999-414159 Applic. Date: 1999-10-08

Inventor: BOSCH H WILLIAM [US]; COOPER EUGENE R [US]; MCGURK SIMON L [US]


Application No.: US20030113890A1  Published: 19/Jun/2003

Title: Nematode-extracted serine protease inhibitors and anticoagulant proteins

Applicant/Assignee:

Application No.: 09/498272   Filing Date: 04/Feb/2000

Abstract:Proteins which have activity as anticoagulants and/or serine protease inhibitors and have at least one NAP domain and are described. Certain of these proteins have factor Xa inhibitory activity and others have activity as inhibitors of factor VIIa/TF. These proteins can be isolated from natural sources as nematodes, chemically synthesized or made by recombinant methods using various DNA expression systems.

Priority: US1997-809455 Applic. Date: 1997-11-24; US1994-326110 Applic. Date: 1994-10-18

Inventor: VLASUK GEORGE PHILLIP [US]; STANSSENS PATRICK ERIC HUGO [BE]; MESSENS JORIS HILDA LIEVEN [BE]; LAUWEREYS MARC JOSEF [BE]; LAROCHE YVES RENE [BE]; JESPERS LAURENT STEPHANE [BE]; GANSEMANS YANNICK GEORGES JOZE [BE]; MOYLE MATTHEW [US]; BERGUM PETER W [US]


Application No.: US20030114869A1  Published: 19/Jun/2003

Title: Intravascular system for occluded blood vessels and guidewire for use therein

Applicant/Assignee: KENSEY NASH CORPORATION

Application No.: 10/355754   Filing Date: 31/Jan/2003

Abstract:A system and method for opening a lumen in an occluded blood vessel, e.g., a coronary bypass graft, of a living being. The system comprises an atherectomy catheter having a working head, e.g., a rotary impacting impeller, and a debris extraction sub-system. The atherectomy catheter is located within a guide catheter. The working head is arranged to operate on, e.g., impact, the occlusive material in the occluded vessel to open a lumen therein, whereupon some debris may be produced. The debris extraction sub-system introduces an infusate liquid at a first flow rate adjacent the working head and withdraws that liquid and some blood at a second and higher flow rate, through the guide catheter to create a differential flow adjacent the working head, whereupon the debris is withdrawn in the infusate liquid and blood for collection outside the being's body.

The introduction of the infusate liquid may also be used to establish an unbalanced flow adjacent the working head to enable the atherectomy catheter to be steered hydrodynamically. A guide wire having an inflatable balloon on its distal end may be used with the atherectomy catheter to block the flow of debris distally, while enabling distal tissues to be perfused with an oxygenating liquid. At least one flow control port may be provided in the guide catheter to prevent collapse of the vessel being revascularized. A cradle is provided to fix the guide catheter and guide wire in position within the body of the being while enabling the atherectomy catheter to be advanced along the guide wire and through the guide catheter.

The guide catheter includes a wear resistant coating and is constructed so that its distal end includes plural sections of different outside diameters, with the distal most section being of the smallest outside diameter. A control console is provided to establish various modes of operation of the system based on manual inputs via switches or voice commands via voice recognition circuitry. A video panel displays the various modes of operation and instructions to the operator.

Priority: US2000-690976 Applic. Date: 2000-10-18; US2000-594131 Applic. Date: 2000-06-14; US1999-233712 Applic. Date: 1999-01-19; US1997-900598 Applic. Date: 1997-07-25; US1996-690438 Applic. Date: 1996-07-26

Inventor: NASH JOHN E [US]; FISHER WILLIAM T [US]; DODSON CHARLES W [US]; HENDERSON JOHN MICHAEL [US]; KAUFMANN JOSEPH W [US]


Application No.: US20030119714A1  Published: 26/Jun/2003

Title: Treatment of male sexual dysfunction

Applicant/Assignee:

Application No.: 10/017273   Filing Date: 12/Dec/2001

Abstract:The use of an inhibitor of a neuropeptide Y (NPY), preferably of a NPY Y1 receptor, which inhibitor is selective for an NPY or NPY Y1 receptor associated with male genitalia, in the preparation/manufacture of a medicament for the treatment or prevention of male erectile dysfunction (MED).

Priority: GB20000030647 Applic. Date: 2000-12-15; GB20010008730 Applic. Date: 2001-04-06; GB20010009910 Applic. Date: 2001-04-23; GB20010011037 Applic. Date: 2001-05-04; GB20010020679 Applic. Date: 2001-08-24; US2001-895367 Applic. Date: 2001-06-29; US2001-905846 Applic. Date: 2001-07-13; US20010265358P Applic. Date: 2001-01-31; US20010291722P Applic. Date: 2001-05-17

Inventor: NAYLOR ALASDAIR MARK [GB]; VAN DER GRAAF PIETER HADEWIJN [GB]; WAYMAN CHRISTOPHER PETER [GB]


Application No.: US20030120198A1  Published: 26/Jun/2003

Title: Spray dry process for applying anticoagulant on a syringe barrel

Applicant/Assignee: BECTON, DICKINSON AND COMPAN, A NEW JERSEY CORPORATION

Application No.: 10/293978   Filing Date: 13/Nov/2002

Abstract:A method for coating a substrate surface, such as an interior portion of a syringe is provided. An aqueous anticoagulant solution is atomized onto the substrate surface and dried by the forced flow of warm air. Water is removed during the drying leaving a coating of anticoagulant. A concentrated aqueous anticoagulant solution is used to reduce the time required for drying. A syringe having an interior portion coated with anticoagulant is also provided.

Priority: US20010350613P Applic. Date: 2001-11-13

Inventor: BARKELL PAUL [GB]; CHURCH STEPHEN [GB]


Application No.: US20030120202A1  Published: 26/Jun/2003

Title: Magnetic extracorporeal circuit for removal of medical agents

Applicant/Assignee:

Application No.: 10/032211   Filing Date: 21/Dec/2001

Abstract:A method and system for delivering a medical agent to targeted tissues in a patient, and subsequently removing systemically distributed medical agent to minimize exposure of non-targeted portions of a patient's body to the medical agent. The patient is treated with a targeted medical agent that includes a therapeutic component, a targeting component, and a magnetically attracted component. The targeting component, such as an antibody known to be attracted to an antigen present at the target, causes a concentration of the targeted medical agent to occur at the targeted tissue. The medical agent not concentrated at the targeted tissue is removed by withdrawing and magnetically filtering a portion of the patient's blood to remove the targeted medical agent, and returning the filtered blood to the patient.

Priority:

Inventor: GORDON LUCAS S [US]


Application No.: US20030120337A1  Published: 26/Jun/2003

Title: Barrier device for ostium of left atrial appendage

Applicant/Assignee: ATRITECH, INC

Application No.: 10/308032   Filing Date: 03/Dec/2002

Abstract:A membrane applied to the ostium of an atrial appendage for blocking blood from entering the atrial appendage which can form blood clots therein is disclosed. The membrane also prevents blood clots in the atrial appendage from escaping therefrom and entering the blood stream which can result in a blocked blood vessel, leading to strokes and heart attacks. The membranes are percutaneously installed in patients experiencing atrial fibrillations and other heart conditions where thrombosis may form in the atrial appendages. A variety of means for securing the membranes in place are disclosed. The membranes may be held in place over the ostium of the atrial appendage or fill the inside of the atrial appendage.

The means for holding the membranes in place over the ostium of the atrial appendages include prongs, stents, anchors with tethers or springs, disks with tethers or springs, umbrellas, spiral springs filling the atrial appendages, and adhesives. After the membrane is in place a filler substance may be added inside the atrial appendage to reduce the volume, help seal the membrane against the ostium or clot the blood in the atrial appendage. The membranes may have anticoagulants to help prevent thrombosis. The membranes be porous such that endothelial cells cover the membrane presenting a living membrane wall to prevent thrombosis. The membranes may have means to center the membranes over the ostium. Sensors may be attached to the membrane to provide information about the patient.

Priority: US1999-428008 Applic. Date: 1999-10-27

Inventor: VAN TASSEL ROBERT A [US]; HAUSER ROBERT G [US]


Application No.: US20030124504A1  Published: 03/Jul/2003

Title: Additive solution for blood preservation

Applicant/Assignee:

Application No.: 10/295781   Filing Date: 15/Nov/2002

Abstract:There is provided compositions and methods for the storage of red blood cells. The compositions are additive solutions comprising adenine, dextrose, mannitol, NaH2PO4, and optionally NaCl and/or NH4Cl. Composition are preferably used with oxygen-depletion refrigerated storage of red blood cells and may optionally be employed with nutrient supplements extending the useful shelf life of stored blood.

Priority: US20010332405P Applic. Date: 2001-11-16

Inventor: BITENSKY MARK W [US]; YOSHIDA TATSURO [US]


Application No.: US20030124705A1  Published: 03/Jul/2003

Title: Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates

Applicant/Assignee: HAMILTON CIVIC HOSPITAL RESEARCH DEVELOPMENT INC

Application No.: 10/101568   Filing Date: 20/Mar/2002

Abstract:Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.

Priority: US1996-768035 Applic. Date: 1996-12-17; US1995-564976 Applic. Date: 1995-11-30; US20010277619P Applic. Date: 2001-03-22

Inventor: BERRY LESLIE ROY [CA]; ANDREW MAUREEN [CA]; CHAN ANTHONY KAM CHUEN [CA]


Application No.: US20030125528A1  Published: 03/Jul/2003

Title: Process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon

Applicant/Assignee:

Application No.: 10/256482   Filing Date: 27/Sep/2002

Abstract:An improved process is described for preparing Schiff base condensation adduct final products whose components comprise a protein having beneficial activity in animals, and an aromatic o-hydroxy aldehyde, which comprises bringing together the above-mentioned components in an aqueous environment at a pH of 7.0 or higher to form a reaction mixture, under conditions effective to drive said condensation reaction substantially to completion by removing from about 97.0% to about 99.9% by weight, preferably from about 98.0% to about 99.0% by weight of the water already present or produced during said condensation reaction, consistent with maintaining the integrity of the condensation reactants and adduct final product, and to assure a rate of conversion to said condensation adduct final product, i.e., with resulting yield of said condensation adduct final product of equal to or greater than about 98.5% by weight, preferably equal to or greater than about 99.5% by weight based on the weight of the reactants. Preferred aromatic o-hydroxy aldehydes comprise o-vanillin

salicylaldehyde

2,3-dihydroxybenzaldehyde

2,6-dihydroxybenz-aldehyde

2-hydroxy-3-ethoxybenzaldehyde

or pyridoxal. A very wide range of proteins may be employed. The improved process provides yields over 90% and substantially quantitative conversion of the aldehyde and protein to the condensation adduct.

Priority: US1999-337985 Applic. Date: 1999-06-22; US19980090714P Applic. Date: 1998-06-26

Inventor: HAY BRUCE A [US]; CLARK MICHAEL T [US]


Application No.: US20030125881A1  Published: 03/Jul/2003

Title: Apparatus and method for plasmapheresis

Applicant/Assignee:

Application No.: 10/302682   Filing Date: 22/Nov/2002

Abstract:A method and apparatus for obtaining the plasma portion from whole blood is provided which utilized a processor controlled plasmapheresis device and/or blood input pump to withdraw donor-weight specific plasma volumes and blood volumes from an individual.

Priority: US20010337215P Applic. Date: 2001-11-26

Inventor: RYAN VINCENT J [US]


Application No.: US20030129665A1  Published: 10/Jul/2003

Title: Methods for qualitative and quantitative analysis of cells and related optical bio-disc systems

Applicant/Assignee:

Application No.: 10/230959   Filing Date: 29/Aug/2002

Abstract:A clinical diagnostic assay is performed on an optical bio disc and is read with a disc drive. Methods and apparatus for detecting and quantifying specific blood cell analytes in biological samples using optical bio disc is disclosed. The method for determining the quantity of a specific type of blood cell in a biological sample includes binding an antibody to a capture zone on the disc, providing a sample to the capture zone, remove portions of the sample that are not bound in the capture zone, and counting bound cells. Also described is method and apparatus for performing a cluster designation count with an optical disc and disc drive and method for making an optical assay disc for performing such cluster designation count.

Priority: US20010334131P Applic. Date: 2001-11-30; US20020355644P Applic. Date: 2002-02-05; US2001-988728 Applic. Date: 2001-11-20; US20010315937P Applic. Date: 2001-08-30; US20010328246P Applic. Date: 2001-10-10; US20010386072P Applic. Date: 2001-10-19; US20010386073P Applic. Date: 2001-10-19; US20010386071P Applic. Date: 2001-10-26; US20010344977P Applic. Date: 2001-11-07; US20010338679P Applic. Date: 2001-11-13; US20020358479P Applic. Date: 2002-02-19

Inventor: SELVAN GOWRI PYAPALI [US]; GORDON JOHN FRANCIS [US]; BRAZIL KAREN JEAN [US]; URCIA JOSEPH ROBY IRINGAN [US]


Application No.: US20030133929A1  Published: 17/Jul/2003

Title: Method of treating infectious diseases

Applicant/Assignee:

Application No.: 10/168905   Filing Date: 25/Nov/2002

Abstract:A method of treating an animal infected by an infectious agent having a lipid envelope or membrane, the method including draining blood from the animal, separating blood cells from plasma, contacting the plasma with a solvent system comprising a solvent in which lipids are soluble and in which hematological and biochemical constituents are substantially stable, for a time sufficient to reduce active levels of the infectious agent in the plasma, separating the plasma from the solvent system and reintroducing the plasma into the animal, whereby dissolved lipids are separated with and remain in the solvent system.

Priority: AU2000PQ08469 Applic. Date: 2000-06-29; WO2000AU01603 Applic. Date: 2000-12-28; WO2001IB01099 Applic. Date: 2001-06-21

Inventor: CHAM BILL E [AU]


Application No.: US20030137067A1  Published: 24/Jul/2003

Title: Compositions having a combination of immediate release and controlled release characteristics

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/268928   Filing Date: 11/Oct/2002

Abstract:Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of the nanoparticulate active agent particles, and at least one active ingredient having a microparticulate particle size.

Priority: US20010328405P Applic. Date: 2001-10-12

Inventor: COOPER EUGENE R [US]; RUDDY STEPHEN B [US]


Application No.: US20030138349A1  Published: 24/Jul/2003

Title: Blood processing system

Applicant/Assignee: MISSION MEDICAL, INC

Application No.: 10/265297   Filing Date: 03/Oct/2002

Abstract:A blood processing system (2), includes a housing (4), to which a user control panel is mounted, having an access opening (47) therein. A cassette assembly (22), mounted to the housing for movement between a use position covering the access opening and a cassette-replacement position, includes a cassette holder and cassette (26) removably mounted to the holder. The cassette includes in part by tubing aligned with a through-hole (45) in the cassette. A door (34) is mounted to the housing for movement between a latched position, capturing the cassette between the panel and the door, and a released position. Independently-driven roller assemblies (46, 54, 72) pass part-way through the access opening to capture first tubing portions (44A, 52A, 68A) between the roller tracks (100, 102, 104) and the roller assemblies for peristaltic pumping of fluid.

A number of movable pinch elements (48, 80, 90, 96) are extendable through the front panel to selectively pinch the tubing against the door and thus seal the tubing.

Priority: US1999-419216 Applic. Date: 1999-10-15; US19980104557P Applic. Date: 1998-10-16

Inventor: ROBINSON THOMAS C [US]; SAHINES THOMAS P [US]; D ELIA RICHARD R [US]; FERNANDEZ ROBERT K [US]; HICKMAN FRANK [US]


Application No.: US20030143759A1  Published: 31/Jul/2003

Title: Assays for determining anticoagulant cofactor activity

Applicant/Assignee:

Application No.: 09/912947   Filing Date: 25/Jul/2001

Abstract:Methods are disclosed for determining, in a sample derived from a human, the functional activity of a component of the human blood coagulation system, which activity can be correlated to conversion of a substrate specific for activated Protein C (APC), by measuring in an assay medium containing the sample and a substrate for APC, the conversion of the substrate by APC and correlating the conversion to the functional activity of the component. When the component is anticoagulant Factor V, at least one of exogenous APC, Protein S or an inhibitor of Protein S activity is added to the medium. When the component is Protein C, APC, or Protein S, exogenous anticoagulant Factor V or an inhibitor of anticoagulant activity of Factor V is added to the medium. Methods are also disclosed for diagnosing a blood coagulation/anticoagulation disorder or for determining a predisposition thereto in a human by determining anticoagulant Factor V activity in an assay medium containing a sample derived from the human.

Priority: US1995-500917 Applic. Date: 1995-10-20

Inventor: DAHLBACK BJORN [SE]


Application No.: US20030146170A1  Published: 07/Aug/2003

Title: Whole blood collection and processing method

Applicant/Assignee: GAMBRO, INC

Application No.: 10/358381   Filing Date: 03/Feb/2003

Abstract:A method is disclosed for collecting and processing whole blood. Whole blood is collected at several remote donor sites and transported to a central blood-processing center, where information regarding demand for blood products is used to direct processing of whole blood into blood products. Whole blood is initially collected in collection bags unattached to satellite bags instead of commonly used multiple bag sets. When the determination is made at the blood processing center as to which blood products are to be made, the appropriate satellite bags and/or other system components are sterile docked to the blood-collection bag and the whole blood is processed. The use of blood-collection bags initially unattached to satellite bags eliminates waste and simplifies the transportation and processing of whole blood.

Also disclosed are blood collection systems that remove leukocytes and collect whole blood into blood-collection bags unattached to satellite bags.

Priority: US20020353277P Applic. Date: 2002-02-01

Inventor: CORBIN FRANK [US]; URDAHL STEVEN GAGE [US]


Application No.: US20030148256A1  Published: 07/Aug/2003

Title: Red blood cell resuspension solution and method

Applicant/Assignee:

Application No.: 10/366806   Filing Date: 14/Feb/2003

Abstract:The present invention provides an improved aqueous solution for suspending and storing red blood cells. The solution includes sodium citrate, a combination of sodium biphosphate and sodium phosphate dibasic, adenine, and mannitol. The solution is formulated at a low osmolarity and has a physiological pH of approximately 7.4. The solution simultaneously maintains stored red cells ATP and 2,3-BPG.

Priority: US1999-268405 Applic. Date: 1999-03-15; US1996-742279 Applic. Date: 1996-10-31; US1995-491099 Applic. Date: 1995-06-16; US1994-216734 Applic. Date: 1994-03-22; US1990-610478 Applic. Date: 1990-11-07

Inventor: PAYRAT JEAN-MARC [BE]; HOGMAN CLAES F [SE]; DEBRAUWERE JACK [BE]; MATHIAS JEAN MARIE [BE]


Application No.: US20030152563A1  Published: 14/Aug/2003

Title: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots

Applicant/Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Application No.: 10/253518   Filing Date: 23/Sep/2002

Abstract:Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.

Priority: US1999-454666 Applic. Date: 1999-12-03; WO1999US10547 Applic. Date: 1999-05-12; US19980086262P Applic. Date: 1998-05-21

Inventor: MUZYKANTOV VLADIMIR R [US]; HIGAZI ABD AL-ROOF [US]; MURCIANO JUAN CARLOS [ES]; CINES DOUGLAS [US]; TAYLOR RONALD P [US]


Application No.: US20030152567A1  Published: 14/Aug/2003

Title: Protease for activating clotting factor VII

Applicant/Assignee: AVENTIS BEHRING GMBH ZLB BEHRING GMBH

Application No.: 10/319592   Filing Date: 16/Dec/2002

Abstract:A protease for activating the blood clotting factor VII is described, which a) is inhibited by the presence of aprotinin, b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and c) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more brands in the molecular weight range from 50 to 75 kDa and kDa in the reduced state has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa. The proenzyme of this protease is also characterized. Further, a process for obtaining this protease and its use in hemorrhage prophylaxis or hemostasis is described. Moreover, a test system for the qualitative and quantitative detection of a protease which activates the blood clotting factor VII is described.

Priority: DE19981018495 Applic. Date: 1998-04-24; DE19981027734 Applic. Date: 1998-06-22; DE19981051332 Applic. Date: 1998-11-06; DE19981051336 Applic. Date: 1998-11-06; DE19981051335 Applic. Date: 1998-11-06; DE19991003693 Applic. Date: 1999-02-01; US1999-295316 Applic. Date: 1999-04-21

Inventor: ROEMISCH JUERGEN [DE]; FEUSSNER ANNETTE [DE]; STOEHR HANS-ARNOLD [DE]


Application No.: US20030152639A1  Published: 14/Aug/2003

Title: Novel wound healing composition not containing bovine-derived activating reagents

Applicant/Assignee:

Application No.: 10/323861   Filing Date: 17/Dec/2002

Abstract:A wound care preparation free from bovine-derived activating agents is disclosed for use in wound care, for both topical wounds and surgical wounds. The preparation is isolated by first obtaining an amount of whole blood from the patient and treating the whole blood with one or more anti-clotting agents, subjecting the whole blood to a centrifugation process to obtain an amount of platelet-rich plasma, adding to the platelet-rich plasma an amount of anti-clotting neutralizing agent, and mixing the platelet-rich plasma with a structural matrix to increase viscosity of the preparation. In use, the viscous preparation can be applied directly to a wound or surgery incision and the viscous preparation may be mixed with other wound healing agents, growth matrices, or promoters such as anti-fungal agents, anti-biotic agents, and preservatives.

Priority: US2001-898316 Applic. Date: 2001-07-03

Inventor: BRITTON CALVIN [US]; DELLINGER ALEX [US]; LIMBIRD JIM [US]; KELLER CARL [US]; WORDEN CHARLES [US]


Application No.: US20030153074A1  Published: 14/Aug/2003

Title: Method for extending the useful shelf-life of refrigerated red blood cells by nutrient supplementation

Applicant/Assignee:

Application No.: 10/295772   Filing Date: 15/Nov/2002

Abstract:There is provided methods and compositions for the storage of red blood cells. The compositions are metabolic supplements which are preferably added to refrigerated red blood cells suspended in an additive solution. Red blood cells are preferably stored under conditions of oxygen-depletion. Metabolic compositions comprises pyruvate, inosine, adenine, and optionally dibasic sodium phosphate and/or monobasic sodium phosphate.

Priority: US20010332409P Applic. Date: 2001-11-16

Inventor: BITENSKY MARK W [US]; YOSHIDA TATSURO [US]


Application No.: US20030153900A1  Published: 14/Aug/2003

Title: Autonomous, ambulatory analyte monitor or drug delivery device

Applicant/Assignee: SARNOFF CORPORATION ROSEDALE MEDICAL, INC

Application No.: 10/131268   Filing Date: 23/Apr/2002

Abstract:The invention relates to analyte monitoring/drug (pharmaceutical agent) delivery device. The invention is suited for monitoring various blood constituents such as glucose. The device has a housing that at least partially encloses a plurality of microneedles disposed on a carrier and an electronics portion. Each microneedle is in fluid communication with a corresponding microchannel. Each microneedle is individually addressable. That is, each microneedle can be extended and retracted individually via an actuator. The electronics portion includes a processor and associated circuitry (e.g., memory, supporting electronics and the like), a motor or the like, a sensor, a power supply (e.g., battery) and optionally an interface. In general, the processor controls the operation of the device and is data communication with the actuator, motor, sensor and interface.

The invention provides for autonomous operation, that is, without intervention of the user. The invention can optionally provide for calibration without intervention of the user. The invention can also provide for semi-continuous monitoring for day and night time. The invention can provide for up to four, or more, weeks of operation. The invention can provide for a device that is relative small in size, and therefore unobtrusive. The invention can also provide for device with remote control and interactive electronics. The invention may be also used for the delivery of various pharmaceutical agents including high potency drugs to minimize patient intervention and minimize discomfort.

Priority: US20020355195P Applic. Date: 2002-02-08

Inventor: ACETI JOHN GREGORY [US]; MCBRIDE STERLING EDUARD [US]; MORONEY RICHARD MORGAN [US]; GREGORY CHRISTOPHER CARTER [US]; ZANZUCCHI PETER JOHN [US]


Application No.: US20030156983A1  Published: 21/Aug/2003

Title: Fluidic device for medical diagnostics

Applicant/Assignee:

Application No.: 10/330456   Filing Date: 26/Dec/2002

Abstract:A fluidic medical diagnostic device permits measurement of analyte concentration or a property of a biological fluid, particularly the coagulation time of blood. The device has at one end a sample port for introducing a sample and at the other end a bladder for drawing the sample to a measurement area. A channel carries the sample from the sample port to the measurement area, and a stop junction, between the measurement area and bladder, halts the sample flow. The desired measurement can be made by placing the device into a meter which measures a physical property of the sample-typically, optical transmittance-after it has interacted with a reagent in the measurement area.

Priority: US1999-333765 Applic. Date: 1999-06-15; US19980093421P Applic. Date: 1998-07-20

Inventor: SHARTLE ROBERT JUSTICE [US]; PAN VICTOR [US]; LEMKE JOHN [US]; CIZDZIEL PHILIP [US]


Application No.: US20030156984A1  Published: 21/Aug/2003

Title: Fluidic device for medical diagnostics

Applicant/Assignee: LIFESCAN, INC

Application No.: 10/330790   Filing Date: 26/Dec/2002

Abstract:A fluidic medical diagnostic device permits measurement of analyte concentration or a property of a biological fluid, particularly the coagulation time of blood. The device has at one end a sample port for introducing a sample and at the other end a bladder for drawing the sample to a measurement area. A channel carries the sample from the sample port to the measurement area, and a stop junction, between the measurement area and bladder, halts the sample flow. The desired measurement can be made by placing the device into a meter which measures a physical property of the sample-typically, optical transmittance-after it has interacted with a reagent in the measurement area.

Priority: US1999-333765 Applic. Date: 1999-06-15; US19980093421P Applic. Date: 1998-07-20

Inventor: LEMKE JOHN [US]; SHARTLE ROBERT JUSTICE [US]; PAN VICTOR [US]; CIZDZIEL PHILIP [US]


Application No.: US20030158252A1  Published: 21/Aug/2003

Title: Aminoguanidines and alkoxyguanidines as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 10/359078   Filing Date: 06/Feb/2003

Abstract:Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula I. The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Priority: US1997-979234 Applic. Date: 1997-11-26; US19960031822P Applic. Date: 1996-11-26

Inventor: TOMCZUK BRUCE E [US]; SOLL RICHARD M [US]; LU TIANBAO [US]; FEDDE CYNTHIA L [US]; ILLIG CARL R [US]; MARKOTAN THOMAS P [US]; STAGNARO THOMAS P [US]


Application No.: US20030158598A1  Published: 21/Aug/2003

Title: System for sustained-release delivery of anti-inflammatory agents from a coated medical device

Applicant/Assignee: CONTROL DELIVERY SYSTEMS, INC

Application No.: 10/345064   Filing Date: 14/Jan/2003

Abstract:The subject invention provides medical devices having a coating disposed on at least one surface, wherein the coating includes a polymer matrix and a low solubility anti-inflammatory corticosteroid formulation, or low solubility codrug or prodrug of an anti-inflammatory corticosteroid formulation.

Priority: US2002-245840 Applic. Date: 2002-09-17; US20010322428P Applic. Date: 2001-09-17; US20020372761P Applic. Date: 2002-04-15

Inventor: ASHTON PAUL [US]; CHEN JIANBING [US]


Application No.: US20030158607A1  Published: 21/Aug/2003

Title: Tissue repair fabric

Applicant/Assignee: ORGANOGENESIS INC

Application No.: 10/376788   Filing Date: 28/Feb/2003

Abstract:This invention is directed to prosthesis, which, when implanted into a mammalian patient, serves as a functioning replacement for a body part, or tissue structure, and will undergo controlled biodegradation occurring concomitantly with bioremodeling by the patient's living cells. The prosthesis is treated so that it is rendered non-antigenic so as not to elicit a significant humoral immune response. The prosthesis of this invention, in its various embodiments, thus has dual properties. First, it functions as a substitute body part, and second, it functions as bioremodeling template for the ingrowth of host cells.

Priority: US2001-843172 Applic. Date: 2001-04-26; US1997-930756 Applic. Date: 1997-10-07; WO1996US03336 Applic. Date: 1996-03-12; US1995-417868 Applic. Date: 1995-04-07

Inventor: CARR ROBERT M [US]; CONDON KIMBERLIE D [US]; TERMIN PAUL L [US]; YOUNG JANET HARDIN [US]


Application No.: US20030163931A1  Published: 04/Sep/2003

Title: Method for making homogeneous spray-dried soild amorphous drug dispersions utilizing modified spray-drying apparatus

Applicant/Assignee: PFIZER INC

Application No.: 10/353746   Filing Date: 28/Jan/2003

Abstract:Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers.

Priority: US20020354080P Applic. Date: 2002-02-01

Inventor: BEYERINCK RONALD A [US]; DEIBELE HEATHER L M [US]; DOBRY DAN E [US]; RAY RODERICK J [US]; SETTELL DANA M [US]; SPENCE KEN R [US]


Application No.: US20030165573A1  Published: 04/Sep/2003

Title: Purification of red blood cells by separation and diafiltration

Applicant/Assignee: BIOPURE CORPORATION

Application No.: 10/090428   Filing Date: 28/Feb/2002

Abstract:Red blood cells are purified by separating whole blood, such as by centrifugation, to form a red blood cell fraction and a liquid fraction. The whole blood can be defibrinated or treated to prevent coagulation prior to separation. Preferably, the whole blood is bovine blood. The red blood cell fraction is then diafiltered to purify the red blood cells. The purified red blood cells can then be lysed to form a lysate of purified red blood cells. The purified red blood cells and the lysate of purified red blood cells are suitable for use in producing hemoglobin blood substitute.

Priority:

Inventor: HOUTCHENS ROBERT A [US]; GAWRYL MARIA S [US]; LIGHT WILLIAM R [US]; BAQAI JAVED [US]


Application No.: US20030166017A1  Published: 04/Sep/2003

Title: Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease

Applicant/Assignee: MILLENNIUM PHARMACEUTICALS, INC

Application No.: 10/008093   Filing Date: 09/Nov/2001

Abstract:The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cardiovascular diseases.

Priority: US20000248185P Applic. Date: 2000-11-09; US20000257417P Applic. Date: 2000-12-22

Inventor: MCCARTHY JEANETTE [US]


Application No.: US20030170241A1  Published: 11/Sep/2003

Title: Composition for the treatment of heart failure

Applicant/Assignee:

Application No.: 10/204218   Filing Date: 20/Feb/2003

Abstract:The present invention relates to the use of an immunomodulating agent, in particular intravenous immunoglobulin (IVIG), in the manufacture of a medicament for use in the treatment of non-viral or non-autoimmune induced heart disorders or non-viral or non-autoimmune associated phases of heart disorders or the symptoms associated therewith. Particular heart disorders to be treated are selected from the group comprising chronic CHF, chronic (stable) angina pectoris and acute coronary syndromes. Pharmaceutical compositions for use in the treatment of such disorders comprising immunomodulating agents are also provided.

Priority: GB20000005867 Applic. Date: 2000-03-10

Inventor: AUKRUST PAL [NO]; FROLAND STIG [NO]; SIMONSEN SVEIN [NO]; AASS HALFDAN [NO]; FJELD JAN [NO]; ANDREASSEN ARNE [NO]; IHLEN HALFDAN [NO]; KJEKSHUS JOHN [NO]; NITTER-HAUGE SIGURD [NO]; UELAND THOR [NO]; GULLESTAD LARS [NO]; LIEN EGIL [NO]


Application No.: US20030175150A1  Published: 18/Sep/2003

Title: Apheresis system with anticoagulant flow control

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 10/372882   Filing Date: 24/Feb/2003

Abstract:An apheresis system is disclosed which may include a separation chamber

a suspension flow path which communicates at one end with the separation chamber and includes a connector at the other end for connecting to a source of cellular suspension

an anticoagulant flow path which communicates at one end with the suspension flow path and includes a connector at the other end for connecting to an anticoagulant source

and a return flow path which communicates at one end with the separation chamber and communicates at the other end with a connector for connection directly to the suspension source or to the suspension flow path for returning one or more suspension components to the source.

The anticoagulant flow path includes a flow restriction, such as an internal flow restriction, which limits the free flow of anticoagulants into the suspension flow path while preferably not completely stopping the flow of anticoagulant. The restriction may take various forms, but the preferred construction comprises a tubing segment of reduced inside diameter, providing resistance to the free flow of anticoagulant in the event of operator error or mechanical failure.

Priority: US1998-042260 Applic. Date: 1998-03-13

Inventor: GRIMM DANIEL J [US]


Application No.: US20030176837A1  Published: 18/Sep/2003

Title: Reinforced monorail balloon catheter

Applicant/Assignee: MEDTRONIC VASCULAR, INC

Application No.: 10/393581   Filing Date: 19/Mar/2003

Abstract:The invention is a dilation catheter which comprises an elongated catheter shaft, a guide wire tube, and an angioplasty balloon. The distal end of the balloon is attached to the distal portion of the guide wire tube, and the proximal portion of the balloon is attached to the distal portion of the catheter shaft. A stiffening wire is attached to the inner wall of the catheter shaft at a plurality of points along its length. The distal extremity of the guide wire tube is decreased in size relative to the proximal portion of the guide wire tube. A fluid is contained within the guide wire lumen.

Priority: US2001-788896 Applic. Date: 2001-02-19; US1997-859654 Applic. Date: 1997-05-20; US1996-737055 Applic. Date: 1996-10-24

Inventor: FITZMAURICE THOMAS K [IE]; GILSON PAUL [IE]; DUANE PATRICK J E [IE]


Application No.: US20030180357A1  Published: 25/Sep/2003

Title: Pharmaceutical tablet

Applicant/Assignee:

Application No.: 10/359939   Filing Date: 06/Feb/2003

Abstract:A pharmaceutical tablet is provided comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.

Priority: US20020355705P Applic. Date: 2002-02-07

Inventor: MARTINO ALICE C [US]; NOACK ROBERT M [US]; PIERMAN STEVEN A [US]


Application No.: US20030180762A1  Published: 25/Sep/2003

Title: Mild enrichment of foetal cells from peripheral blood and use thereof

Applicant/Assignee:

Application No.: 10/333245   Filing Date: 06/May/2003

Abstract:The invention relates to a procedure for high enrichment of fetal cells as a product, whereby after a withdrawal of maternal blood, the blood fraction and centrifugation, an antibody cocktail with Anti-w, Anti-r antibodies, which specifically bond to transferring receptor molecules as antigens of the surfaces of nucleated stem cells of red blood corpuscles, and Anti-i antibodies, which specifically bond to Antigen-i as antigens of the surfaces of nucleated stem cells of red blood corpuscles, and/or Anti i plus antibodies, which specifically bond to intracellular structures of fetal stem cells and/or the intracellular molecules of fetal stem cells and/or membrane fragments of fetal stem cells is added and fetal cells with 10<5 >to 10<7 >enrichment are separated from the cell preparation.

Priority: DE20001035433 Applic. Date: 2000-07-20

Inventor: TUMA WOLFGANG [DE]; BUNGER GERD [DE]; PITONE MICHAEL [DE]; BURRICHTER HEINRICH [DE]


Application No.: US20030181305A1  Published: 25/Sep/2003

Title: Method and apparatus for the continuous separation of biological fluids into components

Applicant/Assignee: THERAKOS, INC

Application No.: 10/375629   Filing Date: 27/Feb/2003

Abstract:The present invention relates to systems, methods and apparatus for improving the yield for separating components of fluids, for example biological or sensitive fluids such as blood, and improving the component yield, for example, from donated whole blood by separating its components by density in a centrifuge bowl with a multi-axial lumen. The apparatus, system, and method eliminate the need to batch-type separate blood and can reduce the time needed to treat patients suffering from T-cell or white blood cell mediated diseases or conditions to less than 70 minutes. In one aspect, the invention is a centrifuge bowl (10) comprising an outer housing (100)

a core (200)

a lower plate (300)

a lumen (400)

a first bowl channel (420) within said lumen (400) for inflowing said fluid (800)

a second bowl channel (410) for removing a first separated fluid component (810)

and a third bowl channel (740) for removing a second separated fluid component (820).

Priority: US20020361287P Applic. Date: 2002-03-04

Inventor: BRIGGS DENNIS A [US]; HUTCHINSON MICHAEL [US]


Application No.: US20030181411A1  Published: 25/Sep/2003

Title: Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors

Applicant/Assignee:

Application No.: US 2003-392303   Filing Date: 20/Mar/2003

Abstract:Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US20020365524P Applic. Date: 2002-03-20

Inventor: BOSCH H WILLIAM [US]; CARY GRETA G [US]; HOVEY DOUGLAS C [US]; JAIN RAJEEV A [US]; KLINE LAURA J [US]; MERISKO-LIVERSIDGE ELAINE [US]; OSTRANDER KEVIN D [US]


Application No.: US20030181689A1  Published: 25/Sep/2003

Title: Percarboxylated polysaccharides, and a process for their preparation

Applicant/Assignee: FIDIA FARMACEUTICI S.P.A

Application No.: 10/376369   Filing Date: 28/Feb/2003

Abstract:The present invention relates to percarboxylated polysaccharide selected from the group consisting of gellan, carboxymethylcellulose, pectic acid, pectin and hyaluronic acid derivatives

the process for their preparation and their use in the pharmaceutical, biomedical, surgical and healthcare fields.

Priority: WO2001EP10062 Applic. Date: 2001-08-31; IT2000PD00208 Applic. Date: 2000-08-31

Inventor: BELLINI DAVIDE [IT]; CRESCENZI VITTORIO [IT]; FRANCESCANGELI ANDREA [IT]


Application No.: US20030181766A1  Published: 25/Sep/2003

Title: Amidino derivatives, and anticoagulants and thrombosis therapeutic agents containing them

Applicant/Assignee: EISAI CO., LTD

Application No.: 10/294198   Filing Date: 14/Nov/2002

Abstract:Amidino derivatives represented by the following general formula (I): {where X is a group represented by R<1>SO2NR<2>- (wherein R<1 >represents optionally substituted C6-14 aryl, etc. and R<2 >represents hydrogen atom, etc.), etc., Ar<1 >represents 2,6-naphthylene, etc., R<3 >represents hydrogen atom, etc. and Y represents carboxyphenyl, etc.}and their pharmacologically acceptable salts or solvates.

Priority: JP20010350637 Applic. Date: 2001-11-15; JP20020307358 Applic. Date: 2002-10-22

Inventor: SATOH TAKASHI [JP]; OKAMOTO YASUSHI [JP]; ASANO OSAMU [JP]; WATANABE NOBUHISA [JP]; NAGAKURA TADASHI [JP]; SAEKI TAKAO [JP]; INOUE ATSUSHI [JP]; SAKURAI MASAHIRO [JP]


Application No.: US20030185869A1  Published: 02/Oct/2003

Title: Nanoparticulate compositions having lysozyme as a surface stabilizer

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 10/357514   Filing Date: 04/Feb/2003

Abstract:The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.

Priority: US20020353230P Applic. Date: 2002-02-04

Inventor: WERTZ CHRISTIAN F [US]; RYDE NIELS P [US]


Application No.: US20030185893A1  Published: 02/Oct/2003

Title: Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles

Applicant/Assignee: BEND RESEARCH, INC

Application No.: 10/351568   Filing Date: 24/Jan/2003

Abstract:Homogeneous solid amorphous dispersions of drugs in concentration-enhancing polymers are formed in desirable larger particle sizes with minimal fines by using an atomizer and process conditions capable of producing droplets having an average diameter of at least 50 microns and a D10 of at least 10 microns.

Priority: US20020353986P Applic. Date: 2002-02-01

Inventor: BEYERINCK RONALD A [US]; RAY RODERICK J [US]; DOBRY DAN E [US]; SETTELL DANA M [US]


Application No.: US20030186213A1  Published: 02/Oct/2003

Title: Storage solution containing photosensitizer for inactivation of biological contaminants

Applicant/Assignee:

Application No.: 10/374907   Filing Date: 25/Feb/2003

Abstract:A platelet/additive solution comprising bicarbonate, citrate and glucose. Additionally, a platelet/additive and treatment solution comprising bicarbonate, citrate, glucose and a photosensitizer.

Priority: US2000-725426 Applic. Date: 2000-11-28

Inventor: MCBURNEY LAURA [US]; GOODRICH RAYMOND P [US]


Application No.: US20030187023A1  Published: 02/Oct/2003

Title: Sulfone derivatives, process for their production and use thereof

Applicant/Assignee:

Application No.: 10/333308   Filing Date: 16/Jan/2003

Abstract:A compound represented by the formula: wherein R is a cyclic hydrocarbon group, or the like

W is a bond, or the like

X is a divalent hydrocarbon group, or the like

Y and Z are each independently -N(R<6>)- or the like

ring A is a nitrogen-containing heterocyclic ring, or the like

R5 and R6 are independently hydrogen atom, a hydrocarbon group, or the like

Z' is imidoyl group, or the like

a is 0, 1 or 2

and b is 0 or 1, or a salt thereof.

Priority: JP20000221065 Applic. Date: 2000-07-17

Inventor: KUBO KEIJI [JP]; MIYAWAKI TOSHIO [JP]; KAWAMURA MASAKI [JP]


Application No.: US20030191115A1  Published: 09/Oct/2003

Title: Lactam-containing compounds and derivatives thereof as factor Xa inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB PHARMA COMPANY

Application No.: 10/245122   Filing Date: 17/Sep/2002

Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US20010324165P Applic. Date: 2001-09-21; US20020402317P Applic. Date: 2002-08-09

Inventor: PINTO DONALD J P [US]; QUAN MIMI L [US]; ORWAT MICHAEL J [US]; LI YUN-LONG [US]; HAN WEI [US]; QIAO JENNIFER X [US]; LAM PATRICK Y S [US]; KOCH STEPHANIE L [US]


Application No.: US20030191139A1  Published: 09/Oct/2003

Title: Thrombin inhibitors

Applicant/Assignee: UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY

Application No.: 10/275215   Filing Date: 31/Jan/2003

Abstract:The invention relates to compounds of formula I D-CO-B-A-Het and pharmaceutically acceptable salts thereof where substituents in description have the specified meanings. The compounds are used as thrombin inhibitors.

Priority: SI20000000111 Applic. Date: 2000-05-05; WO2001GB01997 Applic. Date: 2001-05-04

Inventor: KIKELJ DANIJEL [SI]; PETERLIN LUCIJA [SI]; MARINKO PETRA [SI]; BREZNIK MATEJ [SI]; STREGNAR MOJCA [SI]; TRAMPUZ BAKIJA ALENKA [SI]; FORTUNA MARJANA [SI]


Application No.: US20030191449A1  Published: 09/Oct/2003

Title: Systems for delivering agents into targeted tissue of a living being

Applicant/Assignee: KENSEY NASH CORPORATION

Application No.: 10/405394   Filing Date: 02/Apr/2003

Abstract:A system for accessing targeted tissue within the living being and introduction of particles at select locations into the myocardium and other select tissues. The system includes an instrument and a plurality of flowable particles to be delivered by the instrument via an externally applied force. The particles to the tissue may include one or more of pharmaceuticals, biologically active agents, radiopaque materials, etc.

Priority: US1999-368410 Applic. Date: 1999-08-05

Inventor: NASH JOHN E [US]; EVANS DOUGLAS G [US]; HOGANSON DAVID M [US]


Application No.: US20030191526A1  Published: 09/Oct/2003

Title: Barrier device for ostium of left atrial appendage

Applicant/Assignee: ATRITECH, INC

Application No.: 10/397311   Filing Date: 27/Mar/2003

Abstract:A membrane applied to the ostium of an atrial appendage for blocking blood from entering the atrial appendage which can form blood clots therein is disclosed. The membrane also prevents blood clots in the atrial appendage from escaping therefrom and entering the blood stream which can result in a blocked blood vessel, leading to strokes and heart attacks. The membranes are percutaneously installed in patients experiencing atrial fibrillations and other heart conditions where thrombosis may form in the atrial appendages. A variety of means for securing the membranes in place are disclosed. The membranes may be held in place over the ostium of the atrial appendage or fill the inside of the atrial appendage.

The means for holding the membranes in place over the ostium of the atrial appendages include prongs, stents, anchors with tethers or springs, disks with tethers or springs, umbrellas, spiral springs filling the atrial appendages, and adhesives. After the membrane is in place a filler substance may be added inside the atrial appendage to reduce the volume, help seal the membrane against the ostium or clot the blood in the atrial appendage. The membranes may have anticoagulants to help prevent thrombosis. The membranes be porous such that endothelial cells cover the membrane presenting a living membrane wall to prevent thrombosis. The membranes may have means to center the membranes over the ostium. Sensors may be attached to the membrane to provide information about the patient.

Priority: US1999-428008 Applic. Date: 1999-10-27

Inventor: VAN TASSEL ROBERT A [US]; HAUSER ROBERT G [US]


Application No.: US20030194420A1  Published: 16/Oct/2003

Title: Process for loading a drug delivery device

Applicant/Assignee:

Application No.: 10/121430   Filing Date: 11/Apr/2002

Abstract:The invention provides methods for incorporating one or more compositions, each containing at least one active ingredient, into a preformed water-soluble pharmaceutical carrier device. Sustained delivery devices and methods of using such devices are also provided.

Priority:

Inventor: HOLL RICHARD [US]; KRAVIG KASEY [US]; JEFFERS SCOTT [US]; OSBORNE DAVID W [US]; BEAUDOIN A GERALD [US]; POSHUSTA AMY [US]


Application No.: US20030195611A1  Published: 16/Oct/2003

Title: Covering and method using electrospinning of very small fibers

Applicant/Assignee:

Application No.: 10/314086   Filing Date: 06/Dec/2002

Abstract:A versatile covering process enabled through the identification and manipulation of a plurality of variables present in the electrospinning method of the present invention. By manipulating and controlling various identified variables, it is possible to use electrospinning to predictably produce thin materials having desirable characteristics. The fibers created by the electrospinning process have diameters averaging less than 100 micrometers. Proper manipulation of the identified variables ensures that these fibers are still wet upon contacting a target surface, thereby adhering with each other to form a cloth-like material and, if desired, adhering to the target surface to form a covering thereon. The extremely small size of these fibers, and the resulting interstices therebetween, provides an effective vehicle for drug and radiation delivery, and forms an effective membrane for use in fuel cells.

Priority: US20020372721P Applic. Date: 2002-04-11

Inventor: GREENHALGH SKOTT E [US]; KIEFER ROB [US]; SCHWARTZ ROBERT S [US]


Application No.: US20030199014A1  Published: 23/Oct/2003

Title: In vitro methods for screening for blood coagulation disorders using metal ions

Applicant/Assignee: INSTRUMENTATION LABORATORY, S.P.A

Application No.: 10/331731   Filing Date: 30/Dec/2002

Abstract:In vitro methods for qualitative screening and/or quantitative determination of the functional activity of components of the Protein C anticoagulant pathway of blood coagulation are described. The methods entail measuring the conversion rate of a substrate by an enzyme, the activity of which is related to the Protein C anticoagulant activity, in a blood sample of a human comprising coagulation factors and said substrate, after at least partial activation of coagulation through the intrinsic, extrinsic or common pathway and triggering coagulation by adding calcium ions

and comparing said conversion rate with the conversion rate of a normal human blood sample determined in the same way. The methods include the addition of additional metal ions to the sample to enhance activity, sensitivity and resolution. Kits and reagents for use in the methods are also provided.

Priority: EP19980105043 Applic. Date: 1998-03-19; US2002-050441 Applic. Date: 2002-01-16; US1999-273413 Applic. Date: 1999-03-19

Inventor: ROSEN BERT STEFFEN [SE]; HALL CHRISTINA MARIA YVONNE [SE]


Application No.: US20030199428A1  Published: 23/Oct/2003

Title: Onset of force development as a marker of thrombin generation

Applicant/Assignee: HEMODYNE, INC

Application No.: 10/405472   Filing Date: 03/Apr/2003

Abstract:Platelet contractile force (PCF) is used as a surrogate marker of thrombin generation. PCF generation occurs concomitant with the burst of prothrombin fragment F 1+2 release. The time between assay start and PCF onset is identified as the thrombin generation time (TGT), and is used in assessing risk of bleeding, in diagnosing various disorders, and in monitoring the effects of pharmaceutical and other treatments. TGT is prolonged in clotting factor deficiencies and in the presence of direct and indirect thrombin inhibitors. TGT shortens to normal with clotting factor replacement and shortens with administration of rVIIa. TGT is short in thrombophilic states such as coronary artery disease, diabetes and thromboangiitis obliterans and prolongs toward normal with oral and intravenous anticoagulants.

Priority: US20020369559P Applic. Date: 2002-04-04; US20020387409P Applic. Date: 2002-06-11

Inventor: CARR MARCUS [US]


Application No.: US20030199803A1  Published: 23/Oct/2003

Title: Integrated automatic blood collection and processing unit

Applicant/Assignee: MISSION MEDICAL, INC

Application No.: 10/179920   Filing Date: 24/Jun/2002

Abstract:A system for automatically collecting and separating whole blood into its components is described. The system includes a console, which contains all motors, pumps, sensors, valves and control circuitry, and a unique disposable set that includes a cassette supporting a centrifuge with an improved design, pump interfaces with an improved design, component and solution bags, and tubing. Various processes are implemented using a specific disposable set for each process which allows automatic identification of the process to be performed the console.

Priority: US20010300873P Applic. Date: 2001-06-25; US20020374141P Applic. Date: 2002-04-19

Inventor: ROBINSON THOMAS C [US]; ROBINSON THOMAS P [US]; D ELIA RICHARD [US]; SAHINES THOMAS [US]; EIBE PAUL [US]


Application No.: US20030201160A1  Published: 30/Oct/2003

Title: Removal of adenine during a process of pathogen reducing blood and blood components

Applicant/Assignee: GAMBRO, INC GAMBRO INC

Application No.: 10/423200   Filing Date: 24/Apr/2003

Abstract:The methods of this invention involve preventing the formation of a complex between adenine and riboflavin by reducing the amount of adenine in a solution containing blood or blood components to be pathogen reduced.

Priority: US20020375849P Applic. Date: 2002-04-24

Inventor: GOODRICH RAYMOND P [US]; DOANE SUZANN K [US]


Application No.: US20030206828A1  Published: 06/Nov/2003

Title: Whole blood sampling device

Applicant/Assignee: BECKMAN COULTER, INC

Application No.: 10/139569   Filing Date: 06/May/2002

Abstract:A portable hand-held blood sampling device having a self-filling capability includes a blood separation filter. The filter has a plurality of pores sized to permit passage of selected blood constituents such as blood plasma through the device. The device has a separated blood conduit that extends beyond the outlet of the device and is shaped for easy penetration into a self-sealing septum of a blood analyzer. An annular shield extends from the device outlet beyond the conduit to prevent inadvertent contact of the conduit by a user.

Priority:

Inventor: BELL MICHAEL L [US]


Application No.: US20030208258A1  Published: 06/Nov/2003

Title: Vascular grafts surrounding an expanded stent for transplantation

Applicant/Assignee:

Application No.: 10/137721   Filing Date: 02/May/2002

Abstract:The present invention is directed to a vascular graft surrounding an expanded stent for transplantation into a patient.

Priority:

Inventor: REILLY TOM [US]; PICCONE VINCENT A [US]


Application No.: US20030211008A1  Published: 13/Nov/2003

Title: Apparatus for determining platelet inhibitor response

Applicant/Assignee: MEDTRONIC, INC

Application No.: 10/410003   Filing Date: 09/Apr/2003

Abstract:An apparatus is provided for performing an activated clotting time test on a sample of blood containing platelets, the apparatus comprising a plurality of test cells, said cells being adapted for receiving an aliquot portion of said sample, wherein each of said cells comprises an anticoagulant and a platelet inactivating agent, and wherein at least one of said cells further comprises a clotting activator, wherein a clotting time is determined for each of said aliquot portions, and wherein a relative clotting time for each of said aliquot portions comprising the clotting activator is determined as compared to a reference clotting time for said at least one cell containing no clotting activator, wherein said relative clotting times in said cells are determinative of the clotting activation of said clotting activator.

Priority: US2001-811216 Applic. Date: 2001-03-16; US1999-225051 Applic. Date: 1999-01-04; US1996-640277 Applic. Date: 1996-04-30

Inventor: BAUGH ROBERT F [US]; LANE CAROLE G [US]; WILSON ADRIAN C [US]


Application No.: US20030211135A1  Published: 13/Nov/2003

Title: Stent having electrospun covering and method

Applicant/Assignee:

Application No.: 10/313161   Filing Date: 06/Dec/2002

Abstract:A versatile covering process enabled through the identification and manipulation of a plurality of variables present in the electrospinning method of the present invention. By manipulating and controlling various identified variables, it is possible to use electrospinning to predictably produce thin materials having desirable characteristics. The fibers created by the electrospinning process have diameters averaging less than 100 micrometers. Proper manipulation of the identified variables ensures that these fibers are still wet upon contacting a target surface, thereby adhering with each other to form a cloth-like material and, if desired, adhering to the target surface to form a covering thereon. The extremely small size of these fibers, and the resulting interstices therebetween, provides an effective vehicle for drug and radiation delivery, and forms an effective membrane for use in fuel cells.

Priority: US20020372721P Applic. Date: 2002-04-11

Inventor: GREENHALGH SKOTT E [US]; KIEFER ROB [US]; SCHWARTZ ROBERT S [US]


Application No.: US20030211460A1  Published: 13/Nov/2003

Title: Methods for detecting activity of clotting factors

Applicant/Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA

Application No.: 10/312685   Filing Date: 30/Dec/2002

Abstract:Whole blood assays and kits are described for evaluating dosage of factor VIIa or activated protein C, as well as for monitoring responsiveness to factor VIIa or activated protein C.

Priority: US2000-607716 Applic. Date: 2000-06-30; WO2001US20307 Applic. Date: 2001-06-26

Inventor: NELSESTUEN GARY L [US]


Application No.: US20030212054A1  Published: 13/Nov/2003

Title: Substituted amino methyl factor Xa inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/304810   Filing Date: 26/Nov/2002

Abstract:The present application describes substituted-aminomethyl substituted compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Priority: US20010337051P Applic. Date: 2001-12-04

Inventor: QUAN MIMI L [US]; WEXLER RUTH R [US]


Application No.: US20030215502A1  Published: 20/Nov/2003

Title: Fast dissolving dosage forms having reduced friability

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 10/392383   Filing Date: 20/Mar/2003

Abstract:Disclosed is a rapidly disintegrating or dissolving (fast melt) solid dosage form of at least one active agent and at least one pharmaceutically acceptable water-disintegrable or water-soluble excipient, wherein the dosage form has two opposed double-convex surfaces. The dosage form of the invention has the advantage of exhibiting low friability with a very low disintegration time.

Priority: US20020365526P Applic. Date: 2002-03-20

Inventor: PRUSS KARL [US]; WENDEL SUSAN [US]; RUDDY STEPHEN [US]


Application No.: US20030215784A1  Published: 20/Nov/2003

Title: Method and apparatus for inactivation of biological contaminants using photosensitizers

Applicant/Assignee:

Application No.: 10/377524   Filing Date: 28/Feb/2003

Abstract:Methods and apparatuses are provided for inactivation of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an effective, non-toxic amount of an endogenous photosensitizer to a fluid and exposing the fluid to photoradiation sufficient to activate the endogenous photosensitizer whereby microorganisms are inactivated. Other fluids, including juices, water and the like, may also be decontaminated by these methods as may surfaces of foods, animal carcasses, wounds, food preparation surfaces and bathing and washing vessel surfaces. Alloxazines and K- and L-vitamins are among the preferred photosensitizers. Systems and apparatuses for flow-through and batch processes are also provided for decontamination of such fluids using photosensitizers.

Priority: US2000-586147 Applic. Date: 2000-06-02; US1999-357188 Applic. Date: 1999-07-20; US1998-119666 Applic. Date: 1998-07-21

Inventor: DUMONT LARRY JOE [US]; GOODRICH RAYMOND PAUL [US]


Application No.: US20030215832A1  Published: 20/Nov/2003

Title: Method for processing blood samples in order to produce DNA complex patterns for diagnostic applications

Applicant/Assignee:

Application No.: 10/313996   Filing Date: 06/Dec/2002

Abstract:A method for processing blood samples in order to produce DNA complex patterns for diagnostic applications. The method includes the aggregation and deposition of the DNA complex from the blood of a human being in order to form a unique pattern which can be used as a medical diagnostic tool to identify a change in the body caused by a specific physiological or pathological condition. The method identifies a change in the body by comparing the pattern of a person before a specific physiological or pathological condition to the pattern of a person after the condition. The specific condition causing the change is then determined by identifying and associating the unique pattern after the condition to the specific condition or disease based on comparative appearance. The present invention can be used as a diagnostic tool to aid in the determination of, among other things, the sex of a human fetus within a few days after conception, and the presence of a cancerous condition in the earliest stage of the disease.

Priority: US2001-764783 Applic. Date: 2001-01-17

Inventor: PAZ DE RODRIGUEZ GLORIA ELENA [MX]; WU GIN [US]


Application No.: US20030219440A1  Published: 27/Nov/2003

Title: 3-deoxyglucosone and skin

Applicant/Assignee: DYNAMIS THERAPEUTICS, INC

Application No.: 10/198706   Filing Date: 18/Jul/2002

Abstract:The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.

Priority: US20020392530P Applic. Date: 2002-06-27; US20020373103P Applic. Date: 2002-04-17

Inventor: TOBIA ANNETTE [US]; KAPPLER FRANCIS [US]


Application No.: US20030219490A1  Published: 27/Nov/2003

Title: Nanoparticulate megestrol formulations

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 10/412669   Filing Date: 14/Apr/2003

Abstract:The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.

Priority: US20020430348P Applic. Date: 2002-12-03; US20020371680P Applic. Date: 2002-04-12

Inventor: HOVEY DOUGLAS [US]; PRUITT JOHN [US]; RYDE TUULA [US]


Application No.: US20030220383A1  Published: 27/Nov/2003

Title: Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders

Applicant/Assignee: AVENTIS PHARMA DEUTSCHLAND GMBH

Application No.: 10/367546   Filing Date: 14/Feb/2003

Abstract:Inhibitors of the cellular sodium-dependent chloride/bicarbonate exchangers show an inhibiting effect on the secretion of von-Willebrand factor. These inhibitors can therefore be employed for the treatment of thrombotic and inflammatory disorders.

Priority: DE20021006354 Applic. Date: 2002-02-14; US20020366756P Applic. Date: 2002-03-22

Inventor: LANG HANS-JOCHEN [DE]; KLEEMANN HEINZ-WERNER [DE]; SCHNEIDER STEFAN WERNER [DE]; OBERLEITHNER HANS [DE]; NIEMEYER ANDRE [DE]


Application No.: US20030224043A1  Published: 04/Dec/2003

Title: Immediate release dosage forms containing solid drug dispersions

Applicant/Assignee: PFIZER INC

Application No.: 10/355706   Filing Date: 31/Jan/2003

Abstract:High loading immediate release dosage forms containing at least 30 wt % of a solid drug dispersion, at least 5 wt % of a disintegrant and a porosigen are disclosed that exhibit excellent strength and aqueous solubility.

Priority: US20020353840P Applic. Date: 2002-02-01

Inventor: APPEL LEAH E [US]; BYERS JOHN E [US]; CREW MARSHALL D [US]; FRIESEN DWAYNE T [US]; HANCOCK BRUNO C [US]; SCHADTLE STEPHEN J [US]


Application No.: US20030225110A1  Published: 04/Dec/2003

Title: Tetrahydroquinoline derivatives as antithrombotic agents

Applicant/Assignee: BRISTOL-MYERS SQUIBB PHARMA COMPANY

Application No.: 10/223860   Filing Date: 20/Aug/2002

Abstract:This invention relates generally to tetracyclic tetrahydroquinoline compounds, and analogues thereof, and pharmaceutically acceptable salt forms thereof, which are selective inhibitors of serine protease enzymes, especially factor VIIa

pharmaceutical compositions containing the same

and methods of using the same as anticoagulant agents for modulation of the coagulation cascade.

Priority: US20010313549P Applic. Date: 2001-08-20

Inventor: ZHOU JINGLAN [US]; ROBINSON LESLIE [US]; GUBERNATOR NIKOLAUS M [US]; SAIAH EDDINE [US]; BAI XU [US]; GU XIN [US]


Application No.: US20030225115A1  Published: 04/Dec/2003

Title: Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 10/400073   Filing Date: 27/Mar/2003

Abstract:Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR<9 >and Het, R<1>, R<7>, R<8>, R<12>-R<15 >R, R, R, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US2002-241513 Applic. Date: 2002-09-12; US2001-012445 Applic. Date: 2001-12-12; US2001-827292 Applic. Date: 2001-04-06; US2000-482540 Applic. Date: 2000-01-14; US1998-199167 Applic. Date: 1998-11-25; US19980079107P Applic. Date: 1998-03-23; US19970067324P Applic. Date: 1997-12-05; US19970066475P Applic. Date: 1997-11-26

Inventor: LU TIANBAO [US]; TOMCZUK BRUCE E [US]; MARKOTAN THOMAS P [US]; SIEDEM COLLEEN [US]


Application No.: US20030225453A1  Published: 04/Dec/2003

Title: Inflatable intraluminal graft

Applicant/Assignee: TRIVASCULAR, INC

Application No.: 10/289137   Filing Date: 05/Nov/2002

Abstract:A collapsible stent graft for aortic aneurysms comprises a collapsible inner tubular member (26) and an outer layer (24) fused or adhered thereto such as to provide a spiral inflatable member (22) therebetween. The stent graft is inserted into an artery in the collapsed state and then expanded into position by introducing a liquid into the inflatable member and sealing the member. The graft is held in place by an expandable stent (40).

Priority: GB19990004722 Applic. Date: 1999-03-03; US2002-168053 Applic. Date: 2002-06-14

Inventor: MURCH CLIFFORD ROWAN [GB]


Application No.: US20030228358A1  Published: 11/Dec/2003

Title: Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials

Applicant/Assignee:

Application No.: US 2003-355747   Filing Date: 31/Jan/2003

Abstract:A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment.

Priority: US20020354081P Applic. Date: 2002-02-01

Inventor: PERLMAN MICHAEL E [US]; SHANKER RAVI M [US]; BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; RABENSTEIN MARK D [US]; SMITHEY DAN T [US]


Application No.: US20030229373A1  Published: 11/Dec/2003

Title: Apparatus for preventing regeneration of endometrial synechia

Applicant/Assignee:

Application No.: 10/457989   Filing Date: 10/Jun/2003

Abstract:An apparatus for preventing regeneration of endometrial synechia, which comprises: an air injection tube, into which air is injected from the outside

a drainage lumen tube for draining intrauterine residue and blood, in which the air injection tube is received

an air hole formed at one side around an upper end of the drainage lumen tube to eject the air passed through the air injection tube

and a balloon fixed to the drainage lumen tube while covering the air hole formed at one side around the upper end of the drainage lumen tube, the balloon being configured to be inflated to conform to a shape of a woman's uterus within the uterus by the air injected through the air injection tube and air hole. The balloon of the apparatus is adapted to uniformly and safely spread to the whole interior of the uterus including the intrauterine isthmus and fundus uteri, thereby preventing regeneration of endometrial synechia as well as minimizing inconvenience to patients. Furthermore, the apparatus allows a concurrent hormone treatment to be carried out to promote formation of new endometrium.

Priority: KR20020032475 Applic. Date: 2002-06-11

Inventor: LEE WOO-DONG [KR]


Application No.: US20030229390A1  Published: 11/Dec/2003

Title: On-stent delivery of pyrimidines and purine analogs

Applicant/Assignee: CONTROL DELIVERY SYSTEMS, INC

Application No.: 10/401039   Filing Date: 27/Mar/2003

Abstract:Disclosed is a sustained release system that includes a polymer, a nucleoside analog or prodrug or codrug thereof, and optionally one or more additives that reduce the rate of release of the drug from the polymer. The device using such inventive system permits improved drug delivery in a localized manner over a prolonged period of time.

Priority: US2002-245840 Applic. Date: 2002-09-17; US20010322428P Applic. Date: 2001-09-17; US20020372761P Applic. Date: 2002-04-15

Inventor: ASHTON PAUL [US]; CHEN JIANBING [US]


Application No.: US20030232432A1  Published: 18/Dec/2003

Title: Growth of human Mesenchymal Stem Cells (hMSC) using umbilical cord blood serum and the method for the peparation thereof

Applicant/Assignee: RELIANCE LIFE SCIENCES PVT. LTD

Application No.: 10/409458   Filing Date: 08/Apr/2003

Abstract:A method of isolating and growing human mesenchymal stem calls (hMSC) by culturing human stem cells in human umbilical cord blood serum. For this purpose blood is collected from the umbilical cord at the time of birth, after the infant is separated from the umbilical cord, and the blood is collected from an umbilical vein free of anticoagulants. The blood is collected in a blood bag having a collecting needle which is inserted into the umbilical vein and the blood is allowed to flow from the vein into the blood bag, and the blood is allowed to clot at room temperature and the bag is transported to a processing area which is a cGMP clean room. The method also includes aspirating Human Mesenchymal Stem Cells (hMSC) present in bone marrow, diluting bone marrow aspirate with tissue culture medium

plating cell suspension into tissue culture flasks so that Human Mesenchymal Stem Cells (hMSC) can adhere for 24 hours

transferring the resulting supernatant to fresh flasks for the remaining Human Mesenchymal Stem Cells (hMSC) to adhere, feeding cultures every 3 days using the medium and cultures reach confluence by 3 weeks, adding 5-aza cytidine reagent to these cultures at final concentration of 5-20 micro molars and allowing the culture to grow for another 3 days.

Priority: US20020371137P Applic. Date: 2002-04-09

Inventor: BHAT ARAVIND VENKATRAO [IN]


Application No.: US20030235617A1  Published: 25/Dec/2003

Title: Pharmaceutical dosage form for mucosal delivery

Applicant/Assignee:

Application No.: 10/360167   Filing Date: 06/Feb/2003

Abstract:A pharmaceutical tablet is provided comprising an intraorally disintegratable core and an excipient coating adherent thereto, wherein the coating comprises gellan gum. The tablet is suitable for intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, at least in part by absorption of the drug via oral mucosa of the subject.

Priority: US20020355703P Applic. Date: 2002-02-07

Inventor: MARTINO ALICE C [US]; PIERMAN STEVEN A [US]; NOACK ROBERT M [US]; BRITTEN NANCY J [US]


Application No.: US20030236482A1  Published: 25/Dec/2003

Title: Apparatus and method for in-vivo plasmapheresis using periodic backflush

Applicant/Assignee:

Application No.: 10/408657   Filing Date: 04/Apr/2003

Abstract:Apparatus and method for in-vivo plasmapheresis utilizing a plurality of elongated hollow microporous filter fibers periodically interrupt diffusion of blood plasma from a patient, and, for a selected time, backflush fluid into the fibers at a pressure and interval sufficient to cleanse the fiber pores, after which plasma diffusion is resumed. The backflush fluid, preferably a normal saline solution, may contain an anticoagulant such as heparin in suitable concentration for systemic anti-coagulation or for treating the fiber for thromboresistance.

Priority: US2001-754773 Applic. Date: 2001-01-04

Inventor: GORSUCH REYNOLDS G [US]; COOPER TOMMY [US]; HANDLEY HAROLD H [US]


Application No.: US20040001807A1  Published: 01/Jan/2004

Title: Endothelial precursor cells for enhancing and restoring vascular function

Applicant/Assignee: CORNELL RESEARCH FOUNDATION, INC

Application No.: 10/367639   Filing Date: 13/Feb/2003

Abstract:The invention provides methods of treating and preventing loss of tissue vascularization that can occur, for example, upon aging.

Priority: US2002-215271 Applic. Date: 2002-08-08; US20010311238P Applic. Date: 2001-08-09; WO2001US25175 Applic. Date: 2001-08-10; US20020357328P Applic. Date: 2002-02-15

Inventor: EDELBERG JAY [US]; RAFII SHAHIN [US]; HONG MUN [US]; LANZA ROBERT P [US]; WEST MICHAEL D [US]


Application No.: US20040002539A1  Published: 01/Jan/2004

Title: Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC

Application No.: 10/419972   Filing Date: 22/Apr/2003

Abstract:Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: wherein X is O or NR<9 >and R<1>-R<4>, R<6>-R<9>, R<11>, R<12>, R, R, R, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula L The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Priority: US2000-722363 Applic. Date: 2000-11-28; US1997-979234 Applic. Date: 1997-11-26; US19960031822P Applic. Date: 1996-11-26

Inventor: TOMCZUK BRUCE E [US]; SOLL RICHARD M [US]; LU TIANBAO [US]; FEDDE CYNTHIA L [US]; ILLIG CARL R [US]; MARKOTAN THOMAS P [US]


Application No.: US20040006017A1  Published: 08/Jan/2004

Title: Methods for enhanching the lysing of coagulated blood with apolipoproteine2 phenotype

Applicant/Assignee:

Application No.: 10/398880   Filing Date: 17/Jul/2003

Abstract:Methods for enhancing teh lysis of coagulated blood comprise administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof. Additional methods for enhancing the lysis of coagulated blood comprise administering to an individual a specific level of clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the riks of blood coagulation comprise administering to blood a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual.

Priority: WO2001US42719 Applic. Date: 2001-10-12; US20000240407P Applic. Date: 2000-10-13

Inventor: BRODERICK JOSEPH P [US]; CLARK JOSEPH F [US]; WOO DANIEL [US]


Application No.: US20040006062A1  Published: 08/Jan/2004

Title: Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/429461   Filing Date: 05/May/2003

Abstract:The present application describes sulfonylaminovalerolactams and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US20020378313P Applic. Date: 2002-05-06

Inventor: SMALLHEER JOANNE M [US]; PINTO DONALD J [US]; WANG SHUAIGE [US]; QIAO JENNIFER X [US]; HAN WEI [US]; HU ZILUN [US]


Application No.: US20040006065A1  Published: 08/Jan/2004

Title: Bicyclic pyrimidinones as coagulation cascade inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/465426   Filing Date: 19/Jun/2003

Abstract:The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel amino-bicyclic pyrimidinone compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade

for example thrombin, factor Xa, factor XIa, factor IXa, and/or factor VIIa. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

Priority: US20020391784P Applic. Date: 2002-06-26

Inventor: GLUNZ PETER W [US]


Application No.: US20040009972A1  Published: 15/Jan/2004

Title: Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase

Applicant/Assignee:

Application No.: 10/461736   Filing Date: 13/Jun/2003

Abstract:Compounds having the formula (I), are useful as inhibitors of mitochondrial F1F0 ATP hydrolase, wherein R1, R5 and R7 are optional substituents, R2, R3 and R4 are hydrogen, alkyl, or substituted alkyl, or comprise a bond to R, T or Y

Z and Y are selected from C(=O), -CO2-, -SO2-, -CH2-, -CH2C(=O)-, and -C(=O)C(=O)-, or Z may be absent

R and T are CH2-, -C(=O)-, or -CH[(CH2)p(Q)]-, wherein Q is NR10R11, OR10 or CN and p is 0, 1 or 2

R6 is alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, cycloalkyl, heterocyclo, or heteroaryl

R10 and R11 are hydrogen, alkyl, or substituted alkyl

and r and t are 0 or 1.

Priority: US20020389213P Applic. Date: 2002-06-17

Inventor: DING CHARLES Z [US]; HAMANN LAWRENCE G [US]; STEIN PHILIP D [US]; PUDZIANOWSKI ANDREW T [US]


Application No.: US20040013575A1  Published: 22/Jan/2004

Title: Protease inhibitor sample collection system

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 10/436263   Filing Date: 13/May/2003

Abstract:A collection container and a method for collecting a biological sample, particularly whole blood, includes at least one stabilizing agent in an amount effective to stabilize and inhibit protein degradation and/or fragmentation. The stabilizing agent is able to stabilize proteases in the biological sample, particularly at the point of collection, by inhibiting protein degradation and/or fragmentation in the sample when the sample is stored. The stabilizing agent comprises or consists of one or more protease inhibitors.

Priority: US20020379399P Applic. Date: 2002-05-13

Inventor: STEVENS TIMOTHY [US]; HAYWOOD BRUCE [US]; DASTANE AJIT [US]; LIN FU-CHUNG [US]


Application No.: US20040018195A1  Published: 29/Jan/2004

Title: Diabetes-related immunoglobulin derived proteins, compositions, methods and uses

Applicant/Assignee:

Application No.: 10/397786   Filing Date: 26/Mar/2003

Abstract:The present invention relates to at least one novel diabetes related human Ig derived protein or specified portion or variant, including isolated nucleic acids that encode at least one diabetes related Ig derived protein or specified portion or variant, diabetes related Ig derived protein or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Priority: US20020367902P Applic. Date: 2002-03-26

Inventor: GRISWOLD DON EDGAR [US]; LI JIAN [US]; LI LI [US]


Application No.: US20040018242A1  Published: 29/Jan/2004

Title: Nanoparticulate nystatin formulations

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/429245   Filing Date: 05/May/2003

Abstract:The present invention is directed to nanoparticulate compositions comprising nystatin. The nystatin particles of the composition have an effective average particle size of less than about 2000 nm.

Priority: US20020423385P Applic. Date: 2002-11-04; US20020377599P Applic. Date: 2002-05-06; US20020380008P Applic. Date: 2002-05-07

Inventor: CUNNINGHAM JAMES [US]; LIVERSIDGE ELAINE [US]


Application No.: US20040018997A1  Published: 29/Jan/2004

Title: Inactivation of West Nile virus and malaria using photosensitizers

Applicant/Assignee: GAMBRO, INC

Application No.: 10/358073   Filing Date: 03/Feb/2003

Abstract:Methods and apparatuses are provided for inactivation of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an effective, non-toxic amount of a photosensitizer to a fluid and exposing the fluid to photoradiation sufficient to activate the photosensitizer whereby microorganisms are inactivated.

Priority: US2000-586147 Applic. Date: 2000-06-02; US20020353162P Applic. Date: 2002-02-01; US1999-357188 Applic. Date: 1999-07-20; US1998-119666 Applic. Date: 1998-07-21

Inventor: REDDY HEATHER [US]; GOODRICH RAYMOND P [US]


Application No.: US20040019033A1  Published: 29/Jan/2004

Title: Mandelic acid derivatives and their use as throbin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 10/432411   Filing Date: 21/May/2003

Abstract:There is provided a compound of formula I wherein R, R<1>, R<2>, Y and R<3 >have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE20000004458 Applic. Date: 2000-12-01; SE20010000965 Applic. Date: 2001-03-19; SE20010001239 Applic. Date: 2001-04-06; WO2001SE02657 Applic. Date: 2001-11-30

Inventor: INGHARDT TORD [SE]; JOHANSSON ANDERS [SE]; SVENSSON ARNE [SE]


Application No.: US20040019184A1  Published: 29/Jan/2004

Title: Remedies for ischemic disease

Applicant/Assignee: KEIICHI FUKUDA YASUYO HISAKA CHUGAI SEIYAKU KABUSHIKI KAISHA

Application No.: 10/392381   Filing Date: 20/Mar/2003

Abstract:An effective remedy for ischemic disease, which contains human granulocyte colony-stimulating factor (human G-CSF) and hepatocyte growth factor (HGF) as active ingredients, is disclosed. By administering this remedy, an effective therapy particularly for obstructive arteriosclerosis is provided which can eliminate drawbacks with conventional therapies such as kinesitherapy, pharmacotherapy, revascularization and recently proposed therapies such as gene therapy and intramuscular inoculation of bone marrow cells. Furthermore, the remedy of the present invention can become a remedy for ischemic disease such as ischemic cerebrovascular disorder or ischemic heart disease.

Priority: US2003-380200 Applic. Date: 2003-03-13; JP20000277562 Applic. Date: 2000-09-13; WO2001JP07946 Applic. Date: 2001-09-13

Inventor: FUKUDA KEIICHI [JP]; HISAKA YASUYO [JP]; MIYAI TATSUYA [JP]; TAMURA MASAHIKO [JP]


Application No.: US20040023201A1  Published: 02/Oct/2003

Title: Storage solution containing photosensitizer for inactivation of biological contaminants

Applicant/Assignee:

Application No.: 10/374907   Filing Date: 25/Feb/2003

Abstract:A platelet/additive solution comprising bicarbonate, citrate and glucose. Additionally, a platelet/additive and treatment solution comprising bicarbonate, citrate, glucose and a photosensitizer.

Priority: US2000-725426 Applic. Date: 2000-11-28

Inventor: MCBURNEY LAURA [US]; GOODRICH RAYMOND P [US]


Application No.: US20040024342A1  Published: 05/Feb/2004

Title: Extracorporeal fluid circuit and related methods

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Application No.: 10/402912   Filing Date: 28/Mar/2003

Abstract:A circuit for extracorporeal treatment of a body fluid, the circuit including in serial fluidic communication an inlet for receiving the body fluid from a patient, a first pump, a first treatment device for processing the body fluid, a second pump, an outlet for returning processed body fluid to the patient

and a shunt. The shunt is upstream from the first pump and downstream from the second pump.

Priority: US2000-553772 Applic. Date: 2000-04-21; US19990130688P Applic. Date: 1999-04-23

Inventor: WEITZEL WILLIAM FREDERICK [US]; HUMES H DAVID [US]; PAGANINI EMIL PRESLEY [US]; BUFFINGTON DEBORAH ANN [US]; FUNKE ANGELA J [US]


Application No.: US20040028707A1  Published: 12/Feb/2004

Title: Enhanced pharmacokinetic profile of intradermally delivered substances

Applicant/Assignee:

Application No.: 10/443361   Filing Date: 22/May/2003

Abstract:A method for administration of a substance into the dermis of a mammal is disclosed. The method involves administration into the dermis by injection which results in improved systemic absorption relative to that obtained upon subcutaneous administration of the substance.

Priority: US2001-897801 Applic. Date: 2001-06-29

Inventor: PINKERTON THOMAS C [US]


Application No.: US20040028747A1  Published: 12/Feb/2004

Title: Crystalline drug particles prepared using a controlled precipitation process

Applicant/Assignee:

Application No.: 10/213956   Filing Date: 06/Aug/2002

Abstract:Drug particles which are essentially crystalline and have a mean particle size below about 2 microns, when dispersed in water, are described. When added to an aqueous medium at 25-95% of the equilibrium solubility of the drug substance, the drug particles show complete dissolution, as characterized by a 95% reduction in turbidity, in less than 5 minutes. Using a controlled precipitation process to prepare such drug particles is also described. Such drug particles exhibit an enhanced dissolution rate and better stability as compared to particles prepared according to processes described in the prior art.

Priority:

Inventor: TUCKER CHRISTOPHER J [US]; SVENSON SONKE [US]; HITT JAMES E [US]; CURTIS CATHY A [US]


Application No.: US20040029099A1  Published: 12/Feb/2004

Title: Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/323736   Filing Date: 20/Dec/2002

Abstract:Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.

Priority: US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21

Inventor: COOPER EUGENE R [US]; BULLOCK JOHN A [US]; CHIPPARI JOHN R [US]; SCHAEFER JOHN L [US]; PATEL RAKESH A [US]; JAIN RAJEEV [US]; STRASTERS JOOST [US]; RYDE NIELS P [US]; RUDDY STEPHEN B [US]


Application No.: US20040030281A1  Published: 12/Feb/2004

Title: Integrated infusion and aspiration system and method

Applicant/Assignee: BREG, INC

Application No.: 10/218106   Filing Date: 12/Aug/2002

Abstract:An integrated infusion and aspiration system includes of a flow control system and a catheter assembly. The catheter assembly includes an infusion catheter and an aspiration catheter, each having ports located at the distal end of thereof. The distal ends of the catheters are separated so that the aspiration catheter ports can be positioned on an opposing side of a surgical wound site from the infusion catheter ports. Methods of operation of the integrated infusion and aspiration system provides for uninterrupted aspiration with concurrent controlled delivery of an infusion solution such that the infusion solution is substantially evenly dispersed of over the wound site.

Priority:

Inventor: GOBLE E MARLOWE [US]; HOWARD MARK E [US]; MASON JEFFREY T [US]; FALLIN T WADE [US]


Application No.: US20040030377A1  Published: 12/Feb/2004

Title: Medicated polymer-coated stent assembly

Applicant/Assignee:

Application No.: 10/433620   Filing Date: 18/Jun/2003

Abstract:A stent assembly comprising an expensible tubular supporting element and at least one coat of electrospun polymer fibers, each of the at least one coat having a predetermined porosity, the at least one coat including at least one pharmaceutical agent incorporated therein for delivery of the at least one pharmaceutical agent into a body vasculature during or after implantation of the stent assembly within the body vasculature.

Priority: WO2001IL01171 Applic. Date: 2001-12-17; US2001-982017 Applic. Date: 2001-10-19

Inventor: DUBSON ALEXANDER [IL]; BAR ELI [IL]


Application No.: US20040030582A1  Published: 12/Feb/2004

Title: System and method for collecting and transmitting medical data

Applicant/Assignee:

Application No.: 10/636164   Filing Date: 06/Aug/2003

Abstract:A system and method for collecting and transmitting medical and health-related data over a network are disclosed. A measuring device measures a user's physiological attribute and produces a first signal related thereto, which an integration system coupled to the measuring device receives and converts into a second signal for transmitting over the Internet. In accordance with one aspect of a preferred embodiment, the integration system is adapted to read the first signal as it is sent from the measuring device to its display. A communications system transmits the second signal over the Internet to a remote system using any of a variety of techniques known in the art. The remote system extracts the measured physiological attribute and other associated data from the second signal and populates a database. Preferably, a web-based portal provides access to the data for one or more users.

Priority: US2000-724721 Applic. Date: 2000-11-28; US19990168942P Applic. Date: 1999-12-03

Inventor: KERR ROBERT A [US]


Application No.: US20040033222A1  Published: 19/Feb/2004

Title: Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 10/630599   Filing Date: 30/Jul/2003

Abstract:Disclosed are methods for a treating a disease or condition relating to blood coagulation and fibrinolysis using p38 MAP kinase inhibitors.

Priority: US20020403422P Applic. Date: 2002-08-14

Inventor: WOOD CHESTER C [US]; VAN DER POLL TOM [NL]


Application No.: US20040033223A1  Published: 19/Feb/2004

Title: Glycine betaine and its use

Applicant/Assignee:

Application No.: 10/635048   Filing Date: 04/Aug/2003

Abstract:The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.

Priority: BE20010000085 Applic. Date: 2001-02-05; WO2001BE00222 Applic. Date: 2001-12-21; BE19990000144 Applic. Date: 1999-03-02; WO2000BE00021 Applic. Date: 2000-03-01; WO2002BE00013 Applic. Date: 2002-02-04; US2001-945391 Applic. Date: 2001-08-31

Inventor: MESSADEK JALLAL [BE]


Application No.: US20040033267A1  Published: 19/Feb/2004

Title: Nanoparticulate compositions of angiogenesis inhibitors

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/392403   Filing Date: 20/Mar/2003

Abstract:Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US20020366542P Applic. Date: 2002-03-25; US20020365540P Applic. Date: 2002-03-20

Inventor: MERISKO-LIVERSIDGE ELAINE [US]; BOSCH H WILLIAM [US]; CARY GRETA A [US]; PRUITT JOHN [US]; RYDE TUULA [US]; JAIN RAJEEV [US]; WALTERS AMY [US]


Application No.: US20040033551A1  Published: 19/Feb/2004

Title: Assay for low molecular weight heparin

Applicant/Assignee: INTERNATIONAL TECHNIDYNE CORPORATION

Application No.: 10/222345   Filing Date: 16/Aug/2002

Abstract:A prothrombin time reagent for determination of low molecular weight heparin in fresh whole blood and in anti-coagulant treated blood is provided. The reagent is composed of recombinant animal tissue factor, and a mixture of synthetic phospholipids, which mixture includes a phosphatidylalcohol. A formulation buffer which includes a sensitivity adjuster is used in formulating the reagent. The recombinant animal tissue factor includes rabbit brain. The synthetic phospholipids of the mixture include palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylserine (POPS), and a phosphatidylalcohol. The phosphatidyl alcohol includes dioleoylphosphatidylethanol, dioleoylphosphatidylmethanol, dioleoylphosphatidylpropanol, dioleoylphosphatidylbutanol, and dioleoylphosphatidylinositol. The sensitivity adjuster included in the formulation buffer is gamma-Cyclodextrin.

The formulated reagent is air-dried and remains stable for at least 3 weeks at 37 DEG C.

Priority:

Inventor: LEE TED C K [US]; MCBRIDE AMANDA B [US]; LADUCA FRANK M [US]


Application No.: US20040034308A1  Published: 19/Feb/2004

Title: Cuff for blood pressure monitor

Applicant/Assignee: OMRON CORPORATION

Application No.: 10/461868   Filing Date: 16/Jun/2003

Abstract:In a cuff of a blood pressure monitor, a distance along bending of a first expandable portion is set so as to be different from a distance along bending of a second expandable portion at the time of deflation. When a fluid bladder for pressurizing is inflated with a fluid fed thereinto, the second expandable portion expands longer. As a result, force, which is generated on a cuff fixing element which is pushed by the fluid bladder for pressurizing, acts to a vertical direction with respect to an axial direction of a subject.

Priority: JP20020177273 Applic. Date: 2002-06-18

Inventor: INOUE TOMONORI [JP]; SANO YOSHIHIKO [JP]; TANAKA TAKAHIDE [JP]; INAGAKI TAKASHI [JP]; TANIGUCHI MINORU [JP]


Application No.: US20040034336A1  Published: 19/Feb/2004

Title: Charged liposomes/micelles with encapsulted medical compounds

Applicant/Assignee:

Application No.: 10/214959   Filing Date: 08/Aug/2002

Abstract:A charged liposome or micelle encapsulated therapeutic agent or medicament for the treatment of an obstruction in blood vessel. The present method comprises the steps of advancing a delivery catheter with a distal expansion member to the obstruction in a vessel, expanding the expansion member to a configuration wherein the expansion member dilates the obstruction and the expansion member delivers the charged liposomes or micelles with encapsulated therapeutic agents or medicaments to the obstruction. Electrical energy is applied to enhance tissue and cell penetration.

Priority:

Inventor: SCOTT NEAL [US]; SEGAL JEROME [US]


Application No.: US20040034378A1  Published: 19/Feb/2004

Title: Device for implanting occlusion spirals

Applicant/Assignee: DENDRON GMBH

Application No.: 10/202492   Filing Date: 24/Jul/2002

Abstract:Device for implanting occlusion spirals in body cavities or blood vessels with a catheter, an occlusion spiral that can be moved within the catheter in the longitudinal direction, and at least one securing means attached in the occlusion spiral, structured as a flexible lengthwise element, which passes through the length of the occlusion spiral at least in a partial region, which is characterized in that the securing means contains a material with shape memory properties.

Priority: DE20011018017 Applic. Date: 2001-04-10; WO2002EP08241 Applic. Date: 2002-07-24

Inventor: MONSTADT HERMANN [DE]; HENKES HANS [DE]


Application No.: US20040038424A1  Published: 26/Feb/2004

Title: Formaldehyde-ammonium salt complexes for the stabilization of blood cells

Applicant/Assignee: BECKMAN COULTER, INC

Application No.: 10/226825   Filing Date: 23/Aug/2002

Abstract:A stabilization reagent composition, particularly desirable for stabilizing blood samples containing platelets, comprises reactants that generate multiple species of formaldehyde-ammonium complexes

at least one inhibitor of phosphatase enzymatic activity

and at least one inhibitor of protease enzymatic activity. Blood samples and other tissues are stabilized by this composition. Such stabilized samples are produced by methods for stabilizing the tissue by contacting the sample with the composition. Methods for assessing the efficacy of such stabilizing reagents are also included in this invention.

Priority:

Inventor: MAPLES JOHN A [US]


Application No.: US20040038898A1  Published: 26/Feb/2004

Title: Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation

Applicant/Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY

Application No.: 10/646493   Filing Date: 21/Aug/2003

Abstract:This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0.1 mug/ml plasma to about 250 mug/ml plasma or from about 0.5 mug/ml plasma to about 25 mug/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery or any surgery in which obligate clamping of a blood vessel is required. This invention further provides for a pharmaceutical composition which includes an effective amount of a Factor IXa compound and a pharmaceutically acceptable carrier.

Priority: US1998-053872 Applic. Date: 1998-04-01; WO1997US08282 Applic. Date: 1997-05-15; US1996-648561 Applic. Date: 1996-05-16

Inventor: ROSE ERIC [US]; STERN DAVID [US]; SCHMIDT ANN MARIE [US]; SPANIER TALIA [US]


Application No.: US20040038937A1  Published: 26/Feb/2004

Title: Method and device for avoiding alteration of a substance having biological activities

Applicant/Assignee:

Application No.: 10/332609   Filing Date: 25/Aug/2003

Abstract:The invention concerns a method applied to a substance treated to exhibit a biological activity, for example a coagulating or anticoagulation activity. The treated substance has been obtained from a source substance having the biological activity, after a treatment such that the treated substance does not contain any molecule of the source substance in significant amount. The treatment can in particular consist in using a high dilution process of the same type used for producing homeopathic solutions or granules. The method is designed to protect the treated substance from external factors to which it is subjected and is characterised in that it comprises the step which consists in placing the treated substance in a chamber (19), sheltered from electromagnetic fields. The chamber (19) is enclosed with a magnetic shield (19a) made in particular of soft iron or mumetal.

Priority: FR20000009169 Applic. Date: 2000-07-12; WO2001FR02172 Applic. Date: 2001-07-05

Inventor: BENVENISTE JACQUES [FR]; GUILLONNET DIDIER [FR]


Application No.: US20040038986A1  Published: 26/Feb/2004

Title: Carbamate derivatives, process for producing the same and use thereof

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 10/416240   Filing Date: 06/May/2003

Abstract:Novel carbamate derivatives which are useful as drugs because of inhibiting activated blood coagulation factor X and thus exerting an anticoagulant effect. Compounds represented by the formula: wherein R<1 >represents a group represented by the formula: (wherein Y<1 >represents CH=CH, etc.), which may be substituted, etc.

the ring A represents an oxo-substituted nitrogen-containing heterocyclic ring which may be further substituted

R<2 >represents a hydrogen atom, optionally substituted C1-4 alkyl, etc.

R<3 >represents optionally substituted C1-4 alkyl, etc.

and Z represents an optionally substituted nitrogen containing heterocyclic group, etc., or salts thereof.

Priority: JP20000341067 Applic. Date: 2000-11-08; WO2001JP09759 Applic. Date: 2001-11-08

Inventor: ITOH FUMIO [JP]; BANNO HIROSHI [JP]; KAWAMURA MASAKI [JP]; KITAMURA SHUJI [JP]


Application No.: US20040038997A1  Published: 26/Feb/2004

Title: Method of measuring platelet activation

Applicant/Assignee: BARTS AND THE LONDON NHS TRUST

Application No.: 10/415336   Filing Date: 02/Sep/2003

Abstract:Platelet activation is measured by determining Mean Platelet Component (MPC) of suspended blood platelets, using a specific anticoagulant composition. The composition comprises at least one component for effecting platelet sphering (for example EDTA), and at least one platelet antagonist (for example at least one of, and preferably all three of theophylline, adenosine and dipyridamole).

Priority: GB20000027309 Applic. Date: 2000-11-08; WO2001GB04946 Applic. Date: 2001-11-08

Inventor: MACEY MARION G [GB]


Application No.: US20040039437A1  Published: 26/Feb/2004

Title: Medical device exhibiting improved adhesion between polymeric coating and substrate

Applicant/Assignee: MEDTRONIC, INC

Application No.: 10/640701   Filing Date: 13/Aug/2003

Abstract:Polymer-coated medical devices having improved structural integrity and drug elution profile, and related methods. Treatment of a polymeric undercoat layer to reflow the undercoat polymer results in a substrate/coating interface with improved adhesion.

Priority: US20020403479P Applic. Date: 2002-08-13

Inventor: SPARER RANDALL V [US]; HOBOT CHRISTOPHER M [US]; LYU SUPING [US]


Application No.: US20040043505A1  Published: 04/Mar/2004

Title: Collection assembly

Applicant/Assignee:

Application No.: 10/430266   Filing Date: 07/May/2003

Abstract:The present invention is directed to a method and device for collecting and stabilizing a biological sample, particularly a whole blood sample. More specifically, the present invention relates to the use of about 5.6 to about 37.5 mM, preferably about 5.6 to about 10.1 mM, EDTA during collection of the sample and to evacuated fluid sample containers having an amount of EDTA contained therein such that, when the sample is collected, the amount achieved is about 5.6 to about 37.5 mM, preferably about 5.6 to about 10.1 mM, EDTA to stabilize the sample.

Priority: US20020377986P Applic. Date: 2002-05-07

Inventor: WALENCIAK MATTHEW [US]; RAINEN LYNNE [US]; GROELZ DANIEL [DE]; BASTIAN HELGE [DE]; OELMUELLER UWE [DE]


Application No.: US20040048372A1  Published: 11/Mar/2004

Title: Post-partum mammalian placenta, its use and placental stem cells therefrom

Applicant/Assignee: ANTHROGENESIS CORPORATION

Application No.: 10/640428   Filing Date: 12/Aug/2003

Abstract:The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells.

The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.

Priority: US2002-076180 Applic. Date: 2002-02-13; US2001-004942 Applic. Date: 2001-12-05; US20010268560P Applic. Date: 2001-02-14; US20000251900P Applic. Date: 2000-12-06

Inventor: HARIRI ROBERT J [US]


Application No.: US20040051201A1  Published: 18/Mar/2004

Title: Coated stent and method for coating by treating an electrospun covering with heat or chemicals

Applicant/Assignee:

Application No.: 10/313835   Filing Date: 06/Dec/2002

Abstract:A versatile covering process enabled through the identification and manipulation of a plurality of variables present in the electrospinning method of the present invention. By manipulating and controlling various identified variables, it is possible to use electrospinning to predictably produce thin materials having desirable characteristics. The fibers created by the electrospinning process have diameters averaging less than 100 micrometers. Proper manipulation of the identified variables ensures that these fibers are still wet upon contacting a target surface, thereby adhering with each other to form a cloth-like material and, if desired, adhering to the target surface to form a covering thereon. The extremely small size of these fibers, and the resulting interstices therebetween, provides an effective vehicle for drug and radiation delivery, and forms an effective membrane for use in fuel cells.

Priority: US20020372721P Applic. Date: 2002-04-11

Inventor: GREENHALGH SKOTT E [US]; KIEFER ROB [US]; FOX ANN M [US]


Application No.: US20040053351A1  Published: 18/Mar/2004

Title: Method of determining global coagulability and hemostatic potential

Applicant/Assignee: BIOMERIEUX, INC

Application No.: 10/663449   Filing Date: 16/Sep/2003

Abstract:A method is disclosed for determining if a patient is hypercoagulable, hypocoagulable or normal. The test involves providing a test sample from the patient and initiating coagulation in the sample in the presence of an activator, which is added to the sample in an amount which will result in intrinsic tenase-dependent fibrin. Then the formation of the intrinsic tenase-dependent fibrin polymerization is monitored over time so as to derive a time-dependent profile, with the results of the fibrin polymerization monitoring determining whether the patient is hypercoagulable, normal or hypocoagulable. The coagulation activator is added in an amount that triggers a thrombin explosion that is dependent on the propagation phase and amplification pathways. In this way, a single assay can assess the hemostatic potential of a sample.

Priority: US2000-697934 Applic. Date: 2000-10-27

Inventor: FISCHER TIMOTHY J [US]; BAGLIN TREVOR [GB]; TEJIDOR LILIANA [US]


Application No.: US20040053392A1  Published: 18/Mar/2004

Title: Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents

Applicant/Assignee: W2 HOLDINGS, INC

Application No.: 10/419462   Filing Date: 21/Apr/2003

Abstract:The invention relates to thrombospondin fragments found in plasma, their use or use of portions thereof in diagnostic methods, as method calibrators, method indicators, and as immunogens, and as analytes for methods with substantial clinical utility

and their detection in plasma or other bodily fluids for purpose of diagnostic methods, especially for cancer.

Priority: US20020405494P Applic. Date: 2002-08-23

Inventor: WILLIAMS KEVIN J [US]


Application No.: US20040058940A1  Published: 25/Mar/2004

Title: Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)

Applicant/Assignee:

Application No.: 10/451025   Filing Date: 19/Jun/2003

Abstract:The invention relates to a pharmaceutical formulation containing at least one compound of formula (1) wherein R<1>, R<2>, and X have the same meaning as cited in claim 1, and the physiologically acceptable salts thereof and/or solvates and a) at least one antithrombotic or b) at least one calcium antagonist or c) at least one prostaglandin or prostaglandin derivative for producing a medicament for treating angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), pulmonary heart disease, right ventricular failure, atheriosclerosis, permeability conditions of reduced cardiovascular patency, peripheral vascular illnesses, cerebral apoplexy, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, kidney failure, cirrhosis of the liver and for treating female sexual problems.

Priority: DE20001063221 Applic. Date: 2000-12-19; DE20001063884 Applic. Date: 2000-12-21; DE20001064991 Applic. Date: 2000-12-23; WO2001EP13913 Applic. Date: 2001-11-28

Inventor: EGGENWEILER HANS-MICHAEL [DE]; EIERMANN VOLKER [DE]


Application No.: US20040058985A1  Published: 25/Mar/2004

Title: Coumarin analog compounds for safer anticoagulant treatment

Applicant/Assignee: NEW CENTURY PHARMACEUTICALS, INC

Application No.: 10/629858   Filing Date: 30/Jul/2003

Abstract:The present invention relates to the albumin-guided development of coumarin analogs and the analogs developed thereby. The coumarin analogs of the present invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a minimum of metabolic complications and undesirable side effects.

Priority: US20020399126P Applic. Date: 2002-07-30

Inventor: CARTER DANIEL C [US]


Application No.: US20040063632A1  Published: 01/Apr/2004

Title: Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants

Applicant/Assignee: SCHERING AKTIENGESELLSCHAFT BAYER SCHERING PHARMA AG

Application No.: 10/427805   Filing Date: 30/Apr/2003

Abstract:This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Priority: US20020376566P Applic. Date: 2002-05-01

Inventor: LIGHT DAVID [US]; MCLEAN KIRK [US]


Application No.: US20040063730A1  Published: 01/Apr/2004

Title: Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives

Applicant/Assignee:

Application No.: 10/451105   Filing Date: 19/Jun/2003

Abstract:The invention relates to a pharmaceutical preparation containing at least one compound of formula (I), wherein R1, R2, R3, R4 and X have the meanings as cited in claim No. 1, and to their physiologically safe salts and/or solvates, and containing

a) at least one antithrombotic agent or

b) at least one calcium antagonist or

c) at least on prostaglandin or prostaglandin derivative for producing a medicament used for treating angina, hypertension, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, right ventricular failure, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, cerebrovascular accident, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumors, kidney failure, cirrhosis of the liver, and for treating female sexual dysfunctions.

Priority: DE20001063224 Applic. Date: 2000-12-19; DE20001063882 Applic. Date: 2000-12-21; DE20001064993 Applic. Date: 2000-12-23; WO2001EP13916 Applic. Date: 2001-11-28

Inventor: EGGENWEILER HANS-MICHAEL [DE]; EIERMANN VOLKER [DE]


Application No.: US20040063934A1  Published: 01/Apr/2004

Title: Integrin ligands

Applicant/Assignee: ABBOTT GMBH & CO. KG

Application No.: 10/311369   Filing Date: 08/Sep/2003

Abstract:The invention relates to novel compounds which bind to integrin receptors, their use as ligands of integrin receptors, in particular as ligands of the alphavbeta3 integrin receptor, their use, and pharmaceutical preparations comprising these compounds.

Priority: DE20001028575 Applic. Date: 2000-06-14; WO2001EP06779 Applic. Date: 2001-06-15

Inventor: GENESTE HERVE [DE]; KLING ANDREAS [DE]; LANGE UDO [DE]; SEITZ WERNER [DE]; GRAEF CLAUDIA ISABELLA [DE]; SUBKOSKI THOMAS [DE]; HORNBERGER WILFRIED [DE]; LAUTERBACH ARNULF [DE]


Application No.: US20040071861A1  Published: 15/Apr/2004

Title: Method of manufacturing a stent coating and a method of using the stent

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 10/678763   Filing Date: 02/Oct/2003

Abstract:Stents and a method of using the stents to increase blood flow to ischemic tissues in a patient are disclosed.

Priority: US2001-846498 Applic. Date: 2001-04-30

Inventor: MANDRUSOV EVGENIA [US]; CONSIGNY PAUL [US]; HOSSAINY SYED FAIYAZ AHMED [US]; MIRZAEE DARY [US]


Application No.: US20040072750A1  Published: 15/Apr/2004

Title: Compounds and methods for the modulation of CD154

Applicant/Assignee:

Application No.: 10/376425   Filing Date: 28/Feb/2003

Abstract:The invention relates to compounds that are capable of modulating CD154 mobilization and that are useful for stabilizing the thrombotic and/or coagulation process and/or reducing the activation of cells involved in an inflammatory response. The invention also relates to methods useful for identifying such compounds. The invention also relates to the treatment of platelets for transfusion with metalloproteinase inhibitors to treat or prevent inflammation. The present invention also includes compositions and methods to treat injury and disease related to such biological processes.

Priority: US2003-368947 Applic. Date: 2003-02-17; WO2002US13900 Applic. Date: 2002-05-03; US2001-002585 Applic. Date: 2001-11-30; US20010289049P Applic. Date: 2001-05-03

Inventor: PHILLIPS DAVID [US]; YAN YIBING [US]; ALAIMO LISA [US]; PRASAD SRINIVASA [US]


Application No.: US20040072796A1  Published: 15/Apr/2004

Title: Method and composition for preventing pain in sickle cell patients

Applicant/Assignee:

Application No.: 10/418653   Filing Date: 18/Apr/2003

Abstract:A method of preventing pain in a sickle cell patient is disclosed. The method includes orally administering to the patient, an amount of an active agent effective on oral administration to inhibit binding of the patient's sickle erythrocytes to P-selectin on the patient's vascular endothelium. The inhibition may be evidenced in a number of ways. The active agent administration inhibits the adhesion of sickle erythrocytes to vascular endothelium in the patient, thereby preventing patient pain associated with vascular occlusion. Also disclosed are compositions useful in practicing the method.

Priority: US20020373841P Applic. Date: 2002-04-18; US20020373842P Applic. Date: 2002-04-18; US20020373844P Applic. Date: 2002-04-18

Inventor: EMBURY STEPHEN H [US]; MATSUI NEIL M [US]


Application No.: US20040072846A1  Published: 15/Apr/2004

Title: Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives

Applicant/Assignee:

Application No.: 10/451118   Filing Date: 19/Jun/2003

Abstract:The invention relates to a pharmaceutical preparation containing at least one compound of formula (I) wherein R<1>, R<2>, R<3>, R<4>, n and X have the same meaning as cited in claim 1, and the physiologically acceptable salts thereof and/or solvates and a) at least one antithrombotic or b) at least one calcium antagonist or c) at least one prostaglandin or prostaglandin derivative for producing a medicament for treating angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chromic obstructive pulmonary disease (COPD), pulmonary heart disease, right ventricular failure, astheriosclerosis, conditions of reduced cardiovascular patency, peripheral vascular illnesses, cerebral apoplexy, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, kidney failure, cirrhosis of the liver and for treating female sexual problems.

Priority: DE20001063223 Applic. Date: 2000-12-19; DE20001063885 Applic. Date: 2000-12-21; DE20001064992 Applic. Date: 2000-12-23; WO2001EP13915 Applic. Date: 2001-11-28

Inventor: EGGENWEILER HANS-MICHAEL [DE]; EIERMANN VOLKER [DE]


Application No.: US20040077540A1  Published: 22/Apr/2004

Title: Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds

Applicant/Assignee: NASTECH PHARMACEUTICAL COMPANY INC

Application No.: 10/601953   Filing Date: 24/Jun/2003

Abstract:Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject. This effect typically involves inhibition by the permeabilizing agent of homotypic or heterotypic binding between epithelial membrane adhesive proteins of neighboring epithelial cells. Target proteins for this blockade of homotypic or heterotypic binding can be selected from various related junctional adhesion molecules (JAMs), occludins, or claudins. The permeabilizing agent is typically a peptide or peptide analog or mimetic, often selected or derived from an extracellular domain of a mammalian JAM, occludin or claudin protein.

Priority: US20020392512P Applic. Date: 2002-06-28

Inventor: QUAY STEVEN C [US]


Application No.: US20040077638A1  Published: 22/Apr/2004

Title: Novel integrin receptor antagonists

Applicant/Assignee:

Application No.: 10/344449   Filing Date: 08/Sep/2003

Abstract:The invention relates to novel compounds which bind to integrin receptors, their use as ligands of integrin receptors, in particular as ligands of the alphavbeta3 integrin receptor, and pharmaceutical preparations comprising these compounds.

Priority: DE20001028575 Applic. Date: 2000-06-14; WO2001EP09224 Applic. Date: 2001-08-09

Inventor: GENESTE HERVE [DE]; KLING ANDREAS [DE]; LAUTERBACH ARNULF [DE]; GRAEF CLAUDIA ISABELLA [DE]; SUBKOSKI THOMAS [DE]; HORNBERGER WILFRIED [DE]


Application No.: US20040082499A1  Published: 29/Apr/2004

Title: Perturbed membrane-binding compounds

Applicant/Assignee: NST NEUROSURVIVAL TECHNOLOGIES, LTD

Application No.: 10/433668   Filing Date: 31/Oct/2003

Abstract:The present invention provides uses of compounds that bind selectively to cells undergoing perturbations and alterations of their normal membrane organization, while binding to a lesser degree to cell having membranes of normal organization. These compounds are termed perturbed-membrane-binding compounds (PMBC). The PMBC group of compounds includes new compounds and also known compounds.

Priority: WO2001IB02282 Applic. Date: 2001-12-03; IL20000140114 Applic. Date: 2000-12-06; IL20010141571 Applic. Date: 2001-02-21; IL20010145210 Applic. Date: 2001-08-30

Inventor: ZIV ILAN [IL]; SHIEVAN ANAT [IL]; EBNER SHARON [IL]


Application No.: US20040084372A1  Published: 06/May/2004

Title: Method and apparatus for kidney dialysis

Applicant/Assignee:

Application No.: 10/695526   Filing Date: 27/Oct/2003

Abstract:A number of improvements relating to methods and apparatuses for kidney dialysis are disclosed. These include checking of dialysate bypass status using flow measurement

using a flow sensor to confirm the absence of ultrafiltration during bypass

automatic testing of ultrafiltration function by removal of a discrete volume from a portion of the dialysate flow path coupled with a pressure test of that part of the flow path

using a touch screen user interface

bar graph profile programming of ultrafiltration, sodium, and bicarbonate parameters

using a RAM card to upload treatment instructions to, and to download treatment data from, the machine

automatic setting of proportioning mode (acetate or bicarbonate) based on connections of concentrate lines

predicting dialysate conductivity values based on brand and formulation of concentrates

minimizing no-flow dead time between dialysate pulses

initiating operation in a timed mode from a machine power-off condition

preserving machine mode during machine power-fail condition

calibration scheduling and reminding

automatic level adjusting

and blood leak flow rate detecting.

Priority: US2000-711240 Applic. Date: 2000-11-13; US1998-067922 Applic. Date: 1998-04-28; US1995-479688 Applic. Date: 1995-06-07; US1993-122047 Applic. Date: 1993-09-14; US1991-688174 Applic. Date: 1991-04-19

Inventor: CONNELL MARK E [US]; BEDIENT ROBERT A [US]; ELSEN RAYMOND [BE]; HOGARD MICHAEL E [US]; JOHNSON HARLEY D [US]; KELLY THOMAS D [US]; LONG JEAN MCEVOY [US]; PETERSON BRUCE A [US]; PRESTON WILLIAM G [US]; SMEJTEK DALIBOR J [US]


Application No.: US20040086496A1  Published: 06/May/2004

Title: Composition derived from biological materials and method of use and preparation

Applicant/Assignee: NATIONAL UNIVERSITY OF SINGAPORE NATIONAL HEART CENTER

Application No.: 10/288166   Filing Date: 04/Nov/2002

Abstract:The invention provides a novel composition and methods of its preparation and uses. The composition comprises as main components serum and a gelling agent and is useful in various medical applications. The composition may be used to coat a medical device, as a biological glue, or as dressings, membranes, scaffolding or hydrogel useful in bioengineering applications. One or more therapeutic products may be added to the composition and the composition is also a vehicle for delivery of therapeutic products.

Priority:

Inventor: PEDDAREDDIGARI VIJAY GOPAL RED [US]; LIM TAI TIAN [SG]; EL OAKLEY REIDA MENSHAWE [SG]


Application No.: US20040086543A1  Published: 06/May/2004

Title: Method for attachment of biomolecules to medical device surfaces

Applicant/Assignee: MEDTRONIC, INC

Application No.: 10/620180   Filing Date: 15/Jul/2003

Abstract:A method for making a medical device having at least one biomolecule immobilized on a substrate surface is provided. One method of the present invention includes immobilizing a biomolecule comprising an unsubstituted amide moiety on a biomaterial surface. Another method of the present invention includes immobilizing a biomolecule on a biomaterial surface comprising an unsubstituted amide moiety. Still another method of the present invention may be employed to crosslink biomolecules comprising unsubstituted amide moieties immobilized on medical device surfaces. Additionally, one method of the present invention may be employed to crosslink biomolecules comprising unsubstituted amide moieties in solution, thereby forming a crosslinked biomaterial or a crosslinked medical device coating.

Priority: US1999-257543 Applic. Date: 1999-02-24; US1998-067188 Applic. Date: 1998-04-27; US1997-001994 Applic. Date: 1997-12-31; US1996-635187 Applic. Date: 1996-04-25; US1997-984922 Applic. Date: 1997-12-04; US1996-694535 Applic. Date: 1996-08-09; US1998-012056 Applic. Date: 1998-01-22; US1998-010906 Applic. Date: 1998-01-22

Inventor: KEOGH JAMES R [US]; TRESCONY PAUL V [US]


Application No.: US20040087546A1  Published: 06/May/2004

Title: Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases

Applicant/Assignee: CELGENE CORPORATION

Application No.: 10/411656   Filing Date: 11/Apr/2003

Abstract:Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Priority: US20020424730P Applic. Date: 2002-11-06

Inventor: ZELDIS JEROME B [US]


Application No.: US20040087647A1  Published: 06/May/2004

Title: NEW AMINO ACID DERIVATIVES

Applicant/Assignee: ASTRAZENECA AB

Application No.: 10/606349   Filing Date: 26/Jun/2003

Abstract:There is provided amino acid derivatives of formula I, wherein p, q, R<1>, R<2>, R<3>, R<4>, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: GB19950026411 Applic. Date: 1995-12-22; SE19950002487 Applic. Date: 1995-07-06; SE19950002504 Applic. Date: 1995-07-07; SE19950002505 Applic. Date: 1995-07-07; SE19950003923 Applic. Date: 1995-11-07; SE19950004349 Applic. Date: 1995-12-05; WO1996SE00878 Applic. Date: 1996-07-02; US2001-995564 Applic. Date: 2001-11-29; US2000-537344 Applic. Date: 2000-03-29; US1996-687466 Applic. Date: 1996-08-07

Inventor: GUSTAFSSON DAVID [SE]; NYSTROM JAN-ERIK [SE]


Application No.: US20040087765A1  Published: 06/May/2004

Title: Peptides, the production and use thereof for binding immunoglobulins

Applicant/Assignee: FRESENIUS MEDICAL CARE AFFINA GMBH

Application No.: 10/415665   Filing Date: 08/Aug/2003

Abstract:Peptides having the following amino acid sequence as well as peptides or proteins which contain this amino acid sequence: R<1>-X01-X02-X03-X04-X05-X06-X07-X08-X09-X10-X11-X12-X13-R<2>. These peptides have a high affinity for immunoglobulins. Applications of the peptides according to the invention are also described.

Priority: EP20000124418 Applic. Date: 2000-11-08; WO2001EP12933 Applic. Date: 2001-11-08

Inventor: RONSPECK WOFGANG [DE]; EGNER RALF [DE]; WINKLER DIRK [DE]; KUNZE RUDOLF [DE]


Application No.: US20040088038A1  Published: 06/May/2004

Title: Porous metal for drug-loaded stents

Applicant/Assignee:

Application No.: 10/283951   Filing Date: 30/Oct/2002

Abstract:An intravascular stent for controlled release of therapeutic drugs and for delivery of the therapeutic drugs in localized drug therapy in a blood vessel having a tubular stent member formed of a microcellular porous metal capable of absorbing and releasing therapeutic drugs, wherein a thin layer of a polymeric material is applied to an outer surface of the tubular stent member. A method of making a polymer coated, porous metal stent having sufficient strength and capable of absorbing and releasing therapeutic drugs for the delivery of same in localized drug therapy at an intravascular site is also disclosed herein.

Priority:

Inventor: DEHNAD HOUDIN [US]; KLEINE KLAUS [US]; KRAMER PAMELA A [US]; CARLSON JAMES M [US]


Application No.: US20040091546A1  Published: 13/May/2004

Title: Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use

Applicant/Assignee:

Application No.: 10/472071   Filing Date: 23/Oct/2003

Abstract:This invention discloses a process for making nanopanticles of amphiphilic copolymers by flash precipitation. Nanoparnicles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in an nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers. Furthermore, the resulting particles exhibit sufficient stability for post processing as desired. The invention also discloses two apparatuses for the production of nanoparticles of amphiphilic copolymers by flash precipitation.

Priority: WO2002US10715 Applic. Date: 2002-03-29

Inventor: JOHNSON BRIAN K [US]; PRUD HOMME ROBERT K [US]


Application No.: US20040091952A1  Published: 13/May/2004

Title: Reagent kit for detecting lupus anticoagulant

Applicant/Assignee: SYSMEX CORPORATION

Application No.: 10/622736   Filing Date: 21/Jul/2003

Abstract:A reagent kit capable of distinguishing between a blood sample containing lupus anticoagulant and blood samples from individuals having other anticoagulant diseases is disclosed. The reagent kit comprises two coagulation time reagents containing phosphatidylserine in a different phosphatidylserine content ratio to the total content of phospholipids from each other, threreby giving different coagulation times with use of corresponding coagulation time reagent.

Priority: JP20020216782 Applic. Date: 2002-07-25

Inventor: OKUDA MASAHIRO [JP]


Application No.: US20040092890A1  Published: 13/May/2004

Title: Catheter lock solution including a photo-oxidant

Applicant/Assignee:

Application No.: 10/276035   Filing Date: 13/Jun/2003

Abstract:This invention relates to compositions, methods and devices relating to the infusion of a catheter lock solution into an indwelling catheter. Inventive compositions, methods and devices aid in diminishing the effects of infection in the catheters and occlusion of the catheters. An inventive lock solution includes an anticoagulant and a photo-oxidant, and preferably has a density suitable for retention of the solution in a catheter during the lock period.

Priority: WO2001US15177 Applic. Date: 2001-05-10

Inventor: ASH STEPHEN R [US]


Application No.: US20040097583A1  Published: 20/May/2004

Title: Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders

Applicant/Assignee:

Application No.: 10/360943   Filing Date: 07/Feb/2003

Abstract:Inhibitors of the cellular sodium/hydrogen exchangers show an inhibiting effect on the secretion of von-Willebrand factor and/or increased expression of P-selectin. These inhibitors can therefore be employed for the treatment of thrombotic and inflammatory disorders.

Priority: DE20021006358 Applic. Date: 2002-02-14; US20020366743P Applic. Date: 2002-03-22

Inventor: LANG HANS-JOCHEN [DE]; SCHNEIDER STEFAN WERNER [DE]; OBERLEITHNER HANS [DE]; NIEMEYER ANDRE [DE]


Application No.: US20040102374A1  Published: 27/May/2004

Title: Methods for controlling the lysis of coagulated blood with apolipoprotein e4 theno type

Applicant/Assignee:

Application No.: 10/398882   Filing Date: 17/Jul/2003

Abstract:Methods for inhibiting the lysis of coagulated blood comprise administering to blood a lysis-inhibiting amount of apolipoprotein E4 (Apo E4) or a therapeutic derivative thereof. Methods for reducing the risk of excessive blood clot lysis comprise administering the blood a lysis-inhibiting amount of Apo E4 or a therapeutic derivative thereof. Additional methods for inhibiting the lysis of coagulated blood comprise administering to an individual's blood a specific level of a lysis-inhibiting amount of Apo E4 wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risk of excessive blood clot lysis comprise administering to an individual's blood a specific level of a lysis-inhibiting amount of Apo E4, wherein the specific level is based upon the apolipoprotein phenotype of the individual.

Additional methods for enhancing the lysis of coagulated blood comprise administering to blood containing a clot lysis agent an Apo E peptide fragment.

Priority: US20000240174P Applic. Date: 2000-10-13; WO2001US31909 Applic. Date: 2001-10-12

Inventor: BRODERICK JOSEPH P [US]; CLARK JOSEPH F [US]; WOO DANIEL [US]


Application No.: US20040102415A1  Published: 27/May/2004

Title: Composition and methods for tissue preservation

Applicant/Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERAN'S AFFAIRS

Application No.: 10/257176   Filing Date: 14/Jul/2003

Abstract:The present invention provides for compositions and methods for the preservation of tissues and organs ex vivo and in situ. In addition, the present invention provides for kits that may be used in the preparation of the solutions of the present invention. The present invention also provides a device for perfusing tissues and organs with the solutions of the present invention.

Priority: US2000-546860 Applic. Date: 2000-04-10; WO2001US11834 Applic. Date: 2001-04-10

Inventor: THATTE HEMANT [US]; BISWAS KUNDA [US]; KHURI SHUKRI [US]; MICHEL THOMAS [US]


Application No.: US20040105778A1  Published: 03/Jun/2004

Title: Gamma irradiation of solid nanoparticulate active agents

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 10/654600   Filing Date: 04/Sep/2003

Abstract:The present invention relates to methods for terminal sterilization of solid forms of nanoparticulate active agent compositions via gamma irradiation. The nanoparticulate active agent has an effective average particle size of less than about 2 microns, prior to incorporation into a solid form for sterilization. The resultant sterilized compositions exhibit excellent redispersibility, homogeneity, and uniformity. Also encompassed are compositions made via the described method and methods of treating animals and humans using such compositions.

Priority: US20020415749P Applic. Date: 2002-10-04

Inventor: LEE ROBERT [US]; HILBORN MATTHEW [US]; KLINE LAURA [US]; KELLER JANINE [US]


Application No.: US20040105858A1  Published: 03/Jun/2004

Title: Diagnosis and treatment of infertility

Applicant/Assignee:

Application No.: 10/651690   Filing Date: 28/Aug/2003

Abstract:The present invention relates generally to the regulation of immune responses of subjects for the diagnosis and treatment of infertility. More particularly, methods that downregulate T helper 1 (Th1) immunity or upregulate T helper 2 (Th2) immunity are used to enhance reproductive outcomes in subjects with recurrent spontaneous abortions or implantation failures by changing the balance of T helper 1 and T helper 2 immune responses. Ratios of Th1 and Th2 activities can also be used for diagnosis of infertility in these subjects.

Priority: US20020406804P Applic. Date: 2002-08-29

Inventor: KIM JOANNE YOUNG HEE KWAK [US]; BEER ALAN E [US]; GILMAN-SACHS ALICE [US]


Application No.: US20040105881A1  Published: 03/Jun/2004

Title: Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Applicant/Assignee:

Application No.: 10/357618   Filing Date: 04/Feb/2003

Abstract:The invention describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates of at least two more soluble substances amongst said three system components, at least one of which is an active ingredient and preferably a drug

the third component, alternatively, can take the role of a drug. The patent further deals with the use of said combinations in pharmaceutical preparations capable of transporting drugs into the body of warm blood creatures. This is made possible by the drug loading capability of said aggregates with the highly flexible and deformable coating, which renders the resulting drug carriers highly adaptable. The patent finally reveals suitable methods and favourable conditions for carrier manufacturing and application.

Priority: US20020417847P Applic. Date: 2002-10-11

Inventor: CEVC GREGOR [DE]; VIERL ULRICH [DE]


Application No.: US20040105889A1  Published: 03/Jun/2004

Title: Low viscosity liquid dosage forms

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 10/420927   Filing Date: 23/Apr/2003

Abstract:The present invention relates to liquid dosage forms of nanoparticulate active agents having very low viscosities.

Priority: US20020430348P Applic. Date: 2002-12-03

Inventor: RYDE TUULA [US]; RYDE NIELS [US]; BOSCH H WILLIAM [US]; PRUITT JOHN D [US]; WERTZ CHRISTIAN F [US]


Application No.: US20040106094A1  Published: 03/Jun/2004

Title: Red blood cell composition

Applicant/Assignee:

Application No.: 10/608200   Filing Date: 27/Jun/2003

Abstract:The present invention provides an improved aqueous solution for suspending and storing red blood cells. The solution includes sodium citrate, a combination of sodium biphosphate and sodium phosphate dibasic, adenine, and mannitol. The solution is formulated at a low osmolarity and has a physiological pH of approximately 7.4. The solution simultaneously maintains stored red cells ATP and 2,3-BPG.

Priority: US1999-268405 Applic. Date: 1999-03-15; US1996-742279 Applic. Date: 1996-10-31; US1995-491099 Applic. Date: 1995-06-16; US1994-216734 Applic. Date: 1994-03-22; US1990-610478 Applic. Date: 1990-11-07

Inventor: PAYRAT JEAN-MARC [BE]; HOGMAN CLAES F [SE]; MATHIAS JEAN MARIE [BE]


Application No.: US20040106633A1  Published: 03/Jun/2004

Title: Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

Applicant/Assignee: 3-DIMENSIONAL PHARMACEUTICALS, INC ORTHO-MCNEIL PHARMACEUTICALS, INC

Application No.: 10/714988   Filing Date: 17/Nov/2003

Abstract:Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR<9 >and Het, R<1>, R<7>, R<8>, R<12>-R<15>, R, R, R, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin.

The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US2003-400073 Applic. Date: 2003-03-27; US2002-241513 Applic. Date: 2002-09-12; US2001-012445 Applic. Date: 2001-12-12; US2001-827292 Applic. Date: 2001-04-06; US2000-482540 Applic. Date: 2000-01-14; US1998-199167 Applic. Date: 1998-11-25; US19980079107P Applic. Date: 1998-03-23; US19970067324P Applic. Date: 1997-12-05; US19970066475P Applic. Date: 1997-11-26

Inventor: LU TIANBAO [US]; TOMCZUK BRUCE E [US]; MARKOTAN THOMAS P [US]; SIEDEM COLLEEN [US]


Application No.: US20040109790A1  Published: 10/Jun/2004

Title: Vacuum loaded test strip with stop junction and bypass channel

Applicant/Assignee:

Application No.: 10/666846   Filing Date: 18/Sep/2003

Abstract:A fluidic medical diagnostic device-permits measurement of analyte concentration or a property of a biological fluid, particularly the coagulation time of blood. The device has at one end a sample port for introducing a sample and at the other end a bladder for drawing the sample to a measurement area. A channel carries the sample from the sample port to the measurement area, and a stop junction, between the measurement area and bladder, halts the sample flow. The desired measurement can be made by placing the device into a meter which measures a physical property of the sample-typically, optical transmittance-after it has interacted with a reagent in the measurement area.

Priority: US2002-264662 Applic. Date: 2002-10-03; US1999-333765 Applic. Date: 1999-06-15; US19980093421P Applic. Date: 1998-07-20

Inventor: SHARTLE ROBERT JUSTICE [US]; CHOW HERBERT [US]; HARTMANN CHRISTA [US]


Application No.: US20040110242A1  Published: 10/Jun/2004

Title: Method of assaying lupus anticoagulant and assay reagent

Applicant/Assignee: EISAI CO., LTD

Application No.: 10/472283   Filing Date: 18/Sep/2003

Abstract:A monoclonal antibody having inhibitory activity on blood coagulation reactions, which reacts with prothrombin forming a complex with phosphatidylserine but does not react with prothrombin not forming a complex with phosphatidylserine

and a method for measuring inhibitory activity of test plasma on blood coagulation reactions, which comprises the steps of (1) measuring inhibitory activity of the test plasma on the blood coagulation reactions and inhibitory activity of this on the blood coagulation reactions, and (2) comparing the inhibitory activity of the test plasma with the inhibitory activity of this antibody.

Priority: JP20010077366 Applic. Date: 2001-03-19; WO2002JP02599 Applic. Date: 2002-03-19

Inventor: ATSUMI TATSUYA [JP]; KOIKE TAKAO [JP]


Application No.: US20040115134A1  Published: 17/Jun/2004

Title: Novel nifedipine compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/712259   Filing Date: 14/Nov/2003

Abstract:The present invention is directed to nanoparticulate compositions comprising nifedipine. The nifedipine particles of the composition have an effective average particle size of less than about 2 microns.

Priority: US2000-666539 Applic. Date: 2000-09-21; US2002-075443 Applic. Date: 2002-02-15; US2000-715117 Applic. Date: 2000-11-20; US2003-345312 Applic. Date: 2003-01-16; US1999-337675 Applic. Date: 1999-06-22; US2003-276400 Applic. Date: 2003-01-15

Inventor: MERISKO-LIVERSIDGE ELAINE [US]


Application No.: US20040115822A1  Published: 17/Jun/2004

Title: Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition

Applicant/Assignee:

Application No.: 10/658165   Filing Date: 09/Sep/2003

Abstract:The present invention provides a method of characterizing the transfer of an analyte from a non-aqueous liquid composition to an aqueous medium and in particular to an in vitro method for measuring the dissolution of a drug from a sustained release dosage form.

Priority: US20020410147P Applic. Date: 2002-09-12

Inventor: SCHAPAUGH RANDAL LEE [US]; NORTH JAMIE K [US]; CIOLKOWSKI EDWARD L [US]; EATON LESLIE C [US]


Application No.: US20040115837A1  Published: 17/Jun/2004

Title: Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition

Applicant/Assignee:

Application No.: 10/658164   Filing Date: 09/Sep/2003

Abstract:The present invention provides a method of measuring the dissolution rate of an analyte in a non-aqueous liquid composition and in particular to in vitro methods for measuring the dissolution rate of a drug in a sustained release dosage form.

Priority: US20020429260P Applic. Date: 2002-11-27

Inventor: SCHAPAUGH RANDAL LEE [US]; CIOLKOWSKI EDWARD L [US]; EATON LESLIE C [US]


Application No.: US20040116930A1  Published: 17/Jun/2004

Title: Bone plates

Applicant/Assignee:

Application No.: 10/731173   Filing Date: 08/Dec/2003

Abstract:Sets of bone plates and components thereof for use with particular bones or regions of bones, such as periarticular regions of an elbow. These bone plates may be configured for easy identification, easy fitting, and/or as anatomical templates, among others.

Priority: WO2002US18623 Applic. Date: 2002-06-10

Inventor: O'DRISCOLL SHAWN W [US]; JENSEN DAVID G [US]


Application No.: US20040120937A1  Published: 24/Jun/2004

Title: Blood therapy process

Applicant/Assignee: THERAPY PATENT CORPORATION

Application No.: 10/324518   Filing Date: 19/Dec/2002

Abstract:The new ideal is the transfusion of natural blood, artificial blood plasma or artificial blood plasma mixed with natural blood, while draining natural blood for therapy of poison, snake bite, leukemia, aged persons, other cancers, allergies and other undiscovered uses. Some concerns in such blood therapy, is the blood be live, well warmed and well oxygenated, possibly with a heart lung machine. Also, that blood pressure is carefully monitored. If artificial blood plasma is substituted for whole blood, the concern would be careful monitoring for internal and external bleeding as artificial blood plasma does not clot. These therapies are not warranted to improve health. These are untested medical therapies and the inventor and Therapy Patent Corporation accepts no risk or liability for loss of health or death that may occur do to experimental work that may occur with these therapies. Perhaps testing and experimentation on animals should be considered before testing and experimentation on humans is considered.

Priority:

Inventor: WILSON JAMES BRIAN [US]


Application No.: US20040121015A1  Published: 24/Jun/2004

Title: Controlled-Release of an active substance into a high fat environment

Applicant/Assignee: PFIZER INC

Application No.: 10/727217   Filing Date: 03/Dec/2003

Abstract:A controlled release delivery composition which can be administered to a high fat use environment such as the human gastrointestinal tract following a high fat meal. The delivery composition is embodied as a core surrounded by an asymmetric polymeric membrane. In a preferred embodiment, the asymmetric polymeric membrane is cellulose acetate.

Priority: US20020432860P Applic. Date: 2002-12-11

Inventor: CHIDLAW MARK B [US]; FRIESEN DWAYNE T [US]; HERBIG SCOTT M [US]; NIGHTINGALE JAMES A S [US]; OKSANEN CYNTHIA A [US]; WEST JAMES B [US]


Application No.: US20040121421A1  Published: 24/Jun/2004

Title: Homocysteine assay adaptable to screening

Applicant/Assignee:

Application No.: 10/655607   Filing Date: 03/Sep/2003

Abstract:A homocysteine assay that can be performed on very small quantities of blood is described. This assay is suitable for screening, including screening newborns for homocysteinuria.

Priority: US20020408315P Applic. Date: 2002-09-03

Inventor: HAN QINGHONG [US]; TAN YUYING [US]


Application No.: US20040122063A1  Published: 24/Jun/2004

Title: Ethylenediamine derivatives

Applicant/Assignee: DAIICHI PHARMACEUTICAL CO., LTD

Application No.: 10/240725   Filing Date: 30/Jul/2003

Abstract:The invention relates a compound represented by the formula (1): Q<1>-Q<2>-C(=O)-N(R<1>)-Q<3>-N(R<2>)-T<1>-Q<4 > (1) wherein R<1 >and R<2 >represent H or the like

Q<1 >represents an aromatic ring, heterocyclic ring or the like

Q<2 >represents a single bond, aromatic ring, heterocyclic ring or the like

Q<3 >represents a group or the like, Q<4 >represents an aromatic ring, heterocyclic ring or the like

and T<1 >represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.

Priority: JP20000108047 Applic. Date: 2000-04-05; WO2001JP02945 Applic. Date: 2001-04-05

Inventor: YOSHINO TOSHIHARU [JP]; NAGATA TSUTOMU [JP]; HAGINOYA NORIYASU [JP]; YOSHIKAWA KENJI [JP]; KANNO HIDEYUKI [JP]; NAGAMOCHI MASATOSHI [JP]


Application No.: US20040122507A1  Published: 24/Jun/2004

Title: Multi-lumen vascular grafts having improved self-sealing properties

Applicant/Assignee: SCIMED LIFE SYSTEMS, INC

Application No.: 10/328081   Filing Date: 23/Dec/2002

Abstract:The present invention provides an implantable graft, including a primary tubular body having a first outer wall surface and a first inner wall surface defining a primary blood contacting lumen, and a secondary tubular body having a second outer wall surface and a second inner wall surface. The secondary tubular body is located about the primary tubular body to form a space therebetween. The primary and secondary tubular bodies are joined by at least one rib.

Priority:

Inventor: HENDERSON JAMIE S [US]


Application No.: US20040124146A1  Published: 01/Jul/2004

Title: Porous spun polymeric structures and method of making same

Applicant/Assignee: SCIMED LIFE SYSTEMS, INC BOSTON SCIENTIFIC SCIMED, INC

Application No.: 10/331213   Filing Date: 30/Dec/2002

Abstract:A non-woven polymeric matrix for separating leukocytes from a blood sample includes a non-woven three dimensional matrix formed from polymeric fibers having a predetermined pore volume fraction including a defined channel configuration, a predetermined pore size in the range of from about 10 mum to about 250 mum, and a plurality of connections between the plurality of fibers. The matrix is configured so as to remove at least about 98% of leukocytes from at least one unit of packed red blood cells. Methods of making and using the matrix are also provided.

Priority:

Inventor: DAO KINH-LUAN D [US]; CHIN YEM [US]; ZHONG SHENG-PING [US]; MOHAN KSHITIJ [US]; VU LIEM [US]


Application No.: US20040124157A1  Published: 01/Jul/2004

Title: Apparatus for the continuous separation of biological fluids into components and method of using same

Applicant/Assignee: THERAKOS, INC

Application No.: 10/654742   Filing Date: 03/Sep/2003

Abstract:The present invention provides an apparatus for separating components of a fluid having an outer housing containing a core wherein three separate fluid pathways are provided to allow continuous separation of biological fluids.

Priority: US2003-375628 Applic. Date: 2003-02-26; US2003-375629 Applic. Date: 2003-02-27; US20020361287P Applic. Date: 2002-03-04; US2003-654794 Applic. Date: 2003-09-03; US2003-654803 Applic. Date: 2003-09-03

Inventor: BRIGGS DENNIS [US]; GARA STEVE [US]; WATTERS TOM [US]; HUTCHINSON MIKE [US]


Application No.: US20040127790A1  Published: 01/Jul/2004

Title: Measurement of capillary related interstitial fluid using ultrasound methods and devices

Applicant/Assignee:

Application No.: 10/682808   Filing Date: 09/Oct/2003

Abstract:The present invention provides for methods and devices for monitoring capillary related interstitial thickness. The invention also includes methods of measuring capillary related interstitial fluid, as well as cardiac, vascular, renal and hepatic function. Specific devices, particularly probes, are provided for such methods.

Priority: WO1998US17238 Applic. Date: 1998-08-19; US2000-650431 Applic. Date: 2000-08-28; US1997-914527 Applic. Date: 1997-08-19

Inventor: LANG PHILIPP [US]; MENDLEIN JOHN D [US]


Application No.: US20040127840A1  Published: 01/Jul/2004

Title: Blood separation apparatus and method of using the same

Applicant/Assignee:

Application No.: 10/654794   Filing Date: 03/Sep/2003

Abstract:An apparatus and method for extracorporeal blood separation and treatment. A cassette has integral flexible tubing which is routed above apertures or is otherwise exposed so that pressure can be applied to prevent fluid flow through a selected section of tubing. A hub within the cassette preferably connects sections of the tubing. A kit comprising the cassette and a separation bowl, UV chamber, and patient collection and return components is adapted to be operated by a non-disposable tower which comprises peristaltic pumps with pump heads which engage flexible tubing loops of the cassette, a cavity for receiving the UV chamber, and a centrifuge chamber, with all operations controlled by a programmed processor.

Priority: US2003-375628 Applic. Date: 2003-02-26; US20020361287P Applic. Date: 2002-03-04

Inventor: GARA STEVE [US]; BRIGGS DENNIS [US]


Application No.: US20040127841A1  Published: 01/Jul/2004

Title: Method for collecting a desired blood component and performing a photopheresis treatment

Applicant/Assignee: THERAKOS, INC

Application No.: 10/654803   Filing Date: 03/Sep/2003

Abstract:An improved method for separating whole blood into components and collecting a desired blood component. The method allows a desired blood component to be subjected to centrifugal forces within a separator for prolonged periods of time, yielding a cleaner cut and higher yield of the desired blood component. Whole blood is drawn from a source and pumped into a separator, the undesired blood components are removed from the separator at rates so as to build up the desired blood component in the separator. The desired blood component is only removed after a predetermined amount of the desired blood component has built up in the separator. It is preferred that the desired blood component be buffy coat and that the method be used to perform photopheresis treatments.

In another aspect, the invention is a method of performing a full photopheresis treatment to treat diseases in a reduced time, preferably less than about 70 minutes, and more preferably less than about 45 minutes.

Priority: US2003-375628 Applic. Date: 2003-02-26; US20020361287P Applic. Date: 2002-03-04; US2003-654794 Applic. Date: 2003-09-03; US2003-375629 Applic. Date: 2003-02-27; US2003-654742 Applic. Date: 2003-09-03

Inventor: BRIGGS DENNIS [US]


Application No.: US20040129638A1  Published: 08/Jul/2004

Title: Multi-part substitution infusion fluids and matching anticoagulants

Applicant/Assignee: EDWARDS LIFESCIENCES CORPORATION

Application No.: 10/742137   Filing Date: 19/Dec/2003

Abstract:A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Priority: EP19990201302 Applic. Date: 1999-04-26; US2001-959543 Applic. Date: 2001-10-23; WO2000EP03583 Applic. Date: 2000-04-20

Inventor: CHANG PETER C [NL]; LANNOY JEAN-MICHEL [FR]


Application No.: US20040132123A1  Published: 08/Jul/2004

Title: Methods and kits utilizing heparanase as a diagnostic marker for haemostatic disorders

Applicant/Assignee:

Application No.: 10/475591   Filing Date: 23/Oct/2003

Abstract:Provided is a method of determining a presence, absence, or severity of a haemostatic disorder in a subject. The method is effected by determining a level of heparanase expression or activity in a biological sample obtained from the subject. Also provided are kits for use with the method.

Priority: WO2002IL00362 Applic. Date: 2002-05-09; US20010289535P Applic. Date: 2001-05-09

Inventor: YACOBY-ZEEVI ORON [IL]


Application No.: US20040132688A1  Published: 08/Jul/2004

Title: Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C

Applicant/Assignee:

Application No.: 10/739962   Filing Date: 17/Dec/2003

Abstract:The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in the presence but not absence of APC:protein S, indicating GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer, globotriaosylceramide, lactosylceramide, and galactosylceramide in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. Thus, the present invention provides neutral glycolipids such as GlcCer and Gb3Cer, as anticoagulant cofactors that contribute to the antithrombotic activity of the protein C pathway. The present invention has also determined that a deficiency of plasma GlcCer is a risk factor for thrombosis. Methods are provided to determine individuals at risk for thrombosis, methods of treatment as well as methods of screening for antithrombotic factors from neutral glycolipids.

Priority: US2002-086943 Applic. Date: 2002-02-28; US20010272103P Applic. Date: 2001-02-28; US20010278045P Applic. Date: 2001-03-22

Inventor: GRIFFIN JOHN H [US]; DEGUCHI HIROSHI [US]; FERNANDEZ JOSE [US]


Application No.: US20040133145A1  Published: 08/Jul/2004

Title: Device and process for extracorporeal treatment by citrate anticoagulant

Applicant/Assignee: HOSPAL INTERNATIONAL MARKETING MANAGEMENT SNC GAMBRO LUNDIA AB

Application No.: 10/739273   Filing Date: 19/Dec/2003

Abstract:The invention concerns a device for treating blood by extracorporeal circulation (101) comprising a filter (102) having a first chamber (103) and a second chamber (104) separated by a semi-permeable membrane (105), an arterial line (106) connected to the first chamber (103) of the filter (102), a venous line (108) issuing from the first chamber (103) of the filter (102), a channel (109) used for pre-infusion of a substance for regional anticoagulation and linked to the arterial line (106), a purge channel (110) issuing from the second chamber (104) of the filter (102), an air separator (112) on the venous line (108), a line (112) for post-infusion of a solution at least partially re-establishing the ionic equilibrium of the blood downstream of the air separator (111), and an air detector (113) downstream of the post-infusion line (112).

Finally, the invention concerns a method for treating blood by extracorporeal circulation.

Priority: FR20020016228 Applic. Date: 2002-12-20; US20030453967P Applic. Date: 2003-03-13

Inventor: BENE BERNARD [FR]


Application No.: US20040133146A1  Published: 08/Jul/2004

Title: Device for treating a fluid-like sample such as a whole blood, with treatment fluid, use of such a device and kit containing such a device

Applicant/Assignee: BEST QUALITY B.V

Application No.: 10/476598   Filing Date: 31/Oct/2003

Abstract:A device for treating a fluid-like sample, in particular whole blood, with treatment fluid. The device comprises a tubular container with a first piston and a second piston, with a piston gap between them in which the treatment fluid is located in the initial position. The device further comprises an inlet port to which a capillary can be connected and an outlet port to which a filter can be connected. Furthermore, the device comprises a tubular container so that when the plunger is pushed in the first piston, the first piston moves away from the second piston in order to draw in sample from the inlet port, the two pistons are then moved jointly away from the inlet port to in front of the outlet port, after which the second piston is pushed towards the first piston in order to drive out the mixture of sample and treatment fluid, via the outlet port, through the filter

Priority: NL20001016646 Applic. Date: 2000-11-17; WO2001NL00836 Applic. Date: 2001-11-19

Inventor: BROEK ARJAN JACOB [NL]; VAN DEN BERG MAX [NL]; DE ROOIJ FELIX WILHELMUS MARIE [NL]


Application No.: US20040137071A1  Published: 15/Jul/2004

Title: Nanocapsule encapsulation system and method

Applicant/Assignee: GENESEGUES, INC

Application No.: 10/652814   Filing Date: 29/Aug/2003

Abstract:The present invention generally relates to nanocapsules and methods of preparing these nanocapsules. The present invention includes a method of forming a surfactant micelle and dispersing the surfactant micelle into an aqueous composition having a hydrophilic polymer to form a stabilized dispersion of surfactant micelles. The method further includes mechanically forming droplets of the stabilized dispersion of surfactant micelles, precipitating the hydrophilic polymer to form precipitated nanocapsules, incubating the nanocapsules to reduce a diameter of the nanocapsules, and filtering or centrifuging the nanocapsules.

Priority: US2001-796575 Applic. Date: 2001-02-28; US20000185282P Applic. Date: 2000-02-28

Inventor: UNGER GRETCHEN M [US]


Application No.: US20040141912A1  Published: 22/Jul/2004

Title: Method for targeting chemical compounds to cells and pharmaceutical compositions used therein

Applicant/Assignee:

Application No.: 10/471725   Filing Date: 05/Mar/2004

Abstract:The present invention concerns a method for selectively targeting a medicinally-useful agent into cells in which a phospholipid scramblase (PLS) transport system is activated. The method comprises administering the agent, being a PLS-dependent transported compound (PDTC) to the cells, thereby causing selective transport of the agent into the cells. Examples of the cells are apoptotic cells, activated cells and injured cells. Also disclosed are pharmaceutical compositions for use by the method.

Priority: WO2002IB00758 Applic. Date: 2002-03-14; IL20010142051 Applic. Date: 2001-03-16; IL20020147812 Applic. Date: 2002-01-24

Inventor: ZIV ILAN [IL]; SHIRVAN ANAT [IL]; EBNER SHARON [IL]


Application No.: US20040141925A1  Published: 22/Jul/2004

Title: Novel triamcinolone compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/697716   Filing Date: 31/Oct/2003

Abstract:The invention is directed to nanoparticulate triamcinolone and/or triamcinolone derivative compositions. The triamcinolone or triamcinolone derivative particles of the composition have an effective average particle size of less than about 2 microns.

Priority: US1998-190138 Applic. Date: 1998-11-12; US1999-337675 Applic. Date: 1999-06-22; US2001-004808 Applic. Date: 2001-12-07; US1999-414159 Applic. Date: 1999-10-08; US2003-345312 Applic. Date: 2003-01-16; US2000-715117 Applic. Date: 2000-11-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21; US2003-357514 Applic. Date: 2003-02-04; US20020353230P Applic. Date: 2002-02-04; US20020396530P Applic. Date: 2002-07-16

Inventor: BOSCH H WILLIAM [US]; OSTRANDER KEVIN D [US]; COOPER EUGENE R [US]


Application No.: US20040142012A1  Published: 22/Jul/2004

Title: Geometry retainable devices for body cavities

Applicant/Assignee:

Application No.: 10/470735   Filing Date: 14/Mar/2004

Abstract:A passive or active release device for a medicament or other substance for a target species mammal. The device is of a kind capable of being inserted into a body cavity of a target species mammal and deploying resiliently to one or more retention condition(s). The device is wholly or in part moulded from poly (-caprolactone) (optionally impregnated with at least a physiologically effective agent to be released therefrom or optionally to carry some device or material to be body cavity retained at least for a period). The device is preferably of substantially a "T" or "Y" shape.

Priority: NZ20010509894 Applic. Date: 2001-02-09; WO2002NZ00011 Applic. Date: 2002-02-01

Inventor: BUNT CRAIG ROBERT [NZ]; RATHBONE MICHAEL JOHN [NZ]; OGLE COLIN ROGER [AU]; WYLLIE MARK ANDREW [NZ]


Application No.: US20040144724A1  Published: 29/Jul/2004

Title: Method and device for non-intrusive measurement of blood pressure in a circuit of a dialysis machine

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 10/479796   Filing Date: 05/Dec/2003

Abstract:A method for the non-intrusive measurement of blood pressure in a circuit (3) of a dialysis machine (1), using a device (24) provided with a sleeve (6) forming a portion of the blood circuit (3) and having at least one part (14) which moves according to the pressure difference between the inside and the outside of the sleeve (6), and with an emitter (22) and a receiver (23) of electromagnetic waves

the method comprising the emission of a beam of electromagnetic waves and the receiving of a beam of electromagnetic waves reflected from the moving part (14), in order to measure the displacement of the moving part (14) in such a way as to establish a relationship between the position of the moving part (14) and the pressure of the blood circulating in the sleeve (6).

Priority: WO2002IB01775 Applic. Date: 2002-05-16; IT2001BO00355 Applic. Date: 2001-06-05

Inventor: BOSETTO ANTONIO [IT]; DELNEVO ANNALISA [IT]


Application No.: US20040146516A1  Published: 29/Jul/2004

Title: Lumen-exposed molecules and methods for targeted delivery

Applicant/Assignee: UTAH VENTURES II L.P

Application No.: 10/794899   Filing Date: 05/Mar/2004

Abstract:The present invention provides novel methods and kits for labeling and isolating tissue-specific or organ-specific lumen-exposed molecules. In addition, the present invention provides tissue-specific or organ-specific lumen-exposed polypeptides, which were isolated by the methods herein. Furthermore the present invention provides therapeutic complexes comprising ligands that bind the tissue-specific or organ-specific lumen-exposed polypeptides attached to therapeutic moieties for targeted treatment and prevention.

Priority: US2002-165603 Applic. Date: 2002-06-07; US2000-528742 Applic. Date: 2000-03-20; WO2003US10195 Applic. Date: 2003-03-31; US20010297021P Applic. Date: 2001-06-08; US20010305117P Applic. Date: 2001-07-12; US19990139579P Applic. Date: 1999-06-17; US20020369452P Applic. Date: 2002-04-01

Inventor: ROBEN PAUL [US]; STEVENS ANTHONY C [US]


Application No.: US20040147866A1  Published: 29/Jul/2004

Title: Apparatus and methods for occluding an access tube anastomosed to sidewall of an anatomical vessel

Applicant/Assignee: INTEGRATED VASCULAR INTERVENTIONAL TECHNOLOGIES, L.C., ("IVIT LC")

Application No.: 10/351172   Filing Date: 23/Jan/2003

Abstract:The invention provides vascular access methods, systems and devices facilitating long-term, repeated, percutaneous access to a patient's blood stream. This is provided by an access tube apparatus adapted for anastomosis to the sidewall of a target anatomical vessel. The access tube has a replaceable occluder that fits within the conduit of the access tube in between blood treatments or when vascular access is otherwise not needed. When such access is desired, the percutaneously accessible occluder is simply removed from the access tube.

Priority:

Inventor: BLATTER DUANE D [US]; ORR TROY J [US]; BARRUS MICHAEL C [US]


Application No.: US20040147987A1  Published: 29/Jul/2004

Title: Methods and apparatus for regional and whole body temperature modification

Applicant/Assignee: RADIANT MEDICAL INC RADIANT MEDICAL, INC

Application No.: 10/626007   Filing Date: 24/Jul/2003

Abstract:Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region.

Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority: US1998-138830 Applic. Date: 1998-08-24; US1996-584013 Applic. Date: 1996-01-08; US1994-324853 Applic. Date: 1994-10-18; US1993-015774 Applic. Date: 1993-02-10

Inventor: GINSBURG ROBERT [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]


Application No.: US20040151633A1  Published: 05/Aug/2004

Title: Method for making enhancing the reliability of the traceability of blood samples

Applicant/Assignee: BIOLOG

Application No.: 10/482408   Filing Date: 01/Apr/2004

Abstract:Method for enhancing the reliability of the traceability of blood samples resulting from collection of whole blood in a mother blood bag using sampling kits, whose contents vary depending on the blood products needed and statutory regulations, and which are mainly composed of bags connected to each other by tubes and incorporating at least one filtration unit. Each bag includes an electronic chip capable of memorising and exchanging information with an electronic communication device. This abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

Priority: FR20010009246 Applic. Date: 2001-07-12; WO2002FR02465 Applic. Date: 2002-07-12

Inventor: DE GAULLE ANTOINE [FR]


Application No.: US20040151702A1  Published: 05/Aug/2004

Title: Production and use of a suspension composition comprising an ultrasound contrast medium

Applicant/Assignee:

Application No.: 10/475631   Filing Date: 01/Apr/2004

Abstract:A suspension composition is described, which contains at least one functional component effective in biological tissue and which forms a dosage form for administration into the tissue, whereby the functional component is suspended or dissolved in a suspension fluid, the functional component contains at least one active ingredient, biological cells, bacteria, viruses and/or biological or biocompatible fillers, and an ultrasound contrast medium is contained in the suspension fluid. Uses of the suspension composition, in particular for injection into biological tissue, are also disclosed.

Priority: DE20011019522 Applic. Date: 2001-04-20; WO2002EP04363 Applic. Date: 2002-04-19

Inventor: MARKSTEINER RAINER [AT]


Application No.: US20040156823A1  Published: 12/Aug/2004

Title: Syringe for inducing therapeutically-effective proteins

Applicant/Assignee: ORTHOGEN GENTECHNOLOGIE GMBH

Application No.: 10/378175   Filing Date: 03/Mar/2003

Abstract:A syringe for inducing therapeutically-effective proteins includes a syringe and an inner structure having an inductor disposed thereon for encouraging development of a desired protein.

Priority: US2000-485836 Applic. Date: 2000-07-06; EP19980109186 Applic. Date: 1998-05-20; DE19971035537 Applic. Date: 1997-08-16; WO1998EP04866 Applic. Date: 1998-08-05

Inventor: REINECKE JULIO [DE]; MEIJER HANS [DE]; WEHLING PETER [DE]


Application No.: US20040156833A1  Published: 12/Aug/2004

Title: Devices and methods for implanting transduced cells

Applicant/Assignee: UNIVERSITY OF WASHINGTON

Application No.: 10/765306   Filing Date: 26/Jan/2004

Abstract:Vascular grafts are used in gene therapy to implant autologous vascular smooth muscle cells that have been transduced with the gene of interest. The smooth muscle cells are immobilized within the pores and upon the interior surface of the wall of the graft, which is then coated with vascular endothelial cells and implanted into a patients's vascular system. The grafting device can be used in methods of treatment, such as supplying erythropoietin to a patient, and can be removed easily and replenished as necessary. The process is readily controlled and significantly reduces the risk of a viral gene vector spreading beyond a target cell population.

Priority: US1994-217324 Applic. Date: 1994-03-24

Inventor: OSBORNE WILLIAM R A [US]; GEARY RANDOLPH L [US]; LAU STELLA [US]; CLOWES ALEXANDER W [US]; DALE DAVID C [US]


Application No.: US20040156872A1  Published: 12/Aug/2004

Title: Novel nimesulide compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/697703   Filing Date: 31/Oct/2003

Abstract:The present invention provides nanoparticulate nimesulide compositions. The compositions preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides methods of making and using nanoparticulate nimesulide compositions.

Priority: US2003-276400 Applic. Date: 2003-01-15; US2000-572961 Applic. Date: 2000-05-18

Inventor: BOSCH H WILLIAM [US]; WERTZ CHRISTIAN F [US]


Application No.: US20040156895A1  Published: 12/Aug/2004

Title: Solid dosage forms comprising pullulan

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/705227   Filing Date: 12/Nov/2003

Abstract:Disclosed are solid dosage forms of active agents and pullulan. The solid dosage form has a friability of less than about 1%.

Priority: US20020425264P Applic. Date: 2002-11-12

Inventor: PRUITT JOHN D [US]; HOVEY DOUGLAS C [US]; RYDE TUULA A [US]; BOSCH H WILLIAM [US]; LEE ROBERT W [US]


Application No.: US20040161766A1  Published: 19/Aug/2004

Title: Method for assaying flowing media for microbial toxins

Applicant/Assignee:

Application No.: 10/474694   Filing Date: 07/Apr/2004

Abstract:Testing of flowing media for microbial toxins via whole blood incubation in a flow vessel containing a separation element and assaying for mediators.

Priority: DE20011018446 Applic. Date: 2001-04-12; WO2002DE01086 Applic. Date: 2002-03-25

Inventor: HARTUNG THOMAS [DE]


Application No.: US20040161788A1  Published: 19/Aug/2004

Title: Sample processing

Applicant/Assignee: IQUUM, INC

Application No.: 10/773775   Filing Date: 05/Feb/2004

Abstract:A sample processing tubule may include a first segment, a second segment, and a third segment. Each segment may be defined by the tubule, may be fluidly isolated, at least in part by a breakable seal, may be so expandable as to receive a volume of fluid expelled from another segment, and may be so compressible as to contain substantially no fluid when so compressed. Each segment may contain at least one reagent.

Priority: US20030445304P Applic. Date: 2003-02-05

Inventor: CHEN SHUQI [US]; LEMIEUX BERTRAND [US]; WANG ZIHUA [US]; KOPCZYNSKI KEVIN R [US]; CHEN LINGJUM [US]


Application No.: US20040161812A1  Published: 19/Aug/2004

Title: Method for detecting, treating, and monitoring conditions associated with activation of the coagulation response

Applicant/Assignee:

Application No.: 10/694033   Filing Date: 27/Oct/2003

Abstract:Disclosed is a method that includes steps of identifying conditions each associated with a low level activation of the coagulation response

conducting a clinical evaluation of a patient to determine a possibility that the patient has one of the conditions

if the clinical evaluation indicates the possibility that the patient has one of the conditions, providing a panel of different quantitative blood tests each capable of providing one of an abnormal result indicative of a low level activation of the coagulation response, and a normal result

performing the panel of different quantitative blood tests on the patient

obtaining a result for each of the blood tests

observing the results

and if at least two of the results are abnormal, using the abnormal results to assist in diagnosing the patient with the one of the conditions.

Priority: US2000-637808 Applic. Date: 2000-08-11; US19990148799P Applic. Date: 1999-08-13

Inventor: BERG DAVID E [US]; BERG LOIS HILL [US]; HARRISON HAROLD H [US]


Application No.: US20040162281A1  Published: 19/Aug/2004

Title: Biaryl compounds as serine protease inhibitors

Applicant/Assignee: BIOCRYST PHARMACEUTICALS, INC

Application No.: 10/738027   Filing Date: 18/Dec/2003

Abstract:Compounds of formula (I) are useful as inhibitors of trypsin like serine protease enzymes such as thrombin, factor VIIa, factor Xa, TF/FVIIa, and trypsin. These compounds could be useful to treat and/or prevent clotting disorders, and as anticoagulating agents.

Priority: US2002-127460 Applic. Date: 2002-04-23; WO2001US32582 Applic. Date: 2001-10-22; US20010281735P Applic. Date: 2001-04-06

Inventor: BABU YARLAGADDA S [US]; ROWLAND R SCOTT [US]; CHAND POORAN [US]; KOTIAN PRAVIN L [US]; EL-KATTAN YAHYA [US]; NIWAS SHRI [US]


Application No.: US20040162410A1  Published: 19/Aug/2004

Title: Prodrugs of thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 10/776245   Filing Date: 12/Feb/2004

Abstract:There is provided compounds of formula I, R<1>O(O)C-CH2-(R)Cgl-Aze-Pab-R<2> I wherein R<1 >and R<2 >have meanings given in the description, which are useful as prodrugs of inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (eg thrombosis) or as anticoagulants.

Priority: GB19950026273 Applic. Date: 1995-12-21; SE19960000556 Applic. Date: 1996-02-15; SE19970004542 Applic. Date: 1997-12-05; WO1998SE02191 Applic. Date: 1998-12-01; US2002-074008 Applic. Date: 2002-02-14; US2000-708449 Applic. Date: 2000-11-09; US1999-353644 Applic. Date: 1999-07-15; US1997-776231 Applic. Date: 1997-01-31; WO1996SE01680 Applic. Date: 1996-12-17

Inventor: ANTONSSON THOMAS [SE]; GUSTAFSSON DAVID [SE]; HOFFMANN KURT-JURGEN [SE]; NYSTROM JAN-ERIK [SE]; SORENSEN HENRIK [SE]; SELLEN MIKAEL [SE]


Application No.: US20040164194A1  Published: 26/Aug/2004

Title: System and method for milling materials

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LIMITED

Application No.: 10/732801   Filing Date: 11/Dec/2003

Abstract:A system for milling at least one material, e.g., a drug, is described. The system includes a milling apparatus. In another embodiment of the invention, the system includes at least one milling medium. The milling apparatus includes a chamber having a rotary milling head located in it. The milling head is rotated within the chamber by a magnetic drive system.

Priority: US20010295965P Applic. Date: 2001-06-05; US2002-162333 Applic. Date: 2002-06-04

Inventor: REED ROBERT G [US]; CZEKAI DAVID [US]


Application No.: US20040171013A1  Published: 02/Sep/2004

Title: Method for determining the nature of an infection

Applicant/Assignee:

Application No.: 10/479656   Filing Date: 14/Jan/2004

Abstract:The present invention relates to differential diagnostics, and provides a method for determining if an infection detected in a parent is of bacterial or of viral origin. In the method chemiluminescence of phagocytic cells induced by non-opsonized zymosan in a blood sample is measured and the expression of Complement Receptor 1 (cr1 is determined. The value when multiplying chemiluminescence with the CR1 expression is compared with method-specific average values for bacterial and viral infections. The invention also provides test kits for accomplishing the method of the invention.

Priority: FI20010001168 Applic. Date: 2001-06-04; WO2002FI00472 Applic. Date: 2002-06-03

Inventor: LILIUS ESA-MATTI [FI]; NUUTILA JARI [FI]


Application No.: US20040171093A1  Published: 02/Sep/2004

Title: Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses

Applicant/Assignee:

Application No.: 10/805881   Filing Date: 22/Mar/2004

Abstract:This invention relates to methods for detecting the deficiency of magnesium tightly bound to plasma membranes of somatic cells, referred to as the magnesium binding defect. The invention also relates to methods for assessing certain abnormal physiological states, such as, salt-sensitive essential hypertension, type 2 overt or prediabetes mellitus, and preeclampsia/eclampsia syndrome that are associated with the magnesium binding defect. The invention further relates to methods for generating magnesium deficient cell membranes and for identifying substances which promote binding of magnesium ions to the plasma membranes of somatic cells. Additionally, the invention relates to a binding pair members having affinity for the peptides and promoters of the invention.

Priority: US2002-053669 Applic. Date: 2002-01-24; US1999-265690 Applic. Date: 1999-03-10; US2003-695536 Applic. Date: 2003-10-28; US2002-230133 Applic. Date: 2002-08-29; US2000-635266 Applic. Date: 2000-08-09

Inventor: WELLS IBERT C [US]


Application No.: US20040171625A1  Published: 02/Sep/2004

Title: Compositions and methods for targeting cerebral circulation and treatment of headache

Applicant/Assignee:

Application No.: 10/483509   Filing Date: 12/Jan/2004

Abstract:Methods and compositions for targeting cerebral circulation and treatment of headache include formulations comprising a pharmacologically active substance in a transdermal formulation, which is topically applied to an area of skin superficial to a carotid artery, a temporal artery, a vertebral artery, or to a tender spot associated with a headache. Particularly preferred formulations include a xanthine derivative (e.g., theophylline, caffeine, aminophylline), and may further comprise ketoprofen. Contemplated methods further include methods of advertising use of contemplated compositions.

Priority: WO2001US26459 Applic. Date: 2001-08-23; WO2002US26613 Applic. Date: 2002-08-20

Inventor: FROME BRUCE [US]


Application No.: US20040173696A1  Published: 09/Sep/2004

Title: Milling microgram quantities of nanoparticulate candidate compounds

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/736989   Filing Date: 17/Dec/2003

Abstract:The present invention is directed to a method of milling small quantities of one or more candidate compounds to reduce the particle size of at least one candidate compound to about 2 microns or less. The apparatus used for the milling process can be one or more multi-well plates, or any other suitable apparatus. The resultant products are dispersions of nanoparticulate candidate compounds. The method is particularly suited for increasing the effectiveness of high throughput screening ("HTS").

Priority: US20020433784P Applic. Date: 2002-12-17

Inventor: CUNNINGHAM JAMES [US]; LIVERSIDGE ELAINE [US]; COOPER EUGENE R [US]; LIVERSIDGE GARY G [US]


Application No.: US20040175428A1  Published: 09/Sep/2004

Title: Controlled release by extrusion of solid amorphous dispersions of drugs

Applicant/Assignee: PFIZER INC BEND RESEARCH, INC

Application No.: 10/799536   Filing Date: 11/Mar/2004

Abstract:Controlled release dosage forms for low solubility drugs are disclosed wherein an amorphous solid dispersion of the drug is coated with a non-dissolving and non-eroding coating that controls the influx of water to the core so as to cause extrusion of a portion of the core, as well as a method of treating a disease or disorder comprising administering such dosage form to a person.

Priority: US2000-495061 Applic. Date: 2000-01-31; US19990119406P Applic. Date: 1999-02-10

Inventor: APPEL LEAH E [US]; CURATOLO WILLIAM J [US]; HERBIG SCOTT M [US]; NIGHTINGALE JAMES A S [US]; THOMBRE AVINASH G [US]


Application No.: US20040176375A1  Published: 09/Sep/2004

Title: Benzene acetamide compounds useful as serine protease inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB CO

Application No.: 10/775443   Filing Date: 10/Feb/2004

Abstract:Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, or prodrugs thereof, are useful as serine protease inhibitors, wherein X is -OH, -O(alkyl), -O(aryl), -O(arylalkyl), -NR5(aryl), or -NR5(arylalkyl)

W is hydrogen or -(CR7R8)q-W1

W1 is hydrogen or a bond with R6

Z is a 5-membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, a 9 to 10 membered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R1, R2, R3, R5, R6, R7, and R16 are as defined in the specification.

Priority: US20030446578P Applic. Date: 2003-02-11

Inventor: BISACCHI GREGORY S [US]; MORTON GEORGE C [US]


Application No.: US20040176672A1  Published: 09/Sep/2004

Title: Implantable, retrievable, thrombus minimizing sensors

Applicant/Assignee:

Application No.: 10/758495   Filing Date: 15/Jan/2004

Abstract:A sensor is disclosed, for implantation within a blood vessel to monitor a substance in or property of blood. In one embodiment, the sensor is retrievable. In another embodiment, the sensor has a layer that minimizes the formation of thrombus. A signal representative of the substance in or property of blood is transmitted to an external receiver. In another embodiment, the sensor detects nitric oxide or a nitric oxide metabolite and can be implanted for a period of hours, days, weeks or years. Methods are also disclosed.

Priority: US2002-217202 Applic. Date: 2002-08-09; US2001-041036 Applic. Date: 2001-11-08; US2000-571702 Applic. Date: 2000-05-15

Inventor: SILVER JAMES H [US]; MOSTOWFI DARIUS FREDRICK [US]


Application No.: US20040185112A1  Published: 23/Sep/2004

Title: Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus

Applicant/Assignee: PFIZER, INC

Application No.: 10/766450   Filing Date: 27/Jan/2004

Abstract:Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers.

Priority: US2003-353746 Applic. Date: 2003-01-28; US20020354080P Applic. Date: 2002-02-01

Inventor: BEYERINCK RONALD A [US]; DIEBELE HEATHER L M [US]; DOBRY DAN E [US]; RAY RODERICK J [US]; SETTELL DANA M [US]; SPENCE KEN R [US]


Application No.: US20040185570A1  Published: 23/Sep/2004

Title: Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same

Applicant/Assignee: HEMOVATIONS, LLC

Application No.: 10/395860   Filing Date: 21/Mar/2003

Abstract:An erythrocyte sedimentation rate (ESR) measurement instrument having a Blood Collection Configuration and an ESR Measurement Configuration. The ESR measurement instrument comprises a sedimentation measurement tube having an hollow interior volume containing a predetermined quantity of blood sample diluting agent therewithin and being air/fluid sealed with respect to the ambient environment

and a blood collection tube having a hollow interior volume containing a predetermined quantity of anti-coagulant and being vacuum-sealed with respect to the ambient environment, and physically coupled to the air-sealed sedimentation measurement tube, by at least a portion of the sedimentation measurement tube being inserted within a portion of the hollow interior volume of the blood collection tube.

The sedimentation measurement tube and the blood collection tube are maintained stationarily fixed relative to each other as a unitary assembly having a syringe-like form factor when the ESR measurement instrument is arranged in the Blood Collection Configuration. During this configuration, a needle-supporting connector can be connected to the blood collection tube and a sample of whole blood from a patient vacuum-drawn and injected into the blood collection tube.

After the sample of anti-coagulated blood has been collected in the blood collection tube and the needle-supporting connector is disconnected therefrom, the air/fluid seal of the sedimentation measurement tube can be broken and then the sedimentation measurement tube can be manually plunged into and to the bottom of the hollow interior volume of said blood collection tube, using a single-handed operation to rearrange the ESR measurement instrument into the ESR Measurement Configuration.

The anti-coagulated sample of blood fills up a substantially portion of the sedimentation measurement tube and mixes with the blood sample diluting agent to enable the blood plasma/erythrocyte cell (P/E) interface level within the sedimentation measurement tube to settle downwards toward the blood collection tube during a predetermined time period when said ESR measurement instrument is oriented in a gravity vertical position. By virtue of the present invention, the erythrocyte sedimentation rate (ESR) of the collected blood sample can be measured by determining how far the P/E interface level has moved against graduation markings formed along the length of the sedimentation measurement tube during the predetermined time period.

Priority:

Inventor: BOUBOULIS DENIS A [US]


Application No.: US20040186090A1  Published: 23/Sep/2004

Title: New amidino derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 10/815954   Filing Date: 02/Apr/2004

Abstract:There is provided compounds of formula I wherein R<1>, Rx, Y, R, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE19980004313 Applic. Date: 1998-12-14; US2000-509032 Applic. Date: 2000-03-21

Inventor: INGHARDT TORD [SE]; KARLSSON OLLE [SE]; LINSCHOTEN MARCEL [SE]; NYSTROM JAN-ERIK [SE]


Application No.: US20040186408A1  Published: 23/Sep/2004

Title: Method, system and machine for collecting a biological fluid to which a selected ratio of solution is added

Applicant/Assignee:

Application No.: 10/750143   Filing Date: 31/Dec/2003

Abstract:The invention concerns a method of collecting a biological fluid, in particular blood, with an anticoagulant and/or preservation solution added, in which the biological fluid is collected by natural flow and the anticoagulant and/or preservation solution is added by pumping, the method making provision for measuring the flow of fluid collected and slaving the pumping speed to the measured flow, so as to obtain continuously during collection a given ratio between the quantity of fluid collected and the quantity of anticoagulant and/or preservation solution added. The invention also concerns a collection machine and bag system for implementing the method.

Priority: FR20030001195 Applic. Date: 2003-02-03

Inventor: BEHAGUE MAURICE [FR]; GOUDALIEZ FRANCIS [FR]; VERPOORT THIERRY [FR]


Application No.: US20040186589A1  Published: 23/Sep/2004

Title: Surgical implant, method for the production and use thereof

Applicant/Assignee: AESCULAP AG & CO. KG

Application No.: 10/478128   Filing Date: 30/Apr/2004

Abstract:A surgical implant is made from biocompatible fiber material as a woven textile fabric, in particular in the form of a vascular prosthesis, the woven fabric being so configured that its permeability to blood is so low that the blood impregnates the textile fabric upon implantation and seals it off by coagulating, but does not flow through it.

Priority: DE20011025712 Applic. Date: 2001-05-21; WO2002EP05544 Applic. Date: 2002-05-21

Inventor: BENTELE FRANZ [DE]; GOLDMANN HELMUT [DE]


Application No.: US20040191897A1  Published: 30/Sep/2004

Title: Apparatus and method for harvesting bone marrow

Applicant/Assignee: THE CLEVELAND CLINIC FOUNDATION

Application No.: 10/813986   Filing Date: 31/Mar/2004

Abstract:A minimally invasive apparatus and method for harvesting bone marrow cells, blood, and bone fragments includes a rigid cannula having a proximal end and a distal end with an opening. The distal end includes a cutting tip that is movable axially and radially to cut and disrupt bone tissue while preserving necessary viability among harvested marrow cells. The cannula further includes an inner surface defining an internal passage that extends from the opening toward the proximal end. Suction is applied to the passage to draw disrupted bone marrow cells, blood, and bone fragments into the internal passage for collection. The apparatus may include a rotatable shaft disposed co-axially within the internal passage. The shaft has a distal end with a cutting bit for further cutting and disrupting of bone tissue.

Priority: US20030459199P Applic. Date: 2003-03-31

Inventor: MUSCHLER GEORGE F [US]


Application No.: US20040193178A1  Published: 30/Sep/2004

Title: Multiple joint implant delivery systems for sequentially-controlled implant deployment

Applicant/Assignee: CARDIOMIND, INC

Application No.: 10/746452   Filing Date: 24/Dec/2003

Abstract:The invention provides an atraumatic, low profile device for the delivery of one or more implants into tubular organs or open regions of the body. The implant delivery device may simultaneously or independently release portions of the implant, e.g., the proximal and distal ends of the implant. This independent release feature allows better implant positioning at the target site. Upon deployment, the implants may be placed at the target site without a sheath.

Priority: US20030458323P Applic. Date: 2003-03-26; US20030462219P Applic. Date: 2003-04-10

Inventor: NIKOLCHEV JULIAN [US]


Application No.: US20040193179A1  Published: 30/Sep/2004

Title: Balloon catheter lumen based stent delivery systems

Applicant/Assignee: CARDIOMIND, INC

Application No.: 10/746455   Filing Date: 24/Dec/2003

Abstract:The invention provides an atraumatic, low profile device for the delivery of one or more implants into tubular organs or open regions of the body. The implant delivery device may simultaneously or independently release portions of the implant, e.g., the proximal and distal ends of the implant. This independent release feature allows better implant positioning at the target site. Upon deployment, the implants may be placed at the target site without a sheath.

Priority: US20030458323P Applic. Date: 2003-03-26; US20030462219P Applic. Date: 2003-04-10

Inventor: NIKOLCHEV JULIAN [US]


Application No.: US20040194338A1  Published: 07/Oct/2004

Title: Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus

Applicant/Assignee: PFIZER INC

Application No.: 10/766651   Filing Date: 27/Jan/2004

Abstract:Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers.

Priority: US2003-353746 Applic. Date: 2003-01-28; US20020354080P Applic. Date: 2002-02-01

Inventor: BEYERINCK RONALD A [US]; DIEBELE HEATHER L M [US]; DOBRY DAN E [US]; RAY RODERICK J [US]; SETTELL DANA M [US]; SPENCE KEN R [US]


Application No.: US20040195413A1  Published: 07/Oct/2004

Title: Compositions and method for milling materials

Applicant/Assignee:

Application No.: US 2004-832374   Filing Date: 27/Apr/2004

Abstract:A system for milling at least one material, e.g., a drug. The system includes a milling apparatus and at least one milling medium. The milling apparatus includes a chamber having a rotary milling head located in it. The milling head is rotated within the chamber by a magnetic drive system.

Priority: US20010295965P Applic. Date: 2001-06-05; US2002-162333 Applic. Date: 2002-06-04

Inventor: REED ROBERT G [US]; CZEKAI DAVID [US]


Application No.: US20040197836A1  Published: 07/Oct/2004

Title: Measurement of F-actin in whole blood cellular subsets

Applicant/Assignee:

Application No.: 10/407262   Filing Date: 04/Apr/2003

Abstract:A method for F-actin measurement in a mixture of cells includes fixing the mixture of cells at a selected temperature

labeling at least one type of cells in the mixture of cells using cell type-specific reagents

labeling F-actin using an F-actin probe

and determining a content of the F-actin in each of the at least one type of cell in the mixture of cells. The method may further include incubating separate samples with or without a stimulant before the fixing of the mixture of cells

and comparing the F-actin contents in the same cell types in the separate samples.

Priority:

Inventor: HASHEMI BRIAN B [US]


Application No.: US20040204412A1  Published: 14/Oct/2004

Title: Phenylglycine derivatives useful as serine protease inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/775923   Filing Date: 10/Feb/2004

Abstract:Compounds having the formula (I), or a stereoisomer or pharmaceutically-acceptable salt, or hydrate thereof, are useful as factor VIIa inhibitors, wherein X is -NR6S(O)pR16

W is hydrogen or -(CR7R8)qW1

W1 is hydrogen or a bond with R6

Z is a 5-membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, a 9 to 10 membered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R1, R2, R3, R6, R7, and R16 are as defined in the specification.

Priority: US20030446578P Applic. Date: 2003-02-11; US20030520781P Applic. Date: 2003-11-17

Inventor: GLUNZ PETER W [US]; BISACCHI GREGORY S [US]; MORTON GEORGE C [US]; HOLUBEC ALEXANDRA A [US]; PRIESTLEY E SCOTT [US]; ZHANG XIAOJUN [US]; TREUNER UWE D [DE]


Application No.: US20040204673A1  Published: 14/Oct/2004

Title: Modular infusion device and method

Applicant/Assignee:

Application No.: 10/835770   Filing Date: 30/Apr/2004

Abstract:A device for delivering fluid including a disposable assembly having an exit port assembly and a metering portion of a dispenser for controlling fluid flow to the exit port assembly, and a reusable assembly having a control portion of the dispenser adapted to control the metering portion of the dispenser upon attachment of the reusable assembly and the disposable assembly, a local processor connected to the dispenser and programmed to cause fluid flow to the exit port assembly through the dispenser based upon flow instructions, and a local wireless communication element connected to the local processor for receiving flow instructions from a remote wireless device. The assemblies are adapted to be removably attached, and a power source is contained in the disposable assembly for providing power to the reusable assembly upon attachment of the reusable assembly and the disposable assembly.

Priority: US2002-081394 Applic. Date: 2002-02-22; US20010270970P Applic. Date: 2001-02-22

Inventor: FLAHERTY J CHRISTOPHER [US]


Application No.: US20040206363A1  Published: 21/Oct/2004

Title: Methods for reduction of pressure effects of cardiac tricuspid valve regurgitation

Applicant/Assignee: 3F THERAPEUTICS, INC

Application No.: 10/418663   Filing Date: 17/Apr/2003

Abstract:A method of protecting an upper body and a lower body of a patient from high venous pressures comprising implanting a first stented valve at the superior vena cava and a second stented valve at the inferior vena cava, wherein the first and second valves are configured to permit blood flow towards a right atrium of the patient and prevent blood flow in an opposite direction.

Priority:

Inventor: MCCARTHY PATRICK M [US]; QUIJANO RODOLFO C [US]


Application No.: US20040208786A1  Published: 21/Oct/2004

Title: Autologous coagulant produced from anticoagulated whole blood

Applicant/Assignee:

Application No.: 10/765694   Filing Date: 27/Jan/2004

Abstract:A method for the preparation of a stable autologous or homologous coagulant from whole blood is disclosed. The direct precipitation of anticoagulated whole blood obviates the need for a plasma isolation step with unexpected results. The autologous or homologous coagulant produced by the method of the present invention demonstrated clotting times equivalent to commercially available bovine thrombin and human thrombin preparations, with improved kinetics of growth factor release from activated platelets over preparations of bovine thrombin.

Priority: US20030442974P Applic. Date: 2003-01-27

Inventor: KEVY SHERWIN V [US]; SULLIVAN SHERYL [US]; JACOBSON MAY [US]; BLASETTI LOU [US]


Application No.: US20040209371A1  Published: 21/Oct/2004

Title: Multi-analyte reference solutions

Applicant/Assignee: INSTRUMENTATION LABORATORY COMPANY

Application No.: 10/733871   Filing Date: 11/Dec/2003

Abstract:The present invention provides a reference solution for use in instruments that determine hematocrit levels in biological samples by measuring the resistance and/or conductivity of the biological samples. A reference solution according to the invention achieves conductivities representative of known hematocrit levels in blood, while maintaining tolerable levels of interference with the measurement of other analytes in the reference solution.

Priority: US20020432373P Applic. Date: 2002-12-11

Inventor: CONLON DENNIS ROBERT [US]; MANSOURI SOHRAB [US]; VAGO GIANNANTONIO [IT]


Application No.: US20040209844A1  Published: 21/Oct/2004

Title: Compositions and methods for preventing infection

Applicant/Assignee: LA JOLLA BIOSCIENCES LLC

Application No.: 10/667727   Filing Date: 22/Sep/2003

Abstract:This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to prevent infection. The compositions of the invention can be used to reduce or prevent maternal to fetal transmission of a microorganism and/or to reduce or eliminate a microorganism present in a blood sample or a blood product.

Priority: US20020412399P Applic. Date: 2002-09-20

Inventor: SCHEELE GEORGE A [US]; HILDRETH JAMES E [US]


Application No.: US20040210180A1  Published: 21/Oct/2004

Title: Dialysis catheter system

Applicant/Assignee:

Application No.: 10/823468   Filing Date: 12/Apr/2004

Abstract:The present invention provides a dialysis catheter that is designed to function in reverse-flow, having a dual lumen configuration. An embodiment of the present invention includes two lumen cooperatively configured in a co-axial design. The arterial lumen is circular or oval and extends beyond the termination of the venous lumen. The arterial lumen extracts the blood from the blood vessel for hemodialysis treatment. The venous lumen is also circular or oval. Terminating at a proximal point to the distal end of the arterial lumen, this configuration of the venous lumen aids in preventing recirculation. The venous lumen returns dialyzed blood back into the patient. The venous lumen can further include a plurality of apertures to aid in reducing the risk of fibrin sheath growth. In a method of use, the arterial lumen of the invention preferably resides within the right atrium with the venous lumen positioned within the superior vena cava.

Priority: US20030462908P Applic. Date: 2003-04-15; US20030468891P Applic. Date: 2003-05-08

Inventor: ALTMAN SANFORD D [US]


Application No.: US20040210306A1  Published: 21/Oct/2004

Title: Device for reduction of pressure effects of cardiac tricuspid valve regurgitation

Applicant/Assignee: 3F THERAPEUTICS, INC

Application No.: 10/418677   Filing Date: 17/Apr/2003

Abstract:A method of protecting an upper and a lower body of a patient from high venous pressures comprising: providing an elongate valve stent, wherein the stent comprises a first stent member with a first tissue valve secured to a first support structure being disposed at a first end of the stent and a second stent member with a second tissue valve secured to a second support structure being disposed at an opposite second end of the stent, wherein both support structures are collapsibly expandable, the second end being connected to the first end with at least one elongate connecting member

passing the elongate valve stent through a blood vessel with the first and second support structures in a collapsed position

and securing the first support structure to an inferior vena cava and the second support structure to a superior vena cava with both support structures in an expanded shape.

Priority:

Inventor: QUIJANO RODOLFO C [US]; MCCARTHY PATRICK M [US]


Application No.: US20040215134A1  Published: 28/Oct/2004

Title: Optical detector for enzyme activation

Applicant/Assignee: MEDTRONIC, INC

Application No.: 10/423112   Filing Date: 25/Apr/2003

Abstract:Activation of an enzyme in a bodily fluid is detected based on the amount of cleavage of a substrate for the enzyme. The substrate is tagged with two fluorescent dyes-a donor and an acceptor. The tagged substrate is presented to the bodily fluid. A device emits energy at a first wavelength into the bodily fluid, and detects energy at second and third wavelengths emitted by the dyes in response to the energy at the first wavelength. Prior to enzymatic cleavage of the substrate, the acceptor emits energy at the third wavelength in response to energy at the second wavelength received through fluorescent resonant energy transfer (FRET) from the donor. After enzymatic cleavage of the substrate, the donor emits energy at the second wavelength.

The device can determine the concentration of activated enzyme within the bodily fluid based on the relative intensities of energy at the second and third wavelengths.

Priority:

Inventor: SOYKAN ORHAN [US]; DONOVAN MAURA G [US]


Application No.: US20040215173A1  Published: 28/Oct/2004

Title: Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique

Applicant/Assignee:

Application No.: 10/420094   Filing Date: 22/Apr/2003

Abstract:The present invention is directed to a device for a portable convection enhanced delivery system that allows administering liquids to specific locations within the body, especially tissues and tumors also allowing outsubject treatment. The application system comprises a portable extracorporal pump with a fluid reservoir that is connected via an infusion system to an infusion catheter placeable to any tissue or tumor the fluid should be administered to by high flow microperfusion. The system enables administration of fluids of any kind by convection enhanced delivery also in out-patient treatment. The system can be used for delivering various drugs, proteins, protein toxins, antibodies-for treatment or imaging, proteins in enzyme replacement therapy, growth factors and viruses or oligonucleotides in gene therapy etc. The application methods as well as the surgical method to implant this device are enclosed to this invention.

Priority:

Inventor: KUNST MECHTHILD [DE]


Application No.: US20040219680A1  Published: 04/Nov/2004

Title: Method and apparatus for determining anticoagulant therapy factors

Applicant/Assignee:

Application No.: 10/428708   Filing Date: 02/May/2003

Abstract:A method and apparatus are disclosed for determining a new anticoagulant therapy factor (nATF) for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The new anticoagulant therapy factor (nATF) is based upon a determination of the new fibrinogen transformation rate (nFTR) which, in turn, is dependent on a maximum acceleration point (MAP) for fibrinogen (FBG) conversion. The nATF quantity is also based upon the time to maximum acceleration from the time of reagent injection (TX) into a plasma sample, but does not require the difficulty of obtaining prior art International Normalized Ratio (INR) and International Sensitivity Index (ISI) parameters. The International Normalized Ratio (INR) was created to relate all species' clotting material to human clotting material, and nATF can replace INR in anticoagulant therapy management.

Priority:

Inventor: CARROLL WALLACE E [US]; JACKSON R DAVID [US]


Application No.: US20040220174A1  Published: 04/Nov/2004

Title: Lactam-containing compounds and derivatives thereof as factor Xa inhibitors

Applicant/Assignee: BRISTOL-MYERS-SQUIBB PHARMA COMPANY

Application No.: 10/850587   Filing Date: 20/May/2004

Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4 I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US2002-245122 Applic. Date: 2002-09-17; US20010324165P Applic. Date: 2001-09-21; US20020402317P Applic. Date: 2002-08-09

Inventor: PINTO DONALD J P [US]; QUAN MIMI L [US]; ORWAT MICHAEL J [US]; LI YUN-LONG [US]; HAN WEI [US]; QIAO JENNIFER X [US]; LAM PATRICK Y S [US]; KOCH STEPHANIE L [US]


Application No.: US20040220206A1  Published: 04/Nov/2004

Title: Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/824025   Filing Date: 14/Apr/2004

Abstract:The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt or hydrate form thereof, wherein the variables A, B, L1, L2, X<1>, X<2>, X<3>, X<4 >and W are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system

for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Priority: US20030463452P Applic. Date: 2003-04-16

Inventor: SMALLHEER JOANNE M [US]; QUAN MIMI L [US]; WANG SHUAIGE [US]; BISACCHI GREGORY S [US]


Application No.: US20040220511A1  Published: 04/Nov/2004

Title: Polymer coated device for electrically mediated drug delivery

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 10/425170   Filing Date: 29/Apr/2003

Abstract:The present invention relates to a catheter with an expandable distal end for delivering one or more medicaments. The catheter is manufactured with materials of construction that allow the transfer of electrical energy from the proximal end of the catheter to the distal expandable end. The catheter also has a means for controlling or manipulating the expandable distal end to expand and contract into various configurations. The distal end of the catheter is processed by a specific method of manufacturing whereby the expandable distal end is coated with one or more layers of a hydrogel copolymer wherein at least one layer of which coating encapsulates one or more medicaments and zero or more charged carriers to facilitate the electrophoretic and electro-osmostic mobilities of the medicaments.

Priority:

Inventor: SCOTT NEAL [US]; SEGAL JEROME [US]; SHIH LIH-BIN [US]; BURKOTH TERRY L [US]


Application No.: US20040220585A1  Published: 04/Nov/2004

Title: Implant delivery technologies

Applicant/Assignee: CARDIOMIND, INC

Application No.: 10/745778   Filing Date: 24/Dec/2003

Abstract:The invention provides an atraumatic, low profile device for the delivery of one or more implants into tubular organs or open regions of the body. The implant delivery device may simultaneously or independently release portions of the implant, e.g., the proximal and distal ends of the implant. This independent release feature allows better implant positioning at the target site. Upon deployment, the implants may be placed at the target site without a sheath.

Priority: US20030458323P Applic. Date: 2003-03-26; US20030462219P Applic. Date: 2003-04-10

Inventor: NIKOLCHEV JULIAN [US]


Application No.: US20040223857A1  Published: 11/Nov/2004

Title: Blood component processing systems and methods using fluid-actuated pumping elements that are integrity tested prior to use

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 10/280108   Filing Date: 24/Oct/2002

Abstract:Blood component processing systems and methods are coupled to a blood component processing device. The systems and methods include a fluid circuit that comprises at least one fluid pressure actuated pump station, at least one fluid flow path communicating with the pump station, and at least one valve in the fluid flow path. A control module is sized and configured to interact with the fluid circuit. The control module includes an actuator to selectively apply fluid pressure to the pump station in concert with operation of the valve to pump fluid through the fluid flow path in response to a control program. A controller coupled to the control module includes the control program and a fluid circuit integrity test function.

The fluid circuit integrity test function commands the control module to selectively apply fluid pressure to the pump station in concert with operation of the valve to introduce a fluid within a region of the fluid circuit and to confine the fluid within the region while applying fluid pressure to the pump chamber. The fluid circuit integrity test function generates an integrity output in response to sensing leakage of fluid from the region.

Priority:

Inventor: KLINE TIFFANY [US]; BEDARD PETER [US]; INGO CARSON [US]; BONIQUIT CHRISTOPHER [US]; SCHEIDT ROBERT [US]; NAYAK ABINASH [US]


Application No.: US20040224008A1  Published: 11/Nov/2004

Title: Dissolvable backing layer for use with a transmucosal delivery device

Applicant/Assignee: CEPHALON, INC

Application No.: 10/841893   Filing Date: 07/May/2004

Abstract:A dissolvable backing layer for use with transmucosal drug delivery devices includes a dissolvable hydrophilic region and a non-hydrophilic region that inhibits or slows migration of water, drugs, other active agents, or other molecules through the backing layer. The non-hydrophilic region can be a disperse phase of gaseous voids, droplets of a hydrophobic liquid, solid particles of a hydrophobic material, or water insoluble particles that are not necessarily hydrophobic. In the alternative, the non-hydrophilic region may comprise a continuous layer or component that is readily dispersible upon dissolving of the hydrophilic region. The backing layers may be used within any transmucosal delivery device used to delivery drugs or other active agents across a mucosal surface.

Priority: US20030469507P Applic. Date: 2003-05-09

Inventor: ZHANG HAO [US]


Application No.: US20040224416A1  Published: 11/Nov/2004

Title: Method and kit for testing a multi-channel blood assay cartridge

Applicant/Assignee: MEDTRONIC, INC

Application No.: 10/430623   Filing Date: 06/May/2003

Abstract:A method and kit for testing a multi-channel blood-testing cartridge. In particular, blood-testing cartridges are tested with plasma samples with clotting times measured to indicate whether a batch of cartridges is suitable for testing the blood of a patient.

Priority:

Inventor: GHAI JYOTSNA [US]; THOMPSON MARK A [US]; LUTZ COLLEEN [US]; RAMAMURTHY NARAYANAN A [US]; YUAN CHARLENE X [US]


Application No.: US20040225353A1  Published: 11/Nov/2004

Title: Percutaneous aortic valve

Applicant/Assignee: REX MEDICAL REX MEDICAL, L.P

Application No.: 10/429536   Filing Date: 05/May/2003

Abstract:The present invention provides a valve configured for insertion on the proximal and distal sides of a heart valve annulus to replace the heart valve of a patient. The valve comprises a first substantially annular portion adapted to be positioned on a proximal side of the annulus of a patient and a second substantially annular portion adapted to be positioned on a distal side of the annulus of a patient, wherein at least one of the first and second substantially annular portions is movable towards the other portion to a clamped position to clamp around the annulus. The second portion has a flow restricting portion extending therefrom and is movable between a first position to permit the flow of blood and a second position to restrict the flow of blood.

In one embodiment, the valve has a suture joining the first and second portions to draw the first and second portions into closer proximity and a cinch member to secure the suture to maintain the first and second portions in the clamped position. In another embodiment, the first and second portions are connected by a first segment which biases the first and second portions toward the clamped position.

Priority:

Inventor: MCGUCKIN JAMES F [US]; HINCHLIFFE PETER W J [US]


Application No.: US20040229038A1  Published: 18/Nov/2004

Title: Nanoparticulate meloxicam formulations

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/784900   Filing Date: 24/Feb/2004

Abstract:The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam particles of the composition have an effective average particle size of less than about 2000 nm.

Priority: US20030450705P Applic. Date: 2003-03-03

Inventor: COOPER EUGENE R [US]; RYDE TUULA [US]; PRUITT JOHN [US]; KLINE LAURA [US]


Application No.: US20040230117A1  Published: 18/Nov/2004

Title: Non-contact damage-free ultrasonic cleaning of implanted or natural structures having moving parts and located in a living body

Applicant/Assignee:

Application No.: 10/826232   Filing Date: 16/Apr/2004

Abstract:Ultrasonic, sonic or vibratory energy, delivered non-invasively, minimally invasively or invasively (e.g. surgically), is utilized to provide direct cleaning action at or to the location of the implanted device such as a prosthetic heart valve with undesirable deposits of at least some amount thereon or therein. Such ultra-sound energy may be aided by the use of a drug in association or cooperation with the acoustic irradiation. The "cleaning" acoustic energy may optionally be delivered under the guidance of an imaging modality and may be delivered in a timed or gated manner such that the valve occluders or leaflets are in a preferred position (assuming they are functioning) during exposures.

Priority: US20030463918P Applic. Date: 2003-04-17

Inventor: TOSAYA CAROL A [US]; SLIWA JOHN W [US]


Application No.: US20040230152A1  Published: 18/Nov/2004

Title: Extra-corporeal Blood Processing Method and Apparatus Based on Donor Characteristics

Applicant/Assignee: GAMBRO, INC GAMBRO BCT, INC

Application No.: 10/709196   Filing Date: 20/Apr/2004

Abstract:Methods and apparatus particularly involving the separation of blood into blood components and the collection of such components are disclosed. In one aspect, an extra-corporeal method for the collection of plasma and red blood cells is provided, wherein the collection of plasma and red blood cells may occur simultaneously or subsequently utilizing the same dual stage blood processing vessel. The flow of blood to the blood processing vessel and return of uncollected blood components may be provided via a single needle, wherein blood is removed from and returned to a donor/patient during alternating blood removal and blood return submodes. Platelet separation and collection options are also described. In either case, prior to red blood cell collection, a set-up phase may be carried out to set a predetermined hematocrit and AC ratio.

Replacement fluid delivery may optionally also be provided either substantially continuously during any collection phase(s) and/or in a bolus mode.

Priority: US2001-803304 Applic. Date: 2001-03-09; US20000188133P Applic. Date: 2000-03-09

Inventor: BAINBRIDGE MARLENE [US]; KELLER MURIEL [US]; GORDON TIMOTHY M [US]; MCATEER MICHAEL J [US]; BUTZKE SCOTT D [US]


Application No.: US20040235078A1  Published: 25/Nov/2004

Title: Kits for screening for blood coagulation disorders

Applicant/Assignee: INSTRUMENTATION LABORATORY COMPANY INSTRUMENTATION LABORATORY SPA

Application No.: 10/856108   Filing Date: 28/May/2004

Abstract:In vitro methods for qualitative screening and/or quantitative determination of the functional activity of components of the Protein C anticoagulant pathway of blood coagulation are described. The methods entail measuring the conversion rate of a substrate by an enzyme, the activity of which is related to the Protein C anticoagulant activity, in a blood sample of a human comprising coagulation factors and said substrate, after at least partial activation of coagulation through the intrinsic, extrinsic or common pathway and triggering coagulation by adding calcium ions

and comparing said conversion rate with the conversion rate of a normal human blood sample determined in the same way. The methods include the addition of additional metal ions to the sample to enhance activity, sensitivity and resolution. Kits and reagents for use in the methods are also provided.

Priority: EP19980105043 Applic. Date: 1998-03-19; US2002-331731 Applic. Date: 2002-12-30; US2002-050441 Applic. Date: 2002-01-16; US1999-273413 Applic. Date: 1999-03-19

Inventor: ROSEN BERT STEFFEN [SE]; HALL CHRISTINA MARIA YVONNE [SE]


Application No.: US20040235847A1  Published: 25/Nov/2004

Title: Tetrahydroquinoline derivatives useful as serine protease inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/796396   Filing Date: 09/Mar/2004

Abstract:The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables A, B, L1, L2, X<1>, X<2>, X<3>, X<4>, R<4>, R<5>, R<13>, R<14>, R<15 >and R<16 >are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system

for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Priority: US20030453812P Applic. Date: 2003-03-11

Inventor: QUAN MIMI L [US]; WANG CAILAN [US]; ZHOU JINGLAN [US]; HANGELAND JON J [US]; SEIFFERT DIETMAR A [US]; KNABB ROBERT M [US]


Application No.: US20040236262A1  Published: 25/Nov/2004

Title: Multiple ratio fluid dispenser

Applicant/Assignee: ARTERIOCYTE MEDICAL SYSTEMS, INC

Application No.: 10/876147   Filing Date: 24/Jun/2004

Abstract:A double syringe delivery system is disclosed for holding a pair of syringes in a manner so as to accommodate the simultaneous activation of the plunger of each syringe in order to effect simultaneous delivery of the contents of each syringe. The delivery system includes a delivery mechanism for delivering the contents of both syringes to a site of application. The delivery system further includes a support member that is positioned between the two syringe bodies. The elongated support member has resilient, C-shaped clamps on one end of the support member. The clamps are designed to be removably clamped onto the applicator so that the syringe barrels will be held together in a parallel manner. The elongated support member further comprises finger grips. A plunger connects the two syringe plungers so that they can also be simultaneously activated.

Priority: US2002-212430 Applic. Date: 2002-08-05; US20020388822P Applic. Date: 2002-06-14

Inventor: MCINTOSH KEVIN D [US]; ALBRECHT RICHARD M [US]


Application No.: US20040237970A1  Published: 02/Dec/2004

Title: Hemostatic compositions and uses therefor

Applicant/Assignee:

Application No.: 10/749330   Filing Date: 31/Dec/2003

Abstract:The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to achieve hemostasis at an increased rate. More specifically the present invention relates to hemostatic compositions that achieve a hemostatic effect at a distance from the site of application of the composition, and a method for administering such a composition to effectively reduce localized vascular complications associated with treating a breach or puncture in a vein or artery and reduce the time to achieve hemostasis.

Priority: US20020437349P Applic. Date: 2002-12-31

Inventor: VOURNAKIS JOHN N [US]; FINKIELSZTEIN SERGIO [US]


Application No.: US20040241205A1  Published: 02/Dec/2004

Title: Matrices for drug delivery and methods for making and using the same

Applicant/Assignee: MOLECULAR INSIGHT PHARMACEUTICALS, INC

Application No.: 10/838423   Filing Date: 04/May/2004

Abstract:In one aspect, biocompatible matrices such as sol-gels encapsulating a reaction center may be administered to a subject for conversion of prodrugs into biologically active agents. In certain embodiments, the biocompatible matrices of the present invention are sol-gels. In one embodiment, the enzyme L-amino acid decarboxylase is encapsulated and implanted in the brain to convert L-dopa to dopamine for treatment of Parkinson's disease.

Priority: US2002-077475 Applic. Date: 2002-02-15; US2000-503438 Applic. Date: 2000-02-14; US19990119828P Applic. Date: 1999-02-12

Inventor: BABICH JOHN W [US]; ZUBIETA JON [US]; BONAVIA GRANT [US]


Application No.: US20040242455A1  Published: 02/Dec/2004

Title: 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor

Applicant/Assignee: KISSEI PHARMACEUTICAL CO., LTD

Application No.: 10/486137   Filing Date: 06/Feb/2004

Abstract:The present invention relates to a 5-amidino-N-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R<1 >is a hydrogen atom or a lower alkyl group

R<2 >represents a hydrogen atom, an optionally substituted lower alkyl group, etc.

R<3 >is a di(lower alkyl)amino group, a lower alkyl group, a cycloalkyl group, etc.

Q is a hydrogen atom or an optionally substituted lower alkyl group

and Z is a hydrogen atom or a hydroxy group, etc., or a pharmaceutically acceptable salt thereof, which exerts a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same, a pharmaceutical use thereof and an intermediate thereof.

Priority: JP20010242905 Applic. Date: 2001-08-09; WO2002JP08093 Applic. Date: 2002-08-08

Inventor: OKAZAKI KOSUKE [JP]; UCHIDA MASAHIKO [JP]; KOBAYASHI HIROAKI [JP]; KAI YUICHIRO [JP]; TAKEUCHI HIDEKI [JP]; YOKOYAMA KENJI [JP]; TERAO YOSHIRO [JP]; SUZUKI RITSU [JP]


Application No.: US20040242492A1  Published: 02/Dec/2004

Title: Mandelic acid derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 10/487805   Filing Date: 26/Feb/2004

Abstract:There is provided a compound of formula (1) and pharmaceutically-acceptable derivatives (including prodrugs) thereof. Which compound and derivatives are useful as, or are as useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE20010002921 Applic. Date: 2001-08-30; WO2002SE01557 Applic. Date: 2002-08-30

Inventor: INGHARDT TORD [SE]; JOHANSSON ANDERS [SE]; SVENSSON ARNE [SE]


Application No.: US20040245189A1  Published: 09/Dec/2004

Title: Integrated automatic blood collection and processing unit

Applicant/Assignee: MISSION MEDICAL, INC

Application No.: 10/891343   Filing Date: 14/Jul/2004

Abstract:A system for automatically collecting and separating whole blood into its components is described. The system includes a console, which contains all motors, pumps, sensors, valves and control circuitry, and a unique disposable set that includes a cassette supporting a centrifuge with an improved design, pump interfaces with an improved design, component and solution bags, and tubing. Various processes are implemented using a specific disposable set for each process which allows automatic identification of the process to be performed the console.

Priority: US2002-179920 Applic. Date: 2002-06-24; US20010300873P Applic. Date: 2001-06-25; US20020374141P Applic. Date: 2002-04-19

Inventor: ROBINSON THOMAS C [US]; ROBINSON THOMAS P [US]; D ELIA RICHARD [US]; SAHINES THOMAS [US]; EIBE PAUL [US]


Application No.: US20040249332A1  Published: 09/Dec/2004

Title: Extra-corporeal Dual Stage Blood Processing Method and Apparatus

Applicant/Assignee: GAMBRO, INC

Application No.: 10/709194   Filing Date: 20/Apr/2004

Abstract:Methods and apparatus particularly involving the separation of blood into blood components and the collection of such components are disclosed. In one aspect, an extra-corporeal method for the collection of plasma and red blood cells is provided, wherein the collection of plasma and red blood cells may occur simultaneously or subsequently utilizing the same dual stage blood processing vessel. The flow of blood to the blood processing vessel and return of uncollected blood components may be provided via a single needle, wherein blood is removed from and returned to a donor/patient during alternating blood removal and blood return submodes. Platelet separation and collection options are also described. In either case, prior to red blood cell collection, a set-up phase may be carried out to set a predetermined hematocrit and AC ratio.

Replacement fluid delivery may optionally also be provided either substantially continuously during any collection phase(s) and/or in a bolus mode.

Priority: US2001-803304 Applic. Date: 2001-03-09; US20000188133P Applic. Date: 2000-03-09

Inventor: BAINBRIDGE MARLENE [US]; KELLER MURIEL [US]; GORDON TIMOTHY M [US]; MCATEER MICHAEL J [US]; BUTZKE SCOTT D [US]


Application No.: US20040251332A1  Published: 16/Dec/2004

Title: Method of using a small scale mill

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD ELAN PHARMA INTERNATIONAL, LIMITED

Application No.: 10/833045   Filing Date: 28/Apr/2004

Abstract:A small-scale or micro media-mill and a method of milling materials or products, especially pharmaceutical products, use a dispersion containing attrition milling media and the product to be milled. The milling media can be polymeric, formed of polystyrene or cross-linked polystyrene, having a nominal diameter of no greater than 500 microns. Other sizes include 200 microns and 50 microns and a mixture of these sizes. The mill has a relatively small vessel having an opening, an agitator, a coupling and a motor. The agitator can have a rotor and a shaft extending therefrom. The rotor can be cylindrical or have other configurations, and can have tapered end surfaces. The coupling can close the vessel opening, or attaching the coupling to the motor can close the opening. The coupling has an opening through which the rotor shaft extends into the motor.

A sealing mechanism, such as a mechanical or lip seals the shaft while permitting the rotor shaft to rotate. The vessel can contain one or more ports for circulating the dispersion, where milling can be made in batches or recirculated through the milling chamber. The media can be retained in the vessel or recirculated along with the process fluid. The rotor is dimensioned so that its outer periphery is spaced with a small gap from an inner surface of the vessel. The vessel also can have a way of cooling the dispersion.

Priority: US2001-037566 Applic. Date: 2001-10-19; US2000-583893 Applic. Date: 2000-05-31; US19990137142P Applic. Date: 1999-06-01

Inventor: REED ROBERT GARY [US]; CZEKAI DAVID A [US]; BOSCH HENRY WILLIAM [US]; MOESGAARD RYDE NIELS-PETER [US]


Application No.: US20040254158A1  Published: 16/Dec/2004

Title: 1,1-Disubstituted cycloalkyl derivatives as factor Xa inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/430024   Filing Date: 05/May/2003

Abstract:The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

Priority: US20020379357P Applic. Date: 2002-05-10; US20020415367P Applic. Date: 2002-10-02

Inventor: QIAO JENNIFER X [US]; PINTO DONALD J [US]; ORWAT MICHAEL J [US]; FRIEDRICH SARAH R [US]; HAN WEI [US]


Application No.: US20040254166A1  Published: 16/Dec/2004

Title: Substituted phenyl acetamides and their use as protease inhibitors

Applicant/Assignee: JOHNSON & JOHNSON PHARMACEUTICALS RESEARCH & DEVELOPMENT, L.L.C

Application No.: 10/816544   Filing Date: 01/Apr/2004

Abstract:Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof

wherein R<3>-R<6>, R<11>, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.

Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US20030461421P Applic. Date: 2003-04-10

Inventor: KREUTTER KEVIN D [US]; LEE LILY [US]; LU TIANBAO [US]; MOHAN VENKATRAMAN [US]; PATEL SHARMILA [US]; HUANG HUI [US]; XU GUOZHANG [US]; FITZGERALD MARK [US]


Application No.: US20040254514A1  Published: 16/Dec/2004

Title: Wearable ultrafiltration device

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 10/846618   Filing Date: 17/May/2004

Abstract:An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Priority: US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]


Application No.: US20040258757A1  Published: 23/Dec/2004

Title: Liquid dosage compositions of stable nanoparticulate active agents

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LTD

Application No.: 10/619539   Filing Date: 16/Jul/2003

Abstract:The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent.

Priority: US20020396530P Applic. Date: 2002-07-16

Inventor: BOSCH H WILLIAM [US]; HILBORN MATTHEW R [US]; HOVEY DOUGLAS C [US]; KLINE LAURA J [US]; LEE ROBERT W [US]; PRUITT JOHN D [US]; RYDE NIELS P [US]; RYDE TUULA A [US]; XU SHUQIAN [US]


Application No.: US20040258758A1  Published: 23/Dec/2004

Title: Nanoparticulate topiramate formulations

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LTD

Application No.: 10/766960   Filing Date: 30/Jan/2004

Abstract:The present invention is directed to nanoparticulate compositions comprising topiramate. The topiramate particles of the composition have an effective average particle size of less than about 2 microns.

Priority: US20030444377P Applic. Date: 2003-01-31; US20030477789P Applic. Date: 2003-06-12; US20030511318P Applic. Date: 2003-10-16

Inventor: GUSTOW EVAN [US]; RYDE TUULA [US]; COOPER EUGENE R [US]


Application No.: US20040259864A1  Published: 23/Dec/2004

Title: Substituted pyrimidinone derivatives as ligands of integrin receptors

Applicant/Assignee:

Application No.: 10/469176   Filing Date: 24/May/2004

Abstract:The invention relates to novel substituted pyrimidone derivatives which bind to integrin receptors, to their preparation and to their use.

Priority: DE20011008995 Applic. Date: 2001-02-23; WO2002EP01865 Applic. Date: 2002-02-21

Inventor: GENESTE HERVE [DE]; KLING ANDREAS [DE]; ZECHEL JOHANN-CHRISTIAN [DE]; LAUTERBACH ARNULF [DE]; SEITZ WERNER [DE]; GRAEF CLAUDIA ISABELLA [DE]; SUBKOWSKI THOMAS [DE]; HORNBERGER WILFRIED [DE]; SPRIESTERSBACH RAINER [DE]


Application No.: US20040260231A1  Published: 23/Dec/2004

Title: Integrated infusion and aspiration system and method

Applicant/Assignee: BREG, INC

Application No.: 10/896515   Filing Date: 22/Jul/2004

Abstract:An integrated infusion and aspiration system includes of a flow control system and a catheter assembly. The catheter assembly includes an infusion catheter and an aspiration catheter, each having ports located at the distal end of thereof. The distal ends of the catheters are separated so that the aspiration catheter ports can be positioned on an opposing side of a surgical wound site from the infusion catheter ports. Methods of operation of the integrated infusion and aspiration system provides for uninterrupted aspiration with concurrent controlled delivery of an infusion solution such that the infusion solution is substantially evenly dispersed of over the wound site.

Priority: US2002-218106 Applic. Date: 2002-08-12

Inventor: GOBLE E MARLOWE [US]; HOWARD MARK E [US]; MASON JEFFREY T [US]; FALLIN T WADE [US]


Application No.: US20040265864A1  Published: 30/Dec/2004

Title: Device and method for high-throughput quantification of mRNA from whole blood

Applicant/Assignee: HITACHI CHEMICAL CO., LTD HITACHI CHEMICAL RESEARCH CENTER, INC

Application No.: 10/796298   Filing Date: 09/Mar/2004

Abstract:Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.

Priority: US2003-698967 Applic. Date: 2003-10-30; WO2003US12895 Applic. Date: 2003-04-24; US20020375472P Applic. Date: 2002-04-24

Inventor: MITSUHASHI MASATO [US]


Application No.: US20040267356A1  Published: 30/Dec/2004

Title: Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 10/865222   Filing Date: 10/Jun/2004

Abstract:A mechanical dilatation and medicament delivery device for enlarging a flow passage of a vessel by dilating and delivering a liposome or micelle-encapsulated therapeutic agent or medicament to an obstruction in the vessel. The present invention comprises a substantially cylindrically shaped expansion member and includes a means engaged to the expansion member for altering the distance between the proximal end and the distal end of the expansion member thereby transforming the expansion member between a diametrically contracted configuration to diametrically expanded configuration. A liposome or micelle-encapsulated therapeutic agent or medicament is coated on either the expansion member, or incorporated into a substrate coated on the expansion member.

The present method comprises the steps of advancing the coated expansion member to the obstruction in a vessel and applying opposed forces on said expansion member in an axial direction to move the expansion member to an expanded configuration wherein the expansion member dilates the obstruction and the expansion member either passively or actively delivers a liposome or micelle-encapsulated therapeutic agent or medicament to the obstruction.

Priority: US2002-135709 Applic. Date: 2002-04-30

Inventor: SCOTT NEAL [US]; SEGAL JEROME [US]


Application No.: US20040268421A1  Published: 30/Dec/2004

Title: Animal model for medical device testing and training using xenografted organ structures such as blood vessels

Applicant/Assignee:

Application No.: US 2003-610318   Filing Date: 30/Jun/2003

Abstract:

Priority:

Inventor: TEARNEY GARY J [US]; CAPLAN JAY D [US]


Application No.: US20050004049A1  Published: 06/Jan/2005

Title: Novel griseofulvin compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 10/683154   Filing Date: 14/Oct/2003

Abstract:The present invention is directed to nanoparticulate compositions comprising griseofulvin. The griseofulvin particles of the composition preferably have an effective average particle size of less than about 2 microns.

Priority: US2002-175851 Applic. Date: 2002-06-21; US1997-815346 Applic. Date: 1997-03-11

Inventor: LIVERSIDGE GARY G [US]


Application No.: US20050004652A1  Published: 06/Jan/2005

Title: Method for left atrial appendage occlusion

Applicant/Assignee:

Application No.: 10/830964   Filing Date: 22/Apr/2004

Abstract:Disclosed is an occlusion device for use in a body lumen such as the left atrial appendage. The occlusion device includes an occlusion member and may also include a stabilizing member. The stabilizing member inhibits compression of the left atrial appendage, facilitating tissue in-growth onto the occlusion member. Methods are also disclosed.

Priority: US1999-435562 Applic. Date: 1999-11-08; US1998-187200 Applic. Date: 1998-11-06

Inventor: VAN DER BURG ERIC J [US]; CICCO DINO DE [US]; FRAZIER ANDREW G C [US]; KHAIRKAHAN ALEX K [US]; KRIEDLER MARC S [US]; LESH MICHAEL D [US]; ROUE CHAD C [US]


Application No.: US20050008629A1  Published: 13/Jan/2005

Title: Encapsulated AGF cells

Applicant/Assignee: INTERPORE ORTHOPAEDICS, A DELAWARE CORPORATION

Application No.: 10/434442   Filing Date: 07/May/2003

Abstract:This invention provides a composition of encapsulated blood constituents. The invention provides methods to make and use the encapsulated blood constituents, e.g., to stimulate and support tissue regeneration with autologous growth factors.

Priority: US20020379116P Applic. Date: 2002-05-08

Inventor: ARM DOUGLAS M [US]


Application No.: US20050008707A1  Published: 13/Jan/2005

Title: Nanoparticulate megestrol formulations

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/878623   Filing Date: 29/Jun/2004

Abstract:The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.

Priority: US2003-412669 Applic. Date: 2003-04-14; US20020371680P Applic. Date: 2002-04-12; US20020430348P Applic. Date: 2002-12-03

Inventor: HOVEY DOUGLAS [US]; PRUITT JOHN [US]; RYDE TUULA [US]


Application No.: US20050009895A1  Published: 13/Jan/2005

Title: 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/858364   Filing Date: 01/Jun/2004

Abstract:The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel 3,4-disubstituted benzamidines and benzylamines, or a stereoisomer or pharmaceutically acceptable salt form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade

for example thrombin, factor Xa, factor XIa, factor IXa, and/or factor VIIa. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

Priority: US20030475645P Applic. Date: 2003-06-04

Inventor: PRIESTLEY E SCOTT [US]; ZHANG XIAOJUN [US]


Application No.: US20050011823A1  Published: 20/Jan/2005

Title: Extracorporeal blood treatment machine

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 10/771377   Filing Date: 05/Feb/2004

Abstract:The invention relates to an extracorporeal blood treatment machine in which a blood circuit (3) is equipped with an inlet line leading to a filtration unit (2) and with an outlet line (3b) from the filtration unit

a fluid circuit comprises an inlet line (4a) leading to the filtration unit and an outlet line (4b) from the filtration unit so as to allow a fluid taken from a primary container (5) to circulate within the filtration unit, thus enabling the treatment of the patient's blood. There is further an infusion line (6) acting on the outlet line of the blood circuit, which is supplied by an auxiliary fluid container (7). The inlet line of the fluid circuit is equipped with at least an infusion branch (8) acting on the outlet line of the blood circuit so as to enable the intensive therapy machine to manage therapies with large exchange of fluids.

Priority: IT2003MI00212 Applic. Date: 2003-02-07; US20030469839P Applic. Date: 2003-05-13

Inventor: DELNEVO ANNALISA [IT]; RIBOLZI FRANCESCO [IT]; TONELLI CLAUDIO [IT]; BARALDI VINCENZO [IT]; ZACCARELLI MASSIMO [IT]; CHEVALLET JACQUES [FR]; DUCHAMP JACQUES [FR]; ABERKANE AZIZ [FR]; MEYSSONNIER GABRIEL [FR]; POUCHOULIN DOMINIQUE [FR]


Application No.: US20050013845A1  Published: 20/Jan/2005

Title: Adhesive bioerodible ocular drug delivery system

Applicant/Assignee:

Application No.: 10/706603   Filing Date: 12/Nov/2003

Abstract:The present invention provides bioerodible, water-soluble pharmaceutical carriers for ocular (e.g., transconjunctival or transcorneal) delivery of pharmaceuticals for either systemic or local therapy.

Priority: US20020425508P Applic. Date: 2002-11-12

Inventor: WARREN STEPHEN L [US]; OSBORNE DAVID W [US]; HOLL RICHARD [US]


Application No.: US20050014127A1  Published: 20/Jan/2005

Title: Method for selectively removing virus and leukocytes eliminating material and eliminating apparatus

Applicant/Assignee:

Application No.: 10/492652   Filing Date: 03/Sep/2004

Abstract:It is intended to provide a method whereby a virus and leukocytes can be simultaneously eliminated from virus-containing blood and platelets can be recovered at a high yield, and a material and an apparatus therefor. A water-soluble carrier having surface which is capable of capturing a virus and leukocytes in blood but allows the permeation of platelets therethrough is brought into contact with virus-containing blood. Thus the virus and leukocytes can be simultaneously removed from the blood while platelets can be recovered at a high yield.

Priority: JP20010318512 Applic. Date: 2001-10-16; WO2002JP10766 Applic. Date: 2002-10-16

Inventor: ONODERA HIROKAZU [JP]; YOSHIDA MAKOTO [JP]


Application No.: US20050014787A1  Published: 20/Jan/2005

Title: 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof

Applicant/Assignee:

Application No.: 10/495063   Filing Date: 13/Sep/2004

Abstract:The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R<1 >is an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkenyl group, a cycloalkyl group or a lower acyl group etc.

Q is a hydrogen atom or an optionally substituted lower alkyl group

and Z is a hydrogen atom or a hydroxy group etc., or a pharmaceutically acceptable salt thereof, which exert a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same and an intermediate thereof. These compounds are useful as preventives or remedies for various diseases such as brain infarction, cerebral thrombosis, cerebral embolism, TIA, cerebral vascular jerk, Alzheimer's diseases, myocardial infarction, heart attack, heart failure, thrombosis, pulmonary infarction and pulmonary embolism.

Priority: JP20010345435 Applic. Date: 2001-11-09; WO2002JP11199 Applic. Date: 2002-10-29

Inventor: UCHIDA MASAHIKO [JP]; KOBAYASHI HIROAKI [JP]; KAI YUICHIRO [JP]; YOKOYAMA KENJI [JP]; TERAO YOSHIHIRO [JP]; MURANAKA HIDEYUKI [JP]


Application No.: US20050019412A1  Published: 27/Jan/2005

Title: Novel glipizide compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 10/701064   Filing Date: 05/Nov/2003

Abstract:The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.

Priority: US1999-337675 Applic. Date: 1999-06-22; US1998-164351 Applic. Date: 1998-10-01; US2003-276400 Applic. Date: 2003-01-15

Inventor: BOSCH H WILLIAM [US]; RYDE NIELS P [US]


Application No.: US20050019742A1  Published: 27/Jan/2005

Title: Methods for assessment of platelet aggregation

Applicant/Assignee:

Application No.: 10/686309   Filing Date: 15/Oct/2003

Abstract:Methods for measuring platelet aggregation in a blood sample, for measuring the efficacy of anti-platelet therapies at the point of care, and for detecting the presence of platelet micro-aggregates in a blood sample. Several differences between the methods of the present invention and previously disclosed procedures for practicing such methods while using a hematology analyzer will allow for achieving about 0.98 correlation relative to light transmission aggregometry. These differences allow the methods of the present invention to be used at the point of care for assessing, e.g., the efficacy of anti-platelet therapy, particularly GPIIb-IIIa antagonists.

Priority: US20020419056P Applic. Date: 2002-10-15

Inventor: JENNINGS LISA K [US]; WHITE MELANIE M [US]


Application No.: US20050019744A1  Published: 27/Jan/2005

Title: Ultrasound-assisted ischemic reperfusion

Applicant/Assignee: LA JOLLA BIOENGINEERING INSTITUTE

Application No.: 10/627275   Filing Date: 25/Jul/2003

Abstract:A method for stimulating perfusion and minimizing postischemic reperfusion injury. A patient is selected having compromised perfusion in a tissue or in the microcirculation of an organ. An ultrasound transducer is applied to a location near the tissue. The transducer is activated to initiate exposure of the tissue to ultrasound at a frequency of 100 KHz to 2.5 MHz for 0.5 to 15 minutes duration, wherein local vasodilatation is stimulated. In certain cases, the methods further include a step of confirming that local vasodilatation is stimulated by measuring enhancement in perfusion. Ultrasound devices are also described for carrying out the methods. The devices and methods can be used to enhance myocardial perfusion, cerebral perfusion, and perfusion of transplanted tissues.

Priority:

Inventor: BERTUGLIA SILVIA [IT]


Application No.: US20050020645A1  Published: 27/Jan/2005

Title: Diamine derivatives

Applicant/Assignee: DAIICHI PHARMACEUTICAL CO., LTD

Application No.: 10/773344   Filing Date: 09/Feb/2004

Abstract:A compound represented by the general formula (1): Q<1>-Q<2>-T<0>-N(R<1>)-Q<3>-N(R<2>)-T<1>-Q<4> (1) wherein R<1 >and R<2 >are hydrogen atoms or the like

Q<1 >is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like

Q<2 >is a single bond or the like

Q<3 >is a group in which Q<5 >is an alkylene group having 1 to 8 carbon atoms, or the like

and T<0 >and T<1 >are carbonyl groups or the like

a salt thereof, a solvate thereof, or an N-oxide thereof.

The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Priority: JP20010398708 Applic. Date: 2001-12-28; JP20010311808 Applic. Date: 2001-10-09; JP20010243046 Applic. Date: 2001-08-09; JP20010187105 Applic. Date: 2001-06-20; US2004-481629 Applic. Date: 2004-06-01; WO2002JP06141 Applic. Date: 2002-06-20; WO2002JP08119 Applic. Date: 2002-08-08

Inventor: OHTA TOSHIHARU [JP]; KOMORIYA SATOSHI [JP]; YOSHINO TOSHIHARU [JP]; UOTO KOUICHI [JP]; NAKAMOTO YUMI [JP]; NAITO HIROYUKI [JP]; MOCHIZUKI AKIYOSHI [JP]; NAGATA TSUTOMU [JP]; KANNO HIDEYUKI [JP]; HAGINOYA NORIYASU [JP]; YOSHIKAWA KENJI [JP]; NAGAMOCHI MASATOSHI [JP]; KOBAYASHI SYOZO [JP]; ONO MAKOTO [JP]


Application No.: US20050025705A1  Published: 03/Feb/2005

Title: Thrombosis animal models and their use in drug discovery and development

Applicant/Assignee:

Application No.: 10/896383   Filing Date: 22/Jul/2004

Abstract:The present invention includes animal models useful for the study of thrombosis and the use of such models in drug discovery and development. The present invention relates to the induction of thrombus formation in a murine animal model by contacting a blood vessel with a low concentration of ferric chloride (FeCl3). It is found for the first time in the present invention that the use of low ferric chloride concentrations permits thrombus formation which can be treated by known antithrombotic agents at desirable concentrations. Thus, the present invention permits the study of compounds for their possible use as antithrombotic agents under conditions which provide clinically meaningful results. Compounds discovered using the inventive animal models and methods of treatment using such compounds are also included. Gunmetal mice useful as animal thrombosis models are also included.

Priority: US20030489311P Applic. Date: 2003-07-22

Inventor: WANG XINKANG [US]


Application No.: US20050025818A1  Published: 03/Feb/2005

Title: Transdermal warfarin system

Applicant/Assignee: ALZA CORPORATION

Application No.: 10/900804   Filing Date: 27/Jul/2004

Abstract:Composition of matter for application to a body surface or membrane to administer warfarin by permeation through the body surface or membrane, the composition comprising warfarin to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the warfarin or warfarin and enhancer composition and methods for the transdermal administration of the warfarin and warfarin/enhancer composition.

Priority: US20030490739P Applic. Date: 2003-07-28

Inventor: GALE ROBERT M [US]


Application No.: US20050031544A1  Published: 10/Feb/2005

Title: Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases

Applicant/Assignee:

Application No.: 10/635820   Filing Date: 07/Aug/2003

Abstract:This invention relates to a method and system for improving diagnostic imaging and/or delivering therapeutically active agents for control of hyperlipidemia and infectious diseases (bacterial or viral), comprising nanoscale block copolymer assemblies carrying drug molecules in its core and receptor peptide in the corona surrounding the core, forming larger micelle or vesicle aggregates with target molecules such as LDL molecules and surface lipid of microorganisms.

Priority:

Inventor: NJEMANZE PHILIP CHIDI [NG]


Application No.: US20050031616A1  Published: 10/Feb/2005

Title: Controlled platelet activation to monitor therapy of ADP antagonists

Applicant/Assignee: ACCUMETRICS, INC

Application No.: 10/886155   Filing Date: 06/Jul/2004

Abstract:A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant

2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation

3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface

4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.

Priority: US20030485703P Applic. Date: 2003-07-08

Inventor: COLLER BARRY S [US]; DURBIN DENNIS [US]


Application No.: US20050031689A1  Published: 10/Feb/2005

Title: Biointerface membranes incorporating bioactive agents

Applicant/Assignee: DEXCOM, INC

Application No.: 10/842716   Filing Date: 10/May/2004

Abstract:A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.

Priority: US2003-647065 Applic. Date: 2003-08-22; US20030472673P Applic. Date: 2003-05-21; US20040544722P Applic. Date: 2004-02-12

Inventor: SHULTS MARK [US]; BRAUKER JAMES H [US]; CARR-BRENDEL VICTORIA [US]; TAPSAK MARK [US]; MARKOVIC DUBRAVKA [US]


Application No.: US20050031691A1  Published: 10/Feb/2005

Title: Gel stabilized nanoparticulate active agent compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/659706   Filing Date: 11/Sep/2003

Abstract:Disclosed is a solid or semi-solid gelatin nanoparticulate active agent dosage form comprising at least one nanoparticulate active agent and at least one gel forming substance which exhibits gelation sufficient to retain excess water in the solid or semi-solid gelatin form. The active agent particles have an effective average diameter prior to inclusion in the dosage form of less than about 2000 nm. The dosage form of the invention has the advantages of easy administration combined with rapid dissolution of the active agent following administration.

Priority: US20020409587P Applic. Date: 2002-09-11

Inventor: MCGURK SIMON L [US]; CZEKAI DAVID A [US]


Application No.: US20050031693A1  Published: 10/Feb/2005

Title: Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials

Applicant/Assignee: PFIZER INC

Application No.: 10/910448   Filing Date: 03/Aug/2004

Abstract:A pharmaceutical composition comprises a solid adsorbate comprising a drug adsorbed onto a substrate and a lipophilic microphase-forming material. The solid adsorbate may also be co-administered with a lipophilic microphase-forming material to an in vivo use environment. The compositions of the present invention enhance the concentration of drug in a use environment.

Priority: US20030492410P Applic. Date: 2003-08-04

Inventor: BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; SHANKER RAVI M [US]; SMITHEY DANIEL T [US]


Application No.: US20050032140A1  Published: 10/Feb/2005

Title: Methods for predicting susceptibility to cardiovascular disease

Applicant/Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION

Application No.: 10/868748   Filing Date: 15/Jun/2004

Abstract:The assay of soluble endothelial protein C receptor (sEPCR) is useful to predict cardiovascular disease, particularly atherosclerotic cardiovascular disease (ASCVD). An assay for sEPCR is therefore useful to identify individuals at risk of developing ASCVD. An sEPCR ELISA assay is particularly useful for this purpose. Elevated sEPCR is indicative of an increased risk of developing cardiovascular disease.

Priority: US20030483386P Applic. Date: 2003-06-27

Inventor: KUROSAWA SHINICHIRO [US]; STEARNS-KUROSAWA DEBORAH J [US]


Application No.: US20050033132A1  Published: 10/Feb/2005

Title: Analyte measuring device

Applicant/Assignee:

Application No.: 10/846150   Filing Date: 14/May/2004

Abstract:An implantable analyte-measuring device including a membrane adapted to promote vascularization and/or interfere with barrier cell layer formation. The membrane includes any combination of materials, architecture, and bioactive agents that facilitate analyte transport to provide long-term in vivo performance of the implantable analyte-measuring device.

Priority: US2003-647065 Applic. Date: 2003-08-22; US1999-447227 Applic. Date: 1999-11-22; US1997-811473 Applic. Date: 1997-03-04; US20030472673P Applic. Date: 2003-05-21; US20040544722P Applic. Date: 2004-02-12

Inventor: SHULTS MARK C [US]; BRAUKER JAMES H [US]; CARR-BRENDEL VICTORIA [US]; TAPSAK MARK [US]; MARKOVIC DUBRAVKA [US]; UPDIKE STUART J [US]; RHODES RATHBUN K [US]


Application No.: US20050033263A1  Published: 10/Feb/2005

Title: System and method for restenosis mitigation

Applicant/Assignee: MEDTRONIC-MINIMED, INC

Application No.: 10/638215   Filing Date: 07/Aug/2003

Abstract:A system and method for restenosis mitigation at a trauma site within the vasculature. The system may include a catheter capable of delivering a restenosis mitigating drug and a sensor extending through a lumen in the catheter. The catheter may be positioned adjacent the trauma site and the restenosis mitigating drug may be delivered to the trauma site through the catheter. The restenosis mitigating drug or some other parameter may be sensed by the sensor.

Priority:

Inventor: GOTTLIEB REBECCA [US]; ENEGREN BRADLEY J [US]; SHAH RAJIV [US]


Application No.: US20050037132A1  Published: 17/Feb/2005

Title: Anti-thrombogenic surfaces and process for their production

Applicant/Assignee:

Application No.: 10/422152   Filing Date: 24/Apr/2003

Abstract:The invention relates to anti-thrombogenic surfaces and a process for making said surfaces. The process is primarily used for the anti-thrombogenic coating of hydrophobic surfaces of medical products coming into direct contact with blood and coagulable blood products.

Priority: US20020375002P Applic. Date: 2002-04-25

Inventor: HORRES ROLAND [DE]; HOFFMANN MICHAEL [DE]; KUESTERS SABINE [DE]; LINSSEN MARITA KATHARINA [DE]


Application No.: US20050037331A1  Published: 17/Feb/2005

Title: Apparatuses and methods for reducing albumin in samples

Applicant/Assignee:

Application No.: 10/804592   Filing Date: 19/Mar/2004

Abstract:The present invention is directed to apparatuses and methods for reducing the content of albumin in serum, plasma and/or blood samples. The apparatuses comprise an insoluble support with a ligand attached thereto. According to certain embodiments of the invention, the ligand is a bromosulfophthalein, Cibacron Blue or Warfarin ligand or salts or esters thereof. Also provided are methods of making the apparatus, as well as kits and albumin-depleted samples produced by the methods of the present invention.

Priority: US20030494664P Applic. Date: 2003-08-13; US20030506634P Applic. Date: 2003-09-25; US20030506579P Applic. Date: 2003-09-26; US20030531377P Applic. Date: 2003-12-19

Inventor: GALBRAITH WILLIAM [US]


Application No.: US20050037964A1  Published: 17/Feb/2005

Title: Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity

Applicant/Assignee: THE SCRIPPS RESEARCH INSTITUTE

Application No.: 10/886766   Filing Date: 08/Jul/2004

Abstract:Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two examples of such recombinant APC mutants are KKK191-193AAA-APC and RR229/230M-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apoptosis.

At risk patients include, for example, those suffering (severe) sepsis, ischemia/reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided.

Priority: US20030485792P Applic. Date: 2003-07-08

Inventor: GRIFFIN JOHN H [US]; MOSNIER LAURENT O [US]; GALE ANDREW J [US]


Application No.: US20050038030A1  Published: 17/Feb/2005

Title: Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 10/465538   Filing Date: 19/Jun/2003

Abstract:The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel amino-bicyclic pyrazinone and pyridinone compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade

for example thrombin, factor Xa, factor XIa, factor IXa, and/or factor VIIa. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

Priority: US20020391785P Applic. Date: 2002-06-26

Inventor: ZHANG XIAOJUN [US]


Application No.: US20050042177A1  Published: 24/Feb/2005

Title: Novel compositions of sildenafil free base

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/895405   Filing Date: 21/Jul/2004

Abstract:The present invention is directed to nanoparticulate compositions comprising sildenafil free base. The sildenafil free base particles of the composition have an effective average particle size of less than about 2000 nm.

Priority: US20030489101P Applic. Date: 2003-07-23

Inventor: RYDE TUULA A [US]; HOVEY DOUGLAS C [US]; BOSCH H WILLIAM [US]


Application No.: US20050045540A1  Published: 03/Mar/2005

Title: Method and apparatus for kidney dialysis

Applicant/Assignee:

Application No.: 10/938486   Filing Date: 09/Sep/2004

Abstract:A number of improvements relating to methods and apparatuses for kidney dialysis are disclosed. These include checking of dialysate bypass status using flow measurement

using a flow sensor to confirm the absence of ultrafiltration during bypass

automatic testing of ultrafiltration function by removal of a discrete volume from a portion of the dialysate flow path coupled with a pressure test of that part of the flow path

using a touch screen user interface

bar graph profile programming of ultrafiltration, sodium, and bicarbonate parameters

using a RAM card to upload treatment instructions to, and to download treatment data from, the machine

automatic setting of proportioning mode (acetate or bicarbonate) based on connections of concentrate lines

predicting dialysate conductivity values based on brand and formulation of concentrates

minimizing no-flow dead time between dialysate pulses

initiating operation in a timed mode from a machine power-off condition

preserving machine mode during machine power-fail condition

calibration scheduling and reminding

automatic level adjusting

and blood leak flow rate detecting.

Priority: US2003-695526 Applic. Date: 2003-10-27; US2000-711240 Applic. Date: 2000-11-13; US1998-067922 Applic. Date: 1998-04-28; US1995-479688 Applic. Date: 1995-06-07; US1993-122047 Applic. Date: 1993-09-14; US1991-688174 Applic. Date: 1991-04-19

Inventor: CONNELL MARK E [US]; BEDIENT ROBERT A [US]; ELSEN RAYMOND [BE]; HOGARD MICHAEL E [US]; JOHNSON HARLEY D [US]; KELLY THOMAS D [US]; LONG JEAN MCEVOY [US]; PETERSON BRUCE A [US]; PRESTON WILLIAM G [US]; SMEJTEK DALIBOR J [US]


Application No.: US20050048026A1  Published: 03/Mar/2005

Title: Remedies for ischemic diseases

Applicant/Assignee:

Application No.: 10/380200   Filing Date: 13/Mar/2003

Abstract:An effective agent for treating ischemic disease, the agent containing human granulocyte colony-stimulating factor (human G-CSF) as an active ingredient is disclosed. By administering this therapeutic agent, an effective therapy particularly for obstructive arteriosclerosis is provided which can eliminate drawbacks with conventional therapies, such as kinesitherapy, pharmacotherapy, and revascularization, and recently proposed therapies, such as gene therapy and intramuscular transplantation of bone marrow cells. Furthermore, the therapeutic agent can be used as an agent for treating ischemic disease, such as ischemic cerebrovascular disorder or ischemic heart disease.

Priority: JP20000277562 Applic. Date: 2000-09-13; WO2001JP07946 Applic. Date: 2001-09-13

Inventor: MIYAI TATSUYA [JP]; TAMURA MASAHIKO [JP]


Application No.: US20050049539A1  Published: 03/Mar/2005

Title: Control system for driving fluids through an extracorporeal blood circuit

Applicant/Assignee:

Application No.: 10/654670   Filing Date: 03/Sep/2003

Abstract:A control deck and system for controlling and driving blood fluids through an extracorporeal blood circuit kit. In one aspect, the invention is a deck having an improved mechanism for securing a cassette in place during treatment operations. The improved deck comprises catches for slidably receiving tabs of the cassette and one or more rotating clamps for locking and securing the cassette in a loaded position. In another aspect the invention is a system for controlling and driving blood fluids having infrared communication abilities to transmit and receive real time data. In still another aspect, the invention is a system for controlling and driving blood fluids having an upright tower design that reduces the footprint of the system. In this embodiment, a centrifuge chamber is positioned in an upper portion of the system while the control deck and photoactivation chamber are located in a base portion of the system.

Priority:

Inventor: O'HARA GERALD P [US]; HUTCHINSON MIKE [US]; MARTIN SCOTT P [US]; BRIGGS DENNIS [US]; THORNE CHRISTIAN E [US]; GARA STEVE [US]


Application No.: US20050049692A1  Published: 03/Mar/2005

Title: Medical device for reduction of pressure effects of cardiac tricuspid valve regurgitation

Applicant/Assignee:

Application No.: 10/653397   Filing Date: 02/Sep/2003

Abstract:An elongate valve stent and methods for protecting an upper or a lower body of a patient from high venous pressures comprising a stent member, the stent member comprising a support structure and a tissue valve, wherein the tissue valve is configured to permit fluid flow in one direction and prevent fluid flow in an opposite direction, and means for anchoring the stent member onto surrounding tissue of the superior vena cava or inferior vena cava.

Priority:

Inventor: NUMAMOTO MICHAEL J [US]; QUIJANO RODOLFO C [US]; TU HOSHENG [US]


Application No.: US20050054942A1  Published: 10/Mar/2005

Title: System and method for therapeutic drug monitoring

Applicant/Assignee:

Application No.: 10/788501   Filing Date: 26/Feb/2004

Abstract:The present invention includes systems and methods for monitoring therapeutic drug concentration in blood by detecting markers, such as odors, upon exhalation by a patient after the drug is taken, wherein such markers result either directly from the drug itself or from an additive combined with the drug. In the case of olfactory markers, the invention preferably utilizes electronic sensor technology, such as the commercial devices referred to as "artificial" or "electronic" noses or tongues, to non-invasively monitor drug levels in blood. The invention further includes a reporting system capable of tracking drug concentrations in blood (remote or proximate locations) and providing the necessary alerts with regarding to ineffective or toxic drug dosages in a patient.

Priority: US2002-178877 Applic. Date: 2002-06-24; US2002-054619 Applic. Date: 2002-01-22

Inventor: MELKER RICHARD J [US]; SACKELLARES JAMES CHRIS [US]; GOLD MARK S [US]


Application No.: US20050054958A1  Published: 10/Mar/2005

Title: Low frequency vibration assisted blood perfusion emergency system

Applicant/Assignee: AHOF BIOPHYSICAL SYSTEMS INC

Application No.: 10/902122   Filing Date: 30/Jul/2004

Abstract:An emergency system for treatment of a patient (20) experiencing an acute vascular obstruction, employing a non-invasive vibrator (10), optimally in conjunction with drugs, for disrupting and lysing thromboses, relieving spasm (if associated), and thereby restoring blood perfusion. Vibrator (10) is operable in the sonic to infrasonic range, with a source output of up to 15 mm. For acute myocardial infarction cases, a pair of contacts (12), are advantageously placed to bridge the sternum at the fourth intercostal space. Vibration is initiated at 50 Hz (or any frequency, preferably within the 20-120 Hz range), and is ideally adjusted to a maximal amplitude (or force) deemed tolerable and safe to the patient (20), preferably with the administration of thrombolytic agents or other form of drug therapy.

A synergistic effect is achieved between vibration and drugs to facilitate the disruption of thromboses, relieve spasm, and restore blood perfusion. In a variation, ultrasonic imaging may be used to direct vibration therapy.

Priority: CA20032439667 Applic. Date: 2003-09-04

Inventor: HOFFMANN ANDREW KENNETH [CA]


Application No.: US20050054978A1  Published: 10/Mar/2005

Title: Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment

Applicant/Assignee:

Application No.: 10/951232   Filing Date: 27/Sep/2004

Abstract:A mechanical dilatation and medicament delivery device for enlarging a flow passage of a vessel by dilating and delivering a therapeutic agent or medicament to an obstruction in the vessel. The present invention comprises a substantially cylindrically shaped expansion member and includes a means engaged to the expansion member for altering the distance between the proximal end and the distal end of the expansion member thereby transforming the expansion member between a diametrically contracted configuration to diametrically expanded configuration. A therapeutic agent or medicament is coated on either the expansion member, or incorporated into an substrate and then coated on the expansion member.

Priority: US2001-997855 Applic. Date: 2001-11-29

Inventor: SEGAL JEROME [US]; SCOTT NEAL [US]


Application No.: US20050056292A1  Published: 17/Mar/2005

Title: Devices for maintaining patency of surgically created channels in tissue

Applicant/Assignee: BRONCUS TECHNOLOGIES, INC

Application No.: 10/894876   Filing Date: 19/Jul/2004

Abstract:Devices and methods for altering gaseous flow within a lung to improve the expiration cycle of an individual, particularly individuals having chronic obstructive pulmonary disease. The methods and devices create channels in lung tissue and maintain the patency of these surgically created channels in tissue. Maintaining the patency of the channels allows air to pass directly out of the lung tissue which facilitates the exchange of oxygen ultimately into the blood and/or decompresses hyper-inflated lungs.

Priority: US2001-908177 Applic. Date: 2001-07-18; US2000-633651 Applic. Date: 2000-08-07; US20030488332P Applic. Date: 2003-07-18; US19990147528P Applic. Date: 1999-08-05; US20000176141P Applic. Date: 2000-01-14

Inventor: COOPER JOEL D [US]


Application No.: US20050058702A1  Published: 17/Mar/2005

Title: Compositions capable of facilitating penetration across a biological barrier

Applicant/Assignee:

Application No.: 10/664989   Filing Date: 17/Sep/2003

Abstract:This invention relates to novel pharmaceutical compositions mixing one or more effectors (anionic impermeable molecules) with a counter ion to the effector (a liquid forming cation). The invention also relates to methods of treating or preventing diseases by administering pharmaceutical compositions to affected subjects.

Priority:

Inventor: BEN-SASSON SHMUEL A [IL]; COHEN EINAT [IL]


Application No.: US20050059132A1  Published: 17/Mar/2005

Title: Protein C variants

Applicant/Assignee:

Application No.: 10/652947   Filing Date: 02/Sep/2003

Abstract:The present invention is concerned with a variant blood coagulation component, which is substantially homologous in amino acid sequences to a wild-type blood coagulation component capable of exhibiting anticoagulant activity in the protein C-anticoagulant system of blood and selected from protein C (PC) and activated protein C (APC), said variant component being capable of exhibiting an anticoagulant activity, that is enhanced in comparison with anticoagulant activity expressed by the corresponding wild-type blood coagulation component, said variant component differing from the respective wild-type component, in that it contains in comparison with said wild-type component at least one amino acid residue modification in it N-terminal amino acid residue sequence that constitutes the Gla-domain of protein C. The present invention is also concerned with methods to produce such variants based on DNA technology, with DNA segments intended for use in the said methods, and with use of said variants for therapeutic and diagnostic purposes.

Priority: WO2002SE00363 Applic. Date: 2002-03-01; US20010272466P Applic. Date: 2001-03-02

Inventor: DAHLBACK BJORN [SE]; NELSESTUEN GARY L [US]


Application No.: US20050059163A1  Published: 17/Mar/2005

Title: Device and methods for collection of biological fluid sample and treatment of selected components

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 10/912263   Filing Date: 05/Aug/2004

Abstract:A collection device and a method for collecting a biological sample, particularly whole blood, includes a separating member to separate the whole blood into its components, and at least reagent positioned to selectively interact with a component of the separated sample. The reagent is able to selectively interact with the plasma/serum, and is prevented from contacting or interacting with the whole blood.

Priority: US20030492313P Applic. Date: 2003-08-05

Inventor: DASTANE AJIT N [US]; MANOUSSAKIS DIMITRIOS [US]; BATTLES CHRISTOPHER A [US]; DICESARE PAUL [US]; RADZIUNAS JEFFREY [US]


Application No.: US20050059914A1  Published: 17/Mar/2005

Title: Massage appliance

Applicant/Assignee: BEIERSDORF AG

Application No.: 10/917586   Filing Date: 13/Aug/2004

Abstract:The present invention is a massage appliance comprising a preparation, a storage container containing the preparation, and a closure for the storage container. The closure comprises a massage device comprising an outlet opening through which the preparation can be applied to the surface to be massaged and an adjustment device comprising a first element with at least one first surface wherein the first surface contacts the surface to be massaged during a massage, and a second element arranged to be moveable relative to the first element. The adjustment device may be used to adjust a massage characteristic value of the first surface. The massage device is positioned at an angle with respect to the main axis of the storage container.

The present invention also includes a method of applying a preparation to the skin, a method of treating rheumatoid arthritis, and a method of warming up using the massage appliance.

Priority: DE20021006257 Applic. Date: 2002-02-15; WO2003EP01350 Applic. Date: 2003-02-12

Inventor: KLEINHENZ SVEN [DE]; FELTEN BERNHARD [DE]


Application No.: US20050059921A1  Published: 17/Mar/2005

Title: Extracorporeal pathogen reduction system

Applicant/Assignee: XEPMED, INC

Application No.: 10/720811   Filing Date: 24/Nov/2003

Abstract:The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal body fluid system.

Priority: US2002-195814 Applic. Date: 2002-07-15; US2000-496613 Applic. Date: 2000-02-02; US20020429126P Applic. Date: 2002-11-26; US20030494895P Applic. Date: 2003-08-13

Inventor: TU HOSHENG [US]; LIN HUN-CHI [US]; CHANG YU-AN [US]


Application No.: US20050061962A1  Published: 24/Mar/2005

Title: Multiple laminar flow-based rate zonal or isopycnic separation with holographic optical trapping of blood cells and other static components

Applicant/Assignee: ARRYX, INC

Application No.: 10/867328   Filing Date: 13/Jun/2004

Abstract:The invention provides a method and apparatus for separating blood into components, may be expanded to include other types of cellular components, and can be combined with holographic optical manipulation or other forms of optical tweezing. One of the exemplary methods includes providing a first flow having a plurality of blood components

providing a second flow

contacting the first flow with the second flow to provide a first separation region

and differentially sedimenting a first blood cellular component of the plurality of blood components into the second flow while concurrently maintaining a second blood cellular component of the plurality of blood components in the first flow. The second flow having the first blood cellular component is then differentially removed from the first flow having the second blood cellular component.

Holographic optical traps may also be utilized in conjunction with the various flows to move selected components from one flow to another, as part of or in addition to a separation stage.

Priority: US2003-630904 Applic. Date: 2003-07-31

Inventor: MUETH DANIEL M [US]; ANDERSON AMY [US]; SHIREMAN JESSICA [US]


Application No.: US20050063913A1  Published: 24/Mar/2005

Title: Novel metaxalone compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LTD

Application No.: 10/912552   Filing Date: 06/Aug/2004

Abstract:The present invention is directed to nanoparticulate compositions comprising metaxalone. The metaxalone particles of the composition have an effective average particle size of less than about 2 microns.

Priority: US20030493446P Applic. Date: 2003-08-08

Inventor: PRUITT JOHN D [US]; RYDE TUULA [US]; BOSCH H WILLIAM [US]


Application No.: US20050064009A1  Published: 24/Mar/2005

Title: Implantable device for treating disease states and methods of using same

Applicant/Assignee: GLOBAL GENE THERAPIES, INC NEXEON MEDICAL SYSTEMS, INC

Application No.: 10/864936   Filing Date: 09/Jun/2004

Abstract:Methods and apparatus are provided for delivering drugs, gene vectors, naturally-occurring or synthetic hormones or proteins or other bioactive agents within a patient's vasculature. In a preferred embodiment, the apparatus comprises a material that elutes or secretes a bioactive agent and is held in place within the patient's vessel by an anchor. The material may comprise a biocompatible, and optionally, absorbable matrix, or a culture medium that sustains and nourishes stem cells, spleen cells or pancreatic islets or other beneficial cells. The anchor and material are sized and/or collapsible from a delivery configuration, in which the anchor and material may be delivered into the patient's vasculature within a delivery sheath, to a deployed configuration, wherein the anchor engages an interior wall of the patient's vessel.

The apparatus of the invention may be temporarily or permanently implanted, and may in addition self reconfigure after a predetermined period of residency.

Priority: US2000-648257 Applic. Date: 2000-08-25

Inventor: BATES MARK C [US]


Application No.: US20050065324A1  Published: 24/Mar/2005

Title: Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents

Applicant/Assignee:

Application No.: 10/782968   Filing Date: 20/Feb/2004

Abstract:The invention relates to thrombospondin fragments found in plasma, their use or use of portions thereof in diagnostic methods, as method calibrators, method indicators, and as immunogens, and as analytes for methods with substantial clinical utility

and their detection in plasma or other bodily fluids for purpose of diagnostic methods, especially for cancer.

Priority: WO2003US26023 Applic. Date: 2003-08-20; US2003-419462 Applic. Date: 2003-04-21; US20020405494P Applic. Date: 2002-08-23

Inventor: WILLIAMS KEVIN J [US]


Application No.: US20050069518A1  Published: 31/Mar/2005

Title: Method for treating occlusive vascular diseases & wound healing

Applicant/Assignee:

Application No.: 10/776383   Filing Date: 11/Feb/2004

Abstract:Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of Nicotine, nicotinic acid analogs thereof, their combination with or without other pro-angiogenesis factors, vasodilator, or other therapeutic modalities to promote angiogenesis in the subject. This is composition and combination thereof is applicable to improving wound healing, erectile dysfunction, improving collateral or blood supply in patients with myocardial infarction, stroke, peripheral artery diseases, and other vascular disorders as disclosed.

Priority: US20030446568P Applic. Date: 2003-02-12

Inventor: MOUSA SHAKER [US]; MOUSA SARAH [US]


Application No.: US20050069527A1  Published: 31/Mar/2005

Title: Cell-based therapies for ischemia

Applicant/Assignee: CASE WESTERN RESERVE UNIVERSITY

Application No.: 10/875643   Filing Date: 24/Jun/2004

Abstract:The invention provides, among other things, methods for treating an ischemic tissue in a subject in need thereof. The invention further provides methods for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides cell-based formulations and related kits.

Priority: US2003-730549 Applic. Date: 2003-12-05; US20020431347P Applic. Date: 2002-12-05

Inventor: LAUGHLIN MARY J [US]; HAYNESWORTH STEPHEN [US]; POMPILI VINCENT [US]


Application No.: US20050069958A1  Published: 31/Mar/2005

Title: Method for simultaneous evaluation of a sample containing a cellular target and a soluble analyte

Applicant/Assignee:

Application No.: 10/672477   Filing Date: 26/Sep/2003

Abstract:A method for evaluating a biological sample containing at least one cell type bearing at least one cellular target and at least one soluble analyte, involves adding to a single container the sample with (i) at least one soluble ligand that binds the cellular target, (ii) either at least one soluble ligand that binds the soluble analyte or at least one competing soluble analyte

and (iii) a solid phase capture medium that binds directly to the soluble analyte, indirectly to the soluble analyte, or to the soluble ligand that binds to the soluble analyte. Various complexes involving the capture medium and soluble analyte, the capture medium and the soluble ligand, and/or the cellular target and a soluble ligand are simultaneously analyzed without physically separating the complexes.

Priority:

Inventor: MILLS RHONDA A [US]; QUINTANA JORGE A [US]; MAPLES JOHN A [US]; SCIBELLI PAUL M [US]


Application No.: US20050070872A1  Published: 31/Mar/2005

Title: Blood bag system and method of inactivating pathogenic microorganisms

Applicant/Assignee:

Application No.: 10/500327   Filing Date: 28/Jun/2004

Abstract:It is intended to provide a blood bag system comprising one or more of containers capable of holding a liquid, and a connecting tube connected liquid-tightly to the container, characterized in that at least one of the containers holds an inactivator that inactivates a pathogenic microorganism contained in blood and/or an anticoagulant

and the inactivator contains as a main component a platinum compound capable of binding to nucleic acids of the microorganism or an aquo complex of the platinum compound. According to the present invention, an effect of inactivating pathogenic microorganisms is increased and an excellent sustained inactivation effect is provided. Furthermore, transfusion of inactivated blood after neutralization treatment enables supply of microbiologically and toxicologically safe blood preparations.

Priority: JP20010400979 Applic. Date: 2001-12-28; WO2002JP13687 Applic. Date: 2002-12-26

Inventor: SATO KENICHI [JP]; KAMEYAMA TOSHIKI [JP]


Application No.: US20050074870A1  Published: 07/Apr/2005

Title: Apparatuses and methods for reducing albumin in samples

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 10/922560   Filing Date: 19/Aug/2004

Abstract:The present invention is directed to apparatuses and methods for reducing the content of albumin in serum, plasma and/or blood samples. The apparatuses comprise an insoluble support with a ligand attached thereto. According to certain embodiments of the invention, the ligand is a bromosulfophthalein, Cibacron Blue or Warfarin ligand or salts or esters thereof. Also provided are methods of making the apparatus, as well as kits and albumin-depleted samples produced by the methods of the present invention.

Priority: US20030506634P Applic. Date: 2003-09-25; US20030506579P Applic. Date: 2003-09-26; US20030531377P Applic. Date: 2003-12-19

Inventor: GALBRAITH WILLIAM [US]


Application No.: US20050075289A1  Published: 07/Apr/2005

Title: Factor VII glycoforms

Applicant/Assignee:

Application No.: 10/725843   Filing Date: 02/Dec/2003

Abstract:The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.

Priority: DK20000001456 Applic. Date: 2000-10-02; DK20010000262 Applic. Date: 2001-02-16; DK20010000430 Applic. Date: 2001-03-14; DK20010000751 Applic. Date: 2001-05-14; US2001-969357 Applic. Date: 2001-10-02; US20000238944P Applic. Date: 2000-10-10; US20010271581P Applic. Date: 2001-02-26; US20010276322P Applic. Date: 2001-03-16

Inventor: PINGEL HANS KURT [DK]; KLAUSEN NIELS KRISTIAN [DK]


Application No.: US20050075597A1  Published: 07/Apr/2005

Title: Vascular access preservation in hemodialysis patients

Applicant/Assignee:

Application No.: 10/940473   Filing Date: 13/Sep/2004

Abstract:The present invention relates generally to the field of hemodialysis, including methods and kits that can be employed to improve hemodialysis therapy. The present invention encompasses methods and kits useful for reducing vascular access complications associated with hemodialysis therapy and prolonging the period of time for which a vascular access site can be used in a patient.

Priority: US20030502878P Applic. Date: 2003-09-12

Inventor: VOURNAKIS JOHN N [US]; FINKIELSZTEIN SERGIO [US]; PARISER ERNST R [US]


Application No.: US20050080397A1  Published: 14/Apr/2005

Title: Safety dialysis needle/catheter system and method of use

Applicant/Assignee: SDA PRODUCT, INC

Application No.: 10/685546   Filing Date: 14/Oct/2003

Abstract:The present invention provides a safety needle/catheter system and method of use for dialysis procedures. The invention includes a safety feature that prevents inadvertent needle sticks by administrators. The invention further includes a catheter portion composed of shape memory materials. The catheter portion has a deformed shape and size that facilitates insertion of the catheter portion and closure of the catheter incision and a recovered shape and size that can reduce the severity of infection and/or clotting, as well as provide improved maintenance and control over proper fluid volume flow during dialysis.

Priority:

Inventor: ALTMAN SANFORD D [US]


Application No.: US20050085760A1  Published: 21/Apr/2005

Title: Medical fluid therapy flow balancing and synchronization system

Applicant/Assignee: BAXTER HEALTHCARE S.A

Application No.: 10/685724   Filing Date: 15/Oct/2003

Abstract:Systems, apparatus and methods that allow external infusion, IV or administration pumps to be synchronized with the internal pumps for a medical fluid therapy machine are provided. The system reduces the time and effort needed to calculate, set-up, enter and maintain flowrates of various fluids, maintained internally or externally with respect to the medical fluid therapy machine. The system also automatically follows therapy requirements, for example, a requirement that one pump/fluid be running/flowing for another pump/fluid to be enabled to run/flow. The system further automatically adjusts for variations in flowrate of one fluid with respect to another. In short, the system provides a more "hands-off", safe and effective method and apparatus for medical fluid therapy fluid delivery.

Priority:

Inventor: WARE LEE C [US]; BOEHNLEIN ARNOLD F [US]


Application No.: US20050085826A1  Published: 21/Apr/2005

Title: Unfolding balloon catheter for proximal embolus protection

Applicant/Assignee: SCIMED LIFE SYSTEMS, INC

Application No.: 10/690004   Filing Date: 21/Oct/2003

Abstract:Devices, systems and methods for removing foreign bodies within a body lumen are disclosed. An unfolding balloon catheter may include an elongated shaft having an intussuscepting balloon that can be actuated within a body lumen to capture and retrieve an intravascular device. The balloon may be configured to radially and/or axially expand when inflated, enveloping the intravascular device. In certain embodiments, the balloon may be formed by folding the ends of a distensible member inwardly, and then bonding the ends of the distensible member to the elongated shaft to form an expandable sleeve. An adhesive layer located along a portion of the elongated shaft may be used to temporarily secure the balloon to the elongated shaft.

Priority:

Inventor: NAIR AJITKUMAR B [US]; RAMZIPOOR KAMAL [US]; NGO TRA H [US]; NGUYEN HIEU T [US]; LE MAGGIE [US]


Application No.: US20050095171A1  Published: 05/May/2005

Title: Device for calculating blood flow in an extracorporeal blood circuit, and an apparatus for treatment of blood using the device

Applicant/Assignee:

Application No.: 10/975082   Filing Date: 28/Oct/2004

Abstract:The invention relates to a device for calculating blood flow and to an apparatus for extracorporeal blood treatment provided with the device. The device includes a memory for receiving and storing either a first datum relating to a blood flow removed from the patient Qb, or a second datum relating to a flow of liquid Qt crossing a tract of the extracorporeal circuit, and a third datum relating to a flow of infusion liquid Qinf flowing through the infusion line. The device also comprises a control unit able to calculate the first datum or the second datum as a function of the third datum relating to the flow of infusion liquid Qinf.

Priority: IT2003MO00293 Applic. Date: 2003-10-29; US20040568068P Applic. Date: 2004-05-03

Inventor: FRESSINET JEAN L [FR]; ZACCARELLI MASSIMO [IT]; ARTIOLI GIANLUCA [IT]


Application No.: US20050100536A1  Published: 12/May/2005

Title: Compositions and minimally invasive methods for treating incomplete tissue repair

Applicant/Assignee:

Application No.: 10/941124   Filing Date: 15/Sep/2004

Abstract:Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to connective tissue is described. The described method and compositions have been shown to provide both pain relief and improved mobility in treatment of lateral epicondylitis.

Priority: US2003-412821 Applic. Date: 2003-04-11; US20020372682P Applic. Date: 2002-04-13

Inventor: MISHRA ALLAN [US]


Application No.: US20050101901A1  Published: 12/May/2005

Title: Wearable continuous renal replacement therapy device

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 10/940862   Filing Date: 14/Sep/2004

Abstract:A continuous renal replacement therapy (CRRT) device adapted to be worn on a portion of the body of a patient. The CRRT device is worn by the patient and operates on rechargeable batteries for more than 5 hours dialysate is used to remove impurities from the blood. The dialysate is recycled and refreshed by a filter section. Less than one liter of dialysate is required to circulate through the wearable CRRT device.

Priority: US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]


Application No.: US20050101992A1  Published: 12/Sep/2002

Title: Method and apparatus for preparing fibrinogen adhesive from whole blood

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 10/072509   Filing Date: 05/Feb/2002

Abstract:A process and apparatus for one-step preparation of fibrinogen adhesive by polyethylene glycol-mediated precipitation from plasma are disclosed. The methods and apparatus of the invention permit preparation of autologous fibrinogen adhesive composition from the patient during surgery, and can be applied generally to provide such compositions. Also disclosed are an apparatus and method for application of sealant comprising this fibrinogen adhesive composition.

Priority: US1997-863883 Applic. Date: 1997-05-28; US1996-703148 Applic. Date: 1996-08-29; US1996-645464 Applic. Date: 1996-05-13; US1995-370793 Applic. Date: 1995-01-10; US1993-090587 Applic. Date: 1993-07-12; US1989-372443 Applic. Date: 1989-06-23

Inventor: EPSTEIN GORDON H [US]


Application No.: US20050107357A1  Published: 19/May/2005

Title: 2,4-dioxo-3-quinazolinylaryl sulfonylureas

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 10/956004   Filing Date: 29/Sep/2004

Abstract:2,4-Dioxo-3-quinazolinylaryl sulfonylurea compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.

Priority: US20030508564P Applic. Date: 2003-10-03

Inventor: SCARBOROUGH ROBERT M [US]; HUANG WOLIN [US]; PANDEY ANJALI [US]; BAUER SHAWN M [US]; ZHANG XIAOMING [US]; JIA ZHAOZHONG J [US]


Application No.: US20050107399A1  Published: 19/May/2005

Title: Cytokine inhibitors

Applicant/Assignee: KEMIA, INC ITHERX PHARMACEUTICALS, INC

Application No.: 10/939324   Filing Date: 10/Sep/2004

Abstract:The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.

Priority: US20030502569P Applic. Date: 2003-09-11; US20030531234P Applic. Date: 2003-12-18; US20040575704P Applic. Date: 2004-05-28; US20040585012P Applic. Date: 2004-07-02

Inventor: BOMAN ERIK [US]; CEIDE SUSANA C [US]; DAHL RUSSELL [US]; DELAET NANCY G J [US]; ERNST JUSTIN [US]; MONTALBAN ANTONIO G [US]; KAHL JEFFREY [US]; LARSON CHRISTOPHER [US]; MILLER STEPHEN [US]; NAKANISHI HIROSHI [US]; ROBERTS EDWARD [US]; SAIAH EDDINE [US]; SULLIVAN ROBERT [US]; WANG ZHIJUN [US]


Application No.: US20050113399A1  Published: 26/May/2005

Title: Substituted isoquinolinones

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 10/956006   Filing Date: 29/Sep/2004

Abstract:Isoquinolinone compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.

Priority: US20030508402P Applic. Date: 2003-10-03

Inventor: SCARBOROUGH ROBERT M [US]; KANE-MAGUIRE KIM A [US]; MARLOWE CHARLES K [US]; SMYTH MARK S [US]; ZHANG XIAOMING [US]


Application No.: US20050113565A1  Published: 26/May/2005

Title: Pegylated factor VII glycoforms

Applicant/Assignee:

Application No.: 10/609701   Filing Date: 30/Jun/2003

Abstract:The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.

Priority: DK20020000964 Applic. Date: 2002-06-21; WO2003DK00420 Applic. Date: 2003-06-20; US20020394778P Applic. Date: 2002-07-01

Inventor: KLAUSEN NIELS K [DK]; BJORN SOREN [DK]; BEHRENS CARSTEN [DK]; GARIBAY PATRICK W [DK]


Application No.: US20050119330A1  Published: 02/Jun/2005

Title: Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases

Applicant/Assignee:

Application No.: 10/801729   Filing Date: 15/Mar/2004

Abstract:Methods of treating lung proliferative vascular disorders by administering an antiproliferative agent are provided. A preferred antiproliferative agent is a HMG-CoA reductase inhibitor, preferably simvastatin. Vascular occlusion in the pulmonary arteries of the patient is reduced as a result of the treatment through a reduction in neointimal hyperplasia and medial hypertrophy, and the restoration of normal endothelial cell function. The treatment also results in a reversal of right side cardiac hypertrophy. Lung proliferative vascular disorders that can be treated include primary pulmonary hypertension, secondary pulmonary hypertension, Eisenmenger's syndrome, chronic thromboembolic disease, pulmonary fibrosis, obliterative bronchiolitis, or lymphangioleiomyomatosis. Dosages and pharmaceutical formulations are provided.

Priority: US20030455470P Applic. Date: 2003-03-17

Inventor: KAO PETER N [US]; PEARL RONALD G [US]; NISHIMURA TOSHIHIKO [US]; FAUL JOHN L [US]


Application No.: US20050119486A1  Published: 02/Jun/2005

Title: Diamine derivatives

Applicant/Assignee: DAIICHI SANKYO COMPANY, LIMITED

Application No.: 10/481262   Filing Date: 14/Jul/2004

Abstract:A compound represented by the general formula (1): Q<1>-Q<2>-T<0>-N(R<1>)-Q<3>-N(R<2>)-T<1>-Q<4> (1) wherein R<1 >and R<2 >are hydrogen atoms or the like

Q<1 >is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like

Q<2 >is a single bond or the like

Q<3 >is a group in which Q<5 >is an alkylene group having 1 to 8 carbon atoms, or the like

and T<0 >and T<1 >are carbonyl groups or the like

a salt thereof, a solvate thereof, or an N-oxide thereof.

The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Priority: JP20010187105 Applic. Date: 2001-06-20; JP20010243046 Applic. Date: 2001-08-09; JP20010311808 Applic. Date: 2001-10-09; JP20010398708 Applic. Date: 2001-12-28; WO2002JP02683 Applic. Date: 2002-03-20

Inventor: OHTA TOSHIHARU [JP]; KOMORIYA SATOSHI [JP]; YOSHINO TOSHIHARU [JP]; UOTO KOUICHI [JP]; NAKAMOTO YUMI [JP]; NAITO HIROYUKI [JP]; MOCHIZUKI AKIYOSHI [JP]; NAGATA TSUTOMU [JP]; KANNO HIDEYUKI [JP]; HAGINOYA NORIYASU [JP]; YOSHIKAWA KENJI [JP]; NAGAMOCHI MASATOSHI [JP]; KOBAYASHI SYOZO [JP]; ONO MAKOTO [JP]


Application No.: US20050119598A1  Published: 02/Jun/2005

Title: High citrate dialysate and uses thereof

Applicant/Assignee: ADVANCED RENAL TECHNOLOGIES

Application No.: 10/984374   Filing Date: 08/Nov/2004

Abstract:The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5+-5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73+-5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23+-0.19 to 1.34+-0.2 (p=0.01). This increased urea clearance may be the result of the anticoagulant property of citrate maintaining patency of the dialyzer membrane. The increase in pre-dialysis serum HCO3 may represent increased delivery from the dialysate and production from citric acid.

Priority: US2000-667489 Applic. Date: 2000-09-22; US19990155514P Applic. Date: 1999-09-22

Inventor: CALLAN ROBIN [US]; COLE JAMES J [US]


Application No.: US20050121604A1  Published: 09/Jun/2005

Title: Multiple laminar flow-based particle and cellular separation with laser steering

Applicant/Assignee: ARRYX, INC

Application No.: 10/934597   Filing Date: 03/Sep/2004

Abstract:The invention provides a method, apparatus and system for separating blood and other types of cellular components, and can be combined with holographic optical trapping manipulation or other forms of optical tweezing. One of the exemplary methods includes providing a first flow having a plurality of blood components

providing a second flow

contacting the first flow with the second flow to provide a first separation region

and differentially sedimenting a first blood cellular component of the plurality of blood components into the second flow while concurrently maintaining a second blood cellular component of the plurality of blood components in the first flow. The second flow having the first blood cellular component is then differentially removed from the first flow having the second blood cellular component.

Holographic optical traps may also be utilized in conjunction with the various flows to move selected components from one flow to another, as part of or in addition to a separation stage.

Priority: US2004-867328 Applic. Date: 2004-06-13; US20040571141P Applic. Date: 2004-05-14; US20030499957P Applic. Date: 2003-09-04; US20030511458P Applic. Date: 2003-10-15

Inventor: MUETH DANIEL [US]; PLEWA JOSEPH [US]; SHIREMAN JESSICA [US]; ANDERSON AMY [US]; GRUBER LEWIS [US]; ROSENBAUM NEIL H [US]


Application No.: US20050124036A1  Published: 09/Jun/2005

Title: Method for producing recombinant proteins in micro-organisms

Applicant/Assignee:

Application No.: 10/503910   Filing Date: 19/Jan/2005

Abstract:The invention relates to a method for producing a recombinant functional plasminogen in micro-organisms, and to a method for identifying plasminogen activators. The nucleic acid sequence coding for the fuctional part of the plasminogen is fused with a nucleic acid molecule coding for at least one signal peptide. The nucleic acid molecule coding for the plasminogen and the nucleic acid molecule coding for the signal peptide are combined with codons for interfaces of proteases which ensure the separation of the signal peptide. The recombinant plasminogen or the corresponding plasmin is suitable for treating wounds which are slow to heal or not healing, by application of the enzyme in an appropriate formulation.

Priority: WO2003DE00341 Applic. Date: 2003-02-06; EP20020002716 Applic. Date: 2002-02-06; US20020357809P Applic. Date: 2002-02-21

Inventor: SUSILO RUDY [DE]; KORTING HANS C [DE]; GASSEN HANS G [DE]; HILS MARTIN [DE]; PASTERNACK RALF [DE]


Application No.: US20050124664A1  Published: 09/Jun/2005

Title: Urea thiadiazole inhibitors of plasminogen activator inhibior-1

Applicant/Assignee:

Application No.: 10/969703   Filing Date: 20/Oct/2004

Abstract:Methods of treating disorders associated with elevated levels of PAI-1 are disclosed comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of formula (I), or a pharmaceutically-acceptable salt, prodrug, stereoisomer or solvate thereof, wherein: A is aryl o heteroaryl, and R1-R12, are defined herein. The invention also pertains to pharmaceutical compositions and compounds within the scope of formula (I) as well as medicaments and articles of manufacture comprising compounds of formula (I).

Priority: US20030515906P Applic. Date: 2003-10-30

Inventor: SARTORI ERIC [FR]; MAILLET MAGALI [FR]; PAUGAM MARIE F [FR]; NICOLAI ERIC [FR]; LAWRENCE MICHAEL [US]


Application No.: US20050124667A1  Published: 09/Jun/2005

Title: Oxamide inhibitors of plasminogen activator inhibitor-1

Applicant/Assignee:

Application No.: 10/969480   Filing Date: 20/Oct/2004

Abstract:Methods of treating disorders associated with elevated levels of PAI-1 are disclosed comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of formula at least one compound of formula (I), or a pharmaceutically-acceptable salt, prodrug, stereoismer or solvate thereof, wherein: A is aryl or heteroaryl, X is O or S, and R1-R9 and R18 are defined herein. The invention also pertains to pharmaceutical compositions and compounds within the scope of formula (I) as well as medicaments and articles of manufacture comprising compounds of formula (I).

Priority: US20030515895P Applic. Date: 2003-10-30

Inventor: SARTORI ERIC [FR]; MAILLET MAGALI [FR]; PAUGAM MARIE F [FR]; NICOLAI ERIC [FR]; LAWRENCE MICHAEL [US]; ATWAL KARNAIL S [US]


Application No.: US20050124862A1  Published: 09/Jun/2005

Title: Thyroid hormone analogs and methods of use

Applicant/Assignee: ORDWAY RESEARCH INSTITUTE, INC ALBANY COLLEGE OF PHARMACY

Application No.: 10/943072   Filing Date: 15/Sep/2004

Abstract:Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Priority: US20030502721P Applic. Date: 2003-09-15

Inventor: MOUSA SHAKER A [US]; DAVIS FAITH B [US]; DAVIS PAUL J [US]


Application No.: US20050124965A1  Published: 09/Jun/2005

Title: Phosphatase inhibitor sample collection system

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 10/998682   Filing Date: 29/Nov/2004

Abstract:A collection container and a method for collecting a biological sample, particularly whole blood, includes at least one stabilizing agent in an amount effective to stabilize and inhibit protein degradation and/or fragmentation. The stabilizing agent is able to stabilize proteases in the biological sample, particularly at the point of collection, by inhibiting protein degradation and/or fragmentation in the sample when the sample is stored. The stabilizing agent comprises or consists of one or more protease inhibitors.

Priority: US20030527790P Applic. Date: 2003-12-08

Inventor: HAYWOOD BRUCE C [US]


Application No.: US20050136103A1  Published: 23/Jun/2005

Title: Compositions capable of facilitating penetration across a biological barrier

Applicant/Assignee:

Application No.: 10/942300   Filing Date: 16/Sep/2004

Abstract:This invention relates to novel pharmaceutical compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering these compositions to affected subjects.

Priority: US2003-665184 Applic. Date: 2003-09-17; US2003-664989 Applic. Date: 2003-09-17; US20030503615P Applic. Date: 2003-09-17

Inventor: BEN-SASSON SHMUEL A [IL]; COHEN EINAT [IL]


Application No.: US20050136455A1  Published: 23/Jun/2005

Title: Soluble transferrin receptor

Applicant/Assignee: ROCHE DIAGNOSTICS OPERATIONS, INC

Application No.: 10/971870   Filing Date: 22/Oct/2004

Abstract:The invention concerns a method for detecting coronary syndromes, in particular, coronary artery disease (CAD), using risk markers.

Priority: EP20030023980 Applic. Date: 2003-10-22; EP20040010822 Applic. Date: 2004-05-06

Inventor: LEHMANN PAUL [DE]; ROEDDIGER RALF [DE]


Application No.: US20050137180A1  Published: 23/Jun/2005

Title: Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy

Applicant/Assignee: MIRAVANT PHARMACEUTICALS, INC

Application No.: 10/965849   Filing Date: 18/Oct/2004

Abstract:Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease.

Priority: US2002-159005 Applic. Date: 2002-05-31; US20010295345P Applic. Date: 2001-05-31

Inventor: ROBINSON BYRON C [US]; LEITCH IAN M [US]; GREENE STEPHANIE [US]; RYCHNOVSKY STEVE [US]


Application No.: US20050137381A1  Published: 23/Jun/2005

Title: Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 10/741214   Filing Date: 19/Dec/2003

Abstract:This disclosure covers polymers, some of which are useful in medical device applications. The polymers comprise at least two different blocks, at least one L1 block with the formula and at least one L2 block with the formula Medical devices comprising these polymers, mixtures of these polymers with therapeutic agents, and methods of making these polymers and mixtures are within the scope of this disclosure. Some of these medical devices are implantable within a mammalian body, such as in a body lumen.

Priority:

Inventor: PACETTI STEPHEN D [US]


Application No.: US20050137385A1  Published: 23/Jun/2005

Title: IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses

Applicant/Assignee: CENTOCOR, INC

Application No.: 10/840789   Filing Date: 06/May/2004

Abstract:Novel anti-IL-23p40 specific human Ig derived proteins, including, without limitation, antibodies, fusion proteins, and mimetibodies, isolated nucleic acids that encode the anti-IL-23p40 Ig derived proteins, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, are useful for therapeutic compositions, methods and devices. Preferably, the anti-IL-23p40 specific human Ig derived proteins do not bind the p40 subunit of IL-12 and, thus, do not neutralize IL-12-related activity.

Priority: US20030469366P Applic. Date: 2003-05-09

Inventor: BENSON JACQUELINE [US]; CUNNINGHAM MARK [US]


Application No.: US20050137516A1  Published: 23/Jun/2005

Title: Method and apparatus for collecting and processing blood

Applicant/Assignee: FENWAL, INC

Application No.: 10/826420   Filing Date: 16/Apr/2004

Abstract:Method and apparatus are disclosed for collecting and separating whole blood into one or more components. A disposable blood separation fluid circuit is provided which is adapted to cooperate with a reusable separation controller. The fluid circuit includes a fluid flow path for communication with a blood source and an initial collection chamber in fluid communication with the fluid flow path. The fluid flow path is connected to a blood source

and a quantity of whole blood is collected from the source in the initial collection container. The source is then disconnected from the disposable fluid circuit. The disposable fluid circuit is mounted in association with the reusable controller and the collected blood is processed through the disposable fluid circuit assembly to separate it into the desired components.

Priority: US20030532310P Applic. Date: 2003-12-23

Inventor: MIN KYUNGYOON [US]; BROWN RICHARD I [US]


Application No.: US20050139547A1  Published: 30/Jun/2005

Title: Plasma on demand tube

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 11/015949   Filing Date: 17/Dec/2004

Abstract:A device for separating plasma from whole blood is provided having an evacuated primary collection chamber capable of fluid communication through a porous filter to an evacuated secondary collection chamber. An agglutinating agent is provided within the primary collection chamber so as to aggregate blood cells within a whole blood sample. The porous filter has a pore size which is small enough to capture the aggregated blood cells therein, yet large enough to permit plasma to transfer therethrough under pressures associated with conventional evacuated blood collection tubes. The primary and secondary collection chambers may be provided in separate containers or tubes, with transfer occurring therebetween through a transfer device including the porous filter therein.

Priority: US20030532509P Applic. Date: 2003-12-24

Inventor: MANOUSSAKIS DIMITRIOS [US]; LOSADA ROBERT J [US]


Application No.: US20050142129A1  Published: 30/Jun/2005

Title: Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor

Applicant/Assignee:

Application No.: 10/272187   Filing Date: 15/Oct/2002

Abstract:The present invention provides methods of using a blood clotting inhibitor to reduce post-surgical morbidity and mortality. In particular, perioperative use of a blood clotting inhibitor decreases surgical complications without significant adverse effects and is cost effective.

Priority:

Inventor: MANGANO DENNIS T [US]


Application No.: US20050143384A1  Published: 30/Jun/2005

Title: Amide thiadiazole inhibitors of plasminogen activator inhibitor-1

Applicant/Assignee:

Application No.: 10/969692   Filing Date: 20/Oct/2004

Abstract:Methods of treating disorders associated with elevated levels of PAI-1 are disclosed comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of formula at least one compound of formula (I), or a pharmaceutically-acceptable salt, prodrug, stereoisomer or solvate thereof, wherein: A is aryl or heteroaryl and R1-R11, are defined herein. The invention also pertains to pharmaceutical compositions and compounds within the scope of formula (I) as well as medicaments and articles of manufacture comprising compounds of formula (I).

Priority: US20030515898P Applic. Date: 2003-10-30

Inventor: SARTORI ERIC [FR]; MAILLET MAGALI [FR]; PAUGAM MARIE F [FR]; NICOLAI ERIC [FR]; LAWRENCE MICHAEL [US]


Application No.: US20050143684A1  Published: 30/Jun/2005

Title: Apheresis methods and devices

Applicant/Assignee:

Application No.: 11/067405   Filing Date: 22/Feb/2005

Abstract:An apheresis method that includes drawing blood from a mammal, adding an amount of an agent effective in preventing coagulation, wherein the agent is an anticoagulant, extracting one or more constituent components from the blood, wherein an extracted blood and constituent component result therefrom, and diminishing the activity of said anticoagulant by introducing an antidote, wherein the amount of antidote introduced is coupled with the amount of anticoagulant added. The antidote is provided either to the processed blood prior to reintroduction to the donor or directly to the donor. The invention also includes an apheresis machine that includes an antidote delivery conduit, wherein the antidote delivery conduit delivers an amount of antidote that is coupled with an amount of anticoagulant delivered.

Priority: US2001-008857 Applic. Date: 2001-11-02; US20000245901P Applic. Date: 2000-11-03

Inventor: BOLAN CHARLES [US]; LEITMAN SUSAN F [US]; CULLIS HERB [US]


Application No.: US20050147664A1  Published: 07/Jul/2005

Title: Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/979792   Filing Date: 03/Nov/2004

Abstract:The present invention is directed to compositions of one or more nanoparticulate active agents, at least one PEG-derivatized surface stabilizer, and at least one antibody or fragment thereof, and methods of using such compositions for targeting delivery of the one or more active agents to a desired site. The one or more active agents preferably have a particle size of about 2 microns or less. The targeted delivery can be used, for example, for disease sensing, imaging, or drug delivery.

Priority: US20030519251P Applic. Date: 2003-11-13

Inventor: LIVERSIDGE ELAINE [US]; CUNNINGHAM JAMES [US]


Application No.: US20050152950A1  Published: 14/Jul/2005

Title: Method and apparatus for macromolecular delivery using a coated membrane

Applicant/Assignee:

Application No.: 10/990535   Filing Date: 18/Nov/2004

Abstract:This invention relates to the delivery of medicines, macromolecules, or other treating materials to tissues and/or fluids that are to be injected or placed within a human or animal body. The invention describes a method of introducing a treating material to fluids ex corpora using a malleable fracture stabilization device with micropores for directed drug delivery (U.S. Pat. No. 5,466,262) into which a medicine has been incorporated, an apparatus for managing macromolecular distribution (U.S. Pat. No. 5,653,760) that has been coated with a treating material, or any surface to which has been affixed a treating material. The invention describes the use of a disposable housing that contains a semipermeable membrane to which a treating material has been affixed. The invention teaches the use of a dialysis membrane to which heparin or other anticoagulant has been affixed, thereby substantially preventing thrombosis on the membrane while limiting the amount of heparin that must be given systemically. Furthermore, the present invention provides a new and useful mechanism to deliver a treating material directly into the intravenous line from a pre-labeled vial, at a precise rate, and in a minimum volume of fluid. This invention can also be used to deliver treating materials directly to cells and tissues at a defined rate, while at the same time permitting small metabolites and other small toxins to wash away.

Priority: US1997-918217 Applic. Date: 1997-08-25; US1995-557423 Applic. Date: 1995-11-13

Inventor: SAFFRAN BRUCE N [US]


Application No.: US20050154442A1  Published: 14/Jul/2005

Title: Bifurcated stent delivery system

Applicant/Assignee:

Application No.: 10/757646   Filing Date: 13/Jan/2004

Abstract:A catheter assembly comprises a catheter which includes a catheter shaft and a balloon positioned thereon. A rotatable sheath is rotatably disposed about a portion of the catheter. The rotatable sheath has a first portion inner diameter and a second portion inner diameter, which are different.

Priority:

Inventor: EIDENSCHINK TRACEE [US]; WEBER JAN [US]


Application No.: US20050158239A1  Published: 21/Jul/2005

Title: Perturbed membrane-binding compounds and methods of using the same

Applicant/Assignee: NST NEUROSURVIVAL TECHNOLOGIES LTD

Application No.: 10/799586   Filing Date: 15/Mar/2004

Abstract:The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.

Priority: US20040536493P Applic. Date: 2004-01-15; US20040537289P Applic. Date: 2004-01-20

Inventor: ZIV ILAN [IL]; SHIRVAN ANAT [IL]


Application No.: US20050159383A1  Published: 21/Jul/2005

Title: 3-deoxyglucosone and skin

Applicant/Assignee: DYNAMIS THERAPEUTICS, INC

Application No.: 10/966967   Filing Date: 15/Oct/2004

Abstract:The invention relates to the discovery that 3-deoxyglucosone (3DG) and other alpha-dicarbonyl sugars associated diseases and disorders are present and produced in the skin. Further, the invention relates to the discovery that amadorase, an enzyme that mediates 3DG synthesis, is also present in the skin. Thus, the invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.

Priority: WO2003US12003 Applic. Date: 2003-04-17; US2002-198706 Applic. Date: 2002-07-18; US20020373103P Applic. Date: 2002-04-17; US20020392530P Applic. Date: 2002-06-27

Inventor: TOBIA ANNETTE [US]; KAPPLER FRANCIS [US]


Application No.: US20050159388A1  Published: 21/Jul/2005

Title: Non-nucleotide compositions and method for inhibiting platelet aggregation

Applicant/Assignee: INSPIRE PHARMACEUTICALS, INC

Application No.: 10/971766   Filing Date: 21/Oct/2004

Abstract:This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XI, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds according to Formulae I and III-XI.

Priority: US20030513845P Applic. Date: 2003-10-21

Inventor: PLOURDE ROBERT JR [US]; SHAVER SAMMY R [US]; ABREO MELWYN A [US]; ALFARO-LOPEZ LORENZO J [US]; FENG YANGBO [US]; HARVEY DANIEL F [US]; KHASANOVA TATYANA V [US]; TU CHI [US]


Application No.: US20050159417A1  Published: 21/Jul/2005

Title: Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/009480   Filing Date: 10/Dec/2004

Abstract:Disclosed are methods for a treating a disease or condition relating to blood coagulation and fibrinolysis using p38 MAP kinase inhibitors.

Priority: US2003-630599 Applic. Date: 2003-07-30; US20020403422P Applic. Date: 2002-08-14

Inventor: WOOD CHESTER C [US]; VAN DER POLL TOM [NL]


Application No.: US20050159457A1  Published: 21/Jul/2005

Title: Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors

Applicant/Assignee:

Application No.: 11/032297   Filing Date: 10/Jan/2005

Abstract:Phenyl acetamide compounds are described, including compounds of Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof

wherein R<3>-R<6>, R<11>, B, Y and W are set forth in the specification. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as thrombin and factor Xa. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Priority: US2002-262871 Applic. Date: 2002-10-03; US2001-971000 Applic. Date: 2001-10-05; US20000238132P Applic. Date: 2000-10-06

Inventor: PAN WENXI [US]; LU TIANBAO [US]; MARKOTAN THOMAS P [US]; TOMCZUK BRUCE E [US]


Application No.: US20050164926A1  Published: 28/Jul/2005

Title: Novel recombinant anticoagulant proteins

Applicant/Assignee:

Application No.: 10/516908   Filing Date: 17/Mar/2005

Abstract:Novel recombinant anticoagulation proteins, methods of their use and methods of their production are described. In particular, recombinant fusions of annexin V (ANV) and Kunitz protease inhibitors (KPI) that possess potent anticoagulant activity are provided. The fusions, abbreviated ANV:KPI, utilize ANV having high affinity for phosphatidyl-L-serine with various KPI's to target serine proteases in membrane-associated coagulation complexes in the blood coagulation cascade. ANV:KPIs are potentially useful antithrombotic drugs permitting localized passivation of thrombogenic vessel walls and associated thrombi.

Priority: US20020386932P Applic. Date: 2002-06-06; WO2003US17442 Applic. Date: 2003-06-04

Inventor: WUN TZE C [US]


Application No.: US20050165343A1  Published: 28/Jul/2005

Title: Autotransfusion device

Applicant/Assignee: SORIN GROUP ITALIA S.R.L

Application No.: 10/990341   Filing Date: 16/Nov/2004

Abstract:An autotransfusion device having: a first line and a first pump, the first line being connected to the inlet of a blood centrifugation cell, and branches of the first line being (i) connected to a red blood cell container, (ii) provided with a coupling, and (iii) being suitable to be connected to the patient

a second line connected to the outlet of a blood centrifugation cell and two branches of the second line being provided with two couplings

and a third line and a second pump, the third line being connected to the first line in an intermediate position between the first pump and the blood centrifugation cell, and branches of the third line (i) being connected to a physiological solution container and (ii) being provided with a coupling.

Priority: IT2003MI02341 Applic. Date: 2003-11-28

Inventor: VALLUZZI MARGHERITA [IT]; SIMONINI GIAMPAOLO [IT]


Application No.: US20050171512A1  Published: 04/Aug/2005

Title: DEVICES, SYSTEMS AND METHODS FOR PATIENT INFUSION

Applicant/Assignee: INSULET CORPORATION

Application No.: 10/904960   Filing Date: 07/Dec/2004

Abstract:A method for transcutaneously delivering fluid to a patient including providing at least one disposable infusion pump, wherein the pump includes a housing adapted to be mounted on a patient's skin, a transcutaneous patient access tool for extending through the housing and providing transcutaneous access to the patient, a reservoir prefilled with a therapeutic fluid, a dispenser for causing fluid from the reservoir to flow to the transcutaneous patient access tool, a processor connected to the dispenser and programmed to cause a flow of fluid from the reservoir to the transcutaneous patient access tool based on flow instructions, and a wireless receiver connected to the processor for receiving flow instructions from a remote controller and for delivering the flow instructions to the processor.

Priority: US2003-695547 Applic. Date: 2003-10-28; US2001-943992 Applic. Date: 2001-08-31; US20000231476P Applic. Date: 2000-09-08

Inventor: FLAHERTY J C [US]


Application No.: US20050171599A1  Published: 04/Aug/2005

Title: Device for use in intraluminal grafting

Applicant/Assignee:

Application No.: 10/499017   Filing Date: 01/Apr/2005

Abstract:An engagement device for an intraluminal graft or stent which aids in securing and sealing the graft or stent in place within a vessel of a patient. The device comprises a main body which is radially expandable within the vessel wherein the main body also includes a receiving region to receive and engage the intraluminal graft or stent.

Priority: AU2001PR09692 Applic. Date: 2001-12-20; WO2002AU01725 Applic. Date: 2002-12-19

Inventor: WHITE GEOFFREY H [AU]


Application No.: US20050176083A1  Published: 11/Aug/2005

Title: Recombinant protein c variants

Applicant/Assignee:

Application No.: 10/506080   Filing Date: 15/Nov/2004

Abstract:The present invention is concerned with a variant blood coagulation component, which is substantially homologous in amino acid sequence to a wild-type blood coagulation component capable of exhibiting anticoagulant activity in the protein C-anticoagulant system of blood and selected from protein C (PC) and activated protein C (APC), said variant component being capable of exhibiting an anticoagulant activity, that is enhanced in comparison with the anticoagulant activity expressed by the corresponding wild-type blood coagulation component, and said variant component differing from the respective wild-type component, in that it contains in comparison with said wild-type component at least one amino acid residue modification in its N-terminal amino acid residue sequence that constitutes the Gla-domain of protein C and at least one amino acid residue modification in the serine-protease domain of protein C. The present invention is also concerned with methods to produce such variants based on DNA technology

with DNA segments intended for use in the said methods

and with use of said variants for therapeutic and diagnostic purposes.

Priority: WO2003SE00331 Applic. Date: 2003-02-28; US20020360181P Applic. Date: 2002-03-01; US20020401042P Applic. Date: 2002-08-06

Inventor: DAHLBACK BJORN [SE]


Application No.: US20050176678A1  Published: 11/Aug/2005

Title: Compounds and method for coating surfaces in a haemocompatibe manner

Applicant/Assignee:

Application No.: 10/513982   Filing Date: 08/Nov/2004

Abstract:The invention concerns oligosaccharides and polysaccharides as well as the use of these oligosaccharides and/or polysaccharides, which contain the sugar unit N-acylglucosamine or N-acylgalactosamine for the production of hemocompatible surfaces as well as methods for the hemocompatible coating of surfaces with said oligosaccharides and/or polysaccharides, which imitate the common biosynthetic precursor substance of heparin, heparan sulphates and chitosan. The invention further describes methods for producing said oligosaccharides and/or polysaccharides and discloses various possibilities of using hemocompatibly coated surfaces. The invention relates particularly to the use of said oligosaccharides and/or polysaccharides on stents with at least one according to invention deposited hemocompatible coating, which contains an antiproliferative, antiinflammatory and/or antithrombotic active agent, methods for the preparation of said stents as well as the use of said stents for the prevention of restenosis.

Priority: DE20021021055 Applic. Date: 2002-05-10; WO2003DE01253 Applic. Date: 2003-04-15; US20020378676P Applic. Date: 2002-05-09

Inventor: HORRES ROLAND [DE]; LINSSEN MARITA K [DE]; HOFFMANN MICHAEL [DE]; HOFFMANN ERIKA [DE]; DI BAISE DONATO [DE]; FAUST VOLKER [DE]


Application No.: US20050181061A1  Published: 18/Aug/2005

Title: Extrusion process for forming chemically stable drug multiparticulates

Applicant/Assignee: PFIZER INC

Application No.: 11/004165   Filing Date: 03/Dec/2004

Abstract:Reduced levels of drug degradation in drug-containing multiparticulates are obtained by an extrusion/melt-congeal process.

Priority: US20030527315P Applic. Date: 2003-12-04

Inventor: RAY RODERICK J [US]; APPEL LEAH E [US]; NEWBOLD DAVID D [US]; FRIESEN DWAYNE T [US]; MCCRAY SCOTT B [US]; LYON DAVID K [US]; WEST JAMES B [US]; CREW MARSHALL D [US]


Application No.: US20050183259A1  Published: 25/Aug/2005

Title: Apparatus and method for crimping a stent assembly

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 10/784337   Filing Date: 23/Feb/2004

Abstract:A stent assembly comprises a rotatable sheath and a stent. The assembly is crimped or reduced in diameter prior to loading onto a catheter by one or more crimping apparatuses. One crimping apparatus comprises a blade having a stepped configuration. A mandrel may be used to support the assembly during crimping. The mandrel may have an expandable region. A protective sheath may be used to protect the stent during crimping and to redirect the crimping forces to desired locations about the assembly.

Priority:

Inventor: EIDENSCHINK TRACEE [US]; WEBER JAN [US]; JAGGER KARL A [US]; BROWN TERRY V [US]


Application No.: US20050186193A1  Published: 25/Aug/2005

Title: Method and kit for treatment of tissue injury

Applicant/Assignee:

Application No.: 11/085987   Filing Date: 22/Mar/2005

Abstract:Methods and kits are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. The kit includes components for the preparation of platelet-rich plasma from the patient's blood and components for administration to an area in need of vascularization. The methods and kits are useful for the treatment of tendinosis, and in particular, lateral epicondylitis and plantar fasciitis.

Priority: US2004-941124 Applic. Date: 2004-09-15; US2003-412821 Applic. Date: 2003-04-11; US20050655668P Applic. Date: 2005-02-23; US20020372682P Applic. Date: 2002-04-13

Inventor: MISHRA ALLAN [US]


Application No.: US20050186198A1  Published: 25/Aug/2005

Title: Serine protease inhibitors

Applicant/Assignee: GENENTECH, INC

Application No.: 11/088511   Filing Date: 24/Mar/2005

Abstract:Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.

Priority: US2002-224114 Applic. Date: 2002-08-19; US2000-509104 Applic. Date: 2000-03-21; WO2000US00673 Applic. Date: 2000-01-11; US19990115772P Applic. Date: 1999-01-13; US19990152029P Applic. Date: 1999-09-01

Inventor: ALIAGAS-MARTIN IGNACIO [US]; ARTIS DEAN R [US]; DINA MICHAEL S [US]; FLYGARE JOHN A [US]; GOLDSMITH RICHARD A [US]; MUNROE REGINA A [US]; OLIVERO ALAN G [US]; PASTOR RICHARD [US]; RAWSON THOMAS E [US]; ROBARGE KIRK D [US]; SUTHERLIN DANIEL P [US]; WEESE KENNETH J [US]; ZHOU AIHE [US]; ZHU YAN [US]


Application No.: US20050187605A1  Published: 25/Aug/2005

Title: Electrospun skin capable of controlling drug release rates and method

Applicant/Assignee:

Application No.: 10/313496   Filing Date: 06/Dec/2002

Abstract:A versatile covering process enabled through the identification and manipulation of a plurality of variables present in the electrospinning method of the present invention. By manipulating and controlling various identified variables, it is possible to use electrospinning to predictably produce thin materials having desirable characteristics. The fibers created by the electrospinning process have diameters averaging less than 100 micrometers. Proper manipulation of the identified variables ensures that these fibers are still wet upon contacting a target surface, thereby adhering with each other to form a cloth-like material and, if desired, adhering to the target surface to form a covering thereon. The extremely small size of these fibers, and the resulting interstices therebetween, provides an effective vehicle for drug and radiation delivery, and forms an effective membrane for use in fuel cells.

Priority: US20020372721P Applic. Date: 2002-04-11

Inventor: GREENHALGH SKOTT E [US]; KIEFER ROB [US]


Application No.: US20050187611A1  Published: 25/Aug/2005

Title: Drug coating with topcoat

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 11/116256   Filing Date: 27/Apr/2005

Abstract:A coating and method for a coating an implantable device or prostheses are disclosed. The coating includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed herein. The coating further includes a topcoat which covers less than the entire surface of the undercoat and wherein the topcoat comprises a polymeric material substantially free of pores and porosigens. The polymeric material of the topcoat can be a biostable, biocompatible material which provides long term non-thrombogenicity to the device portion during and after release of the biologically active material.

Priority: US2003-603115 Applic. Date: 2003-06-24; US2001-942716 Applic. Date: 2001-08-30; US2000-573506 Applic. Date: 2000-05-18; US1997-996410 Applic. Date: 1997-12-22; US1996-663518 Applic. Date: 1996-06-13; US1995-526273 Applic. Date: 1995-09-11; US1995-424884 Applic. Date: 1995-04-19

Inventor: DING NI [US]; HELMUS MICHAEL N [US]


Application No.: US20050191716A1  Published: 01/Sep/2005

Title: Apparatus and methods for monitoring and modifying anticoagulation therapy of remotely located patients

Applicant/Assignee: ZYCARE, INC

Application No.: 11/115824   Filing Date: 27/Apr/2005

Abstract:A patient apparatus is configured to receive and analyze information regarding patient compliance with anticoagulation medication and self-test coagulation regimens related to anticoagulation therapy. In addition, a patient apparatus is configured to receive data from a patient, including physiological data, pathophysiological data, biological data, psychological data, neuropsychological data, and/or behavioral data. Utilizing the received patient data, a patient apparatus can modify a warfarin regimen using an algorithm contained within the apparatus. The apparatus can communicate the modified warfarin regimen to the patient and to third parties, such as remotely located healthcare providers. In addition, the apparatus can prompt a patient when to perform a self-test and can prompt a patient to seek immediate medical attention, or to directly contact medical help, when so warranted.

Priority: US2000-480432 Applic. Date: 2000-01-11

Inventor: SURWIT RICHARD S [US]; ALLEN LYLE M III [US]; MORRIS JAMES J JR [US]; ORTEL THOMAS L [US]


Application No.: US20050196440A1  Published: 08/Sep/2005

Title: Mucoadhesive drug delivery devices and methods of making and using thereof

Applicant/Assignee:

Application No.: 11/007053   Filing Date: 08/Dec/2004

Abstract:The present invention relates to mucoadhesive drug delivery devices and their methods of preparation and use. More specifically the present invention relates to mucoadhesive drug delivery devices comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents and one or more mucoadhesive agents. The mucoadhesive drug delivery devices may also include one or more pharmacologically active agents. The drug delivery devices of the present invention adhere to mucosal tissue, thereby providing a vehicle for delivery of the pharmacologically active agent(s) through such tissue.

Priority: US20030527962P Applic. Date: 2003-12-08

Inventor: MASTERS DAVID B [US]; BERG ERIC P [US]


Application No.: US20050196459A1  Published: 08/Sep/2005

Title: Carvedilol salts, anhydrates and/or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods

Applicant/Assignee: FLAMEL TECHNOLOGIES S.A

Application No.: 10/996780   Filing Date: 24/Nov/2004

Abstract:The field of the invention is that of oral pharmaceutical medicinal products or compositions, more particularly of the type of those comprising one or more active principles. The aim of the invention is to provide an improved oral medicinal product that can be administered in one or more daily doses, with modified release of active principle (in particular an active principle), for improving the prophylactic and therapeutic efficacy of such a medicinal product. This aim is achieved by means of the multimicrocapsular oral pharmaceutical form according to the invention in which the release of the AP is controlled by means of a double mechanism of triggering the release: "time triggering" and "pH triggering". This medicinal product comprises microcapsules with modified release of active principle, each containing a core comprising the active principle and one or more swelling agents, and at least one coating making possible the modified release of the active principle.

Priority: US20030524991P Applic. Date: 2003-11-25; US20040605680P Applic. Date: 2004-08-30

Inventor: CASTAN CATHERINE [FR]; GUIMBERTEAU FLORENCE [FR]; MEYRUEIX REMI [FR]; SOULA GERARD [FR]


Application No.: US20050202000A1  Published: 15/Sep/2005

Title: Novel remombinant staphylokinase derivant and its preparation method and application thereof

Applicant/Assignee: FUDAN UNIVERSITY

Application No.: 10/182160   Filing Date: 22/Jan/2003

Abstract:The present invention relates to the biotechnology field, more particularly, to novel recombinant staphylokinase (RGD/KGD-Sak) derivatives and the preparation the thereof. The derivatives, have a low polymerizing ability, low immunogenicity and a bifunctionality of thrombolytics and anticoagulant. Based on the line, structural analysis of the monomer and dimer of recombinant staphylokinases and their biochemical properties, we designed two novel bifunctional staphylokinase molecular structures. Mutant genes were constructed by PCR site-directed mutagenesis which were then recombined with a prokaryotic vector and used to transform E. coli.

Engineered strains with a high expression level were selected by screening and propagated by fermentation, followed by disruption of the cells, centrifugation to collect inclusion bodies, renaturation, and purification of RGD/KGD-SAK through a two-step method. After lyophilized, the polymerizing ability and immunogenicity of the products decreased significantly. The derivatives can not only activate fibrinogen to lyse thrombus, but also significantly inhibit the platelet aggregation induced by ADP, suggesting that they have the bifunctionality of thrombolytics and anticoagulant.

Priority: CN20001011627 Applic. Date: 2000-01-28; WO2001CN00102 Applic. Date: 2001-01-23

Inventor: SONG HOUYAN [CN]; SONG GANG [CN]


Application No.: US20050202002A1  Published: 15/Sep/2005

Title: Protease for activating clotting factor VII

Applicant/Assignee: ZLB BEHRING GMBH

Application No.: 11/118396   Filing Date: 02/May/2005

Abstract:A protease for activating the blood clotting factor VII is described, which (a) is inhibited by the presence of aprotinin, (b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and (c) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more brands in the molecular weight range from 50 to 75 kDa and kDa in the reduced state has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa. The proenzyme of this protease is also characterized. Further, a process for obtaining this protease and its use in hemorrhage prophylaxis or hemostasis is described. Moreover, a test system for the qualitative and quantitative detection of a protease which activates the blood clotting factor VII is described.

Priority: DE19981018495 Applic. Date: 1998-04-24; DE19981027734 Applic. Date: 1998-06-22; DE19981051332 Applic. Date: 1998-11-06; DE19981051336 Applic. Date: 1998-11-06; DE19981051335 Applic. Date: 1998-11-06; DE19991003693 Applic. Date: 1999-02-01; US2002-319592 Applic. Date: 2002-12-16; US1999-295316 Applic. Date: 1999-04-21

Inventor: ROMISCH JURGEN [DE]; FEUSSNER ANNETTE [DE]; STOHR HANS-ARNOLD [DE]


Application No.: US20050208200A1  Published: 22/Sep/2005

Title: Drug coating with topcoat

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 11/116052   Filing Date: 27/Apr/2005

Abstract:A coating and method for a coating an implantable device or prostheses are disclosed. The coating includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed therein. The coating further includes a topcoat which covers less than the entire surface of the undercoat and wherein the topcoat comprises a polymeric material substantially free of pores and porosigens. The polymeric material of the topcoat can be a biostable, biocompatible material which provides long term non-thrombogenicity to the device portion during and after release of the biologically active material.

Priority: US2003-603115 Applic. Date: 2003-06-24; US2001-942716 Applic. Date: 2001-08-30; US2000-573506 Applic. Date: 2000-05-18; US1997-996410 Applic. Date: 1997-12-22; US1996-663518 Applic. Date: 1996-06-13; US1995-526273 Applic. Date: 1995-09-11; US1995-424884 Applic. Date: 1995-04-19

Inventor: DING NI [US]; HELMUS MICHAEL N [US]


Application No.: US20050208462A1  Published: 22/Sep/2005

Title: Additive solution for blood preservation

Applicant/Assignee: HEMANEXT LLC

Application No.: 11/128576   Filing Date: 13/May/2005

Abstract:There is provided compositions and methods for the storage of red blood cells. The compositions are additive solutions comprising adenine, dextrose, mannitol, NaH2PO4, and optionally NaCl and/or N4HCl. Composition are preferably used with oxygen-depletion refrigerated storage of red blood cells and may optionally be employed with nutrient supplements extending the useful shelf life of stored blood.

Priority: US2002-295781 Applic. Date: 2002-11-15; US20010332405P Applic. Date: 2001-11-16

Inventor: BITENSKY MARK W [US]; YOSHIDA TATSURO [US]


Application No.: US20050208610A1  Published: 22/Sep/2005

Title: Method of producing an anticoagulation effect

Applicant/Assignee: CRYPTOME PHARMACEUTICALS LTD HEALTHLINX LIMITED

Application No.: 10/897068   Filing Date: 23/Jul/2004

Abstract:A method for producing an anticoagulation effect in a blood coagulation assay, said method comprising contacting a sample of blood with an effective amount of apolipoprotein CIII or fragment, derivative, homologue, analogue, chemical equivalent, functional equivalent or mimetic thereof.

Priority: AU20030903906 Applic. Date: 2003-07-25

Inventor: AUTELITANO DOMINIC J [AU]; BERNDT MICHAEL C [AU]; RAJIC ANTONIO [AU]; SMITH A I [AU]; TALBO GERT H [AU]


Application No.: US20050214877A1  Published: 29/Sep/2005

Title: Method for monitoring resting and activated platelets in unfixed blood samples

Applicant/Assignee: PPD BIOMARKER DISCOVERY SCIENCES, LLC

Application No.: 11/075024   Filing Date: 07/Mar/2005

Abstract:The amount of platelet surface proteins in a sample may be measured by collecting a sample containing platelets into a collection tube containing a platelet stabilizing composition, labeling the platelet surface protein and detecting by cytometry.

Priority: US2001-957624 Applic. Date: 2001-09-20; US20000234065P Applic. Date: 2000-09-20

Inventor: WYANT TIMOTHY L [US]; RAJU PAUL A [US]; KANTOR AARON B [US]


Application No.: US20050220681A1  Published: 06/Oct/2005

Title: Microchemical nanofactories

Applicant/Assignee: OREGON STATE UNIVERSITY STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATEU

Application No.: 11/086074   Filing Date: 21/Mar/2005

Abstract:Embodiments of an apparatus, system, and method for chemical synthesis and/or analysis are disclosed. One embodiment of a disclosed apparatus comprises a laminated, microfluidic structure defining a reactor and a separator. Such apparatuses, or portions thereof, generally have dimensions ranging from about 1 micrometer to about 100 micrometers. To implement synthetic processes, disclosed embodiments of the apparatus generally include at least one valve, and often plural, selectively actuatable valves. Detectors, including optical detectors, also can be used to detect product and other materials as they flow by, or are otherwise presented to, the detector. Individual apparatuses may be coupled both in series and in parallel to form a system for making chemical compounds.

The apparatus is particularly useful for making compounds requiring iterative reaction schemes, and further can be used to make compounds having morphological structures that resemble the morphology of the apparatus itself, such as dendrimers.

Priority: US20040554901P Applic. Date: 2004-03-19; US20040554997P Applic. Date: 2004-03-19

Inventor: CHANG CHIH-HUNG [US]; PAUL BRIAN K [US]; REMCHO VINCENT T [US]


Application No.: US20050224405A1  Published: 13/Oct/2005

Title: Connector for a fluid line in an extracorporeal circuit

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 11/100532   Filing Date: 07/Apr/2005

Abstract:The connector for a fluid line of an extracorporeal circuit comprises a tubular body which internally defines a fluid passage, a first connection port predisposed for coupling to the fluid line, a second connection port predisposed for coupling to a male Luer connector borne by an external element, and a closure element of the second connection port. The closure element is formed of a breakable membrane made in a single piece with the tubular body. On coupling, the membrane is broken by the truncoconical projection of the male Luer connector. The connector connects a service line of an extracorporeal circuit to a pressure sensor of a dialysis machine.

Priority: IT2004MO00082 Applic. Date: 2004-04-13; US20040522430P Applic. Date: 2004-09-30

Inventor: NERI ROBERTO [IT]; PALTRINIERI ANDREA [IT]


Application No.: US20050226845A1  Published: 13/Oct/2005

Title: Method of treatment using interferon-tau

Applicant/Assignee:

Application No.: 11/040706   Filing Date: 21/Jan/2005

Abstract:Methods of treating a disease or condition responsive to interleukin-10 therapy in a mammal are provided. In one form, a method includes orally administering a therapeutically effective amount of interferon tau to the mammal. In other forms of the invention, the method includes administering a second therapeutic agent to the mammal in addition to interleukin-10 either simultaneously or sequentally.

Priority: US2004-884741 Applic. Date: 2004-07-02; US2004-824710 Applic. Date: 2004-04-14; US2004-825068 Applic. Date: 2004-04-14; US2004-825382 Applic. Date: 2004-04-14; US2004-825457 Applic. Date: 2004-04-14; US20040552279P Applic. Date: 2004-03-10

Inventor: LIU CHIH-PING [US]; VILLARETE LORELIE H [US]


Application No.: US20050232969A1  Published: 20/Oct/2005

Title: Methods of treatment with Syk inhibitors

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 11/107324   Filing Date: 15/Apr/2005

Abstract:The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.

Priority: US20040563710P Applic. Date: 2004-04-19

Inventor: ANDRE PATRICK [US]; PHILLIPS DAVID R [US]; HOMCY CHARLES [US]


Application No.: US20050232981A1  Published: 20/Oct/2005

Title: Compositions capable of facilitating penetration across a biological barrier

Applicant/Assignee:

Application No.: 11/105763   Filing Date: 14/Apr/2005

Abstract:This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium. The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.

Priority: US20040562345P Applic. Date: 2004-04-15

Inventor: BEN-SASSON SHMUEL A [IL]


Application No.: US20050233000A1  Published: 20/Oct/2005

Title: System and a method for producing layered oral dosage forms

Applicant/Assignee: HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P

Application No.: 10/825870   Filing Date: 16/Apr/2004

Abstract:A method for producing an oral medication includes dispensing a structural material, the structural material including one of a polymer or a gelatin, curing the structural material, and dispensing a jettable pharmaceutical solution onto the cured structural material.

Priority:

Inventor: FIGUEROA IDDYS D [US]; RUIZ ORLANDO [US]


Application No.: US20050233001A1  Published: 20/Oct/2005

Title: Nanoparticulate megestrol formulations

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/093149   Filing Date: 30/Mar/2005

Abstract:The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.

Priority: US2004-878623 Applic. Date: 2004-06-29; US2003-412669 Applic. Date: 2003-04-14; US20020371680P Applic. Date: 2002-04-12; US20020430348P Applic. Date: 2002-12-03

Inventor: HOVEY DOUGLAS [US]; PRUITT JOHN [US]; RYDE TUULA [US]


Application No.: US20050233302A1  Published: 20/Oct/2005

Title: Compositions and methods for the storage of red blood cells

Applicant/Assignee:

Application No.: 11/060026   Filing Date: 17/Feb/2005

Abstract:The present invention provides an aqueous composition for storage of red blood cells consisting essentially of: adenine

dextrose

at least one non-metabolizable membrane-protectant sugar

and a specifically defined pH buffering system. Also provided are improved methods for preserving red blood cells and methods for increasing the viability, membrane retention, and recoverability while suppressing apoptosis, hemolysis, and post-reinfusion clearance of stored red blood cells which utilize the novel compositions.

Priority: US20040545582P Applic. Date: 2004-02-18

Inventor: HESS JOHN R [US]; GREENWALT TIBOR J [US]


Application No.: US20050234382A1  Published: 20/Oct/2005

Title: Infusion device for medical fluids

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 11/104447   Filing Date: 13/Apr/2005

Abstract:An infusion device comprises a pusher for a plunger of a syringe containing a liquid to be infused. A load cell measures the push force. An encoder associated to a motor commanding the pusher measures the displacement of the pusher. A controller signals an alarm when the ratio between the variation of the push force and the displacement exceeds a predetermined threshold. The device, which serves for infusing an anticoagulant into an extracorporeal blood circuit in a dialysis apparatus, is able to signal an onset of an anomalous situation of lack of infusion in good time.

Priority: IT2004MO00085 Applic. Date: 2004-04-20; US20040522442P Applic. Date: 2004-10-01

Inventor: TONELLI CLAUDIO [IT]; LIGABUE ANDREA [IT]; CESTARI SILVANO [IT]


Application No.: US20050234387A1  Published: 20/Oct/2005

Title: Process for controlling an infusion device

Applicant/Assignee: GAMBRO LUNDIA AB

Application No.: 11/104446   Filing Date: 13/Apr/2005

Abstract:A process comprises the phases of: activating a pusher, which exerts a push force on a plunger of a syringe containing the infusion liquid

measuring the push force by means of a load cell

comparing the push force with a maximum threshold

halting the pusher when the maximum threshold is exceeded

after a predetermined pause, restarting the pusher and emitting a consent signal indicating correct loading of the syringe if, within a certain time from the restart, the push force again exceeds the maximum threshold. The infusion device serves to inject an anticoagulant into an extracorporeal blood circuit. The control process guarantees against loss of infusion due to an incorrect initial loading of the syringe

Priority: IT2004MO00086 Applic. Date: 2004-04-20; US20040522439P Applic. Date: 2004-10-01

Inventor: TONELLI CLAUDIO [IT]; LIGABUE ANDREA [IT]; CESTARI SILVANO [IT]


Application No.: US20050236329A1  Published: 27/Oct/2005

Title: Metabolic detoxification and method

Applicant/Assignee:

Application No.: 11/064566   Filing Date: 23/Feb/2005

Abstract:An extracorporeal filtration and detoxification system and method generally comprise separating ultrafiltrate from cellular components of blood, treating the ultrafiltrate independently of the cellular components in a recirculation circuit, recombining treated ultrafiltrate and the cellular components, and returning whole blood to the patient. A recirculation circuit generally comprises an active cartridge including active cells operative to effectuate a selected treatment

in some embodiments, the active cells are the C3A cell line.

Priority: US20040565888P Applic. Date: 2004-04-27

Inventor: BROTHERTON JOHN D [US]; HE DAR [US]


Application No.: US20050238697A1  Published: 27/Oct/2005

Title: System and a method for starch-based, slow-release oral dosage forms

Applicant/Assignee:

Application No.: 10/832702   Filing Date: 27/Apr/2004

Abstract:A system for producing a slow release oral dosage of medication includes a starch based media, and an oral dosage formulation jetted onto the starch based media.

Priority:

Inventor: CHINEA VANESSA I [US]; CHEN TIENTEH [US]


Application No.: US20050238725A1  Published: 27/Oct/2005

Title: Nanoparticulate compositions having a peptide as a surface stabilizer

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LTD

Application No.: 10/978695   Filing Date: 02/Nov/2004

Abstract:The present invention is directed to nanoparticulate active agent compositions comprising at least one peptide as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.

Priority: US20030517106P Applic. Date: 2003-11-05

Inventor: CUNNINGHAM JAMES [US]; LIVERSIDGE ELAINE M [US]


Application No.: US20050240145A1  Published: 27/Oct/2005

Title: Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment

Applicant/Assignee:

Application No.: 10/865221   Filing Date: 10/Jun/2004

Abstract:A mechanical dilatation and medicament delivery device for enlarging a flow passage of a vessel by dilating and delivering a liposome or micelle-encapsulated therapeutic agent or medicament to an obstruction in the vessel. The present invention comprises a substantially cylindrically shaped expansion member and includes a means engaged to the expansion member for altering the distance between the proximal end and the distal end of the expansion member thereby transforming the expansion member between a diametrically contracted configuration to diametrically expanded configuration. A liposome or micelle-encapsulated therapeutic agent or medicament is coated on either the expansion member, or incorporated into a substrate coated on the expansion member. The present method comprises the steps of advancing the coated expansion member to the obstruction in a vessel and applying opposed forces on said expansion member in an axial direction to move the expansion member to an expanded configuration wherein the expansion member dilates the obstruction and the expansion member either passively or actively delivers a liposome or micelle-encapsulated therapeutic agent or medicament to the obstruction.

Priority: US2002-135709 Applic. Date: 2002-04-30

Inventor: SCOTT NEAL [US]; SEGAL JEROME [US]


Application No.: US20050240225A1  Published: 27/Oct/2005

Title: Accelerated healing with intraoperative combination of suture and autogenous blood components

Applicant/Assignee: ARTHREX, INC

Application No.: 11/112003   Filing Date: 22/Apr/2005

Abstract:A suture combined intraoperatively with autogenous blood components. At least one strand of suture is placed into a sterile container. Blood obtained from a patient is separated, using a centrifuge, for example, to retrieve certain healing components such as autogenous growth factors, to obtain an autogenous blood suspension. The autogenous blood suspension is added to the sterile container containing the strand of suture. The suture wicks up biologic components of the autogenous blood suspension to produce an enhanced suture. Surgical repairs using the enhanced suture are conducted by suturing a tear to itself or to bone, for example. Post-operatively, the biologic components leach from the suture to accelerate healing of the repair.

Priority: US20040564241P Applic. Date: 2004-04-22

Inventor: SCHMIEDING REINHOLD [US]; GRAFTON R D [US]


Application No.: US20050242034A1  Published: 03/Nov/2005

Title: Method and apparatus for kidney dialysis

Applicant/Assignee: BAXTER INTERNATIONAL INC

Application No.: 11/175072   Filing Date: 05/Jul/2005

Abstract:A number of improvements relating to methods and apparatuses for kidney dialysis are disclosed. These include checking of dialysate bypass status using flow measurement

using a flow sensor to confirm the absence of ultrafiltration during bypass

automatic testing of ultrafiltration function by removal of a discrete volume from a portion of the dialysate flow path coupled with a pressure test of that part of the flow path

using a touch screen user interface

bar graph profile programming of ultrafiltration, sodium, and bicarbonate parameters

using a RAM card to upload treatment instructions to, and to download treatment data from, the machine

automatic setting of proportioning mode (acetate or bicarbonate) based on connections of concentrate lines

predicting dialysate conductivity values based on brand and formulation of concentrates

minimizing no-flow dead time between dialysate pulses

initiating operation in a timed mode from a machine power-off condition

preserving machine mode during machine power-fail condition

calibration scheduling and reminding

automatic level adjusting

and blood leak flow rate detecting.

Priority: US2004-938486 Applic. Date: 2004-09-09; US2003-695526 Applic. Date: 2003-10-27; US2000-711240 Applic. Date: 2000-11-13; US1998-067922 Applic. Date: 1998-04-28; US1995-479688 Applic. Date: 1995-06-07; US1993-122047 Applic. Date: 1993-09-14; US1991-688174 Applic. Date: 1991-04-19

Inventor: CONNELL MARK E [US]; BEDIENT ROBERT A [US]; ELSEN RAYMOND [BE]; HOGARD MICHAEL E [US]; JOHNSON HARLEY D [US]; KELLY THOMAS D [US]; LONG JEAN M [US]; PETERSON BRUCE A [US]; PRESTON WILLIAM G JR [US]; SMEJTEK DALIBOR J [US]


Application No.: US20050244459A1  Published: 03/Nov/2005

Title: Coating compositions for bioactive agents

Applicant/Assignee:

Application No.: 11/099997   Filing Date: 06/Apr/2005

Abstract:A coating composition and related method for use in applying a bioactive agent to a surface in a manner that will permit the bioactive agent to be released from the coating in vivo. The composition is particularly well suited for coating the surface of implantable medical device, such as a stent or catheter, in order to permit the device to release bioactive agent to the surrounding tissue over time. The composition includes a plurality of compatible polymers having different properties that can permit them to be combined together to provide an optimal combination of such properties as durability, biocompatibility, and release kinetics.

Priority: US20040559821P Applic. Date: 2004-04-06

Inventor: DEWITT DAVID M [US]; FINLEY MICHAEL J [US]; LAWIN LAURIE R [US]


Application No.: US20050245433A1  Published: 03/Nov/2005

Title: Materials and methods for modulating metabolism

Applicant/Assignee: OMEGA BIO-PHARMA (I.P.3) LIMITED

Application No.: 11/118737   Filing Date: 29/Apr/2005

Abstract:The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications.

Priority: US20040567899P Applic. Date: 2004-05-03; US20040637618P Applic. Date: 2004-12-20

Inventor: CHAN BILL P [CN]; WONG GARY K P [HK]; XU JINXIAN [CN]; CHI FRANCIS [HK]


Application No.: US20050245565A1  Published: 03/Nov/2005

Title: Diamine derivatives

Applicant/Assignee: DAIICHI PHARMACEUTICAL CO., LTD

Application No.: 10/481629   Filing Date: 01/Jun/2004

Abstract:A compound represented by the general formula (1): Q<1>-Q<2>-T<0>-N(R<1>)-Q<3>-N(R<2>) -T<1>-Q<4 > (1) wherein R<1 >and R<2 >are hydrogen atoms or the like

Q<1 >is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like

Q<2 >is a single bond or the like

Q<3 >is a group in which Q<5 >is an alkylene group having 1 to 8 carbon atoms, or the like

and T<0 >and T<1 >are carbonyl groups or the like

a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Priority: JP20010187105 Applic. Date: 2001-06-20; JP20010243046 Applic. Date: 2001-08-09; JP20010311808 Applic. Date: 2001-10-09; JP20010398708 Applic. Date: 2001-12-28; WO2002JP02683 Applic. Date: 2002-03-20; WO2002JP06141 Applic. Date: 2002-06-20

Inventor: OHTA TOSHIHARU [JP]; KOMORIYA SATOSHI [JP]; YOSHINO TOSHIHARU [JP]; UOTO KOUICHI [JP]; NAKAMOTO YUMI [JP]; NAITO HIROYUKI [JP]; MOCHIZUKI AKIYOSHI [JP]; NAGATA TSUTOMU [JP]; KANNO HIDEYUKI [JP]; HAGINOYA NORIYASU [JP]; YOSHIKAWA KENJI [JP]; NAGAMOCHI MASATOSHI [JP]; KOBAYASHI SYOZO [JP]; ONO MAKOTO [JP]


Application No.: US20050245671A1  Published: 03/Nov/2005

Title: Polymer resin formulation having anti-microbial or anti-cogulability and preparation method thereof

Applicant/Assignee:

Application No.: 10/519345   Filing Date: 23/Dec/2004

Abstract:The present invention relates to an anti-microbial or anti-coagulating polymer resin and a method for preparing the same, and a medical appliance or instrument using the same, and more particularly to a method for preparing an anti-microbial or anti-coagulating medical polymer resin comprising the steps of simply mixing a polymer resin with at least one kind of pharmaceutically active material without using a solvent. The pharmaceutically active material is preferably an anti-microbial or anti-coagulant.

According to the present invention, an anti-microbial or anti-coagulating material that is safe to a human body is mixed with a polymer resin by simple addition in an environmentally favorable non-solvent method, thereby maintaining superior anti-microbial effects even after high temperature molding, minimizing a released amount of anti-microbial to increase anti-microbial effect durability, and solving a toxic problem in a body. Therefore, the present invention can be extensively applied for medical appliances/instruments for a human body.

Priority: KR20020035793 Applic. Date: 2002-06-25; WO2003KR01249 Applic. Date: 2003-06-25

Inventor: MOON WOENG-SIG [KR]; KIM JAE-CHUL [KR]; BYOUN YOUN-SEOP [KR]; CHUNG KYOO-HYUN [KR]; KANG HEUN-SOO [KR]; KONG KI-OH [KR]; HWANG JUNG-HWA [KR]


Application No.: US20050245894A1  Published: 03/Nov/2005

Title: Methods and apparatuses for drug delivery to an intravascular occlusion

Applicant/Assignee: MEDTRONIC VASCULAR, INC

Application No.: 11/159777   Filing Date: 23/Jun/2005

Abstract:A method for delivering a drug to the site of an intravascular occlusion. A guidewire having a balloon at one end is advanced across the occlusion using a guide catheter, and the balloon is inflated distal to the occlusion to occlude the blood vessel. An aspiration catheter is then inserted into the vessel with its tip less than about 5 mm from the surface of the balloon, and a drug is delivered which flows distal to proximal to treat the occlusion.

Priority: US2000-537471 Applic. Date: 2000-03-24; US1998-049857 Applic. Date: 1998-03-27; US1997-813807 Applic. Date: 1997-03-06; US1997-975723 Applic. Date: 1997-11-20; US1998-049712 Applic. Date: 1998-03-27; US1997-812139 Applic. Date: 1997-03-06; US1996-650464 Applic. Date: 1996-05-20

Inventor: ZADNO-AZIZI GHOLAM-REZA [US]


Application No.: US20050255091A1  Published: 17/Nov/2005

Title: Hydrogels for biomedical applications

Applicant/Assignee:

Application No.: 11/122471   Filing Date: 05/May/2005

Abstract:The invention relates to methods for the formation of hydrogels by the intensive mixing of aqueous compositions containing copolymers of opposite chirality. Such hydrogels may he bioresorbable and are useful for medical applications within mammalian bodies.

Priority: US20040571102P Applic. Date: 2004-05-14

Inventor: LOOMIS GARY L [US]


Application No.: US20050255535A1  Published: 17/Nov/2005

Title: Compositions, kit and one-step method for monitoring compounds having anti-factor Xa and/or anti factor IIa activities

Applicant/Assignee:

Application No.: 11/127540   Filing Date: 11/May/2005

Abstract:Provided are compositions and methods for accurate determination of the concentration of anticoagulant in a sample such as a blood or plasma sample. The compositions can contain a Factor X compound and Factor V compound, and additional components as well. Methods for performing the assay include one-step methods in which a sample is added to a coagulation assay composition, and time is monitored from the point of adding the sample and coagulation assay composition to an endpoint, such as clot formation.

Priority: US20040570312P Applic. Date: 2004-05-11

Inventor: YIN THYE [US]


Application No.: US20050255600A1  Published: 17/Nov/2005

Title: PORTABLE SAMPLE ANALYZER CARTRIDGE

Applicant/Assignee: HONEYWELL INTERNATIONAL INC

Application No.: 10/908460   Filing Date: 12/May/2005

Abstract:A sample analyzer cartridge for use at a point of care of a patient such as in a doctor's office, in the home, or elsewhere in the field. By providing a removable and/or disposable cartridge with all of the needed reagents and/or fluids, the sample analyzer can be reliably used outside of the laboratory environment, with little or no specialized training.

Priority: US20040571235P Applic. Date: 2004-05-14

Inventor: PADMANABHAN ARAVIND [US]; COX JAMES A [US]; CABUZ CLEOPATRA [US]


Application No.: US20050256028A1  Published: 17/Nov/2005

Title: Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase

Applicant/Assignee:

Application No.: 10/846486   Filing Date: 13/May/2004

Abstract:Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, including various disease conditions, that increase in severity and/or occurrence during one or more phases of the menstrual cycle. Also provided are systems and kits for use in practicing the subject methods.

Priority:

Inventor: YUN ANTHONY J [US]; LEE PATRICK Y [US]


Application No.: US20050260681A1  Published: 24/Nov/2005

Title: Method of altering the binding specificity of proteins by oxidation-reduction reactions

Applicant/Assignee:

Application No.: 11/108826   Filing Date: 19/Apr/2005

Abstract:The binding specificity of at least one protein suspended or dissolved in a liquid medium is reversibly altered by exposing the protein to an oxidizing agent or an electric current. A masked protein such as an autoantibody can be detected, isolated and recovered from a biological fluid by subjecting the biological fluid to an oxidizing agent or an electric current to change the binding specificity of masked proteins contained therein.

Priority: US2004-863365 Applic. Date: 2004-06-09; US20030476607P Applic. Date: 2003-06-09

Inventor: MCINTYRE JOHN A [US]


Application No.: US20050267097A1  Published: 01/Dec/2005

Title: Lactam-containing compounds and derivatives thereof as factor xa inhibitors

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 11/198801   Filing Date: 05/Aug/2005

Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4 I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US2004-850587 Applic. Date: 2004-05-20; US2002-245122 Applic. Date: 2002-09-17; US20010324165P Applic. Date: 2001-09-21; US20020402317P Applic. Date: 2002-08-09

Inventor: PINTO DONALD J [US]; QUAN MIMI L [US]; ORWAT MICHAEL J [US]; LI YUN-LONG [US]; HAN WEI [US]; QIAO JENNIFER X [US]; LAM PATRICK Y [US]; KOCH STEPHANIE L [US]


Application No.: US20050267134A1  Published: 01/Dec/2005

Title: Non-nucleotide composition and method for inhibiting platelet aggregation

Applicant/Assignee: INSPIRE PHARMACEUTICALS, INC

Application No.: 11/124619   Filing Date: 05/May/2005

Abstract:This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation, preferably in a reversible manner. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.

Priority: US2004-971766 Applic. Date: 2004-10-21; US20030513845P Applic. Date: 2003-10-21

Inventor: PLOURDE ROBERT JR [US]; SHAVER SAMMY R [US]; DOUGLASS JAMES G III [US]; WATSON PAUL S [US]; BOYER JOSE L [US]; TU CHI [US]; ABREO MELWYN A [US]; ALFARO-LOPEZ LORENZO J [US]; FENG YANGBO [US]; HARVEY DANIEL F [US]; KHASANOVA TATYANA V [US]


Application No.: US20050269250A1  Published: 08/Dec/2005

Title: Medical system, method and apparatus employing MEMS

Applicant/Assignee: FENWAL, INC

Application No.: 11/198804   Filing Date: 05/Aug/2005

Abstract:A biological suspension processing system is disclosed that may include a suspension treatment device for treating one or more components of a biological suspension, a first fluid flow path for introducing a suspension into the treatment device and a second fluid flow path for withdrawing a constituent of the suspension from the device. At least one microelectromechanical (MEM) sensor communicates with one of the fluid flow paths for sensing a selected characteristic of the fluid therewith. The MEM sensor may be located elsewhere, such as on a container or bag and communicate with the interior for sensing a characteristic of the fluid contained therein. A wide variety of characteristics may be sensed, such as flow rate, pH, cell type, cell antigenicity, DNA, viral or bacterial presence, cholesterol, hematocrit, cell concentration, cell count, partial pressure, pathogen presence, or viscosity.

Priority: US2002-031112 Applic. Date: 2002-01-14; WO2001US21188 Applic. Date: 2001-07-03; US20000216640P Applic. Date: 2000-07-07

Inventor: CORK WILLIAM H [US]; ULMES JAMES J [US]; WEST RICHARD L [US]; LO YING-CHENG [US]; WEBER MARK C [US]; MIN KYUNGYOON [US]


Application No.: US20050271696A1  Published: 08/Dec/2005

Title: Medical device having a surface including a biologically active agent therein, and methods

Applicant/Assignee: MEDTRONIC, INC

Application No.: 11/138545   Filing Date: 26/May/2005

Abstract:The present invention provides a medical device, and methods of preparing and using a medical device. The medical device has a surface including a biologically active agent therein. The methods are particularly useful for preparing, for example, coated stents having a biologically active agent within the coating.

Priority: US20040574739P Applic. Date: 2004-05-27

Inventor: DINH THOMAS Q [US]; PADUA RODOLFO [US]; CASAS-BEJAR JESUS [US]


Application No.: US20050272148A1  Published: 08/Dec/2005

Title: Method of collecting placental stem cells

Applicant/Assignee: ANTHROGENESIS CORPORATION

Application No.: 11/187400   Filing Date: 21/Jul/2005

Abstract:A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.

Priority: US2001-004942 Applic. Date: 2001-12-05; US20000251900P Applic. Date: 2000-12-06

Inventor: HARIRI ROBERT J [US]


Application No.: US20050272810A1  Published: 08/Dec/2005

Title: Compositions comprising nebivolol

Applicant/Assignee: FOREST LABORATORIES HOLDINGS LIMITED

Application No.: 11/141235   Filing Date: 31/May/2005

Abstract:Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.

Priority: US20040577423P Applic. Date: 2004-06-04

Inventor: DAVIS ERIC [US]; O'DONNELL JOHN [US]; BOTTINI PETER [US]


Application No.: US20050273047A1  Published: 08/Dec/2005

Title: System and method for transdermal delivery of an anticoagulant

Applicant/Assignee:

Application No.: 11/144005   Filing Date: 01/Jun/2005

Abstract:A device for transdermally delivering an anticoagulant agent by electrotransport. Preferably, the anticoagulant comprises a benzamidine or a naphthamidine derivative. A particularly preferred benzamidine derivative is a 2-[3-[4-(4-piperidinyloxy)anilino]-1-propenyl]benzamidine derivative. The devices are configured to maintain a plasma concentration of 20-80 ng/mL or providing a flux in the range of approximately 20-40 mg/day. Suitable current densities include 0.050 and 0.10 mA/cm<2>. Methods of the invention include delivering the anticoagulants to precisely maintain the desired plasma concentrations. The invention also comprises treating thromboembolic disease and inhibiting Factor Xa.

Priority: US20040576905P Applic. Date: 2004-06-03

Inventor: TAKHAR SUDEEP [US]; PADMANABHAN RAMA V [US]; PHIPPS JOSEPH B [US]; SUBRAMONY JANARDHANAN A [US]


Application No.: US20050274673A1  Published: 15/Dec/2005

Title: Whole blood collection and processing method

Applicant/Assignee: GAMBRO, INC

Application No.: 11/166285   Filing Date: 24/Jun/2005

Abstract:A method is disclosed for collecting and processing whole blood. Whole blood is collected at several remote donor sites and transported to a central blood-processing center, where information regarding demand for blood products is used to direct processing of whole blood into blood products. Whole blood is initially collected in collection bags unattached to satellite bags instead of commonly used multiple bag sets. When the determination is made at the blood processing center as to which blood products are to be made, the appropriate satellite bags and/or other system components are sterile docked to the blood-collection bag and the whole blood is processed. The use of blood-collection bags initially unattached to satellite bags eliminates waste and simplifies the transportation and processing of whole blood. Also disclosed are blood collection systems that remove leukocytes and collect whole blood into blood-collection bags unattached to satellite bags.

Priority: US2003-358381 Applic. Date: 2003-02-03; US20020353277P Applic. Date: 2002-02-01

Inventor: CORBIN FRANK III [US]; URDAHL STEVEN G [US]


Application No.: US20050276861A1  Published: 15/Dec/2005

Title: Ex-vivo application of solid microparticulate therapeutic agents

Applicant/Assignee:

Application No.: 11/148453   Filing Date: 09/Jun/2005

Abstract:The present invention is concerned with a method of preparing and delivering small particles of a pharmaceutically active material to a mammalian subject for treating diseases or disorders. A preferred embodiment entails: (i) the collection of tissue cells from an animal donor, (ii) selective or non-selective growth of these cells in a cell culture medium to which is added solid particles of a therapeutically active compound, mostly free of a drug carrier (about 10% or less, by weight), and having an average particle size of less than about 100 microns, (iii) contacting the cells in the cell culture medium with the solid particles of therapeutically active compound causing the particles to be taken up by the cells into either the intracellular compartment of the cultured cells, attachment of the active compound as particles to the periphery of such cells, or a combination of intracellular uptake and attachment to the cell surface, (iv) optionally, isolation and/or resuspension of the cells prepared in steps i through iii, (v) administering the cells to the mammalian subject. The pharmaceutically active material can be administered intravenously, intramuscularly, subcutaneously, intradermally, intra-articularly, intrathecally, epidurally, intracerebrally, via buccal route, rectally, topically, transdermally, orally, intranasally, via pulmonary route, intraperitoneally, or combinations thereof. After administration, the loaded cells transport the pharmaceutical composition as particles.

Priority: US20040579891P Applic. Date: 2004-06-15

Inventor: KIPP JAMES E [US]; RABINOW BARRETT E [US]


Application No.: US20050277108A1  Published: 15/Dec/2005

Title: Method for extending the useful shelf-life of refrigerated red blood cells by nutrient supplementation

Applicant/Assignee: HEMANEXT LLC THE TRUSTEES OF BOSTON UNIVERSITY

Application No.: 11/138135   Filing Date: 26/May/2005

Abstract:There are provided methods and compositions for the storage of red blood cells. The compositions are metabolic supplements that are preferably added to refrigerated red blood cells suspended in an additive solution. Red blood cells are preferably stored under conditions of oxygen-depletion. Metabolic compositions comprises pyruvate, inosine, adenine, and optionally dibasic sodium phosphate and/or monobasic sodium phosphate.

Priority: US2002-295772 Applic. Date: 2002-11-15; US20010332409P Applic. Date: 2001-11-16

Inventor: BITENSKY MARK W [US]; YOSHIDA TATSURO [US]


Application No.: US20050277130A1  Published: 15/Dec/2005

Title: Post protein hydrolysis removal of a potent ribonuclease inhibitor and the enzymatic capture of DNA

Applicant/Assignee: UNIVERSITY OF SOUTH FLORIDA

Application No.: 11/035667   Filing Date: 14/Jan/2005

Abstract:The present invention concerns compositions and methods of extracting infectious pathogens from a volume of blood. In one embodiment, the method includes the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The present invention also concerns materials and methods for removing aurintricarboxylic acid (ATA) from a sample.

Priority: US2003-604779 Applic. Date: 2003-08-15; WO2004US26606 Applic. Date: 2004-08-16; US20040481892P Applic. Date: 2004-01-14

Inventor: EWERT MATT [US]; AMUSO PHIL [US]; CANNONS ANDREW [US]


Application No.: US20050281746A1  Published: 22/Dec/2005

Title: Anticoagulant contrast media

Applicant/Assignee:

Application No.: 11/153254   Filing Date: 14/Jun/2005

Abstract:The present invention provides novel anticoagulant contrast agents, which comprise an organic scaffolding moiety, an organic anticoagulant moiety, and an imaging moiety. The invention also provides anticoagulant contrast media and methods of visualizing internal structures utilizing the novel anticoagulant contrast agents and anticoagulant contrast media.

Priority: US20040580624P Applic. Date: 2004-06-16

Inventor: MELTON LAURA J [US]


Application No.: US20050282771A1  Published: 22/Dec/2005

Title: Methods for treating bleeding disorders using sulfated polysaccharides

Applicant/Assignee: AVIGEN, INC BAXTER INTERNATIONAL, INC BAXTER HEALTHCARE S.A

Application No.: 11/140504   Filing Date: 27/May/2005

Abstract:Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

Priority: US20040574845P Applic. Date: 2004-05-27

Inventor: JOHNSON KIRK W [US]


Application No.: US20050283222A1  Published: 22/Dec/2005

Title: Apparatus for delivering endoluminal prostheses and methods of making and using them

Applicant/Assignee: ENDOTEX INTERVENTIONAL SYSTEMS, INC

Application No.: 11/197577   Filing Date: 03/Aug/2005

Abstract:An apparatus for delivering a stent into a blood vessel includes a sheath having a rounded bullet-shaped distal portion including a plurality of flexible leaflets integrally molded thereto. The stent is disposed in its contracted condition within a lumen of the sheath proximate the distal portion. A bumper is slidably disposed within the lumen that includes a helical compression coil, a bumper element attached to the helical coil including a blunt distal edge for abutting the stent, and an extension element extending distally from the bumper element through the stent and between the leaflets to facilitate introducing the apparatus over a guidewire. The sheath is formed by inserting a bullet into a blunt-ended tube, and inserting the tube into a bullet-shaped bore in a heated die until the tube material is softened and deforms into a rounded bullet shape. Slits are then cut into the distal portion to create the leaflets.

Priority: US2000-664970 Applic. Date: 2000-09-18

Inventor: BETELIA RAINIER [US]; GILLIS EDWARD M [US]; ROURKE JONATHAN M [US]; YANG YI [US]


Application No.: US20050284815A1  Published: 29/Dec/2005

Title: MEDICAL TREATMENT SYSTEM AND METHOD

Applicant/Assignee: INTEGRATED SENSING SYSTEMS, INC

Application No.: 11/160403   Filing Date: 22/Jun/2005

Abstract:A treatment system and method for treating a fluid withdrawn and then returned to a living body. The system includes outgoing and incoming fluid lines connected to the living body for transporting the fluid from the living body, through the treatment system, and back to the living body, a device for altering at least the density of the fluid as it flows through the system, and a sensing unit within the system and comprising a device for sensing the density of the fluid as the fluid flows through the sensing unit. The sensing device may be a micromachined Coriolis-based sensor also capable of sensing mass flow rate.

Priority: US20040582976P Applic. Date: 2004-06-28

Inventor: SPARKS DOUGLAS R [US]; NAJAFI NADER [US]


Application No.: US20050287516A1  Published: 29/Dec/2005

Title: Medium and method for preserving platelets, red blood cells, and other non-nucleus cells and platelets-containing composition

Applicant/Assignee:

Application No.: 11/157838   Filing Date: 22/Jun/2005

Abstract:The present invention provides a platelet-containing composition prepared by contacting platelets with a medium for preserving. The medium comprises anticoagulant, cryoprecipitate and thrombin. The present invention also provides a method for long-term preservation of platelets, comprising the steps of: (a) adding anticoagulants, cryoprecipitate, thrombin in normal saline

(b) adding a platelet-containing medium into the solution formed in step (a)

and(c) lyophilizing the platelet-containing solution formed in step (b). Moreover, the present invention yet provides a medium for preserving non-nucleus cells.

Priority: TW20040119184 Applic. Date: 2004-06-29

Inventor: SU CHENG-YAO [TW]; LIN CHENG-CHIH [TW]


Application No.: US20050288251A1  Published: 29/Dec/2005

Title: Treatment and prevention of abnormal cellular proliferation

Applicant/Assignee: THE UNIVERSITY OF IOWA RESEARCH FOUNDATION THE GENERAL HOSPITAL CORPORATION

Application No.: 11/082213   Filing Date: 16/Mar/2005

Abstract:This invention provides a method for inhibiting or preventing the abnormal growth of cells, including transformed cells, by administering an effective amount of O-acylated heparin derivative. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanism (e.g. loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors)

(2) benign and malignant cells of other proliferative disease in which aberrant cellular proliferation occurs

(3) aberrant smooth muscle cell proliferation, such as might occur following treatment for coronary atherosclerosis such as angioplasty or the insertion of a stent into an occluded vessel.

Priority: US20040553800P Applic. Date: 2004-03-16

Inventor: HALES CHARLES A [US]; GARG HARI G [US]; YU LUNYIN [US]; LINHARDT ROBERT J [US]

...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
US Applications Published from 2006 -2009
 
Provisional Applications in Blood Anticlot Technology,
Medications and Medical Devices
US PROVISIONAL PATENT APPLICATIONS IN BLOOD ANTICLOT TECHNOLOGY PUBLISHED FROM 2001 TO 2005
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included drugs, medications, formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors,
heparin, warfarin and related technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve and select highly
relevant documents.
Clck to enlarge and view details